{"title": "PDF", "author": "PDF", "url": "https://tuprints.ulb.tu-darmstadt.de/2102/1/Dissertation_Nicole_Hoettecke.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Entwicklung und Synthese von \n\u03b3-Sekretase-Modulatoren zur Behandlung von \nMorbus Alzheimer \n \nVom Fachbereich Chemie \nder Technischen Universit\u00e4t Darmstadt \n \n \nzur Erlangung des akademischen Grades eines \nDoctor rerum naturaliu m (Dr. rer. nat.) \n \n \ngenehmigte \nkumulative Dissertation \n \nvorgelegt von \nDipl.- Biochem. Nicole H\u00f6ttecke \naus Lippstadt \n    \nReferent: Prof. Dr. Boris Schmidt Korreferent: Prof. Dr. Harald Kolmar Korreferent: PD Dr. Andreas Ludwig (RWTH Aachen) \n \nTag der Einreichung: 16. Dezember 2009 Tag der m\u00fcndlichen Pr\u00fcfung: 08. Februar 2010 \n \nDarmstadt 2010 \nD17 \n \n   \n \n          \n \n                       \n           \n \n                 Die vorliegende Arbeit wurde unter der Le itung von Herrn Prof. Dr. Boris Schmidt am \nClemens Sch\u00f6pf-Institut f\u00fcr Organische Chemie  und Biochemie der Tec hnischen Universit\u00e4t \nDarmstadt von Oktober 2006 bis Dezember 2009 angefertigt.  \n \n  Teile dieser Arbeit sind bereits ve r\u00f6ffentlicht oder zur Ver\u00f6ffentlichung \neingereicht: \n \n1) Stefanie Baumann, Nicole H\u00f6 ttecke, Boris Schmidt, \u201c \uf067-Secretase as a target for \nAD\u201c, in Medicinal Chemistry of Alzheimer Di sease, ed. A. Martinez, Research \nSignpost, 2008 . \n \n2) Nicole H\u00f6ttecke, Stefanie Baumann Bioforum  2008 , 6, 32-34.  \n\u201cAlzheimer-Demenz: Ein Pla(qu) e mit Hoffnung auf Besserung?\u201c \n \n3) Nicole H\u00f6ttecke, Stefanie Baumann, Ali Taghavi, Hannes A. Braun and Boris \nSchmidt, \u201cDrug Development and Diagnostics for Alzheimer's Disease Up to 2008\u201c, in Frontiers in Medicinal Chemistry Vol. 4, Ed.:  Atta-ur-Rahman, A.B. \nReitz, pp. 730-766, Bentham Books 2009 . \n \n4) Stefanie Baumann, Nicole H\u00f6ttecke, Robe rt Schubenel, Karlheinz Baumann, Boris \nSchmidt  Bioorg. Med. Chem. Lett.  2009 , 19, 6986-6990. \n\u201cNSAID-derived \uf067-secretase modulators. Part III: Membrane anchoring.\u201d \n \n5) Jessica Pruessmeyer, Christian Martin, Fr anz M. Hess, Nicole Schwarz, Sven \nSchmidt, Tanja Kogel, Nicole Hoettecke,  Boris Schmidt, Antonio Sechi, Stefan \nUhlig, Andreas Ludwig J. Biol. Chem.  Zur Publikation angenommen. \n(http://www.jbc.org/cgi/doi/10.1074/jbc.M109.059394) \u201cThe disintegrin and metalloproteina se 17 (ADAM17) mediates inflammation-\ninduced shedding of syndecan-1 a nd -4 by lung epithelial cells.\u201d \n \n6) Nicole H\u00f6ttecke, Andreas Ludwig, Sabine Foro, Boris Schmidt Neurodegener. \nDis., Zur Publikation angenommen: 09.12 .09. \u201cImproved synthesis of the \nADAM10 inhibitor GI254023X.\u201d \n \n7) Nicole H\u00f6ttecke, Matthias Gralle, Maria Angela C. Dani, Karlheinz Baumann, \nFred Wouters, Christian Czech, Boris Schmidt Nature Chem. Biol. , eingereicht. \n\u201cThe Modulation of A \uf062 production involves dimerization of APP.\u201d \n \n8) Nicole H\u00f6ttecke, Miriam Liebeck, Karl heinz Baumann, Robert Schubenel, Edith \nWinkler, Harald Steiner, Boris Schmidt ChemMedChem , eingereicht: 02.12.09. \n\u201cInhibition of \uf067-secretase by the CK1 inhibitor IC261 does not depend on CK1.\u201d \n \n9) Nicole H\u00f6ttecke, Andrea Zall, Daniel Ki eser, Eva Fuchs, Katrin Schneider, Dirk \nSteinbacher, Robert Schubenel, Karlheinz Baumann, Boris Schmidt J.Med.Chem ., \nwird im Januar 2010 einger eicht. \u201cNSAID-derived \uf067-secretase modulators: PartIV: \nThe isosteric replacement of a carboxylic acid on a carbazole scaffold.\u201d \n \n \n \n   \n \n   \n     Danken m\u00f6chte ich: \n \nProf. Dr. Boris Schmidt f\u00fcr die interessa nte Themenstellung, die Unterst\u00fctzung und \nHilfestellungen w\u00e4hrend dies er Arbeit. Die zahlreichen Hilfestellungen und die vielen \ninteressanten fachlichen Diskussionen konnten diese Arbeit erst erm\u00f6glichen. \n PD Dr. Andreas Ludwig f\u00fcr die Finanzier ung und Unterst\u00fctzung w\u00e4hrend der Synthese des \nADAM10 Inhibitors. Prof. Dr. Kolmar f\u00fcr die Bereitschaft als Korrefe rent zu fungieren. Und seiner Arbeitsgruppe \nf\u00fcr die gemessenen HPLCs  Dem BMBF, DFG, TU Darmstadt und RWTH Aach en f\u00fcr die Finanzierung dieser Arbeit. \n Meinen Kollegen Steffi, Daniel, Andrea, Thom as, Fabio, Alex, Estella, Azadeh und Ali die \nimmer ein offenes Ohr hatten und mir immer he lfend zur Seite gestanden haben. Ohne das \ngute Verh\u00e4ltnis w\u00e4ren es lange drei Jahre gewo rden. Meinen Studenten Mille, Katrin, Dirk, \nStefan und Norman f\u00fcr eine tolle und lustig e Zeit im Labor und deren guten Ergebnisse. \nMeinen Kooperationspartnern von Hoffmann- LaRoche Dr. Karlheinz Baumann und Dr. \nChristian Czech f\u00fcr die Beantwortung all mein er Fragen w\u00e4hrend meines Aufenthaltes in \nBasel und der Testung der Substanzen. Robert Schube nel f\u00fcr die tollen zwei Wochen in Basel \nund die Durchf\u00fchrung des Assays f\u00fcr all unsere Verbindungen. \n Der analytischen Abteilung der TU Darmstadt: Frau Rudolf und Frau Sahinalp f\u00fcr das schnelle Anfertigen der Massenspektren. \nDr. Meusinger, Herrn Runzheimer und Fr au Jungk f\u00fcr die schnelle Messung der NMR \nAuftr\u00e4ge. Frau Foro f\u00fcr die Durchf\u00fchrung und Auswert ung der R\u00f6ntgenstrukturanalyse sowie der \nBestimmung der Elementaranalysen.  \nMeiner Familie und Freunden f\u00fcr die imme rw\u00e4hrende Unterst\u00fctzung und Aufbauhilfen \nw\u00e4hrend dieser Zeit. Meinem Freund Uwe f\u00fcr die vielen gefahren en Kilometer w\u00e4hrend dieser Zeit. Seine \nuneingeschr\u00e4nkte Unterst\u00fctzung in jedem Bereich meines Lebens war mir immer eine wichtige St\u00fctze.   \n \n   \n           \n \n        \n iInhaltsverzeichnis: \n \nInhaltsverzeichnis i \nAbk\u00fcrzungsverzeichnis  iii \n  \n1 Einleitung 1 \n1.1  Alzheimer-Demenz 1 \n1.1.1  APP Metabolismus 3 1.2 \uf067-Sekretase 5 \n1.2.1 Inhibition der \uf067-Sekretase 9 \n1.2.1.1  Peptidische Inhibitoren 10 \n1.2.1.2  Semi-peptidische Inhibitoren 11 1.2.1.3  Nicht-peptidische Inhibitoren 13 1.2.2  Modulation der \uf067-Sekretase 16 \n1.2.2.1  Nichtsteroidale Antirheumatika 16 \n1.2.3  Vorarbeiten 18 1.3  ADAM10 19 1.3.1  Aufbau 19 1.3.1.1  Metalloproteinasen-Dom\u00e4ne 20 1.3.1.2  Disintegrin-Dom\u00e4ne 21 1.3.2  Funktion 22 1.3.3  Lokalisierung 22 1.3.4  Inhibition von ADAM10 23 \n2 Zielsetzung  25 \n3 Kumulativer Teil der Dissertation 27 \n3.1 Interessante Targets  in der Alzheimer-Demenz Forschung und Ans\u00e4tze \neiner Diagnostik f\u00fcr eine Fr\u00fcherkennung der Alzheimer-Demenz. 27 \n3.2 Die \uf067-Secretase als ein interessantes Target  f\u00fcr die Behandlung der \nAlzheimer-Demenz 57 \n3.3 Untersuchungen der Membrananker-Eigenschaften von \nNSAID-abgeleiteten \uf067-Sekretase Modulatoren 93 \n3.4 Untersuchung der Bindungstasche von NSAID-abgeleiteten \n\uf067-Sekretase-Modulatoren durch Deri vatisierung der Seitenkette und 127  \n  iiAustausch der Carbons\u00e4urefunk tion durch S\u00e4ureisostere  \n3.5 Untersuchungen zur Identifiz ierung der Bindungsstelle von \nNSAID-abgeleiteten \uf067-Sekretase-Modulatoren 155 \n3.6 Untersuchungen zum Einfluss der Casein Kinase 1 auf die \uf067-Sekretase 167 \n3.7 Synthese des selektiven ADAM10 Inhibitors GI254023X f\u00fcr \nUntersuchungen von Entz\u00fcndungsprozessen 179 \n4 Zusammenfassung  217 \n5 Ausblick 219 \n6 Literaturverzeichnis 221  \n iiiAbk\u00fcrzungsverzeichnis: \n \nA\uf062 amyloides- \uf062-Peptid \nAbb. Abbildung \nAChE Acetylcholinesterase Hemmer  \nAD Alzheimer-Demenz \nADAM A disintegrin and metalloproteinase protease \nAla, A Alanin Aph-1 anterior pharynx defective-1   \nAPP amyloides Vorl\u00e4uferprotein Arg, R Arginin \nAS Aminos\u00e4uren \nAsn, N Asparagin \nAsp, D Asparagins\u00e4ure \nBACE \n\uf062-site APP-cleavinge enzyme  \nbzw. beziehungsweise COX-1 Cyclooxygenase-1 \nCR Cystein reiche- Dom\u00e4ne  \nCSF cerebrospinal fluid   \nCT cytoplasmatische Dom\u00e4ne CTF C-Terminales-Fragment  \nCys, C Cystein \nd Tag \nDis Disintergrin-Dom\u00e4ne  \nED EGF- like- Dom\u00e4ne  \net al. Et alia \nFAD famili\u00e4re Alzheimer-Demenz  \nFDA Food and Drug Administration \nGln, Q Glutamin \nGlu, E Glutamins\u00e4ure \nGly, G Glycin \nGSI \uf067-Sekretase-Inhibitor \nGSM \uf067-Sekretase-Modulator \nh Stunde \nHEK Human Embryonic Kidney  \nHis, H Histidin HTS high-throughput-screening \nIC\n50 mittlere inhibitorische Konzentration \nIle, I Isoleucin \nkDa Kilodalton \nkg Kilogramm \nLeu, L Leucin \nLys, K Lysin \nMCT1 Monocarboxylat-Transporter 1  \n  iv Met, M Methionin \nmg Milligramm \nMMP Metalloproteinase \nMP Metalloproteinase- Dom\u00e4ne  \nNct Nicastrin \nNFTs Neurofibrill\u00e4re B\u00fcndel \nNGF Nervenwachstumsfaktor \nNMDA  N-Methyl-D-Aspartat  \nNSAIDs Nichtsteroidale Antirheumatika \nNTF N-terminales-Fragment  \nPDB Proteindatenbank \nPen-2 presenilin enhancer-2 \nPhe, F Phenylalanin PHF paired helical filament \nPro Propeptid-Dom\u00e4ne  Pro, P Prolin \nPS Pr\u00e4senilin \nrf refluxieren \nRIP Regulated Intra-membrane Proteolysis \nrt Raumtemperatur \nSAR Struktur-Aktivit\u00e4ts-Analyse \nSer, S Serin \nSPP Signalpeptidase \nSVMP snake venom  Metalloproteinase  \nTg transgen \nThr, T Threonin \nTMD Transmembran-Dom\u00e4ne  \nTNF\uf061 Tumornekrosefaktor- \uf061  \nTrp, W Tryptophan \nTyr, Y Tyrosin \nVal, V Valin \nx variable Aminos\u00e4ure \nz.B. zum Beispiel \nZn Zink \nZNS Zentrales Nervensystem \n\uf020\n  \n 11. Einleitung \n1.1 Alzheimer-Demenz \nDie Alzheimer-Demenz (AD) ist die am h\u00e4ufig sten vorkommende Form der Demenz und eine \nverheerende Krankheit, da si e den Betroffenen das Erin nerungsverm\u00f6gen raubt und mit \nstarken Pers\u00f6nlichkeitsver\u00e4nderungen verbund en ist. Die Alzheimerkrankheit wurde zum \nersten Mal 1906 von Alois Alzheimer als eine  \u201ekrankhafte Ver\u00e4nderung der Gehirnrinde\u201c \nbeschrieben. [1-3] In diesen Ver\u00e4nderungen wurden zw ei verschiedene Proteinablagerungen \nidentifiziert: extrazellul\u00e4re, am yloide Plaques und intrazellu l\u00e4re, neurofibrill\u00e4re B\u00fcndel \n(NFTs) (Abb. 1).  \nPlaque\nTanglea) b)\nPlaque\nTangle\nPlaque\nTanglea) b)\n \nAbb. 1: Histologische F\u00e4rbungen der a) extrazellul\u00e4ren  amyloiden Plaques und b) intrazellul\u00e4ren \nneurofibrill\u00e4ren B\u00fcndeln, welche als pathologische Ursache der Alzheimer-Demenz angesehen werden. Diese \nF\u00e4rbungen wurden in Kooperation mit dem Klinikum Darmstadt angefertigt. \n \nEin gro\u00dfes Problem stellt die Diagnose von AD da r, da es schwierig ist die Symptome von \n\u201enormaler\u201c Vergesslichkeit \u00e4lterer Menschen  zu unterscheiden. Zuverl\u00e4ssig kann die \nDiagnose Alzheimer-Demenz erst bei einer Autops ie best\u00e4tigt werden durch die AD-typische \nHirnatrophie und histologischem Nachweis der Plaques und NFTs in der Hirnregion \nAmmonshorn. Ist die Diagnose gest ellt, gibt es verschiedene  Ans\u00e4tze f\u00fcr eine Behandlung, \nwelche jedoch nur die Symptome verbessern, aber nicht die Krankheit selbst heilen k\u00f6nnen. \nVerschiedene Wirkstoffklassen werden derz eit auf ihre Wirksamkeit zur Behandlung von AD \nuntersucht, wie zum Beispiel  Acetylcholinesterase-He mmer (AChE), Agonisten der \nnikotinergen und muskarinergen Rezeptore n, Antioxidantien, Aktivatoren des \nNeurotrophin-Signalweges, sowie die Verabrei chung des Nervenwachstumsfaktors (NGF). \nEbenso werden entz\u00fcndungshemmende Medi kamente wie Cyclooxygenase-1 (COX-1) oder \nCOX-2 Inhibitoren untersucht, da Entz \u00fcndungsvorg\u00e4nge im Gehirn von AD-Patienten \nbeobachtet werden. Aus dem gro\u00dfen Forschungsinte resse resultieren weltweit bisher etwa 50 \nWirkstoffkandidaten f\u00fcr die AD-Therapie und \u00fcber 500 f\u00fcr Neurodegenerative Erkrankungen \nim Allgemeinen. Verschiedene Wirkstoffe befinde n sich derzeit im fortgeschrittenen Stadium  \n 2 der Entwicklung, wie z.B. AChE Inhibitoren, NMDA ( N-Methyl-D-Aspartat) \nRezeptor-Antagonisten oder Serotonin-Rezeptor-A gonisten. Au\u00dferdem gibt  es verschiedene \nAns\u00e4tze zur Immunisierung (z.B. Elan,  Cytos Biotechnology ).[4] Bis 2001 wurde die Bildung \nvon Plaques als die wichtigste Ursache von AD angesehen und somit war bis zu diesem Zeitpunkt deren Reduktion das Hauptziel in der AD-Forschung. Heute werden jedoch zum \neinen aus Tau Protein bestehende paired helical filaments  (PHFs) und zum anderen l\u00f6sliches \nA\uf062 (amyloides- \uf062-Peptid) und deren fr\u00fchen O ligomere als pathologisch e Ursache angesehen. \nDurch die Gabe von AChE Inhi bitoren wie Galantamin ( 1), Tacrin ( 2), Donepezil ( 3) oder \nRivastigmin ( 4) wurden leichte Verbesserungen der kognitiven F\u00e4higkeiten von Patienten in \neinem fr\u00fchen Stadium von AD beobachtet (Abb. 1) . Diese Inhibitoren ve rhindern den Abbau \ndes Neurotransmitters Acetylcholin, welcher be i Alzheimer-Patienten nicht mehr gebildet \nwird. Durch den Acetylcholin-Mangel wird die \u00dcbermittelung von Informationen im Gehirn zun\u00e4chst nur verringert, aber letzten Endes ganz verhindert, was zu einem Absterben der \nZellen durch programmierten Zelltod (Apoptose) f\u00fchrt und es resultiert eine AD typische \nGehirnatrophie. Die Therapie mit AChE Inhibi toren kann jedoch nur die Symptome im fr\u00fchen \nStadium der Krankheit verringern, die Kr ankheit selbst jedoch nicht heilen.  \nDer NMDA-Rezeptor-Antagonist Memantin ( 5) l\u00e4sst den Eintritt von Ionen in die Zelle \nwieder zu und hebt somit die sch\u00e4dliche Wirkung des Neurotransmitters Glutamat auf, welche zum Absterben von Nervenzelle n f\u00fchrt (Abb. 2). Verbindung 5 wurde als erstes Medikament \nseiner Klasse f\u00fcr mittlere bis schwere F\u00e4lle von AD im Jahre 2002 zugelassen. Aber nichts \ndesto trotz gibt es noch kein Medikament, welches AD heilen kann. \n \nNOO\nH\nHO\n1 GalantaminNNH2\n2 TacrinN O\nOO\n3 Donezepil\nN\nO NO\nH\n4 Rivastigmin 5 MemantinNH2\n \nAbb. 2:  Wirkstoffe, die derzeit f\u00fcr eine symptomatische Behandlung der Alzheimer-Demenz angewendet \nwerden.  \n 31.1.1 APP Metabolismus \nDie Plaques bestehen aus dem amyloiden- \uf062-Peptid (A \uf062), welches durch einen \u201efalschen\u201c \nAbbau des membranst\u00e4ndigen, amyloiden Vorl\u00e4uferproteins (APP) gebildet wird. APP kann \nauf zwei verschiedenen Wegen abgeba ut werden: 1) \u00fcber den \u201enormalen\u201c, \nnicht-amyloidogenen Weg und 2) \u00fcber den am yloidogenen Weg, welcher f\u00fcr die Bildung des \npathogenen A \uf062 verantwortlich ist. (Abb. 3)  \nsAPP\uf061\nsAPP\uf062\np3\nA\uf062\n\uf067-Sekretase \uf067-Sekretase \uf061-Sekretase \uf062-Sekretase\nC83 APP C99\nnicht-amyloidogene Weg amyloidogene WegPlaques\nsAPP\uf061\nsAPP\uf062\np3\nA\uf062\n\uf067-Sekretase \uf067-Sekretase \uf061-Sekretase \uf062-Sekretase\nC83 APP C99\nnicht-amyloidogene Weg amyloidogene WegPlaques\n \nAbb. 3 Abbau des Transmembranproteins APP durch \uf062- und \uf067-Sekretase f\u00fchrt zu amyloiden Plaques.  \n \nBei dem nicht-amyloidogenen Weg, der bei ge sunden Menschen einen Anteil von etwa 90% \nausmacht, wird APP zun\u00e4chst von der \uf061-Sekretase, einer membrangebundenen \nMetalloprotease, in der A \uf062-Sequenz geschnitten, was zu dem l\u00f6slichen Fragment sAPP \uf061 und \ndem membrangebundenen Fragment C83 f\u00fchrt.[5] Bei anschlie\u00dfender Spaltung von C83 durch \ndie \uf067-Sekretase, einer membrangebundenen Aspartylpr otease, wird das ni cht zur Aggregation \nneigende Peptid p3 freigesetzt. Wi rd APP jedoch sequentiell von den beiden \nAspartylproteasen \uf062- und \uf067-Sekretase abgebaut, dann  entsteht pathogenes A \uf062. Die \n\uf062-Sekretase ( \uf062-site APP-cleavinge enzyme  oder BACE-1) generier t ein extrazellul\u00e4res \nFragment (sAPP \uf062) und ein intrazellul\u00e4res, membrangebund enes Fragment C99, aus dem nach \nSpaltung durch die \uf067-Sekretase A \uf062-Peptide unterschiedlicher L\u00e4nge  entstehen. Die h\u00e4ufigsten \nA\uf062-Peptide sind A \uf06238, A\uf06240 und A\uf06242, welche aus 38, 40 bzw. 42 Aminos\u00e4uren (AS) \nbestehen.[6] F\u00fcr die Aggregation gilt: je l\u00e4nger ein A \uf062-Fragment ist, desto besser und schneller \nkann es sich zusammenlagern. Hierbei werd en besonders die fr\u00fchen Oligomere von \naggregiertem A \uf062 als pathologische Ursache angesehen, woraus folgt, dass die Bildung von \nA\uf06238 eher unbedenklich und A \uf06242 toxisch ist. Um die Entstehung von A \uf062 zu verhindern, \nk\u00f6nnte nun z.B. die \uf061-Sekretase aktiviert oder die \uf062- bzw. \uf067-Sekretase inhibiert werden. Da  \n 4 die \uf061-Sekretase bei diversen Entz\u00fcndungsmechanis men eine wichtige Rolle spielt, ist eine \nAktivierung mit Risiken behaftet. Die \uf062-Sekretase (\uf062-site APP-cleaving enzyme , BACE) \nexistiert in zwei Isoformen BACE-1 und 2, welc he eine wichtige Rolle in der Myelinisierung \nvon Nervenzellen \u00fcbernehmen,[3] die jedoch in AD-Patienten weitgehend abgeschlossen ist. \nBisher konnten aber nur wenige oral verf\u00fcgba re und damit f\u00fcr klinische Studien geeignete \nInhibitoren erhalten werden. Auch  eine vollst\u00e4ndige Inhibition der \uf067-Sekretase w\u00fcrde, \u00e4hnlich \nwie bei BACE, unerw\u00fcnschte Nebenwirkungen verursachen. Neben APP spaltet die \n\uf067-Sekretase n\u00e4mlich weitere Transmembranprot eine vom Typ-1 wie Notch, welches f\u00fcr die \nZellproliferation und -differenz ierung notwendig ist, sowie E- und N-Cadherin, CD44, ErbB4, \nLRP und Nectin-1.[7] Diese unerw\u00fcnschte Totalinhibition ka nn jedoch durch eine allosterische \nRegulation umgangen werden. So genannte \uf067-Sekretase-Modulatoren (GSM) regulieren den \nAPP-Metabolismus derart, dass vermehrt A \uf06238 und weniger pathologisches A \uf06242 gebildet \nwird. Aus diesem Grund ist die Modulation der \uf067-Sekretase ein interessantes Ziel in der \nTherapie der Alzheimer-Demenz.   \n 51.2\uf020\uf067-Sekretase \nDie \uf067-Sekretase ist ein membranst\u00e4ndiger En zymkomplex, der aus vier Proteinen \nzusammengesetzt ist: Pr\u00e4senilin (PS), Nicastrin (Nct), anterior pharynx defective-1  (Aph-1) \nund presenilin enhancer-2 (Pen-2).[8] (Abb. 4) Jedes dieser Prot eine in dem Enzymkomplex \nist f\u00fcr die Aktivit\u00e4t notwenig, da nur de r komplette Enzymkomplex Aktivit\u00e4t zeigt.  \n123456 789\nPS-NTFPS-CTF\nAsp AspAph-1\nPen-2 Nct123456 789\nPS-NTFPS-CTF\nAsp AspAph-1\nPen-2 Nct\n \nAbb. 4:  Der membrangebundene Enzymkomplex der \uf067-Sekretase besteht in de r aktiven Form  aus vier \nUntereinheiten, welche alle f\u00fcr die Aktivit\u00e4t des Enzyms wichtig sind. \n \nDie beiden Pr\u00e4seniline (PS1 und PS2 ) kontrollieren die Aktivit\u00e4t der \uf067-Sekretase und \nMutationen in den codierenden Genen auf Chro mosom 14 bzw. 1 f\u00fchren zu famili\u00e4ren, d.h. \nvererbbaren Formen der AD (FAD). Die \uf067-Sekretase Aktivit\u00e4t hingegen beruht zum gr\u00f6\u00dften \nTeil auf der Aktivit\u00e4t von PS1.[9-10] Diese membranst\u00e4ndige Aspa rtylprotease besteht aus 9 \nTransmembrandom\u00e4nen (TMD) und zwei Aspart aten, welche als katalytisches Homodimer \nagieren und sich auf den Transmembrandom\u00e4nen 6 (Asp257) und 7 (Asp385) befinden.[11-12] \nMutationen dieser beiden AS in M\u00e4usen hatten einen kompletten Aktivit\u00e4tsverlust der \n\uf067-Sekretase zur Folge.[13] Obwohl PS f\u00fcr die Aktivit\u00e4t der \uf067-Sekretase verantwortlich ist, \nf\u00fchrte eine \u00dcberexpression von PS zu keinem  erh\u00f6hten Level der Spaltprodukte NTF bzw. \nCTF ( N-terminale bzw. C-terminale Fragmente), di e f\u00fcr die Aktivit\u00e4t der \uf067-Sekretase \nnotwendig sind.[14] Es muss somit eine Aktivierung von de m, als Holoprotein vorliegenden PS \ndurch zus\u00e4tzliche Untereinheiten (Nct, Aph- 1, Pen-2) erfolgen, die Endoproteolyse. Diese \nwird durch einen Schnitt in dem gro\u00dfen cytoplasmatischen Loop zwischen TMD 6 und 7 ausgef\u00fchrt, was zu dem aktiven Homodimer f\u00fchrt: einem 30 kDa gro\u00dfen NTF und einem \n20 kDa gro\u00dfen CTF.\n[15] Das Verh\u00e4ltnis der Untereinhe iten wurde durch F\u00e4llung und \nanschlie\u00dfenden massenspektroskopischen Un tersuchungen mit 1:1:1:1 bestimmt (Abb. 4).[16] \nNct wurde als erstes Protein aus dem \uf067-Sekretase-Komplex identifiziert.[17] Es ist ein gro\u00dfes \nTyp-1 Transmembranprotein (130 kDa), welches in einer \u201ereife n\u201c und einer \u201eunreifen\u201c Form  \n 6 vorliegen kann, die sich durch den Gr ad der Glykosylierung unterscheiden.[18] Nct besitzt eine \ngro\u00dfe extrazellul\u00e4re N-terminale und eine kleine intrazellul\u00e4re C-terminale Dom\u00e4ne. In ihrer \nnur teilweise glykosylierten, \u201e unreifen\u201c Form kann Nct an das PS-Holoprotein binden und \nunterst\u00fctzt deren sp\u00e4tere Endoproteo lyse und ist somit wichtig f\u00fcr die \uf067-Sekretase \nAktivit\u00e4t.[19-20] Die gro\u00dfe extrazellul\u00e4re Dom\u00e4ne ist f\u00fcr die Substraterkennung sowie f\u00fcr den \nSubstrateintritt in den Komp lex notwendig, indem es mit dem N-Terminus des Substrats \ninteragiert.[19]  \nAph-1, ein 30 kDa gro\u00dfes Protein mit 7-Transm embranen-Dom\u00e4nen, welches mit Nct einen \nSubkomplex bildet, ist f\u00fcr die Stabilis ierung des PS-Holoproteins notwendig.[19, 21-22]  \nPen-2, ein zwei Membrandom\u00e4nenprotein mit 101 AS, ist f\u00fcr die Stabilit\u00e4t des PS-Nct \nSubkomplexes verantwortlich.[23] Seine C-terminale Dom\u00e4ne induziert die Entstehung des \nkatalytisch aktiven PS Homodime rs, die Endoproteolyse, und st abilisiert anschlie\u00dfend die \nbeiden entstehenden Fragmente (PS-NTF and PS-CTF).[19, 24] \nDer Mechanismus f\u00fcr die Zusammenlagerung des \uf067-Sekretase-Komplexes wurde von Zhou et \nal. durch das folgende Modell vorgeschlagen: Zuerst formt das \u201eunreife\u201c Nicastrin einen \nUnterkomplex mit Aph-1 welcher in das endo plasmatische Retikulum eintreten soll. Dort \nwird ein dreigliedriger \u00dcbergangszustand mi t dem PS-Holoprotein gebildet. In diesem \n\u00dcbergangszustand wird Nct vollst\u00e4ndig glykosylie rt und gelangt in den Golgi-Apparat. Beim \nEintritt von Pen-2 in den Komplex wird di e Endoproteolyse von PS in duziert wodurch der \naktive \uf067-Sekretase-Komplex vorliegt.[19] Durch die Endoproteoly se liegt das PS als \nkatalytisches Homodimer in Form des NTF un d des CTFs vor, welches je ein katalytisch \naktives Aspartat tr\u00e4gt. Der Spaltungsmechanismus der \uf067-Sekretase ist identisch mit dem jeder \nanderen Aspartylprotease (Abb. 5).[25]  \n \nN\nHH\nNP1\nO P1\u00b4O\nHOH\nO O\nAspO O\nAspN\nHH\nNP1\nP1\u00b4O\nOO\nO O\nAspO O\nAspH\nHNHH2NP1\nO P1\u00b4O\nOH+\nH H\nO O\nAspHO O\nAsp\n \nAbb. 5: Spaltungsmechanismus einer Aspartylprotease. \n \nEine Besonderheit dieses Spalt ungsmechanismus ist das Verm\u00f6gen der \uf067-Sekretase das \nSubstrat APP in der hydrophoben und daher wa sserarmen Membran zu spalten, ein Vorgang \nder jedoch Wasser ben\u00f6tigt.[26] Dieser Mechanismus wird \u201e Regulated Intra-membrane  \n 7Proteolysis \u201c (RIP) genannt und ben\u00f6tigt einen Tr ansport von Wassermolek\u00fclen in die \nhydrophobe Membran, in der wenig Wasser verf\u00fcgbar ist.[27] Damit die Spaltung auch in der \nMembran stattfinden kann scheint im Inneren des Komplexes eine hydrophile aktive Tasche \nvorzuliegen, die das Wasser f\u00fcr die Sp altung des Substrates bereith\u00e4lt.[26, 28] \nEs wurden noch weitere Proteine identifiziert die mit dem aktiven \uf067-Sekretase Komplex \nassoziiert sind, wie z.B. CD147, das einen regulativen Effekt auf die \uf067-Sekretase zu haben \nscheint. Weitere Bindungspa rtner wurden durch Aufreinigung entdeckt, wie GSK-3, \nPhospholipase D1 und TMP21.[19, 29] \nDa verschieden lange A \uf062-Peptide gebildet werden, scheint die \uf067-Sekretase keine spezielle \nSequenz f\u00fcr die Spaltung des Substrates APP zu besitzen. F\u00fcr das Auftreten der \nverschiedenen A \uf062 Spezies wurde von Lichtenthaler et al.  ein Modell postuliert, in dem das \nSubstrat in \uf061-helicaler Kornformation gespalten wird.[30] Die Windung einer \uf061-Helix setzt \nsich aus 3.6 Aminos\u00e4uren (AS) zusammen, was zur Folge hat, dass sich die AS 40, 43, 46 und \n49 auf der einen Seite der \uf061-Helix befinden und 42, 45 und 48 auf der gegen\u00fcberliegenden \nSeite. Abh\u00e4ngig von der Orientierung des Substr ates zu dem katalytischen Zentrums des \nEnzyms entstehen die verschiedenen A \uf062 Spezies. Das Auftreten von A \uf06238 zusammen mit \nA\uf06242 l\u00e4sst sich durch die Windung in einer \uf061-Helix von 3.6 AS erkl\u00e4ren, wobei hier zum \nAusgleich erst nach der vierten AS ge schnitten wird. Am h\u00e4ufigsten werden A \uf06238, A\uf06240 und \nA\uf06242 gebildet, wobei A \uf06242, welches in Zellen einen Anteil von 5 bis 10% ausmacht, das \ntoxischste ist, da es am meisten zu der Aggr egation zu Plaques neigt. Es werden auch A \uf062 \nSpezies mit 19, 37, 39 sowie 43 bis 48 AS gebild et, jedoch in so geringem Ma\u00dfe, dass sie \nkeine Rolle in der Pathologie von AD spielen.[31] Es gibt aber bislang keine Pr\u00e4zedenzf\u00e4lle f\u00fcr \ndie Spaltung \uf061-helicaler Substrate durch Aspartyl-Proteasen. \nMulthaup et al.  beschrieb 2007 einen neuartigen Mech anismus, welcher die Entstehung der \nverschiedenen A \uf062-Spezies erkl\u00e4rt. Sie beschriebe n, dass zwei APP-Proteine eine \nDimerisierung \u00fcber die AS Gly29 und Gly32, ein GxxxG-Motiv, eingehen und dass diese \nsterische Barriere die Spaltung durch die \uf067-Sekretase zu dem unerw \u00fcnschten, pathologischen \nA\uf06242 hin verschiebt (Abb. 6).[32]  \n  \n 8 \nGA\nI\nIGGA\nI\nIGK KN N\nLM\nGV\nG\nVV\nI\nTA\nVIV\nI\nT\nL\nMLVV\nG\nGV\nVML\nI\nA\nVIT\nV\nI\nTL\nV\nM\nL\nG29\nG33\n37\n38\n\uf06740\n\uf06742\n\uf07a46\n\uf06549\nPresenilin\nAA\nI\nIAAA\nI\nIAK KN N\nLM\nGV\nG\nVV\nI\nAVG\nGVVML\nI\nA\n37\n38\n\uf06740\n\uf0674234\n35\nPresenilin\nGA\nI\nIGGA\nI\nIGK KN N\nLM\nGV\nG\nVV\nI\nTA\nVIV\nI\nT\nL\nMLVV\nG\nGV\nVML\nI\nA\nVIT\nV\nI\nTL\nV\nM\nL\nG29\nG33\n37\n38\n\uf06740\n\uf06742\n\uf07a46\n\uf06549\nPresenilin\nAA\nI\nIAAA\nI\nIAK KN N\nLM\nGV\nG\nVV\nI\nAVG\nGVVML\nI\nA\n37\n38\n\uf06740\n\uf0674234\n35\nPresenilin\n \nAbb. 6  Dimerisierung des Substrates \u00fcber das von Multhaup et al. beschriebene GxxxG-Motiv. \n \nMutationen der beiden Glycine zu Aspara gin, G29A und G32A, zeigten wieder einen \n\u201enormalen\u201c Abbau von APP zu A \uf06238, wo hingegen der Austausch durch Isoleucin oder \nLeucin zu einer drastisc hen Verringerung von dem A \uf062total f\u00fchrt.[33] Es wird vermutet, dass die \nA\uf062-Produktion an die Dimerisierung von C99 ge koppelt ist (Abb. 7). Auch Notch tr\u00e4gt ein \nsolches GxxxG-Motiv, jedoch kann Notch auch als Monomer umgesetzt werden.[34] \n \nC99\nDimer\nAsp Asp\nPen-2PS-NTFPS-CTFAph-1\nNctC99\nDimerC99\nDimer\nAspAsp AspAsp\nPen-2PS-NTFPS-CTFAph-1\nNct Pen-2PS-NTFPS-CTFAph-1\nNct \nAbb. 7 Schematischer Aufbau des \uf067-Sekretase-Komplexes und des Substrates C99, welches als Dimer gespalten \nwird. \n  \n 91.2.1 Inhibition der \uf067-Sekretase \nEine Inhibition der \uf067-Sekretase hat eine Reduktion aller A \uf062-Spezies zur Folge, wodurch AD \nverhindert werden k\u00f6nnte. Eine solche vo llst\u00e4ndige Inhibition w\u00fcrde aber auch die \nSpaltungsrate der anderen Substrate mit wich tigen neuronalen Eigenschaften verringern. Die \n\uf067-Sekretase scheint durch die gro\u00dfe Anzahl an Substraten das \u201eProteasom der Membran\u201c zu \nsein, wodurch das Risiko von unerw\u00fcnschten Ne benwirkungen bei der In hibition deutlich \nerh\u00f6ht wird.[35] Insbesondere ein Eingriff in den St offwechselweg von Notch, welches f\u00fcr die \nembryonale Entwicklung und die Zelldiffe renzierung wichtig ist, lassen die \uf067-Sekretase zu \neinem anspruchsvollen und schwierigen Target f\u00fcr die AD Behandlung werden. Dies wird \nverdeutlicht durch die Tatsache, dass sich PS -/- Knockout-M\u00e4use nicht \u00fcber den Status eines \nEmbryos hinaus entwickelt haben, was jedoch durch einen Einsatz von embryonalen \nStammzellen behoben werden konnte.[36] Der intrazellul\u00e4re Transport von Notch in die \nNeuronen des menschlichen ZNS (Zentrales Ne rvensystem) wird durch eine PS-Inhibition \ndeutlich gesenkt, was zu Einbu\u00dfen in der ne uronalen Morphologie f\u00fchrt. Diese Probleme \nk\u00f6nnen von Wirkstoffen mit einem gro\u00dfen therap eutischen Fenster (d em Verh\u00e4ltnis der \ntherapeutischen Dosi s, d.h. das Ma\u00df der \uf067-Sekretase Inhibition im Vergleich zu der toxischen \nDosis, in diesem Falle der Notch-Inhibiton) umgangen werden.[37] Falls dieses zu klein sein \nsollte k\u00f6nnten diese Wirkstoffe jedoch noch Anwendungsgebiete in der Tumortherapie und bei Bluthochdruck finden. Neuesten Unters uchungen zur Folge w\u00fcrde aber schon eine \n30%ige Reduktion der A \uf062-Sekretion eine kognitive Beeintr\u00e4chtigung verbessern,\n[38-39] wobei \nauch eine bis zu 15%ige Inhibition von Notch ohne Nebenwirkungen verlaufen w\u00fcrde.[36, 39] \nIn den letzten Jahren wurde allerdings der Forschungsschwerpunkt von der Inhibition zu der \nModulation der \uf067-Sekretase gerichtet. Ein Modulator ver\u00e4ndert nur den APP Schnitt der \n\uf067-Sekretase, um mehr erw\u00fcnschtes A \uf06238 und weniger toxisches A \uf06242 zu generieren, ohne die \nSpaltung der anderen Substrate zu beeinflussen.  \nF\u00fcr die Inhibitoren- bzw. Modulatorenentwickl ung w\u00e4re eine R\u00f6ntgenkristallstrukturanalyse \ndes Enzyms n\u00fctzlich, da sie das strukturbasier te Wirkstoffdesign erm\u00f6glichen w\u00fcrde. Es \ngelang bislang nicht den Komple x zu kristallisieren aufgru nd der Membranlokalisation des \n\uf067-Sekretase-Komplexes sowie der notwendigen Li pidstabilisierung. Allerdings existiert eine \nCryoelektronen-mikroskopisc he Aufnahme von der \uf067-Sekretase mit einer Aufl\u00f6sung von \n12\u01fa.[39-41] Diese weist auf verschiedene, kleine  Vertiefungen in der Oberfl\u00e4che des \nKomplexes zu sowohl der cytosolischen als au ch der extrazellul\u00e4ren Seite der Membran hin, \nbei ansonsten gleichm\u00e4\u00dfiger Oberfl\u00e4che. Diese Vertiefungen k\u00f6nnen im Rahmen der \nMessgenauigkeit als Hohlr\u00e4ume gedeutet  werden durch die die entstehenden  \n 10 Spaltungsprodukte den Komplex verlassen k\u00f6nne n. Eine gro\u00dfe Einh\u00f6hlung wird als laterale \nEintrittsstelle des Substrates spekuliert.[40-41]  \nDie meisten selektiven \uf067-Sekretase Inhibitoren (GSIs) wurden durch \nHochdurchsatz-Screenings ( high-throughput-screening , HTS) identifiziert.[42-43] Es wurden \nbereits verschiedene Mechanisme n f\u00fcr die Inhibition beschrieben.[44] Die meisten GSI binden \ndirekt an das aktive Zentrum oder ver\u00e4ndern dieses durch allosterische Wechselwirkungen.[45] \nDie Bindungsstelle der Sulfona mid abgeleiteten GSIs wurde auf PS1 an den AS Lys172, Tyr281 \nund Lys282 identifiziert.[46] Manche Inhibitoren wirken gar nicht direkt auf die \uf067-Sekretase \nsondern die Inhibition ist nur eine Begleiterscheinung, wi e z.B. bei der Stoffklasse der \nIsocumarine. Ebenso k\u00f6nnen Inhibitore n der Signalpeptidase (SPP) auch die \uf067-Sekretase \ninhibieren, welche ein \u00e4hnliches aktiv es Zentrum wie SPP zu haben scheint.[47] \n \n1.2.1.1 Peptidische Inhibitoren \nDie Entwicklung von GSIs begann mit peptidis chen PS1 Inhibitore n wie Mercks L-685,458 \n(6), welcher die \uf067-Sekretase mit einem IC 50 von 17 nM inhibiert (Abb. 8).[48] Aufgrund der \nlipophilen Phenylalanine in der Sequenz von 6 wurde das Vorhandensein einer lipophile \nBindungstasche (P2, P1, P1\u00b4, P2\u00b4, P4\u00b4 und P7\u00b4) in der N\u00e4he der Schnittstelle angenommen \nund sp\u00e4ter durch verschiedene Studien auch belegt.[30] Dieser Befund deutet darauf hin, dass 6 \nals ein \u00dcbergangszustandsanalogon der A \uf06240- und A\uf06242-Schnittstelle agiert. (Abb. 8) Durch \nBiotinylierung ( 6) mit anschlie\u00dfender Photolyse in der Gegenwart von l\u00f6slicher \uf067-Sekretase \nwurde ein 20 kDa gro\u00dfes Fragment mit L-852,505 ( 7) ermittelt, welches durch \nAntik\u00f6rper-Nachweis als PS1-CTF identifizie rt werden konnte. Photolyse von L-852,646 ( 8), \nein Benzophenon-substituiertes L-852,505 Derivat,  lieferte interessanterweise das 34 kDa \ngro\u00dfe PS1-NTF, was darauf hindeutet, dass 7 sowohl mit dem PS-NTF als auch dem PS-CTF \ninteragiert. Ein \u00e4hnlicher \u00dcbergangszustandsinhibitor III-31-C ( 9), basierend auf einem \nHydroxyethylharnstoff-Motiv, zeigt eine Aktivit\u00e4t <300 nM.\n[49] Durch Immobilisierung von 9 \ngelang eine Isolierung und Identifizierung der \uf067-Sekretase Untereinheiten PS-CTF, PS-NTF \nsowie Nicastrin. Dieses gelang jedoch nur mit dem isolierten Komplex und konnte mit der \naktiven Form nicht reproduziert werden. M it der Hilfe von Brij -35 und dem Detergenz \nCHAPSO gelang eine Isolierung de s aktiven Komplexes, welcher in seiner inhibierten Form \nerfolgreich zusammen mit seinen Substraten C83 und C99 gef\u00e4llt werden konnte. Dieses lie\u00df \nauf weitere Inhibitor-Bindungsstel len schlie\u00dfen, welche sich nicht mit dem aktiven Zentrum \n\u00fcberschneiden.  \n 11 \nOH\nNHN\nN\nHNH2\nOOH\nOO\nO\n6 L-685,458\n7 L-852,505: R = O tBu\n8 L-852-646: R = BenzophenonRH\nNHN\nN\nHH\nN\nOOH\nOO\nOHN\nOS\nHNNH\nOOH\nN N\nOOHHN\nON\nHO\nO\nO\n9 III-31-C\n \nAbb. 8: Peptidische \uf067-Sekretase-Inhibitoren. \n \n1.2.1.2 Semi-peptidische Inhibitoren \nEine Struktur-Aktivit\u00e4ts-Analy se des viel versprechenden N-Dichlorphenylalanin-\nGrundger\u00fcstes identifizierte den semi-peptidischen Inhibitor DAPT ( 10). (Abb. 9) F\u00fcr dessen \nAktivit\u00e4t (IC 50 = 20 nM, in HEK Zellen) ist sowohl da s Difluorbenzylessigs \u00e4ure- als auch das \nPhenylglycin-Motiv verantwortlich.[50-51] 10 zeigte eine hohe Effizienz in vivo  nach 3h bei \neiner Dosis von 100 mg/kg, sowohl bei subkutaner (50% A \uf062Kortikal -Reduktion) als auch bei \noraler (40% A \uf062Kortikal -Reduktion) Verabreichung.[52] Ein Nachteil ist, dass DAPT die \nBlut-Hirn-Schranke nicht \u00fcberwinden kann, was f\u00fcr die Behandlung einer Erkrankung des \nzentralen Nervensystems (ZNS) als notwendig erachtet wird.[53-55] Tats\u00e4chlich wurden im \nHirn von M\u00e4usen keine DAPT-Konzentration de tektiert. \u00dcberraschenderweise konnte aber \nein Absetzph\u00e4nomen (Rebound-Effekt) beobach tet werden, dessen Ursache bisher nicht \neindeutig erkl\u00e4rt werden konnte. In einer vo rklinischen Studie wurde zus\u00e4tzlich eine in \nvivo-Toxizit\u00e4t ermittelt, was auf das Eingreifen in  den Notch Signalweg zur\u00fcckzuf\u00fchren ist. \n10 inhibiert den Notch-Signalweg sogar um  das 100-1000-fache selektiver als den \nAPP-Abbau, wodurch eine klinische Studie unm\u00f6glich wurde. Durch Derivatisierung des \nDAPT-Grundger\u00fcstes (Einf\u00fchren eines rotatio nsgehinderten Caprolac tam Ger\u00fcstes sowie \neiner stereoselektiven Einf\u00fchrung einer Hy droxylgruppe) wurde de r potente Inhibitor \nLY-411575 ( 11) bei in vivo  Untersuchungen identifiziert. 11 zeigte eine 20-fach gesteigerte \nAktivit\u00e4t gegen\u00fcber DAPT mit einem IC 50< 1 nM. Nach oraler Verabreichung des weniger \npotenten Diastereomers wurde bei einer Dosis von 1 mg/kg eine  Halbierung des A \uf062Kortikal -  \n 12 und A\uf062Plasma -Levels nach 3h in Tg2576 M\u00e4usen beobachtet.[56] Die Selektivit\u00e4t von 11 \nbez\u00fcglich des APP Abbaus (IC 50 (A\uf06240) = 0.082 nM) und des Notch Abbaus (IC 50 = 0.39 nM) \nl\u00e4sst auf ein kleines therapeutisches Fenster schlie\u00dfen, was eine klinische Studie dieser \nStoffklasse eigentlich ausschlie\u00dft. Eine 15-t\u00e4gige Studie von dem weniger potenten \nLY 450139  (12), welches aber eine geringf\u00fcgig verb esserte APP-Selektivit\u00e4t zeigt, in \nC57BL/6 und TgCRND8 APP \u00fcberexprimierenden M\u00e4usen bei einer Dosis von 1-10 mg/kg/d \nzeigte eine A \uf062-Reduktion, jedoch wurden als Nebenw irkungen die R\u00fcckbildung des Thymus \nund des Darmepithels beobachtet.[57] Trotz des kleinen therap eutischen Fensters und der \nbeobachteten Nebenwirkungen wurde 12 in einer klinischen Studie getestet. In der Studie IIb, \nan der sich 51 AD Patienten beteiligte n, wurden verschiedene Nebenwirkungen, wie \nD\u00fcnndarmverschluss, blutiger Stuhl und Durchfa ll beobachtet. Am Ende  dieser Studie konnte \nin keiner der Gruppen eine kognitive oder f unktionale Verbesserung festgestellt werden.[58] \n \n10 DAPT LY374973 \nIC50 = 20 nMOH\nNO\nN\nHOO\nFF\nOHNO\nN\nH\nFFOH\nN\nO\n11 LY 411575 \nIC50 < 1 nM\n12 LY450139OH\nNO\nN\nHN\nOHO\nOH\nNO\nN\nH\nFFNN\nO\n13 Compound E \nIC50 = 0.3 nM \nAbb. 9: Semipeptidische \uf067-Sekretase-Inhibitoren. \n \nTrotz gro\u00dfem Forschungsaufwand bl eibt der Inhibitionsmechanis mus dieser Stoffklasse noch \nunklar. Unter anderem wurden auch  Photoaffinit\u00e4tsuntersuchungen mit cross-linking  \nEinheiten wie z.B. Benzophenon, Ph enyldiazerin und Biotin an 10, 11 und der potenten \nVerbindung Compound E ( 13) durchgef\u00fchrt. Diese reduzierten die A \uf062-Sekretion stark und \nzeigten eine N\u00e4he zum aktiven Zentrum der \uf067-Sekretase; 10 markierte hierbei das PS-CTF im \nGegensatz zu 11 und 13, welche eher an das PS-NTF binden. Ein kompetitiver Assay von \nDAPT mit 11 bzw. 13 zeigte jedoch dass die beiden  Bindungsstellen sich \u00fcberlappen. \nAnscheinend ist der C-terminale Teil von 11/13 f\u00fcr die Erkennung der Bindungsstelle \nverantwortlich. Ein weiterer Unterschied ist, dass 11/13 ebenso die membranst\u00e4ndige  \n 13Signalpeptidase (SPP) beei nflussen, welche gro\u00df e \u00c4hnlichkeiten mit der \uf067-Sekretase hat, im \nGegensatz zu 10.  \nIn einem spekulativen Mechanismus wi rd vermutet, dass die PS-Bindungstasche \ndipeptidische Inhibitoren bindet, welche Difluorbenz ol-, Phenylglycin- oder \nCaprolactam-Motive tragen, wobei das Caprolactam-Motiv wohl eher  selektiv f\u00fcr die SPP ist. \nZuerst scheinen diese Substanzen an die Di fluorphenyl-Bindungsstelle auf dem PS zu binden \nund anschlie\u00dfend wird ein stabiler Komplex ausg ebildet. Dieser Komplex ist dann in der Lage \nauch an die zweite Bindungstasche zu binden, wodurch dann die Aktivit\u00e4t der \uf067-Sekretase \ninhibiert wird.[59] \n \n1.2.1.3 Nicht-peptidische Inhibitoren \nNeben den peptidischen und semi-peptidischen Inhibitoren wurden verschiedene \nGrundger\u00fcste als moderate Inhibitoren entdeckt,  die ein Sulfonamid-Motiv tragen, wie unter \nanderen Fenchylamin ( 14) oder das Aminoalkohol-Derivat ( 15). Brystol-Myer Squibb \nbeschrieb potente Acetamid-Derivate, wie BMS-299897 ( 16), die die \uf067-Sekretase in einem \nZellassay im nanomolaren Be reich inhibieren (Abb. 10).[36, 60-61] Im Gegensatz zu den \nInhibitoren aus der DAPT-Gruppe konnte mit 16 neben der Verringerung der \nA\uf062-Konzentration im Gehirn auch eine verg leichbare Verringerung im CSF von jungen \nM\u00e4usen in einer Dosis- und Zeit-abh\u00e4ngi gen Weise gezeigt werden. Untersuchungen \nbez\u00fcglich der Inhibition des Notch Signalweges (IC 50 = 105.9 nM) zeigten eine 15-fach \nselektivere Inhibition des APP Abbaus (IC 50 = 7.1 nM). Weitere Untersuchungen zeigten \ndiese gesteigerte Aktivit\u00e4t auch bei Sulfonami den verschiedener Grundger\u00fcste, wie z.B. dem \nTetrahydrochinolin ( 17) ebenso wie bei Sulfon-Grundger\u00fcsten z.B. mit Cyclohexyleinheit, \n(18) die bizyclische Ringe tragen ( 19) oder auch Heterozyklen ( 20).[62-64]  \n  \n 14 SO ONH\n14 IC50 = 1.8 \u00b5MSO\nONH\nOH\n15\nN\nS\nClO O ONN\nO\nOH\n17FCOOH\nNSF\nFClOO\n 16 BMS-299897   \n \nIC50 = 7.1 nM\nS\nSH\nNO\nO\n18O OCl\nF\nFNS ClO\nOHN\nO\nOO\n20 IC50 < 25 nMFNHSO\nO\n19\n \nAbb. 10:  Nicht-peptidische \uf067-Sekretase-Inhibitoren. \n \nGleevec ( 21) war eine der ersten Substanzen, die se lektiv nur den APP Abbau inhibieren und \nNotch auch bei einer >10-fachen Konzentration des IC 50 f\u00fcr A\uf062 von ~75 \u00b5M nicht \nbeeinflusst.[65] (Abb. 11) Es wird vermutet, dass 21 an der ATP Bindungsstelle bindet, da \nnach ATP-Verabreichung die Aktivit\u00e4t der \uf067-Sekretase zur\u00fcckgewonnen werden konnte. \nDieses ist auf die h\u00f6here Bindungsaffinit\u00e4t von ATP zur\u00fcckzuf\u00fchr en, welches Gleevec \nverdr\u00e4ngt. Aufgrund dieses Befunds wird vermutet, dass die \uf067-Sekretase mit seinem \n\uf067-Phosphatrest an ein Acetamid von ATP bindet.[66] \n \nNN\nNHN\nONN\nNNH SO21 Gleevec\n23 NGX267RNS\nNHN\n24 Torrey Pines Serie: 55522  IC50 < 0.2 \u00b5MNHS\nNN\nN\nN\nNN\nONO\nF\n25 E2012  \nAbb. 11:  Selektive Inhibitoren, die nur den APP Abbau durch die \uf067-Sekretase verhindern und den Abbau der \nanderen Substrate wie Notc h nicht beeinflussen.  \n  \n 15Die Strukturklasse de r Aminothiazole (z.B. 22) wurde von Torrey Pines Therapeutics \nbeschrieben, die die A \uf06240/A\uf06242 Bildung mit einer Konzentration von ~30 nM reduzieren \nkonnten.[67] Jedoch wurde nur das Thiazolon-Derivat NGX267 ( 23) soweit entwickelt, dass es \nin die klinische Testung gebr acht werden konnte. Vorklinische  Studien deuten auf eine \nzweifache Wirkung von 23 hin: Zum einen wird der muskarinerge Rezeptor stimuliert, was \ndie Wirkung des Neurotransmitters Acetylcholin  nachahmt und so den Mangel kompensiert, \nder bei AD auftritt. Zum anderen wurde eine A \uf06242 senkende Aktivit\u00e4t in M\u00e4usen und Hasen \nermittelt.[68-69] In der klinischen Phase I wurde ei ne Doppelblindstudie mit verschiedenen \nDosierungen (10 mg, 23 mg, 30 mg, 35 mg) und Placebo mit 90 gesunden M\u00e4nnern im Alter zwischen 18 und 55 durchgef\u00fchrt. Es konnte eine  cholinerge Stimulation ohne nennenswerte \nNebenwirkungen beobachtet werden.\n[70] Die Substanzentwicklung f\u00fcr AD-Therapie wurde \n2009 eingestellt. Zus\u00e4tzlich zu 23 entwickelte Torrey Pines NGX97555 (k eine Struktur ver\u00f6ffentlicht), \nebenfalls aus der Serie 555 ( 24), die in einer vorklinischen St udie untersucht wird. Es wird \neine allosterische Modulation des \uf067-Sekretase-Komplexes in SY5Y Zellen vermutet, welche \ndie Schnittstelle von A \uf062\n40 (IC 50 = 64 nM) und A \uf06242 (IC 50 = 10 nM) zu A \uf06237/38 hin verschiebt, \nohne Notch-Spaltung oder E-Cadherin-Spaltung  zu beeinflussen. Durch diese Eigenschaft \nkann 24 auch als \uf067-Sekretase-Modulator eingeordnet we rden. Eine 3-Tages Studie in \nTg-M\u00e4usen ermittelte eine minimale Dosis f\u00fcr die A \uf06242-Reduktion mit 25-50 mg/kg. \nZusammen mit Eisai hat Torrey Pines einen weiteren Entwicklungskandidaten in der \nvorklinischen Studie.[71] E2012 ( 25) zeigte jedoch in einem hochdosierten, 13 w\u00f6chigem \nUntersuchung Nebenwirkungen in Form von Tr\u00fcbungen der Linse in den Augen von Ratten. Dieses hatte zur Folge, dass die FDA die gleich zeitig durchgef\u00fchrte Phase I Studie im Februar \n2007 unterbrochen hat. Im April 2008 wurde diese wieder aufgenommen, nachdem \numfangreiche Untersuchungen abgeschlosse n waren: Eine 13 w\u00f6chige einmalige \nVerabreichung der h\u00f6chsten Dosis an Affen; und eine 4-w\u00f6chige hochdosierte Verabreichung \nan Ratten.\n[70] Ergebnisse aus der klinischen Phase II werden erst im April 2010 erwartet. [1-2] \n  \n 16 1.2.2 Modulation der \uf067-Sekretase \nIn 2005 beschrieb MerckSharp&Dohme einen selektiven GSM ( 26), welcher eine \nCarbons\u00e4urefunktion tr\u00e4gt (Abb. 12).[72] Diese Carbons\u00e4ure scheint in dieser Modulatorklasse \nf\u00fcr die Verschiebung der A \uf062-Schnittstelle notwendig zu sei n. Interessanterweise wurde nur \neine Verschiebung in den A \uf062-Konzentrationen der verschieden Spezies ermittelt, wodurch der \nA\uf062Total-Spiegel unbeeinflusst blieb. Die Notwe ndigkeit dieser Carbons\u00e4urefunktion wurde \nsp\u00e4ter durch weitere Beispiele (z.B. 27, 28) best\u00e4tigt.[73-75] \n \nN\nOOH\nF3C CF3\n26 27NCOOHCl\nF3C\n28OH\nO\n \nAbb. 12: Modulatoren der \uf067-Sekretase, die die A \uf062-Sekretion vom pathologischen A \uf06242 verringert und dem \nunbedenklichen A \uf06238 erh\u00f6ht.  \n \n1.2.2.1 Nichtsteroidale Antirheumatika \nIm Gehirn von AD-Patienten wu rden Entz\u00fcndungsvorg\u00e4nge sowie deren Mediatoren wie z.B. \nCytokine und Chemokine entdeckt.[76] Aufgrund dieser Entdeckung wurden Hypothesen \nentwickelt, die einen Zusammenhang zwischen den Entz\u00fcndungsvorg\u00e4ngen und der Alzheimer-Demenz herstellen. Eine di eser Hypothesen schl\u00e4gt vor, dass die \nNeurodegeneration in AD erst die Antwort auf die Entz\u00fcndungen im Gehirn darstellt. Diese \nEntz\u00fcndungen sollen erst die Bildung von Pl aques und NFTs und die anschlie\u00dfende \nAggregation ausl\u00f6sen, welche wiederum eine  Immunreaktion ausl\u00f6sen soll. Durch diese \nHypothese w\u00e4ren aber chronische Entz\u00fcndungs vorg\u00e4nge im Gehirn ei ne grunds\u00e4tzliche \nVorraussetzung f\u00fcr AD. Genetische Untersuc hungen unterst\u00fctzen di ese Hypothese, da \nPolymorphismus der codierenden Gene von Entz\u00fcndungsmediatoren wie \nTNF\uf061\uf020(Tumornekrosefaktor- \uf061) oder Interleukinen das Risiko von AD erh\u00f6ht.\n[77]  \nEs konnte gezeigt werden, dass entz\u00fcndungs hemmende Wirkstoffe, die sogenannten \nnichtsteroidalen Antirheumatika (NSAIDs), wie R-Flurbiprofen ( 29), Sulindac-S ( 30) oder \nIbuprofen ( 31) den Fortgang von AD hemmen k\u00f6nnen. (Abb. 13) 29 z.B. zeigt eine selektive \nA\uf06242-Sekretion senkende Aktivit\u00e4t (IC 50 = 34 \u00b5M) und erh\u00f6ht gleichze itig die nich t-toxische \nA\uf06238-Konzentration im Gehirn, wodurch 30 als GSM eingeordnet wird.[78-79] \nInteressanterweise wurde bei der maximalen, nich t-toxischen Konzentrat ion eine um 70 -80%  \n 17verminderte A \uf06242-Sekretion beobachtet, wobei der A \uf06240-Spiegel nicht beeinflusst wird. \nJedoch zeigen nicht alle dieser NS AIDs eine Modulation. Naproxen ( 32) und Aspirin ( 33) \nbeeinflussen die A \uf062-Bildung gar nicht und z.B. Carprofen ( 35) inhibiert die Bildung aller \nA\uf062-Spezies.[78] Untersuchungen in Zellen zeigten, da ss die NSAID-abgeleiteten GSMs \nselektiv den APP-Abbau der \uf067-Sekretase inhibieren und ke inen Effekt auf die anderen \nSubstrate (wie z.B. Notch) der \uf067-Sekretase aus\u00fcben.[78, 80-84] \nFOH\nO\n29 R-Flurbiprofen\nIC50 (A\uf062\uf0342) = 307 \u00b5MOOH\nSF\n30 Sulindac-S\nIC50 (A\uf06242) = 34 \u00b5MOH\nO\n31 Ibuprofen\nIC50 (A\uf06242) = 200 \u00b5M\nOOH\nO\n32 NaproxenOHO\nO\n33 AspirinO\n \nAbb. 13: Ausgew\u00e4hlte NSAIDs beeinflussen die \uf067-Sekretase in Form von Modulatoren ( 29 -31 ), was hingegen \nauf andere Substanzen dieser Klasse nicht zutrifft ( 32 -33 ).  \n \nIn einer chronischen Studie mit hochdosiertem Ibuprofen ( 31) \u00fcber 6 Monaten in \nTg2576-M\u00e4usen, wurde eine Reduktion von sowohl den Entz\u00fcndungsvorg\u00e4ngen als auch der Bildung von Plaques ermittelt.\n[85] In weiteren Untersuchungen m it Ibuprofen in Tiermodellen \nkonnte eine um 50% verminderte Plaquefl\u00e4che  beobachtet werden, ebenso wie eine um \n30- 40% verminderte A \uf062-Konzentration. \n2008 endete die klinische Ph ase III Studie des NSAIDs 29 (Flurizan\u00ae) ohne signifikante, \nkognitive Verbesserungen.[58] Es wurde eine relativ ho he Dosierung von 2x 800 mg/d \ngew\u00e4hlt, da das \u00dcberwinden de r Blut-Hirn-Schranke und somit die Verf\u00fcgbarkeit im Gehirn \nweniger als 5% betr\u00e4gt.[86] \n  \n 18 1.2.3 Vorarbeiten \nPhotoaffinit\u00e4tsstudien m it einer GSM-Photoprobe ( 34) des NSAID-Derivats R-Flurbiprofen \n(29) zeigten, dass 34 nicht an den \uf067-Sekretase-Komplex bindet,[87] sondern an das Substrat \nAPP. (Abb. 14) Die Markierung wurde an den Aminos\u00e4uren 29 -36 (= 625 -632 APP695) von \nA\uf062 lokalisiert, dies entspricht der von Multhaup et al.  beschriebenen Dimerisierungsregion.[32]  \nSchmidt et al.  haben GSMs entwickelt, die als Grundger\u00fcst das NSAID Carprofen ( 35) \naufweisen, welches selbst ein moderater GSI ist. F\u00fcr eine Modulation sind zwei \nFunktionalit\u00e4ten notwendig: eine Carbons\u00e4ure, die vermutlich mit dem Substrat interagiert \nund ein langer lipophiler Rest, welcher f\u00fc r die Orientierung des Modulators (z.B. 36) in der \nMembran verantwortlich zu sein scheint.[88] Des Weiteren gelang der Aktivit\u00e4ts-Transfer auf \nCarbazolderivate ( 37), die im Gegensatz zu Carprofen kein stereogenes Zentrum aufweisen \nund mit einem IC 50 (A\uf06242) von 11 \u00b5M nahezu equipotent sind.[89]  \nOOBiotinO\nON\nHO\nFCOOH\n34 Flurbiprofen-Benzophenon-Biotin\nN\nHClO\nOH\n35 CarprofenNClO\nOH\ndecylNO\ndecyl\n36 BSc3041\nIC50 (A\uf06242) = 3 \u00b5M37 BSc3032\nIC50 (A\uf06242) = 11 \u00b5MO\nOH\n \nAbb. 14:  \uf067-Sekretase-Modulatoren ( 34, 36, 37) aus der Gruppe von Prof. Boris Schmidt, TU Darmstadt. \n \n  \n \n    \n 191.3 ADAM10 \nADAM10 geh\u00f6rt zu der Klasse der \u201e a disintegrin and metall oproteinase protease \u201c \n(ADAM)-Enzyme. Diese Enzymklasse kann in zwei Kategorien eing eordnet werden: die \nmembrangebundenen Enzymen (ADAM) und di ejenigen, die ein zus\u00e4tzliches \nThrombospondin Motiv tragen.[90]  \n \n1.3.1 Aufbau \nADAM10 oder auch MDAM und Kuzbanian ge nannt, ist ein 84.1 kDa (748 AS) gro\u00dfes,[90] in \nder Zellmembran verankertes Enzym welches aus sieben verschiedenen Dom\u00e4nen aufgebaut ist: Propeptid- (Pro), Metalloproteinase- (MP), Disintegrin- (Dis), Cystein-reiche- (CR), \nEGF- like- (ED), Transmembran- (TMD) und der cy toplasmatischen (CT) Dom\u00e4ne (Abb. \n15).\n[91] \n \nPro MP Dis ED CR TM CT Pro MP Dis ED CR TM CT\n \nAbb. 15:  Schematischer Aufbau von ADAM10. \n \nDieser Aufbau ist dem der Zink-abh\u00e4ngigen snake venom  Metalloproteinase (SVMP) sehr \n\u00e4hnlich. Da aber der Spaltungsmechanismus durch ADAM10 noch nicht zufriedenstellend aufgekl\u00e4rt wurde, wird angenommen, dass er \u00e4hnlich zu dem der snake \nvenom -Metalloproteinasen verl\u00e4u ft. Ebenso wie die SVMPs liegt ADAM10 als Zymogen vor \nund ist somit bis zu der Abspaltung der Propep tid-Dom\u00e4ne nicht katalytisch aktiv. Dieses \nwird durch ein Cystein sichergest ellt, welches in der N\u00e4he des C-terminalen Endes der \nPropeptid-Dom\u00e4ne lokalisiert ist und an da s f\u00fcr die Katalyse notwendige Zink-Atom \nkoordiniert.\n[91] Dieser Mechanismus wird als \u201eCystein- switch \u201c bezeichnet.[92] \n  \n 20 1.3.1.1 Metalloproteinase-Dom\u00e4ne \nNach dem \u201eCystein- switch \u201c liegt das aktive Zentrum nun in seiner aktiven Form vor. Auch \nhier wird die Verwandtschaft mit den SVMPS deutlich, welche auf der Metalloproteinase \nDom\u00e4ne die Konsensus-Sequenz: HEXGHNLGXXHD tragen. Dieses Motiv ist bis auf eine \nAminos\u00e4ure, Austausch an Stelle 7: L gegen F, auch in ADAM10 zu finden: \n383HEVGHNFGSPHD394.[93] Die drei His (H) sind f\u00fcr di e Koordination de s katalytisch \naktiven Zink-Atoms verantwortlich und zwei von diesen His liegen auf der so genannten \n\u201eactive site helix \u201c, welche auch die katalytisch aktive Gl u (E) tr\u00e4gt. Diese Helix erstreckt sich \nbis zum Gly (G), wo ein scharfer Loop  die Koordination des dritten His erm\u00f6glicht \n(Abb. 16Abb. 16).[94-95]  \nDa ADAM10 noch nicht in vollst\u00e4ndiger Form kr istallisiert werden kon nte, ist in Abbildung \n15 lediglich das katalytische Zentrum von ADAM17 dargestellt, welches das am meisten homologe ADAM Enzym zu ADAM10 ist und sich von diesem nur in den variablen Aminos\u00e4uren unterscheidet (405 HELGHNFGAEHD416) (Abb. 16, PDB: 3e8r).\n[96]  \n \na) b)\n a) b)\n \nAbb. 16:  a) Aktives Zentrum von ADAM17, welches gro\u00dfe \u00c4hnlichkeit zu ADAM10 aufweist. b) Schematisch \ndargestellte Sekund\u00e4rstruktur des ak tiven Zentrums von ADAM17, die die Ko ordination der drei Histidin-Reste \nan das Zink sicherstellt. \n \nDurch das katalytisch aktive Zink-Atom wird  Wasser koordiniert und dissoziiert zu der \nreaktiven Spezies Zn-OH, (Abb. 17a) welche das Carbonyl-Kohlenstoff im Peptidr\u00fcckgrad \ndes Substrates nukleophil angreift, anschlie\u00dfe nd entsteht ein tetraedrisches Intermediat \n(Abb. 17b). Dieser Vorgang wird durch Depr otonierung durch das katalytisch aktiven \nAspartat unterst\u00fctzt. Die so  entstehende negative Ladung am Sauerstoff wird durch das \nZink-Atom kompensiert. Der Bindungswechsel vom Zink zur\u00fcck zum Carbonyl setzt das \nAmin-Fragment frei, welches von dem als Base  fungierendem Aspart at protoniert wird. \n  \n 21H2O -H\nZnHis\nHis\nHisOH ZnHis\nHis\nHisOH2 ZnHis\nHis\nHisa)\nb)\nZn O\nO AspON\nHH\nNP1\nO P1\u00b4O\nHZnN\nHH\nNP1\nP1\u00b4O\nOOO Asp\nOH\nH2N\nP1\u00b4O\nHis\nHisHisZnOH\nHis\nHisHisON\nHP1O Asp\nO\nHis\nHis\nHisH+H2O -H\nZnHis\nHis\nHisOH ZnHis\nHis\nHisOH2 ZnHis\nHis\nHisa)\nb)\nZn O\nO AspON\nHH\nNP1\nO P1\u00b4O\nHZnN\nHH\nNP1\nP1\u00b4O\nOOO Asp\nOH\nH2N\nP1\u00b4O\nHis\nHisHisZnOH\nHis\nHisHisON\nHP1O Asp\nO\nHis\nHis\nHisH+\n \nAbb. 17: Spaltungsmechanismus einer Zink-abh\u00e4ngigen Metalloproteinase.  \n \n1.3.1.2 Disintegrin-Dom\u00e4ne \nBisher konnten nur die Disinteg rin- und die Cystein-reiche Do m\u00e4ne kristallisiert werden \n(Abb. 18a, PDB:2ao7). Die Disint egrin-Dom\u00e4ne ist vermutlich f\u00fcr die Substraterkennung \nnotwendig, bisher ist jedoch nich t klar, wie das Substrat gena u gebunden wird. Auch hier \nwird wieder durch die Verwandtschaft zu  den SVMPs (Gruppe PIII) ein \u00e4hnlicher \nMechanismus vermutet. Der Bindungsloop der ADAM10 ist 13 Aminos\u00e4uren lang (524CRDDSDCAREGIC536) und tr\u00e4gt am C-Terminus einen wichtigen Cysteinrest \n(Abb. 18b).\n[91] Es werden zwei Bindungsmechanisme n diskutiert: 1) Interaktion des \nCysteinrestes auf dem Bindungsloop mit eine m weiteren Cystein am Substrat unter \nAusbildung einer neuen Disulfidbr\u00fccke oder 2)  eine Umlagerung von bereits existierenden \nDisulfidbr\u00fccken. \na) b)\n a) b)\n \nAbb. 18: a) Disintegrin- und Cystein-reiche Dom\u00e4ne mit dem Bindungsloop aus 13 Aminos\u00e4uren ( b), der \nvermutlich f\u00fcr die Substratbindung verantwortlich ist. \n  \n 22 1.3.2 Funktion \nADAM10 weist unterschiedliche Funktionen auf. 1)  Im Gegensatz zu den SVMPs, welche die \nBindung zwischen Zellen und ihrer extrazellul\u00e4re n Matrix zerst\u00f6ren, unterst\u00fctzt ADAM10 die \nZell-Zell-Interaktionen durch W echselwirkung mit den Integrinen-Rezeptoren, welche in der \nZellmembran lokalisiert sind. Es  wird vermutet, dass durch di ese Interaktion Signale in die \nZelle \u00fcbermittelt werden.[97-98] \n2) Zus\u00e4tzlich wird ADAM10 u.a. auch zu den Sheddases  gez\u00e4hlt, die die extrazellul\u00e4ren \nDom\u00e4nen von Transmembranproteinen abspalte n und somit l\u00f6sliche Ectodom\u00e4nen in den \nextrazellul\u00e4ren Raum entl\u00e4ssen, wo  diese als Mediatoren wirken.[99] Da die ADAM10 ein \ngro\u00dfes Substratspektrum besitz t k\u00f6nnen verschiedene Stoffwech selwege aktiviert werden wie \nz.B. Wachstumsfaktoren und Zytokine (Immuna bwehr) oder der nicht-amyloidogene Weg bei \nAD, aber auch pathologische Stoffwechselwegen wie Krebs.  \n1.3.3 Lokalisierung \nADAM10 ist nahezu in allen Geweben des K\u00f6rpers zu finden. Am meiste n wird es aber in \nNeuronen, Blutgef\u00e4\u00dfen, Leukozyt en (wei\u00dfe Blutk\u00f6rperchen) aber auch in Tumorzellen \ngebildet. Die zahlreichen physiologischen Eigenschaften der ADAM10 sind zum Einen \n\u00e4u\u00dferst wichtig f\u00fcr Entwicklungs- und Repara turprozesse im K\u00f6rp er und zum Anderen \nk\u00f6nnen sie vor Krankheiten sch\u00fctzen (z.B. im Ze ntralen Nervensystem, ZNS) andererseits \nk\u00f6nnen auch Krankheiten ausgel\u00f6st we rden (z.B. Entz\u00fcndungsprozesse).  \nIm ZNS wird ADAM10 in Astrocyten (Blutzufuhr  f\u00fcr Nervenzellen), Mi krogliazellen (Abbau \nvon Zellresten) und Neuronen gebildet. ADAM 10, sowie ADAM9/17, zeigen im ZNS unter \nAnderem Aktivit\u00e4t als \uf061-Sekretase und sind dadurch mit der Alzheimer-Demenz \nverbunden.\n[100-101] Durch die Aktivit\u00e4t der \uf061-Sekretase kann APP vermehrt \u00fcber den nicht \namyloidogenen Weg abgebaut werde n. Hierbei wird APP in der A \uf062 Sequenz (zwischen Lys16 \nund Leu17) gespalten und verhindert som it das Freiwerden von toxischem A \uf062\uf034\uf032.[102] Das \nentstandene membrangebundene sAPP \uf061, dessen Bildung durch NSAIDs erh\u00f6ht werden kann, \nscheint zus\u00e4tzlich noch eine ne uroprotektive Wirkung zu haben.[99, 103] Eine Aktivierung der \n\uf061-Sekretase w\u00e4re also eine M\u00f6 glichkeit um das Entstehen von A \uf062 zu reduzieren, wenn \nADAM10 nicht auch an Entz\u00fcndungsm echanismen beteiligt w\u00e4re. Das Shedding  in anderen \nGeweben des K\u00f6rpers von ADAM10 und 17 setzt au\u00dferdem noch proinflammatorische \nMediatoren wie TNF \uf061 und dessen Rezeptor, Interleukin-6-Rezeptor, membrangebundene \nChemokine oder auch verschiedene Adh\u00e4si onsmolek\u00fcle frei, die die Aktivierung und \nRekrutierung von Leukozyten zur Folge haben. Diese Mediatoren werden mit verschiedenen  \n 23chronischen Krankheiten in Verbindung gebracht, wie zum Beispiel Multiple Sklerose oder \nrheumatische Arthritis. Ebenso werden ADAM 10 und 17 mit dem Wachstum  von Krebszellen \nin Verbindung gebracht, da durch shedding  Wachstumsfaktoren frei werden, die das \nWachstum von Krebszellen zur Folge haben.   \n1.3.4 Inhibition von ADAM10  \nBisher wurden verschiedene I nhibitoren f\u00fcr Metalloproteinasen entwickelt, welche h\u00e4ufig am \nGrundger\u00fcst eine Hydroxams\u00e4ure tragen. Da s Scheitern der klinischen Studien von \nBastimastat ( 38) oder Marimastat ( 39) ist durch unspezifische Hemmung verschiedener \nMetalloproteinasen, u.a. ADAM10, 17, MMP 1, 3, 9 und 13, zu erkl\u00e4ren (Abb. 19).\n[104-106] \nINCB3619 ( 40) wurde 1992 als selektiver Inhibitor des ErbB4 sheddings  beschrieben, \ninhibiert jedoch sowohl ADAM10 (IC 50 = 22 nM) als auch ADAM17 (IC 50 = 14 nM).[90, 107]  \n \n41 GI254023X38 Batimastat 39 MarimastatHOH\nN\nN\nHOSS\nO\nHNOHOH\nN\nNH\nOOH O\nHNO\nHONH\nN\nOO\nN\nHONH\nN\nHOHO ON\n40 INCB3619  \nAbb. 19:  Inhibitoren von ADAM10. \n \nDie Entwicklung des selektiven Inhibitors GI254023X ( 41) wurde 2000 in einem Patent von \nGlaxoSmith&Kline beschrieben. Dieser Inhibitor ist um den Faktor 100 selektiver f\u00fcr die \nInhibition von ADAM10 (IC 50 = 5.3 \u00b5M) im Vergleich zu der verwandten ADAM17 \n(IC 50 = 541 \u00b5M).[106]  \n  \n 24 \nInhibitor:\nHydroxams\u00e4ure\nInhibitor:Hydroxams\u00e4ure\n \nAbb. 20:  Der Inhibitor, der eine Hydroxams\u00e4ure tr\u00e4gt, koord iniert mit dieser das katalytisch aktive Zink-Atom \nund verhindert somit die Aktivierung von Wasser, was notwendig ist f\u00fcr die Peptidspaltung.  \n \nDie Hydroxams\u00e4urefunktion koordiniert an  dem katalytisch aktiven Zink-Atom und \nverhindert so die Aktivierung von Wasser, was zu einer Peptidspaltung f\u00fchren w\u00fcrde \n(Abb. 20).  Die selektive Inhibition von ADAM 10 w\u00e4re also eine gute M \u00f6glichkeit das Wachstum von \nverschiedenen Krebsarten wie Prostata- oder Darmkrebs zu reduzieren sowie zur Behandlung \nvon chronischen Entz\u00fcndungskrankheiten. Da di e Inhibition im ZNS jedoch gegenteilige \nAuswirkungen h\u00e4tte, wie z.B. den Abbau von APP \u00fcber den nicht-amyloidogenen Weg zu \nreduzieren, m\u00fcsste beim Einsatz von Inhibitoren darauf geachtet werden, dass diese die \nBlut-Hirn-Schranke nicht \u00fcberschreiten k\u00f6nnen, dies ist z.B. bei den Hydroxams\u00e4uren, durch \nden hohen Anteil an polaren Gruppen, vermutlich der Fall. \n  \n 252 Zielsetzung  \nDie Entwicklung von Wirkstoffen zur Beha ndlung von Morbus Alzheimer ist ein \ninteressantes Ziel der Medizinischen Chemie. Die Anzahl der Erkrankungen an \nAlzheimer-Demenz wird in den n\u00e4chsten Jahr zehnten zunehmen, bedingt durch den Anstieg \ndes Altersdurchschnitts sowie der Lebenser wartung der Bev\u00f6lkerung in der Bundesrepublik \nDeutschland. \nEin interessantes Target  f\u00fcr die Entwicklung von Wirkstoffen ist die \uf067-Sekretase, da diese das \nProtein (A \uf06242) freisetzt, welches durch Aggregati on zu einem der charakteristischen \npathologischen Ursachen der Alzheime r-Demenz f\u00fchrt: den amyloiden Plaques. \nDa eine vollst\u00e4ndige Inhibition der \uf067-Sekretase pathologische Nebenwirkungen zur Folge hat, \nbesteht die Aufgabenstellung dieser Arbe it in dem Design und  der Synthese von \n\uf067-Sekretase-Modulatoren. Diese verschieben nur die Schnittstelle des Enzyms von A \uf06242 zum \nnicht-pathologischen A \uf06238 ohne die unerw\u00fcnschten Nebenwirkungen der Vollinhibition. \nNeben den amyloiden Plaques sind auch Entz \u00fcndungsvorg\u00e4nge in Gehirnen von Patienten mit \nAlzheimer-Demenz beobachtet worden. Entz \u00fcndungsvorg\u00e4nge sind unter Anderem mit der \nAktivit\u00e4t der zwei Metalloproteinase n ADAM10 und ADAM17 verbunden. Diese beiden \nEnzyme werden auch als Sheddasen  bezeichnet, da sie Transmem branproteine schneiden und \neinen l\u00f6slichen Teil, die Ectodom\u00e4ne, in de n extrazellul\u00e4ren Raum abgeben. Zu diesen \nEctodom\u00e4nen geh\u00f6ren auch proinflammatorisc he Mediatoren, die chronische Entz\u00fcndungen \nausl\u00f6sen k\u00f6nnen. Aus diesem Grund soll ein In hibitor von ADAM10 synthetisiert werden, um \nEntz\u00fcndungsvorg\u00e4nge im menschlichen untersuchen K\u00f6rper zu k\u00f6nnen. \n \n  \n 26  \n 273 Kumulativer Teil der Dissertation \n \n3.1 Interessante Targets  in der Alzheimer-Demenz Forschung und Ans\u00e4tze einer \nDiagnostik f\u00fcr eine Fr\u00fcherke nnung der Alzheimer-Demenz. \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentlicht:  \nNicole H\u00f6ttecke, Stefanie Baumann, Ali Tagh avi, Hannes A. Braun and Boris Schmidt, \n\u201cDrug Development and Diagnostics for Alzheimer's Disease Up to 2008\u201c, in Frontiers in \nMedicinal Chemistry Vol. 4, Ed.: Atta-ur-Rahman, A.B. Reitz , pp. 730-766, Bentham Books \n2009 .  \nMit freundlicher Genehmigung von Bentham Science Publishers Ltd.   \n \nVerschiedene Medikamente sind bereits f\u00fcr die Behandlung der Alzheimer-Demenz \nzugelassen, wie z.B. AChE Inhibito ren und NMDA-Rezeptor-Antagonisten. Diese \nMedikamente k\u00f6nnen jedoch nur die Symptome  der Alzheimer-Demenz verringern, die \nKrankheit selbst jedoch nicht heil en. Eine Immunisierung gegen A \uf062 wird zurzeit von \nverschiedenen Firmen untersucht, und k\u00f6nnte eine  viel versprechende Therapiem\u00f6glichkeit \ndarstellen.  \nEine Inhibition der \uf062-Sekretase, dem Enzym, das den amyloidogenen Weg des APP \nMetabolismus initialisie rt, und eine Inhibition bzw. Modulation der \uf067-Sekretase, welche die \nzur Aggregation neigenden A \uf062-Spezies generiert, si nd weitere interessante Targets  f\u00fcr eine \nBehandlung der Alzheimer-Demenz. \nDas Ph\u00e4nomen, das ausgew\u00e4hlte Cholesterol- senkende Medikamente das Risiko an AD zu \nerkranken senken, wird weiter unt ersucht. Ebenso wird die Beobachtung untersucht, bei der \nM\u00e4use, die Trinkwasser mit einem h\u00f6he ren Kupfer-Gehalt trinken, weniger A \uf062 bilden als die \nKontrollgruppe. \nEin weiterer wichtiger Schw erpunkt in der AD-Forschung is t die Fr\u00fcherkennung von AD. Bis \nheute kann eine AD-Diagnose erst nach dem Tod des Patienten dur ch eine Autopsie eindeutig \nbest\u00e4tigt werden. Die AD-Diagnose besteht im  Nachweis von Plaques und NFTs im Gehirn \nvon Patienten in Kombination mit der AD-typi schen Hirnatrophie. Diese so genannten \nBiomarker im Gehirn von lebenden AD-Patienten nachzuweisen und damit eine eindeutige Diagnose bereits zu Lebzeiten des Patienten zu er halten ist bis heute sehr  schwierig. Es wird \nan Substanzen geforscht die selektiv an  NFTs oder Plaques binden und durch z.B. \nPositronen-Emissions-Tomographie nachgewiesen werden k\u00f6nnen.   \n 28  \n 29Drug Development and Diagnostics for Alzheimer's Disease Up to \n2008  \nNicole H\u00f6ttecke, Stefanie Baumann, Ali Taghavi, Hannes A. Braun and Boris Schmidt * \n \nClemens Sch\u00f6pf-Institute for Organic Chemistry and Biochemistry, TU Darmstadt, Petersenstr. 22, D-64287 \nDarmstadt, Germany  \nAbstract: The exact cause of Alzheimer\u2019s disease is s till unknown; despite the dramatic progress in \nunderstanding. Most gene mutations associated with Alzh eimer\u2019s disease point to th e amyloid precursor protein \nand amyloid \uf062. The \uf061-, \uf062- and \uf067-secretases execute the amyloid precurs or protein processing. Significant \nprogress has been made in the selective inhibition a nd modulation of these proteases, regardless of the \navailability of structural information. Peptidic and nonpe ptidic leads were identified and several drug candidates \nare 2008 in clinical trials. Successful trials demand eith er large cohorts or reliable biological surrogate markers \nfor Alzheimer\u2019s disease. Therefore, several radio markers are under investigation to support such clinical trials \nby PET-imaging. Here we summarize the developments until 2006 and highlight the important developments \nuntil 2008.  \nKey Words:  Alzheimer\u2019s disease, secretase, copper, as partic protease, cholesterol, imaging.  \nINTRODUCTION  \nAlzheimer's disease (AD), the most common dementia, affects nearly 2% of the population in industrialized \ncountries. This epidemic neurodegenerative disorder claims millions of victims per year, not just erasing the memory \nof the patient, but effecting severe social implications. The AD prevalence equals 5.5% above 60 years of age and \nincreases for elderly people [1, 2]. The onset of Alzheimer' s disease is usually after 65 years of age, though earlier \nonset is not uncommon. As age advances, the incidence in creases rapidly and roughly doubles every 5 years [1]. Age \nis the dominant risk factor overruling even the positive impacts of nutrition (low-fat diets), nutritional supplements \nafter onset [3-5]. The previously reported risk reducing eff ects of higher education were not confirmed in more recent \nsurveys. The socio-economic impact of AD, the care need ed for disabled and chronically wasting patients, the \nconsequences for patients, relatives and caretakers alike is a major social and financial issue for the coming decades. \nCurrent annual AD related expenditures total $83.9 billion in the US [6]. 14 Million Americans are likely to be stricken by 2050 [7]. Despite all efforts, the exact cause  of Alzheimer's disease is still unknown, but the pathways \ntowards and away from Alzheimer\u2019s disease become better understood [8]. The process results in neuron and synapse \ndegeneration, reduction of brain regions, memory loss and ul timately in death. There is progress in the definite \ndiagnosis of AD prior to a post-mortem diagnosis. Additional problems arise from other causes of memory loss  \n*Corresponding author: E-mail: schmidt_boris@t-online.de  \nAllen B. Reitz / Atta-ur-Rahman / M. Iqbal Choudhary (Eds.) All rights reserved \u2013 \u00a9 2009 Bentham \nScience Publishers.   \n 30 (e.g. vascular dementia). Several steps in the process offer potential for intervention, these include the amyloid cascade \nand plaque-related proteins [9], hyperphosphorylated tau prot ein [10, 11], zinc, copper and aluminium cations [12-14].  \nESTABLISHED THERAPIES AND NOVEL APPROACHES  \nSome 500 compounds are in development to treat neurodegenerative diseases. At least 10% of these are related to AD \n[15, 16]. The targets derive from a whole range of someti mes well-known receptors and enzymes: GSK-3, PDE 4 and \nmuscarinic M1. nACh modulators, AChE inhibitors, NM DA modulators, 5-HT agonists and several vaccination \nprojects (e.g. Elan, Cytos Biotechnology) are in advanced stag es of research or development. 2 trial failures were \nreported from 2006-2008 alone: Flurizan and Alzhamed. The early rush on fibril formation inhibition resulted in a number of potent inhibitors thereof. However, the activities were confined to in vitro  experiments or limited by poor \nDMPK properties, which excluded further development [17,18]. More recently, this resulted in enhanced activities to \ninterfere with the formation of tau derived paired helical filaments. Methylene blue actually entired phase II trials [19-21]. Few drug candidates (e.g. SKF74652, 1 [22], Scheme  1) went beyond animal testing and convincing clinical \ndata are still wanted. Furthermore, the view on A \uf062 toxicity has changed dramatically. Plaques were seen as the true \nculprit and their removal was one of the therapy goals until 2001. Now, soluble A \uf062 and early oligomers have to take \nthe blame for the A \uf062 associated effects. Thus mature A \uf062 plaques may rather rest in peace.  \nOCl\nOO O\nN\n1SKF-74652NOO\nH\nHO\n2GalantamineNNH2\n3Tacrine\nN O\nOO\n4DonezepilN\nO NO\nH\n5Rivastigmine 6MemantineNH2\n \nScheme 1: Current drugs for therapeutic intervention. ( 2-6). \n \nCholinesterase inhibitors [23-26] produce small improvements in cognitive and global assessments [27, 28], but galantamine ( 2), tacrine ( 3), donepezil ( 4) and rivastigmine ( 5) do not address the severe mortality in the final stages of \nAD. 565 patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated to donepezil or placebo. There were no significant benefits for the 486 patients who completed the 2nd period until the primary endpoints: entry to institutiona l care and progression of disability [25]. This outcome \ncontradicts a previous report: the chosen AChEI was not co st effective, with benefits below minimally relevant \nthresholds [6]. Tacrine is losing ground to the other 3 AChE inhibitors because of hepatotoxic effects [29].  \n  \n 31The message of these studies is obvious: better drugs are needed to treat Alzheimer's disease!  \nMemantine hydrochloride ( 6), first made in 1960 by Ely Lilly as an antidiabetic agent, protects neurons against \noveractivation of N-methyl-D-aspartate receptors and was approved for the treatment of moderate to severe \nAlzheimer\u2019s disease in 2002 as first of its class [6]. Previous attempts utilizing this non-competitive antagonism failed. \nThis was due to CNS side effects such as hallucinations. Me mantine hydrochloride was tested in a 28 weeks trial at 20 \nmg/day against placebo, indicating a significant cognitive improvement. The current strategy to use memantine hydrochloride in combination therapy with the AChEI donezepil was concluded from the outcome of a 24 week trial \nagainst placebo. The combinations halted or slowed furthe r decline, but the magnitude of these effects was modest \n[30]. Furthermore, these results have become questionab le in the light of the recent extended donezepil trials. \nVACCINATION  \nImmunization therapies against A \uf062 hold high potential and are under investigation by several companies [31]. The \nmost advanced companies in this field: Elan Corp plc and Wyeth-Ayerst Laboratories suffered a setback of their joined \nclinical development of AN-1792 in March 2002 [32, 33]. Th e phase IIa trials were abandoned after observation that \nfour out of 372 patients displayed clinical signs consistent with inflammation in the central nervous system. The \nalarming and unexplained brain-shrinkage of 6% on aver age and the lack of cognitive improvement backed the \ndecision to end the trial, but all patients were monitored until December 2002 [34]. Unfortunately, just 13 patients were monitored afterwards, although a small group displayed significant improvements in brain volume and cognitive \nabilities [35]. These positive results suggest further studies wi th improved epitopes or different vaccination strategies. \nA\uf062 vaccination reduces not only extra-and intracellular A \uf062 accumulation, but is accompanied by the clearance of early \ntau pathology. The tau pathology is reduced by the proteasome and depends on tau phosphorylation. \nHyperphosphorylated tau aggregates remained unaffected by this antibody treatment [35]. On the contrary, the \nclearance of tau aggregates was reported for immunotherapy and DAPT treatment. However, A \uf062 deposits were cleared \nwithin 3 days after injection, versus 5 days it took for the reduction of tau lesions [36-39].  \nThus, a causal therapy is still in utter demand, as no existing therapy effectively stops or even cures the disease. The \nincidence of early-onset Alzheimer\u2019s disease in Down syndrome patients indicated chromosome 21 as a likely hotspot \nfor gene location. Mutations linked to early-onset Alzheimer\u2019s disease afflicted families in London and Sweden and additional polymorphisms, that either cause or further AD, provided some insight into the biological pathways and the involvement of the amyloid precursor protein (APP) [40]. The genetic background of AD is quite heterogeneous; a large number of gene associations have been made with localisations on almost every chromosome [41]. Replicated or \nconfirmed associations are few: the late-onset AD is linked to the \uf0654-allele of APOE, but its presence is neither \nnecessary nor sufficient to cause the disease, but there is a dose-dependent relation to the age of onset, which results in \nup to 16x enhanced risk [42]. Another cluster of mutations is located on chromosome 14, on the gene encoding for presenilin 1 [43]. Mouse models expressing mutated human APP and presenilin 1 display many symptoms of AD, \nalthough no model represents the full range of pathologies  of the human disease. Particularly, the inflammation \nprocesses in humans and mice do not adequately relate to each other [44]. The observed loss of neurons (mice [45]) is \naccompanied by plaque formation consisting of amyloid \uf062-peptide in the human prefrontal cortices. But there is \nmounting evidence for a second pool of insoluble A \uf062 in cholesterol enriched low-density membranes, where it \nmoderates membrane fluidity [46].   \n 32 A rational approach to a successful, causal therapy is based on the detailed understanding of A \uf062 formation, deposition \nand the inflammatory consequences. Decisive functions were assigned to the amyloid precursor protein (APP) and its \ndegrading aspartic proteases \uf062-secretase and the presenilins. A simplified APP processing is depicted in Scheme 2. \nThe up to 771 amino acid long APP occurs in 3 isoforms: APP695, APP751, and APP771, this includes a signalling \nsequence, a large extramembraneous sequence and the crucial membrane spanning domain followed by a short cytoplasmic tail. The non-pathological cleavage occurs between Lys\n687-Leu688 (resp. K16L17 in Scheme 2) by the \n\uf061-secretase, which belongs to the ADAM family and is suspected to be TACE or ADAM10.  \n \n   \n \n         \n \n          \nScheme 2. APP amino acid sequence close to the clea vage sites and point mutations in A \uf062 numbering. \n \nThis dominating event leaves just 10% of the APP behind for the \uf062-secretase, produces \uf061-APP and ultimately leads \nto the fragments p3 and C83. The \uf061-secretase is sensitive to membrane choles terol levels and can thus be modulated \n[47, 48]. The most relevant point mutations for A \uf062 formation are K670-M671->NL and V717->F (Stockholm or \nIndiana), which cause familial Alzheimer\u2019s dementia (FAD). The molecular basis of these point mutations is explained \nby their modulation of the secretases. The rate limiting \uf062-secretase usually cleaves between the Met671-Asp672 residues, \nbut prefers the preceding amino acids Asn670-Leu671 of the Swedish mutation over Lys670-Met671. The V717F mutation \naccelerates cleavage after Ala714, which leads to the notorious A \uf06242, the decisive factor in plaque formation. The \nreleased C-terminal fragment interacts in the cytoplasm with an adapter protein, Fe65, and finally induces apoptosis in \nH4-cells [49]. It seemed to be an obvious target to address A \uf062 deposits directly, either by inhibition of plaque \nformation or by enhanced plaque degradation. Several comp anies pursued strategies related to \u201cplaque busters\u201d [50, \n51], but clinical data for this mode of action are still lacking and there is mounting evidence that the plaques are not the \nreal culprit, e.g. AD does not correlate well with total plaque load. Both soluble A \uf062 and early fibrils  are now \ncommonly blamed to be toxic, particularly in the presence of copper cations (see copper section below). This \nhypothesis has its merits and is hard to falsify in vivo  as neither copper nor early fibrils are detectable at the necessary \nresolution. Fortunately, there is evidence for a common mechanism in amyloidogenic diseases, which may hold the \nkey to A\uf062, tau and PrPSc [52].  \n \n\uf020\n  \n 33\uf062-SECRETASE  \n\uf062-Secretase was identified as an aspartic protease despit e the initial lack of selective inhibitors [53]. The key \nfeatures of an aspartic protease were confirmed: the flex ible flap region, which is crucial for substrate docking. The \nkinetics of statine-based inhibitors revealed stepwise mech anism with structural reorganisation and activity modulation \n[54]. The two states: open and closed, contribute to selectivity and activity of the enzyme [7]. Two \uf062-secretases are \nknown BACE1 (ASP2 or memapsin2) and BACE2 with high homology, but subtle differences in the active site and an \nadditional disulfide bridge for BACE1 [55, 56]. BACE2 causes additional cleavages close to Phe20, which are \nreminiscent of \uf061-secretase activity [57]. BACE1 is anchored to the membrane via its transmembrane domain \n(455-480) and may be active as a dimer [58]. BACE1 has a propeptide domain, which is cleaved by furin-like proteases to form mature enzyme. The C-terminal transmembrane domain of BACE1 is not strictly required for \nactivity, but the localization of both enzyme and substrate in the same membrane enhances kinetics and specificity. The C-terminal truncation seems to influence enzyme kinetics even in the absence of membranes. BACE1 maturation \nrequires cysteine bridge formation (Cys\n216/Cys420, Cys278/Cys443, Cys330/ Cys380), N-glycosylation and propeptide \nremoval. Cystein mutants undergo impaired maturation, but obtain catalytic activity. The Cys330/Cys380 bridge was \nfound to be the most important [59]. Crucial for assay development and animal models: BACE1 -/- knockout mice are \nfertile and healthy, and display reduced A \uf062 levels [55, 60, 61]. Selectivity issues arise not only by other aspartic \nproteases, but by the homologous BACE2, which displays a less pathogenic APP cleavage pattern and a distinctly \ndifferent localization [62]. The A \uf062 protein is released by a subsequent proteolysis at Val711-Ile712 or Ala713-Thr714 by \nthe intramembrane protease: \uf067-secretase, resulting in A \uf06240 and A\uf06242. A detailed analysis of BACE distribution, \nstructure, species variation, degradation and properties wa s published recently [63]. BACE inhibition is not the only \nway to modulate the BACE dependent APP cleavage. High levels of ceramide or improved raft association can extend \nthe half life of BACE1 (16h) [62, 64-67] . The myelination of nerve cells is regulated by BACE but this process does \nnot cause an obstacle for therapeutic intervention in adults [68, 69].  \n\uf062-SECRETASE INHIBITORS  \nSeveral inhibitors for \uf062-secretase were identified in cellular assays, but more often than not, the true nature of the \ninhibition mechanism was not reported. Broad sp ectrum protease inhibitors such as pepstatin 7, known aspartic \nprotease inhibitors from Renin and HIV protease programs, or cocktails thereof had little inhibitory effect and gave \nmisleading results. To this date several reviews on secr etase inhibition were published [62, 66, 67, 7073]. Several \npeptide-based inhibitors were patented or published immediately after the disclosure of BACE-inhibitor complex \nX-ray structures [62, 71, 74] (Figs.  1 and 2 show fragments of a homodimeric structure). The active BACE1 used for \nco-crystallisation lacked the transmembrane and intracellular domains and some flexible N-terminal regions were not \nresolved. The high affinity complex of Glu-Val-Asn- \uf059(Leu-Ala)-Ala-Glu-Phe ( 8, OM99-2, Ki = 1.6 nM) and \n\uf062-secretase resulted in complete inhibition of \uf062-secretase activity and allowed crystallisation and structure \ndetermination at 1.9 \u00c5 resolution (PDB: 1FKN, Figs.  1 and 2) [70, 75].  \n 34  \n \nFigure 1. BACE complexed to M99-2 ( 8) \n \nFigure 2.  BACE complexed to OM99-2 ( 8) \n \n \nFigure 3.  Isophthalamide 18 (yellow) and (b) resorcylate 27 (yello w) above the flap. MOE 2004.10 GaussConolly surface green: \nhydro-phobic, blue: hydrophilic (PDB: 1W51, 1TQF) \n  \n 35The inhibitor is located in the active site as intended by design and the hydroxyethylene is coordinated by four \nhydrogen bonds to the two catalytic aspartates. Further 10 hydrogen bonds are established between OM99-2 ( 8), the \nbinding pocket and the flap region. Despite the analogies to other aspartic proteases, there are significant differences in the side chain preferences. S4, S3\u2019 are hydrophilic and r eadily accessible by water. The hydrophilic S4\u2019, which holds \nthe phenylalanine, is located at the surface and contributes little to binding. The subsite specificity was revealed by the cleavage rates of combinatorial substrate mixtures and selective inhibitors. This resulted in \nGlu-Leu-Asp- \uf059(Leu--Ala)-Val-Glu-Phe ( 9, OM00-3, K\ni = 0.31 nM), which is still the most potent inhibitor of \n\uf062-secretase. The hydroxyl group of OM00-3 ( 9) is coordinated by the two active site aspartates Asp32 and Asp228 \nthrough four hydrogen bonds (PDB: 1M4H) [74]. Although very similar to OM99-2 ( 8, \nGlu-Val-Asn- \uf059(Leu-Ala)-Ala-Glu-Phe), the P3, P2, and P2\u2019 residues are exchanged, resulting in a more linear and \nextended conformation at either end. The replacement of the P2\u2019 alanine by valine facilitates binding and allows \nreorientation of the P3\u2019 glutamate and the P4\u2019 phenylalanine. This shifts the C-terminal residue towards the surface of \nthe enzyme and exposes it to the solvent [72]. The structure activity relationship of BACE inhibitors was comprehensively reviewed in 2008 by E. Silvestri [72].  \nThe crystal structure of free BACE (1SGZ) revealed a part of the flap to be locked in an \"open\" position [74]. The \nstructure is essentially the same as BACE1 bound to an inhibi tor, but the flap positions differ by 4.5 \u00c5 at the tips. The \nopen position of the flap is stabilized by two intrafla p hydrogen bonds and is anchored by a new hydrogen bond \ninvolving Tyr\n71 in a novel orientation. The resulting gorge may contribute to sequence and shape selection. A \ngatekeeper function was evident from the unusually small substituent Ala in P2\u2019 ( 8, 1FKN). Thr72 forms the narrowest \npoint (6.5 \u00c5 in apo BACE) between the flap and Arg235, Ser328, and Thr329 on the opposite side and thus contributes to \nthe specificity of BACE. This gatekeeper blocks the acce ss of peptides carrying larger residues in this position, \nalthough pocket P1\u2019 provides more than enough space for a significantly larger residue [76-80]. The small interaction \nof the C-terminal end of the octapeptides OM99-2 ( 8) and OM00-3 ( 9) with the enzyme inspired the design of shorter \npeptidic inhibitors ( 10-13). Different peptidic inhibitors featuring the hydroxyethylene moiety and flanked by \nmultitude of amino acid residues were published (Schemes  3 and 4) [81]. Remarkably, the compact P1\u2019-Ala of potent \ninhibitors has never been replaced by a sterically more demanding group. Several scaffolds are known to provide inhibitors for aspartic proteases.  \n 36 HNNHHN\nNHHNO\nOOH O\nO OOH\nCO2H\n7 Pepstatin\nHNNHHNHN\nNHOO\nOOH\nOO\nO\n10 Tang  (Ki  = 5.9 nM)9 Tang  OM00-3 ( Ki = 0.31 nM)H2NHNNHHNHN\nNHHN\nOO\nOOHO\nNH 2\nOOCO2H\nOCO2H\n8 Tang  OM99-2 ( Ki = 1.6 nM)CO2H\nH2NHNNHHNHN\nNHHN\nOO\nOOH\nOOCO2H\nOCO2HCO2H\nNHHNNHNHH2N\nNHO\nOO\nOHO\nCO2HCO2H\nHONHHNHN\nNHO\nOOH\nOO\nN11 Kiso KMI-370 (IC50 = 3.4 nM,\nHEK-293 IC50 = 0.20 \u00b5M) O\nOHO\n12 Chen (IC50 = 35 nM, \nHEK-293 IC50 =1.23 \u00b5M)\nNHHNOF\nF\nOH ONHOCO2H\nCO2HHO\n13 John (IC 50 = 20 nM, \nHEK-293 IC50 > 10000 nM)NH 2O\nO\nNH 2\n \nScheme 3. BACE inhibitors I.  \n \nAccordingly, statines, norstatines, hydroxyethylamines and hydroxyethylureas can be employed as transition state \nmimetics, yet with dramatic differences in potency. The inhibitor 11 (KMI-370, IC 50 = 3.4 nM) featured a short \nC-terminal end with a dicarboxylic acid and displayed high activity in vitro  and in vivo  (BACE1-HEK293 cells \nEC 50 = 0.20 \u00b5M) [81, 82]. Chen et al.  synthesized (Phe-Ala)-based pentapeptide mimetics like 12 (IC 50 = 35 nM) and \ncame to similar conclusions [83, 84]. The SAR of these two series postulated a benzyl or a 3,5-difluorobenzyl residue \nto occupy the P1 position as realized in compound 13 [85]. A good part of the peptidic heritage was replaced by an \nisophthalamide [86, 87], which functions as the N-terminus in the compounds 14-21 . The switch from the statine core \nto the hydroxyethylene isostere allowed the replacement of the carboxylic acids by smaller groups and resulted in the compact inhibitors ( 16-19 ) with a reduced molecular mass and fewer hydrogen bond donors.   \n 37Pr2NO\nNHO\nOHNHO\nPr2NO\nNHO\nONH18 Astex (IC50 = 200 nM) 19 Elan\n20 Takeda (IC50=  99 nM)Et2NO\nNHO\nNH2NHOF\nOMe 21 Sunesis US 2004147454NHN NHO\nOHO\nPr2NOF\nF\nNH NHO\nOHPr2NOF\nF\nN\nNRPr2N NHHNO OF\nF\nOH ONHOCO2H\n14 Elan (IC 50 = 1 nM, HEK-293 IC 50 = 1 \uf06dM)CO2HPr2N NHNHO OF\nF\nOHO\n15 Elan (IC 50 = 30 nM, HEK-293 IC 50 = 3 \uf06dM)\nPr2N NHNHO O\nOHOMe16 Elan 17 ElanF\nF\nOMeCO2H\n \nScheme 4. BACE inhibitors II.  \n \nThe Elan compounds (13-19) have lost a good part of their peptidic origin, which is mandatory to obtain sufficient oral \nabsorption and blood brain barrier penetration [88]. Significant information was revealed by a novel BACE complexed to a transition state mimetic [89]. Soaking of apo BACE crystals (PDB: 1W50) with small peptidomimetics, which were known to be moderate inhibitors in FRET or cellular assays, resulted in the incorporation of 18 in the active site (PDB: 1W51, Fig. 3a). This peptide mimetic features the isophthalamide to mimic the S2-S4 section and was claimed \nto have an IC\n50 = 200 nM. Some 750 close analogues were revealed in patents by Takeda (20) [90], Glaxo [91-93], \nUpjohn Pharmacia [86, 94], Elan (19) [95-97], Astex [98] and a Sunesis employee  \n(21) [99, 100]. But the amino alcohol 18 held a little surprise, despite the  R-configuration of the alcohol it was far \nmore potent than its S-configured diastereomer or the parent ketone and thus contradicted previous SAR of the \nabsolute configuration. The neighbouring amine receives a proton from the catalytic Asp228 and places its benzyl \nsubstituent in the S2\u00b4 pocket. One of the N-propyl groups of the isophthalamide occupies the S3 pocket and is directed \ntowards the phenyl ring in the S1 pocket. The phenyl rings in both the S1 and the S2\u2019 pocket interact with Tyr71. The \nC-terminal methoxyphenyl is positioned in the S2\u2019 pocket. This success in high-throughput crystallography enabled \nASTEX to license out this programme to GSK in 2003. However, there is a caveat associated with the depicted BACE \ninhibitors featuring the phthalamide moiety. Almost all are good substrates for the PGP-transporter and thus do not reach the required brain concentrations for BACE inhibition.  \nDespite all efforts by the pharmaceutical companies and academic groups, non-peptidic leads for BACE inhibition are \nstill few. The FRET assays of soluble BACE deliver false positive  hits to such a degree, that it is mandatory to profile \npotential hits in a reliable secondary assay, such as a radioligand displacement [101]. This progress in assay development allowed identifying peptidic and non-peptidic lead s. Takeda reported a tetraline (22, Scheme 5), which is \nnot an obvious scaffold for protease inhibition and is likely to stem from high-throughput screening efforts [102]. The activity is poor (IC\n50 = 1 \u03bcM) and the mode of action was not confirmed. Neurologic\u2019s diacid (24) [103] is unlikely to \nbe an easy lead for AD. Latifolin (23), isolated from the heartwood of Dalbergia sissoo, was reported to inhibit the A \uf062 \nsynthesis with an IC 50 of 180 \u03bcM, again a rather weak and unsecured activity [104]. Vertex reported [105] the \nbiphenylpiperazine (25) as BACE inhibitor (IC 50 = 3 \u03bcM) and it was docked into the BACE structure by Park and Lee \n[106, 107]. An unfortunate error \u201cimproved\u201d it to 3 nM, which makes the outcome of this docking very questionable. \nYet similar biphenylated amines (26) were revealed by Actelion [79, 108-110]. MSD undertook the rational design \n[107, 111, 112] of BACE inhibitors like many others [113]  \n 38 ONOMe\nMeO\nOHOH\n22 Takeda23 Latifolin\nO\nONH\nOO2SBn\nHN\nOC5H11\nO N\nN\nPhHN\nNHN\nHalON\nN\nOO\nOO\nHO3PHO2C\n24 Takeda\n25 Vertex 26 Actelion27 MSD FNH 2\n28 De NovoN\nNNNHN\nN ON\nHNO2S\nHN\nO\n29 MSD\n(IC50 = 11 nM)OOHHN\n \nScheme 5. Non-peptidic BACE inhibitors.  \nBut more innovation was obtained by an Automated Ligand Identification System (ALIS): a novel resorcylic acid \nscaffold [109]. The amino pentyl derivative 27 was obtained after subtle modifications of the lead structure and \ndisplayed a moderate inhibition of BACE 1 (IC 50 = 1.4 \u03bcM) and good selectivity towards cathepsin D (IC 50 > 500 \u03bcM). \nA modified BACE 1 (K75A, E77A) was used for co-crystallisation with 27 (PDB: 1TQF, Fig.  3b), which occupies the \nS1-S4 subsites. Quite unusually, the S\u2019 sites and the active site have no direct contact with the inhibitor. The acetamide is engaged in a hydrogen bond to the catalytic water, which is placed between the two aspartates. The 4-fluorophenyl \nmoiety wedges the novel S3 subpocket open and the aminopentyl coils back into the S1 pocket. The S1 and S3 \nsubstituents may be linked together to result in macrolactams with reduced rotational freedom, which may hold the key for improved activity [114]. Extension towards the active site, occupation of P1 by a phenyl group and placement of a \ncyclopropyl in P1\u2019 improved the inhibition to 11 nM for 29 and retained 500-fold selectivity towards cathepsin D \n[115-118]. The compound was co-crystallized with BACE, but there was no entry in the PDB by 11/2004. DeNovo reported several scaffolds and mimetics: sulfonamid es, 1-piperazinylpropan-2-ols and the triazine 28, which may offer \nadditional imaging of A \uf062 fibrils [73]. The implication of BACE1 Cathepsin D similarity were analyzed by L. Marinelli \nrecently [119].  \n\uf067-SECRETASE  \nParadoxical: despite being the secretase reported first, the identity of \uf067-secretase was long subject to debate and the \ndetailed structure is still unknown. The close relation to the Notch pathway, which is important in embryonic \ndevelopment, became less hazy over the years. Notch 1, an integral membrane receptor, is processed by proteases upon \nligand binding. The intramembraneous cleavage is similar to the APP cleavage and requires PS1. The released \nintracellular domain migrates to the nucleus, where it finally activates Notch target genes [120]. The crossover to the Notch pathway hampered attempts towards PS-/- knockout animals, which do not pass the embryonic state, but \nembryonic stem cells may fill part of the gap [121]. The intracellular trafficking of Notch in human CNS neurons is \nreduced by PS1 inhibitors and results in dramatic changes in neurite morphology. Maybe the Notch dysregulation causes the neuritic dystrophy observed in AD brain tissue [122]. Several other substrates are known to be cleaved by \n\uf067-secretase, which seems to be the \u201cproteasome of the me mbrane\u201d [8]. The relevance of the presenilin cofactors: \nPen-2, Aph-1, Nicastrin is well established [123], and even isoforms of these cofactors have been studied at detail \n[124], but the Nicastrin association to FAD was questioned recently [125]. Cell free \uf067-secretase assays are still an art, \ndespite the progress in kinetics and feasibility [126, 127]. Substrate optimisation was crucial for both \uf062-secretase and \n\uf067-secretase assays [128]. The localisation of the active site within the membrane and the cleavage within the membrane \nanchor of C99 turns \uf067-secretase inhibition into a rather slippery fish. Currently, there is only one related enzyme: the \nsignal peptide peptidase, which shares a number of the featur es and problems, but is inserted into the membrane by 7 \ntransmembrane helices [129]. A proposal for the arrangement of the transmembrane helices has been made, but it does not explain the observed cleavage pattern [130]. Moreover, th e importance of the cytoplasmic tail is not acknowledged \nin this model; two sequences of this tail are required fo r ER-retention and Nicastrin binding [131, 132]. The active site \nof \uf067-secretase is still subject to debate, but replacements of both Asp\n257 and Asp385 within the transmembrane regions \nof PS1 (and the analogue replacements in PS2) inhibit \uf067-secretase activity [133, 134]. Furthermore, these Asp257 \nmodifications significantly inhibited the Notch pathway. The Notch pathway may be a druggable target on its own; \napplications in oncology were claimed already [135].  \n\uf020\n \n \n  \n 39\uf067-SECRETASE INHIBITORS  \nNon-peptidic inhibitors of \uf067-secretase are known from the patents by Elan/Eli Lilly, Bristol Myers Squibb and \nDuPont. Peptidic PS1 inhibitors, like Merck\u2019s L-685,458 ( 30) [136-138] are still the most potent inhibitors [139-146]. \nLipophilic di- and tripeptides with bulky N-terminal protection are common inhibitors for \uf062-secretase and \uf067-secretase. \nLacking specificity and the inhibition of serine and cyst eine proteases makes the use of these aldehydes rather \ncumbersome, because the general protease inhibition resu lts in complex concentration activity relationships. \nObviously, this structural motif serves just a tool for a ssay development and labelling [147, 148], e.g. difluoro ketones \nwere used to block endoproteolysis of PS1 and to distinguish \uf067-secretase and the Notch receptor [129]. The inhibition \nby several difluoro ketones supported the point mutation analysis and confirmed the phenylalanine scan of APP [149]. \nThis scan strongly supported a unique \uf061-helical presentation of the C99 fragment to the \uf067-secretase. Initial attempts of \n\uf061-helix induction by \uf067-amino isobutyric acid (Aib) were not convincing [150, 151]. Yet, a surprising activity of an all \nD-tridecapeptide: Boc-VGAibVVIAibTVAIbVIAib-OMe (cell free IC 50 = 0.14 nM) was reported by Wolfe et al . \n[152] A more druglike tetrapeptide mimetic Boc- \uf059(Phe-Phe)- Leu-Val-OMe displayed a cellular IC 50 of 0.4 \u03bcM [129].  \nA giant leap forward was obtained by the serendipitous identification of Merck\u2019s L-685,458 ( 30, Scheme  6). This \npotent inhibitor (IC 50 = 17 nM), which bears lipophilic moieties, was part of several studies which indicate lipophilic \nbinding pockets (P2, P1, P1\u2019, P2\u2019, even P4' and P7') next to the cleavage site [153]. The inversion of the hydroxyethylene moiety reduced the inhibition 270fold. Labelling studies were conducted, linking biotin and photo reactive fragments N- or C-terminally to the core structure to furnish L-852,505 ( 32) and L-852,646 ( 33).  \nLabelled probes with a biotin moiety were isolated and identified by streptavidin enzyme linked conjugates. Both \nattachments of photo reactive benzophenones (L-852,646 ( 33), L-852,505 ( 32) retained potent inhibition (IC\n50 < 1 nM \nfor \uf067-secretase). \nPhotolysis of 32 in presence of solubilized \uf067-secretase-complex provided a protein of 20 kDa, which was identified \nto be PS 1-CTF by western blot. Control experiments revealed binding to wt PS1 but not to PS1 \uf044E9 was found [154]. \nComparative studies with 33 delivered a 34 kDa protein, which was identified to be PS1-NTF.  \nOHN NHN\nNHO\nOOH\nOO\nOOHNHN\nNHNH2\nOOH\nOO\nO\nOHN HN\nNHNH\nOOH\nOO\nOO\nHN\nOS\nHNNH\nO\nHNHN\nNHNH\nOOH\nOO\nOHN\nOS\nHNNH\nOO30 L-685,458  31 III-31-C\n 32  L-852,505\n33 L-852,646\n \nScheme 6. \uf067-Secretase inhibitors I.  \n \nFurther investigation of III-31-C ( 31, IC 50 < 300 nM), with a hydroxyurea transition state motif, on affi-gel 102 led \nto the identification of PS1-CTF, PS1-NTF and Nicastrin [155].  \nDisappointingly, all strategies to free active \uf067-secretase from the affinity gel failed. This is probably due to the high \nbinding affinity of 31 to the target protein complex and partially due to the deep and narrow binding site, which \nrequires strong denaturing conditions to break up the binding interactions.  \nThe co-precipitation of the inhibited \uf067-secretase with its substrates C83 and C99 gave rise to speculations about \nadditional binding sites, where the substrate is recognized prio r to transfer to the active site. These speculations are in \naccordance with the observed promiscuous nature of the clea vage, as they assign the specific recognition to other \ndomains [156-158].  \nTo this day very little structural information is available for the \uf067-secretase complex. Therefore selective, \nnon-peptidic \uf067-secretase inhibitors had to be provided by HTS efforts.  \n 40  DAPT ( 35), a promising inhibitor, was developed by Elan in 2001. DAPT, based on a N-dichlorophenylalanine \nlead, and the phenylglycine and the difluoro phenylacetic acid have been pegged as the crucial functionalities for activity [159]. DAPT is not a prodrug, despite the labile tertiary butyl ester, which may be cleaved at the low pH of the \ngut. The even more labile cyclopropyl methyl ester 36 displayed similar activity [160]. Replacements of the ester by \namides were tolerated, but primary alcohols were almost inactive [161]. The subcutaneous application to mice in a \ndosage of 100 mg/kg resulted in a 50% reduction of cortical A \uf062 levels within 3 hours. A 40% A \uf062 reduction was \nobserved at the dosage of 100 mg/kg orally, again after 3 hours, but no brain levels of DAPT were reported for the latter study. Moreover, there is evidence for the slow removal of tau lesions under DAPT treatment [162]. There were \nseveral reports of in vivo toxicity, mainly because DAPT affects the Notch pathway at higher levels (100-1000x) [134]. \nA biotinylated DAPT-based photo affinity label (DAPT-BB) was used to investigate the competition of sulindac- S (a \nNSAID) and L-685,458 ( 30) for the active site of PS1. DAPT-BB binds to the PS1-CTF. There was no competitive \nreplacement by Sulindac- S up to 100 \u03bcM. The displacement of DAPT-BB by L-685,458 ( 30) depended on the Chapso \nconcentration: full displacement at 0.25% Chapso, but only partial displacement at 1% [163].  \nFurther improvement and variation of the crucial functionalities of DAPT resulted in caprolactam 37 (LY411575), \nwhich is still the gold standard in the field and in LY450139 ( 38). DAPT, 37, and 38 were attached with a \ncross-linking moiety, like benzophenon or phenyldiazirine, as we ll as with biotin, in azide/alkyle fusion processes. A \nstrong A\uf062 secretion reduction shows affinity towards \uf067-secretase and subsequent photoaffinity experiments resulted in \nidentification of PS1-NTF as a target of 37 and 38, compared to the PS1-CTF targeting DAPT [164]. 37 halved plasma \nand cortical A \uf062 levels in young mice already at the oral dosage of 1 mg/kg and therefore 37 and its lesser active \ndiastereomer were administered [165] orally to C57BL/6 and TgCRND8 APP mice for 15 days at 1-10 mg/kg per day. \nThis resulted in the reduction of A \uf062 levels but also in atrophy of the thymus and deterioration of the intestinal \nepithelium. Only a 5-fold higher selectivity of APP (A \uf062\n40 IC50 = 0.082 nM) than Notch (Notch IC 50 = 0.39 nM) was \ndetermined in cellular assays: This small toxicity window will be a crucial issue for clinical trials. Curiously, the A \uf062 \nlowering abilities of DAPT like compounds are not effected by their sometimes poor blood brain barrier penetration.  \nNevertheless, E. Siemer et al.  continued in clinical investigations and reported phase I and II studies of LY450139 \n(38), a less potent but APP cleavage selective \uf067-secretase inhibitor. A 74% reduced A \uf062total with constant A \uf062 levels in \ncerebrospinal fluid (CSF) at an oral dosage of 40 mg/d after 14 days was observed in phase I. Similar data were \nreported in Phase II, with 70 AD patients: 38% plasma A \uf062 reduction with unchanged CSF levels and a secondary \neffect of Barrett oesophagus were observed. Fleisher et al.  reported Phase IIb results: They investigated 51 AD patients \nover a 14 weeks period with randomized doses (100 mg, 140 mg) or a placebo. The study reported reduced plasma \nA\uf06240 by 58% for the 100 mg group and 65% for the 140 mg group, but no significant reduction of CSF A \uf06240 (100 \nmg = 20%, 140 mg = 11%, Placebo = 6%). Three additional s econdary effects to the Barrett oesophagus of Phase II \nwere observed: 1) small bowel obstruction, 2) haemoglobin po sitive stool, and 3) diarrhoea. All in all no differences \nwere seen in cognitive or functional measures of any group [166, 167].  \nThus inhibition of APP processing in the periphery or enhanced clearance of peripheral A \uf062 by neprelysin [168] and \nother degrading enzymes [169] may hold a key for causal treatment.  \nBristol Myers Squibb and Merck [170, 171] disclosed 1000 derivatives of 4-Chloro- N-(2,5-difluorophenyl)-\nbenzenesulfonamides  39. 500 of these were reported to be very good inhibitors of \uf067-secretase activity. The activity \nclustered around the core structure 39, with a wide variation of the substituent R to modulate bioavailability. Less \nactive sulfonamides ( 40, IC 40 = 2 \u03bcMol, Scheme  7) were reported by Amgen and MSD, which featured similar \nbicycloalkane skeletons. They share the arylsulfonamide moiety with 39, but lack the crucial N-alkyl extension [172]. \nDuPont\u2019s hybrid structure 41 [173] bears both signatures of a dipeptide based SAR and a lead, which was identified \nfrom a matrix metalloproteinase (MMP) programme. Removal of the central amide bond of the parent dipeptide, the \nreplacement of the hydroxamic acid by an amide and the introduction of a caprolactam provided good activity and removed some of the problems associated with dipeptide leads. The potent compounds (IC\n50 = 20-90 nM) were related \nto DAPT-like compounds and hybrids of the two series. The difluorophenacyl-caprolactam derivative 42, stemming \nfrom a Scios/DuPont cooperation, proved to be the most potent compound (IC 50 = 0.3 nM) [174, 175].   \n 4135DAPT LY374973OHNO\nNH\nOO\nFF\nOHNO\nNH\nOO\nFF\n36BSc2019\n38LY450139OHNO\nN\nHN\nOHOOHNO\nNH\nFFOH\nN\nO\n37LY 411575\nIC50<1n M\nNF\nF\nS\nOO\nClR\n39 40AmgenHNSO\nOH2NHNO\nONO\nO I125\n41\nH\nNNHO\nNN\nOF\nO\nF42DuPontS\nO2HN\nNHN\nOO\nNN\nO\n43DuPont\nOHNO\nNH\nOHN\nFFNHNAr\n44MSDNN\nNHNHHN\nOCl\n45Boehringer Ingelheim46FlupirtinF\nHN N NH2\nNHCO2Et\n \n \nScheme 7. \uf067-Secretase inhibitors II.  \nDuPont Pharmaceuticals, which was taken over by Bristol- Myers Squibb, went on to elaborate the caprolactam motif \nand described a large number of derivatives in a patent family. Some effort was dedicated to modify the N-terminus in \norder to avoid patent infringement of Elan patents and resulted in the oxazolylsulfonamide 43 [176]. Another \nstraightforward attempt to bypass Elan claims is generalized in compound 44. Moreover, this series was claimed to be \ninactive on Notch signalling [177, 178]. Several other compounds or claims exist for hybrid structures of 36 and 41. A \ncommon feature is an aza caprolactam, which places the phenyl groups in a defined, twisted arrangement. Additional residues can be attached to the amide and the glycine is commonly exchanged for small spirocyclic amino acids or amide excision peptidomimetics. Unfortunately, activities for these compounds were not reported yet. Boehringer-\nIngelheim [179] disclosed diamino pyrimidines ( 45) as non-peptidic inhibitors of \uf067-secretase with an IC\n50 = 4 to \n1000 nM. The patent application is written in German and the most active compound is therefore hidden well. But the \nBI lead resembles flupirtin ( 46), which displayed beneficial effects on the cognitive function in humans [180, 181]. \nMSD bypassed the BMS claims for sulfonamide ( 39) by introduction of a cyclohexyl linker ( 47, Scheme  8). The \nseven-membered lactam reappeared in several MSD structures like 48 or 49 [182], but the insufficient Notch \nselectivity put an end to the promising candidate 48 [183, 184]. Elans N-bicyclic sulfonamide ( 50) was shown to \ninhibit A \uf062 production (IC 50 < 100 nM) even in a cell assay (293sw cells) [185]. Replacement of the sulfonamide \nmoiety by acetamide or sulfones resulted in derivatives like BMS-299897 ( 51) [186] or Scherings N-arylsulfonyl \nheterocyclic amines ( 52) (IC 50 = 1 nM to 1 \u00b5M) [187]. BMS-299897 reduces A \uf062 in brain, CSF and plasma of young \nmice with a 15-fold higher APP selectivity in vitro  (APP IC 50 = 7.1 nM, Notch IC 50 = 105.9 nM) in a dose and time \ndependent manner.  \n  \n 42 F\nF\nO2S\nClO\nNO\nSO2\n47MSD WO 02081435 48MSD (IC50=1 . 9n M )\n49MSD (IC50=0 . 0 7n M )NHN\nN\nHOOOH\nFF\nFNN\nN\nHO O\nCl\nONH2Cl\nS\nNNO O\nOCl\nHN N\n50Elan\nIC50<1 0 0n MFCOOH\nNSF\nFClOO\n51BMS-299897\nIC50=7 . 1n M\nN\nS\nClO OO\nO\nO\n52ScheringF\nFNNOH\nFF NSClFO OH\n53NCO2H\nF3C\n54MSD\nCOOH\nCF3OF3C\n56Cellzome\nIC50<1\u00b5 MNOCOOH\nSOO\n57Schmidt\nIC50(A\uf06242)=7 . 5\u00b5 MCF3COOH\n55Cellzome\nIC50<5 0\u00b5 M \n \nScheme 8. \uf067-Secretase inhibitors III.  \nMutational studies identified three amino acids (L172, T281, L282) at transmembrane domain 3 (TMD), to be \ncrucial for selective \uf067-secretase inhibition by sulfonamides like ELN318463 ( 53) and BMS-299897 ( 51). Zhou et al.  \nshowed a 6.4-fold reduced inhibition by 53 in a L282I mutant, what indicates a direct contact between 53 and L282. \nL172 and T281 in contrast have only an indirect influence on the inhibition potency [188]. These results implicate a \nmediation of \uf067-secretase activity by TMD 3.  \nMSD reported a selective \uf067-secretase modulator (GSM) (54), which reduces A \uf06242 levels with no effect on A \uf06240 and an \nincrease of A \uf06238 levels but constant A \uf062total levels. It seems the carboxylic acid is crucial for desired modulation. (no \ndata shown) [189, 190]. The carboxylic acid is also a motif in Cellzome\u00b4s S-enantiomers of \uf061-substituted arylacetic \nacids  \n(55) or biphenylacetic acids ( 56) and the most potent modulator of the series 56 displays an IC 50 < 1 \u00b5M in SKN \nneuroplast cells [191]. N-Sulfonylated and N-alkylated carbazolyloxy acetic acids have been presented as potent \nmodulators of \uf067-secretase [6]. Introduction of lipophilic substituents: arylsulfone or alkyl, turned 2-carbazolyloxyacetic \nacids into potent \uf067-secretase modulators (e.g. 57 IC50 (A\uf06242) = 7.5 \u00b5M).  \nNON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)  \nNegative outcomes have been reported for the nonsteroidal anti-inflammatory drugs prednisone, diclofenac, \nrofecoxib and naproxen [192]. But promising results were obtained with some COX-1 inhibitors [193-195], both in \nvitro and in a prospective, population-based cohort study of 6989 patients [196]. These convincing clinical results are \nstill in need of a sound rational and experimental validation. The proof of concept is still missing, despite the rapid progress. Potential modes of action were hinted or reporte d several times, but there is much heat and little light: \n\u201cNon-steroidal anti-inflammatory drugs may lower amyloidogenic A \uf062\n42\u201d by inhibition of Rho/ROCK [197]. Yet the \nRho/ROCK inhibitors were applied at concentrations several magnitudes higher than the required IC 50 for Rho/ROCK \ninhibition. In summary, just few NSAIDs ( 58-61 , Scheme  9) display the desired effect, and if they do so, by \nmodulation of \uf067-secretase.   \n 43NO\nO\nClOOH\n60Indomethacin\nA\u00df42IC50= 25-50 \u00b5MFOH\nO\n58R-Flurbiprof en\nIC50(A\uf06242)=3 0 7\u00b5 MOOH\nSF\n59Sulindac sulf ide\nIC50(A\uf06242)=3 4\u00b5 MOH\nO\n61Ibuprof en\nIC50(A\uf06242)=2 0 0\u00b5 M\nOOBiotinO\nON\nHO\nFCOOH\n62Flurbiprofen-benzophenone-biotin  \n \nScheme 9. NSAIDs effect on A \uf062 levels [28, 29]. \n Flurbiprofen 58 (10 and 25 mg/kg/d) elicits non-selective reductions in both A \uf0621-40 and A\uf0621-42 plasma levels, but \nwas found to be toxic. It produced small reductions in A \uf0621-40 in the cortex at 25 mg/kg/d, but did not affect A \uf062 levels \nin the hippocampus or CSF. Contrary to previous reports, sulindac sulfide ( 59) and ibuprofen ( 61) were found to be \nneither toxic nor efficacious at doses up to 50 mg/kg/d [198]. The striking discrepancies between these results and the \nprevious reports by Eriksen [193, 194] and Weggen [199] may be explained by the different methods used to extract \nbrain A\uf062: alkaline guanidine solution versus 70% formic acid. The kinetics of A \uf062 formation in the presence of the two \nNSAIDs and the displacement of an active site directed inhibitor support allosteric, non-competitive modes of action \nof Sulindac sulfide ( 59) and ( R)-Flurbiprofen ( 58) [200] at low concentrations. This results in selective inhibition of \nA\uf06242\uf020\uf020production. However, both NSAIDs shift their mode of action from modulation to complete, non-selective \ninhibition of \uf067-secretase at high concentrations. This remarkable pharmacological behaviour may be explained by the \nstabilisation of dimeric or multimeric enzyme.  \nThe R-enantiomere of flurbiprofen 58 (Flurizan\u00ae) lowered A \uf062 brain levels in murine models. A 12 month phase II \nstudy, with a dosage of 800 mg twice a day, indicated that 48%, of the patients, with a high drug concentration in blood (> 75 g/mL), had benefits in cognitive and behavioural appearance. Two of three study endpoints were achieved. \nHowever, the phase III clinic trial with more than 2400 pa tients failed in 2008 [155]. \u201cThe study did not achieve \nstatistical significance on either of its primary endpoints co gnition and activities of daily living\u201d (Myriad Homepage). \nThe lacking efficacy may be assigned to the poor blood brain barrier penetration of ( R)-flurbiprofen, which is < 5%. \nNevertheless, NSAID derivatives belong to an interesting class of modulators. Kukar  et al. recently reported \nphotoaffinity investigations with flurbiprofen-benzophenone-biotin ( 62), these studies concluded a direct binding of 62 \nto APP, A \uf062 and APP-CTF; but no targeting of this GSM to the \uf067-secretase-complex itself [201]. By contrast Weggen \net al.  and Page et al. identified sulinduc sulfide resistant mutants of PS1 at PS1 transmembrane domains: L166P \n(TMD3), M233V (TMD5) and the extracellular (P117L) [202].  These studies suggest a binding of the modulator to \nPS1 itself. Further investigations are required to determ ine the binding sites of individual NSAIDs and non-NSAID \nderived modulators. Eisai in partnership with Torrey Pi nes Therapeuticals developed E2012, a novel, more potent \n\uf067-secretase-modulator than Flurizan. The definite structure of E2012 is unknown, but a derivative of TorreyPines \nNGX555-series is depicted in Scheme  10.  \nNS\nNHN\nR\n63 NGX555-series  \nScheme 10.  Torrey Pines NGX555-series.  \nLenticular opacity was observed in rats during a 13-week high -dosage safety preclinical trial some side effects. The \nongoing phase I study was immediately suspended by the FDA in February 2007. However, the phase I study was resumed in April 2008 after additional safety studies: a 13-weeks safety study in monkeys, a single dose application at maximum dosage and a 4-week high dosage study in rats. (Torrey Pines Homepage)  \n  \n 44 INDIRECT APPROACHES- OR: DO OUR SOULS RESIDE IN FAT?  \nBrain cholesterol accounts for up to 25% of total body cholesterol and is turned over within a few months. \nIndividuals on a high-cholesterol diet are at increased ri sk to develop AD, but the cholesterol brain levels were \nunaffected in animal models. Some cholesterol lowering drugs  such as pravastatin and lovastatin resulted in reduced \nrisk for AD in retrospective trials. Paradoxically, prospectiv e trials resulted in a rather confusing situation with \ncontradicting outcome, most prospective trials failed to confirm a risk reduction for AD [202-205]. Simvastatin does \nnot reduce risk and pravastatin exerts the effect regardle ss of the blood-brain barrier (BBB) crossing [206, 207]. The \nanswer is not simple; both simvastatin and lovastatin pass the BBB in the prodrug form, prior to hydrolysis to the active acids, and can be detected in the CSF. The rationale fo r this activity is still subject to debate, but three important \nobservations may hold the clue for an explanation: 1.) hyperc holesterolemia results in increased levels of extractable \ntotal A\uf062 in mice 2.) BACE1 was found to be associated to cholesterol stabilized rafts [207] in the plasma membrane \nand 3.) activity of the benign \uf061-secretase is inversely related to choleste rol levels [208]. The relevance of these \ndifferent, yet concerted modes of actions remains to be established in humans, but transgenic mice respond to \nhypercholesterolemia by reduction of soluble A \uf062 [209]. The pleiotropic, non-lipid-related activities may be caused by \nthe inhibition of the isoprenoid synthesis downstream of HMG-CoA reductase, interfering with RAS and thus cell signalling [210]. A specific inhibitor of squalene synthase can inhibit the cholesterol biosynthesis, but does not block \nthe isoprenoid pathway leading to dolichol and ubiquinone. The potential of such inhibitors was published for the \ncholesterol-lowering BM15.766 ( 64, Scheme  11), which resulted in halved A \uf062 brain loads. The plasma A \uf062 levels \ncorrelated well with the plasma cholesterol [202], but the brain cholesterol went down by a meagre 11-13%, which may be explained by uncorrected cholesterol determination. RPR107393 ( 65) and its R- and S-enantiomers are potent \ninhibitors of rat liver microsomal squalene synthase (IC\n50 = 0.6 to 0.9 nM) and modulate A \uf062 levels in transgenic mice \n[13, 211].  \nHO2C\nN\nNCl\nN\nOHN\n65RPR10739364BM15.766\n \nScheme 11.  Cholesterol lowering drugs with impact on A \uf062 levels.  \n \nCOPPER AND CHELATORS  \nThe copper enhanced A \uf062 associated toxicity stimulated investigations of dietary copper and copper homeostasis in \nmice and men [212, 213]. The initial hypothesis had to be revised, as increased copper levels (0.25 g CuSO 4\u00b75 H 2O/L) \nin drinking water turned out to decrease A \uf062 levels in transgenic APP mice. A potential mode of action may be present \nin the reduced superoxide dismutase 1 activity. Metal chelators were frequently investigated to moderate copper levels \nin brain tissue, which were thought to be responsible for A \uf062 toxicity. However, in most in vitro studies, the copper \nconcentrations required to observe the effect were magnitudes higher than found in vivo . Studies in 20 patients with \nclioquinol 66 (Scheme  12), a metal chelator that crosses the blood-brain barrier readily and has similar affinity for zinc \nand copper ions, indicated interesting results. But the lack of a control group in the study left ample room for other \nexplanations, e.g. inflammation stimulus [214]. However, r ecent data from animal models support a benign impact of \nclioquinol on copper homeostasis. Clioquinol was found to mediate copper uptake and counteract copper efflux \nactivities of APP [215]. The improved selectivity of the quinol towards copper was addressed by Prana Biotechnology \n[216], who submitted a multitude of clioquinol analogues to a catalase type assay in the presence of A \uf062. Several \ninhibitors ( 66-69 ) were profiled in rats and the DMPK properties were communicated in a patent application.  \nThe clinical trials of PBT1 ( 67) were abandoned in phase II. Prana Biotechnology reported manufacturing problems as \nthe major reason for the step, as PBT1 was contaminated by process derived impurities which ruled out further investigation. The modified and improved follow up compound PBT2 completed double blinded phase II trials (12 weeks, oral, 50 or 250 mg/day) in September 2007. There were no clinically adverse findings, the higher dosage \nreduced A \uf062\n40 and A\uf06242 concentrations in cerebrospinal fluid (CSF). There was no significant effect on tau CSF levels. \nEfficacy of PBT2 could not be determined because of the small number of patients ( 74), but there were significant \nimprovements at 250 mg/d in the category fluency test [217-219].  \n  \n 45NOH\nI\nCl\n66Clioquinol 67PBT1056NOH\nCl\nNOH\nBr\nNOH\nI\nClNN\n68F FONHN\nN\n69PBT1050  \nScheme 12.  Clioquinols.  \nDIAGNOSTICS - MARKERS FOR AD  \nThe ongoing quest for a diagnostic tool for Alzheimer\u2019s disease has recently made great progress. Early stages of \nAlzheimer\u2019s Disease, at a point where no clinical symptoms  have occurred yet, may be detected with the help of \ntechnologies, such as measuring the cerebrospinal fluid (CSF) for biomarkers like total tau (T-tau), phospho-tau \n(P-tau) and A \uf0621-42/A\uf0621-40 [217-219]; magnetic resonance imaging (MRI) measuring hippocampal and entorhinal cortex \natrophy [220, 221]; fluoro-deoxy-glucose (FDG) positron emission tomography (PET) determining regional \nabnormalities in glucose and oxygen metabolism [222]. However, the large variation in the distribution and severity of both neurophathological changes and neurochemical abnormalities among AD cases renders it very difficult for a \nsingle biomarker to provide accurate results with high e nough sensitivity and specificity. Today, a passably true \ndiagnostic can only be achieved through combining methods, i. e. clinical assessment/ cognitive testing in conjunction \nwith neuroimaging technologies measuring markers such as structural and/ or metabolic changes [223]. Radiotracers \ndo not suffer from the severe drawback of biomarkers that demands CSF fluid sampling which excludes fragment \nsampling in large clinical trials. Moreover, a radiotracer may be more accurate as it directly measures the hallmarks of \nthe disease senile plaques (SPs) and neurofibrillar tangles (NFTs). Today, a combination of A \uf062 imaging and \n18F-fluorodeoxyglucose PET promises greater accuracy for distinguishing patients with mild AD from elderly controls \n[223]. Although being the hallmarks of AD, both amyloid and tau proteins occur in over one hundred different related \ndiseases. Therefore, a tremendous value would be added to an early diagnostic marker that can differentiate AD from other forms of dementia. Lack of such differentiation may cause false diagnosis leading to wrong and deleterious \n\u201ctreatment\u201d of patients. Furthermore, misdiagnoses can resu lt in false negatives in clinical trials, preventing a \npromising drug to reach the market, thus entailing major losses, both for the pharmaceutical company and for patients in hope for a cure. This chapter wi ll present the current status of in vivo  amyloid PET ligands investigated in humans.  \nThe \u201cproof of concept\u201d for human in vivo amyloid imaging was conducted with \n18FFDDNP ( 70) [224], 11C-PIB \n(71) [225], and 11C-SB13 ( 73) [226]. To date, several new radiotracers have been investigated in human AD patients \nby means of PET (Scheme 13).  \n1 [18F] 1,1-dicyano-2-[6-(dimethylamino)-2-naphtalenyl] propene (18FFDDNP) ( 70) [224].  \n2 N-methyl [11C] 2-(4\u00b4-methylaminophenyl)-6-hydroxy-benzothiasole (11C-PIB) ( 71) [225].  \n3 2-(3-[18F] fluoro-4-(methylamino)phenyl)benzo[ d]thiazol-6-ol (18F 3\u2019-F-PIB,  72) [227].  \n4 4-N-methyl[11C] amino-4\u00b4-hydroxystilbene (11C-SB13) ( 73) [226].  \n5 2-(2-[-dimethylaminothizol-5-yl]ethenyl)-6-(2-[fluoro]benzoxazole) (11C-BF-227,  74) [228].  \n6 trans -4-(N-methylamino)-4\u00b4-(2-[2-(2-[18F]fluoro-ethoxy)-ethoxy]-ethoxy)-stilbene (18F-BAY94-9172,  76)  \n[229].  \n7 ([S-methyl-[11C]]N,N-dimethyl-4-(6-(methylthio)imidazo[1,2-a]pyridine-2-yl)aniline) (11C-MeS-IMPY,  77)  \n[230, 231].  \n \n18FFDDNP  70 demonstrated a high signal intensity within the hippocampus, amygdala and entorhinal cortex, \nwhich are associated to areas with high levels of NFT deposition [232]. Slightly less ligand retention was observed in \nthe frontal cortical areas, which are associated with high SP load. This demonstrates certain specificity towards NFTs. \nFurthermore, the signal intensity from the NFT regions showed a correlation to the cognitive status [224]. In addition, with as little as 9% increase in binding compared to controls, ( 70) was able to distinguish all AD cases from control. \nHowever, the inconvenient 2-hour scan time makes it difficult to reproduce results with the same precision and \nprevents the tracer from becoming applied on a widespread clinical scope.  \nWith an estimated 500 human injections, \n11C-PIB ( 71) is the best studied radioligand. 71 has two binding sites: a \nhigh-affinity binding site with B max of 1,407 pmol/g and K d value of 2.5 nM, and a low-affinity binding site with B max \nof 13 nM and K d of 250 nM [233]. 71 also demonstrates an excellent brain uptake and rapid washout. 71 shows an  \n 46 80% increase in cortical binding in AD compared to cont rols, with a measuring time of approx. 20 minutes. A recent \n2-year follow-up PET study has shown that the amyloid load in an AD brain reaches a plateau, all the while a decline in cerebral glucose metabolism and cognitive deterioration can be observed [225, 234]. The plateau indicates a \ndifferent time course for the amyloid load in relation to the functional activity in the brain, possibly indicating the \npredromal stage of AD. This assumption was also supported by a study conducted with 17 mild cognitive impairment \n(MCI) patients. Seven patients who showed a high A \uf062 load (according to  71 retention) converted to AD. Interestingly, \nnon of the ten patients with low A \uf062 load developed AD [235, 236]. Furthermore, excellent correlation of episodic \nmemory and 71 retention in MCI patients was found while demonstrating poor correlation for AD patients [237]. In \nrecent studies, the Pittsburgh Probe ( 71) was able to discriminate AD from frontotemporal dementia (FTD) [238-240]. \nAt brain tissue autopsy, A \uf062 burden did not correlate with the poor cognitive status the late patient exhibited [241]. \nContrary to 70, 71 binds solely to A \uf062 plaques (at tracer concentrations). The above-mentioned results, in combination \nwith the findings from  70 trials suggest that amyloid detection may be a suitable target for early, preclinical detection \nof AD. NFT detection correlates better with the cognitive decl ine in later stages of the disease. Moreover, this idea is \nconsistent with the amyloid hypothesis, classing NFT formation as a downstream event of large SP depositions [242, \n243]. These results suggest that a diagnostic radiotracer for A \uf062 may provide us with a tool for early MCI detection of \ndementia. The 71 probe mainly suffers from two major drawbacks: its unspecific binding to white matter that makes it \ndifficult to analyze the images. Second, and more cr itical, is the short half-life (20.4 min) of the \n11C radioisotope, \nrestricting measurements to places with an on-site cyclotron affording immediate injection into patients. Recently, an \n18F analogue, with a half-life of 109.8 min, namely 18F 3\u2019-F-PIB ( 72), was developed by GE Healthcare and \ninvestigated in humans. With an injected activity of 185 MBq, the tracer showed a higher specific binding in the \ncortical regions, e.g. in the frontal and lateral temporal as well as the posterior cingulated cortex, than compared to \nhealthy controls. Although, a 20% higher white matter uptake was observed, this probe is suggested to be a valuable radiotracer due to its advantageously longer decay time of the \n18F radioisotope and the high cortical uptake. \n Structural analogues to 71 are the stilbene based ligands. The first stilbene ligand investigated in humans, \n11C-SB13 ( 73), showed uptake and retention patterns very similar to 71 [226]. All AD patients could be identified after \na 2-hour scan. An increased 73 uptake was observed in the frontal and posterior temporal-inferior parietal association \ncortices in the AD patients but not in the controls. However, 71 also differentiated from control in the temporal cortex \nof AD patients. When tried in normal rat brain, 73, with it\u2019s moderate lipophilicity (LogP = 2.36), showed a good brain \npenetration and washout after an i v injection [244] and demonstrated a B max value of 14-45 pmol/mg protein with a K d \nof 2.4 nM [245]. \n 11C-BF-227 ( 74) (K i value of 4.3 nM to A \uf0621-42 fibrils) was designed to improve BBB penetration and clearance \nfrom brain tissue [228]. The logP value was measured to 1.75 which is lower than that for 73, but higher than 71. The \nhigher lipophilicity might be the reason for the slower clearance of 74 compared to  71. A higher lipophilicity also \ncauses high nonspecific binding in the brain. Furthermore, compounds with higher lipophilicity bind better to plasma \nprotein and therefore undergo a more rapid metabolism by th e liver resulting in reduced brain uptake. The measured in \nvivo binding of  74 to A\uf062 deposits is lower than that for 71. A possible explanation is that 74 binds preferentially to \ndense amyloid fibrils and less strong to the diffuse plaques containing fewer A \uf062 fibrils. This might result in more \nspecific diagnosis of amyloid deposition in AD patients compared to normal aging or other forms of dementia.  74 also \naccommodates an 18F radioisotope, which is subject of ongoing investigations. However, much more research and \nimprovements are necessary before this ligand becomes a serious competitor to 71 or other ligands tested in humans.  \n7018F-FDDNPNC CN\nNF18\nNN\nN\nS\n7711C-MeS-IMPYNS\nNH\nC11H3\n7111C-PIBHO\nN\nO O18F\n7411C-BF-227NC11H3\nHO\n7311C-SB13\nNHO F18HO7218F3 ' - F - P I BNS\nNHHOF18\nSN\nC11H3\n7518F-FMAPO\nNH\nOOOF18\n7618F-BAY94-917211H3C\n \nScheme 13. AD imaging probes. \n  \n 47Two approaches have been adopted to circumvent the inherent lower lipophilicity of the 18F-labeled ligands [246]. \nAn additional hydroxy group was added onto a stilbene analogue affording 18F-FMAPO ( 75). Measured in a transgenic \nmouse model, 75 demonstrated an excellent brain penetration (5 .55 and 9.75% dose/g at 2 min) with rapid brain \nwashout [247]. B max was in the range of 10-20 pmol/mg in tissue. The ligand displayed high binding affinities for A \uf062 \nplaques in AD brain homogenates K i =5.0+- 1.2 nM. However, this compound has not yet been tested in human \nclinical trials.  \nA second approach to achieve better lipophilicity was to adopt various lengths of polyethylene glycol (PEG) tails. \nThere are many publications evaluating these compounds in vitro  and in vivo . Also, one such ligand has been \ninvestigated in humans. 18F-BAY949172 ( 76) has been shown to bind to A \uf062 plaques (K i = 6.7\u00b10.3 nM), but not to Pick \nbodies, Lewy Bodies, or glial cytoplasmic inclusions [229] . Tangle binding was observed at higher dosages only. For a \nradiotracer to be useful for clinical practice, it must allo w for short scanning time to reduce PET camera traffic. The \ndecay half-life must be long enough to allow centralized production with subsequent distribution to multiple PET sites \nin order to improve access to A \uf062 imaging in a cost-efficient manner. 76 was measured 90 minutes after injection and it \nwas able to distinguish AD from frontotemporal dementia. After 30 min of scan acquisition only, a binding \ndistribution identical to 71 and its long decay half-life from 18F, 76 clearly has favourable results compared to the ones \nreported in 71 PET studies. However, 71 has a higher degree of neocortical bi nding, approx. 70% compared to 57% in \n76 (9% for 70) [248]. The metabolic rate of  76 is similar to that of  71 [249]. Also, some troublesome radiometabolites \n(TR) of 76 cross the BBB due to their lipophilic nature and contribute to background brain radioactivity. Only \nlipophilic and non-charged molecules can cross the BBB. Th erefore, TR can be avoided by designing \u201csmart radio-\nligands\u201d. A \u201csmart radioligand\u201d carries the radioisotope on a group that when metabolized becomes a charged species \ntoo polar to cross the BBB.  \nA respective study was conducted with 11C-MeS-IMPY ( 77) [231]. Two analogues, one with the radiotracer on the \nthiomethyl group 77 and the other with the radiotracer on the N,N-dimethylamine group (MeS-IMPY-C11), were \nprepared and investigated. Interestingly, 77 demonstrated a superior washout of radioactivity to both MeS-IMPY-C11 \nand 71. This effect was assigned to the lower amount of TR in the brain. On the other hand, studies also indicated three \nmajor radiometabolites in various tissue compartments, all of which with less lipophilicity than the ligand itself. \nHowever, once the intact ligand entered the brain, it was protected from further metabolism [231]. Results from the \nclinical trials are underway and it remains to be seen if this compound is as promising in human clinical trials.  \nOUTLOOK  \nDespite the tremendous progress in the field, a \uf067-secretase inhibitor free of Notch activity is still in utter demand. \nThe selective inhibition of \uf067-secretase by NSAIDs is pointing in the right direction: allosteric modulation of the active \nsite, which can be identified by additional cleavage sites mediated by PS1. Confirmed, non-peptidic \uf067-secretase \ninhibitors are few and still have to reveal their true potenti al. Several compounds and vaccinations are entering phase II \nclinical trials and demand improved AD diagnostics. Actually, the vaccination may outpace the other therapies on the \nway to market. Dietary copper is unlikely to be a remedy for late stage AD, but may offer inexpensive prevention.   \n 48 REFERENCES  \n[1] WHO, The World Health Report 2001 Mental Health: New Understanding, New Hope , 2001 .  \n[2] Polvikoski, T.; Sulkava, R.; Myllykangas, L.; Notkola, I. L.; Niinisto, L.; Verkkoniemi, A.; Kainulainen, K.; Kontula, K.; Perez-Tur, J.; \nHardy, J.; Haltia, M. Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology, \n2001 , 56, 1690-6.  \n[3] Gil Gregorio, P.; Ramirez Diaz, S.P.; Ribera Casado, J.M. Dementia and Nutrition. Interven tion study in institutionalized p atients with \nAlzheimer disease. J. Nutr. Health Aging., 2003 , 7, 304-8.  \n[4] Thorsett, E.D.; Latimer, L.H. Therapeu tic approaches to Alzheimer\u2019s disease. Curr. Opin. Chem. Biol., 2000 , 4, 377-382.  \n[5] Grant, W.B. Dietary links to  Alzheimer's disease: 1999 update. J. Alzheimer's Dis., 1999 , 1, 197-201.  \n[6] Cummings, J.L. Alzheimer's disease. N. Engl. J. Med., 2004 , 351, 56-67.  \n[7] Chou, K.C. Insights from modeling the tertiary structure of human BACE2. J. Proteome Res., 2004 , 3, 1069-72.  \n[8] Mattson, M.P. Pathways towards a nd away from Alzheimer's disease. Nature, 2004 , 430, 631-9.  \n[9] Czech, C.; Adessi, C. Disease modifying therapeutic strate gies in Alzheimer's disease targeting the amyloid cascade. Curr. \nNeuropharmacol., 2004 , 2, 295-307.  \n[10] Mandelkow, E.-M.; Mandelkow, E. Tau in Alzheimer's disease. Trends Cell Biol., 1998 , 8, 425-427.  \n[11] Augustinack, J.C.; Schneider, A.; Mandelkow, E.-M.; Hyman, B.T. Specific tau phosphorylation sites correlate with severity  of \nneuronal cytopathology in Alzheimer's disease. Acta Neuropathol., 2002 , 103, 26-35.  \n[12] Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tam mer, A.; \nCarrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Da vis, S.; Beyreuther, K.; Tanzi,  R.E.; Masters, C.L. Metal-p rotein \nattenuation with iodochlorhydr oxyquin (clioquinol) targeting A \uf062 amyloid deposition and toxicity in Alzheimer disease: a pilot phase \n2 clinical trial. Arch. Neurol., 2003 , 60, 1685-91.  \n[13] Bush, A.I.; Masters, C.L.; Tanzi, R.E. Copper, \uf062-amyloid, and Alzheimer's disease: Tapping a sensitive connection. PNAS, 2003 , \n11193-1194.  \n[14] Altmann, P. Aluminium induced disease in subjects with an d without renal failure - does it help us understand the role of aluminium in \nAlzheimer's disease? Alum. Alzheimer's Dis., 2001 , 1-36.  \n[15] Fischer, F.; Matthisson, M.; Herrling, P. List of Drugs in Development for Neurodegenerative Disease. Neurodegener. Dis., 2004 , 1, 50.  \n[16] Kwon, M.-O.; Fischer, F.; Matthisson, M.; Herrling, P. Li st of Drugs in Development fo r Neurodegenerative Disease. Neurodegener. \nDis., 2004 , 1, 113-152.  \n[17] Luond, R.M.; Banziger, M.; Frey, P. Preparation of pipe ridine and piperazine derivatives as inhibitors of the A \uf062 fibril formation. \nWO0047571, 2000.  \n[18] Goldsbury, C.S.; Wirtz, S.; Muller, S.A.; Sunderji, S.; Wick i, P.; Aebi, U.; Frey, P. Studies on the in Vitro Assembly of A\uf0621-40: \nImplications for the Search for A \uf062 Fibril Formation Inhibitors. J. Struct. Biol., 2000 , 130, 217-231.  \n[19] Larbig, G.; Pickhardt, M.; Lloyd, D.G.; Schmidt, B.; Mandel kow, E. Screening for inhibitors of tau protein aggregation int o Alzheimer \npaired helical filaments: a ligand based appr oach results in successful scaffold hopping. Curr. Alzheimer Res., 2007 , 4, 315-323.  \n[20] Pickhardt, M.; Larbig, G.; Khlist unova, I.; Coksezen, A.; Meyer, B.; Mandel kow, E.-M.; Schmidt, B.; Mandelkow, E. \nPhenylthiazolyl-Hydrazide and Its Deri vatives Are Potent Inhibitors of \uf074-Aggregation and Toxicity in Vitro and in Cells. \nBiochemistry, 2007 , 46, 10016-10023.  \n[21] Bulic, B.; Pickhardt, M.; Khlistunova, I.; Biernat, J.; Ma ndelkow, E.M.; Mandelkow, E.; Wald mann, H. Rhodanine-based tau \naggregation inhibitors in cell models of tauopathy. Angew. Chem. Int. Ed. Engl., 2007 , 46, 9215-9.  \n[22] Howlett, D.R.; George, A.R.; Owen, D.E.; Ward, R.V.; Markwe ll, R.E. Common structural features determine the effectiveness  of \ncarvedilol, daunomycin and rolitetracyc line as inhibitors of Alzheimer \uf062amyloid fibril formation. Biochem. J., 1999 , 343, 419-423.  \n[23] Courtney, C.; Farrell, D.; Gray, R.; H ills, R.; Lynch, L.; Sellwood, E.; Edwards, S.; Hardyman, W.; Raftery, J.; Crome, P. ; Lendon, C.; \nShaw, H.; Bentham, P. Long-term donepezil treatment in 565 pa tients with Alzheimer's disease (AD2000): randomised double-blind \ntrial. Lancet, 2004 , 363, 2105-15.  \n[24] Jacobsen, J.S. Alzheimer's disease: an overv iew of current and emerging therapeutic strategies. Curr. Top. Med. Chem., 2002 , 2, \n343-352.  \n[25] Ikeda, S.; Yamada, Y.; Ikegami, N. Economic Evaluation of Donepezil Treatment for Alzheimer's Disease in Japan. Dementia Geriatr. \nCognit. Disord., 2002 , 13, 33-39.  \n[26] Carlson, M.C.; Brandt, J.; Steele, C.; Baker, A.; Stern, Y. ; Lyketsos, C.G. Predictor index of mortality in dementia patie nts upon entry \ninto long-term care. J. Gerontol. A Biol. Sci. Med. Sci., 2001 , 56, M567-70.  \n[27] AD2000 Collaborative Group, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised \ndouble-blind trial. Lancet, 2004 , 363, 2105-2115.  \n[28] Schneider, L.S. AD2000: donepezil in Alheimer's disease. The Lancet, 2004 , 363, 2100-2001.  \n[29] Witt, A.; Macdonald, N.; Kirkpatrick, P. Fr esh from the pipeline: me mantine hydrochloride. Nat. Rev. Drug Discov., 2004 , 3, 109-110.  \n[30] Bachmann, M.F.; Tissot, A.; Ortmann, R.; Lueoend, R.; Stau fenbiel, M.; Frey, P. Vaccine compositions containing amyloid \uf062\uf0201-6 \nantigen epitopes conjugated with viru s-like particles. WO 2004016282, 2004.  \n[31] Schenk, D.; Games, D.; Seubert, P. Immunotherapy with \uf062-amyloid peptide as a potential tr eatment for Alzheimer's disease. Neurosci. \nNews, 2000 , 3, 46-51.  \n[32] Nicoll, J.A.R.; Wilkin son, D.; Holmes, C.; Steart, P.; Markham, H.; Welle r, R.O. Neuropathology of human Alzheimer disease  after \nimmunization with amyloid-bold \uf062 peptide: a case report. Nat. Med., 2003 , 9, 448 - 452.  \n[33] Greenberg, S.M.; Bacskai, B.J.; Hyman, B.T. Alzheimer disease's double-edged vaccine. Nat. Med., 2003 , 9, 389 - 397.  \n[34] Abbott, A. Doctors seek lo st data on Alzheimer's vaccine. Nature, 2004 , 430, 715.  \n[35] Oddo, S.; Billings, L.; Kesslak, J.P.; Cribbs, D.H.; LaFerla, F.M. A \uf062 Immunotherapy Leads to Clearance of Early, but Not Late, \nHyperphosphorylated Tau Aggregates via the Proteasome. Neuron, 2004 , 43, 32132.  \n[36] Saunders, A.M. Gene identifi cation in Alzheimer's disease. Pharmacogenomics, 2001 , 2, 239-249.  \n[37] Holmes, C. Genotype and phenotype in Alzheimer's disease. Br. J. Psychiatry., 2002 , 180, 131-4.  \n[38] Tanzi, R.E.; Bertram, L. New frontiers in Alzheimer's disease genetics. Neuron, 2001 , 32, 181-4.  \n[39] Hardy, J. The Alzheimer family of di seases: many etiologies, one pathogenesis? PNAS, 1997 , 94, 2095-7.  \n[40] Hardy, J.; Myers, A.; Wavrant-De Vri eze, F. Problems and solutions in the genetic analysis of late-onset Alzheimer's disea se. \nNeurodegener. Dis., 2004 , 1, 213-7.  \n[41] Bertram, L.; Tanzi, R.E. Dancing in the dark? Th e status of late-onset Alzheimer's disease genetics. J. Mol. Neurosci., 2001 , 17, 127.  \n[42] Fraser, P.E.; Yang, D.-S.; Yu, G.; L\u00e9vesque, L.; Nishimura,  M.; Arawak, S.; Serpell, L.C.; Rogaev, E.; George-Hyslop, P.S.  Presenilin \nstructure, function and role in Alzheimer disease. BBA-Mol. Basis Dis., 2000 , 1502 , 1-15.  \n[43] Janus, C.; Westaway, D. Transgenic mouse models of Alzheimer's disease. Physiol. Behav., 2001 , 73, 873 \n886.  \n  \n 49[44] Schmitz, C.; Rutten Bart, P.F.; Pielen, A.; Schafer, S.; Wi rths, O.; Tremp, G.; Czech, C.; Blanchard, V.; Multhaup, G.; Re zaie, P.; Korr, \nH.; Steinbusch Harry, W.M.; Pradier, L.; Bayer Thomas, A. Hippocam pal neuron loss exceeds amyloid plaque load in a transgenic \nmouse model of Alzheimer's disease. Am. J. Pathol., 2004 , 164, 1495-502.  \n[45] Eckert, G.P.; Kirsch, C.; Leutz, S.; Wood, W.G.; Muller, W.E. Cholesterol modulates amyloid \uf062-peptide's membrane interactions. \nPharmacopsychiatry, 2003 , 36 Suppl 2 , S136-43.  \n[46] Moss, M.L.; White, J.M.; Lambert, M.H.; Andrews, R.C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. \nToday, 2001 , 6, 417-426.  \n[47] Kinoshita, A.; Whelan, C.M.; Smith, C.J.; Berezovs ka, O.; Hyman, B.T. Direct visualization of the \uf067-secretase-generated \ncarboxyl-terminal domain of the amyloid precursor protein: association with Fe65 and translocation to the nucleus. J. Neurochem., \n2002 , 82, 839-847.  \n[48] Kinoshita, A.; Whelan, C.M.; Berezovska, O.; Hyman, B.T. The \uf067-secretase-generated carboxyl-terminal domain of the amyloid \nprecursor protein induces apoptosis via Tip60 in H4 cells. J. Biol. Chem., 2002 , 277h , 28530-28536.  \n[49] Soto, C. Plaque busters: strategies to i nhibit amyloid formation in Alzheimer's disease. Mol. Med. Today, 1999 , 5, 343-350.  \n[50] Kayed, R.; Glabe, C.G. Immunogens and corresponding antibod ies specific for high molecular we ight aggregation intermediate s \ncommon to amyloids formed from proteins  of differing sequence. WO 2004024090, 2004.  \n[51] Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble a myloid \noligomers implies common mechanism of pathogenesis. Science, 2003 , 300, 486-9.  \n[52] Capell, A.; Steiner, H.; Willem, M.; Kaiser, H.; Meyer, C. ; Walter, J.; Lammich, S.; Multhaup, G.; Haass, C. Maturation an d pro-peptide \ncleavage of \uf067-secretase. J. Biol. Chem., 2000 , 275, 30849-54.  \n[53] Marcinkeviciene, J.; Luo, Y.; Graciani, N.R.; Combs, A.P.; Copeland,  R.A., Mechanism of inhibition of \uf062-site amyloid precursor \nprotein-cleaving enzyme (BACE) by a statine-based peptide. J. Biol. Chem., 2001 , 276, 23790-23794.  \n[54] Leung, D.; Abbenante, G.; Fairlie, D.P. Proteas e Inhibitors: Current Status and Future Prospects. J. Med. Chem., 2000 , 43, 305-341.  \n[55] Farzan, M.; Schnitzler, C.E.; Vas ilieva, N.; Leung, D.; Choe, H. BACE2, a \uf062-secretase homolog, cleaves at the \uf062\uf02dsite and within the \namyloid-\uf062 region of the amyloid- \uf062 precursor protein. PNAS, 2000 , 97, 9712-7.  \n[56] Yan, R.; Munzner, J.B.; Shuck, M.E.; Bie nkowski, M.J. BACE2 functions as an alternative \uf061-secretase in cells. J. Biol. Chem., 2001 , \n276, 34019-27.  \n[57] Westmeyer, G.G.; Willem, M.; Lichtenthaler, S.F.; Lurman, G.; Multhaup, G.; Assfalg-Machleid t, I.; Reiss, K.; Saftig, P.; Haass, C. \nDimerization of \uf062-site \uf062-amyloid precursor protein-cleaving enzyme. J. Biol. Chem., 2004 , 279, 53205-12.  \n[58] Fischer, F.; Molinari, M.; Bodendorf, U.; Paganetti, P. The di sulphide bonds in the catalytic domain of BACE are critical but not \nessential for amyloid precursor  protein processing activity. J. Neurochem., 2002 , 80, 1079-1088.  \n[59] Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B.D.; Babu-Khan, S.; Denis, P.; Fan, W.; Kha, H.; Zh ang, J.; Gong, Y.; Martin, L.; Louis, J.-C.; \nYan, Q.; Richards, W.G.; Citron, M.; Vassar, R. Mice deficient in BACE1, the Alzheimer's \uf062-secretase, have normal phenotype and \nabolished \uf062-amyloid generation. Nat. Neurosci., 2001 , 4, 231-232.  \n[60] Vassar, R. The \uf062-secretase, BACE: a prime drug target for Alzheimer's disease. J. Mol. Neurosci., 2001 , 17, 157-70.  \n[61] Gruninger-Leitch, F.; Schlatter, D. ; Kung, E.; Nelbock, P.; Dobeli, H. S ubstrate and inhibitor profile of BACE \uf062-secretase and \ncomparison with other mammalian aspartic proteases. J. Biol. Chem., 2002 , 277, 4687-4693.  \n[62] Roggo, S. Inhibition of BACE, a Promisi ng Approach to Alzheimer's Disease Therapy. Curr. Top. Med. Chem., 2002 , 2, 359-70.  \n[63] Dominguez, D.-I.; Hartmann, D.; De St rooper, B. BACE1 and Presenilin : Two Unusual Aspartyl Proteases Involved in Alzheimer 's \nDisease. Neurodegener. Dis., 2004 , 1, 168-174.  \n[64] Wolfe, M.S.; Haass, C.  The role of presenilins in \uf067-secretase activity. J. Biol. Chem., 2001 , 276, 54135416.  \n[65] Ishiura, S. New developments in amyloid secretases. Dementia Jpn., 2000 , 14, 236-239.  \n[66] Schmidt, B. Aspartic Proteases  Involved in Alzheimer's Disease. Chem. Bio. Chem., 2003 , 4, 366-378.  \n[67] John, V.; Beck, J.P.; Bienkowski, M.J.; Sinha, S.; Heinrikson, R.L. Human \uf062-secretase (BACE) and BACE inhibitors. J. Med. Chem., \n2003 , 46, 4625-30.  \n[68] Grosch, H.-W.; Kunzel, U.; Hummel, M.; Henseler, M.; Sandhof f, K.; Hasilik, A. Trafficking and processing of cathepsin D. Biomed. \nHealth Res., 1997 , 13, 229-233.  \n[69] Haass, C. Take five-BACE and the \uf067-secretase quartet conduct Alzheimer's amyloid \uf062-peptide generation. EMBO J., 2004 , 23, 483-488.  \n[70] Hong, L.; Turner, R.T.; Koelsch, G.; Shin, D.; Ghosh, A.K.; Tang, J. Crystal structure of memapsin 2 ( \uf062 secretase) in complex with an \ninhibitor OM00-3. Biochemistry, 2002 , 41, 10963-7.  \n[71] Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A.K.; Zhang, X.C.; Tang, J. Structure of the protease domain o f memapsin \n2 (\uf062-secretase) complexed with inhibitor. Science, 2000 , 290, 150-153.  \n[72] Silvestri, R. Boom in the development of non-peptidic \uf062-secretase (BACE1) inhibito rs for the treatment of Alzheimer's disease. Med. \nRes. Rev., 2008 .  \n[73] Limongelli, V.; Marinelli, L.; Cosconati, S.; Braun, H.A.; Schmidt, B.; Novellino, E. Ensemble-Docking Approach on BACE-1:  \nPharmacophore Perception and Guidelines for Drug Design. Chem. Med. Chem., 2007 , 3, 667-678.  \n[74] Hong, L.; Tang, J. Flap  position of free memapsin 2 ( \uf062-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry, \n2004 , 43, 4689-95.  \n[75] Hong, L.; Turner, I.R.T.; Koelsch, G.; Ghosh, A.K.; Tang, J. Memapsin 2 ( \uf062-secretase) as a therapeutic target. Biochem. Soc. Trans., \n2002 , 30, 530-4.  \n[76] Tung, J.S.; Davis, D.L.; Anderson, J.P.; Walker, D.E.; Mamo, S.; Jewett, N.; Hom, R. K.; Sinha, S.; Thorsett, E.D.; John, V. Design of \nsubstrate-based inhibitors of human \uf062-secretase. J. Med. Chem., 2002 , 45, 259-62.  \n[77] Shuto, D.; Kasai, S.; Kimura, T.; Liu, P.; Hidaka, K.; Hama da, T.; Shibakawa, S.; Hayashi, Y.; Hattori, C.; Szabo, B.; Ish iura, S.; Kiso, \nY. KMI-008, a novel \uf062-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and \nsynthesis of substrate-based octapeptides. Bioorg. Med. Chem. Lett., 2003 , 13, 4273-6.  \n[78] Tamamura, H.; Kato, T.; Otaka,  A.; Fujii, N. Synthesis of potent \uf062-secretase inhibitors containing a hydroxyethylamine dipeptide \nisostere and their structure-activity relationship studies. Org. Biomol. Chem., 2003 , 1, 2468-2473.   \n 50 [79] Brady, S.F.; Singh, S.; Crouthamel, M.C.; Holloway, M.K.; Coburn, C.A.; Garsky, V. M.; Bogusky, M.; Pennington, M.W.; Vacc a, J.P.; \nHazuda, D.; Lai, M.T. Rationa l design and synthesis of se lective BACE-1 inhibitors. Bioorg. Med. Chem. Lett., 2004 , 14, 601-4.  \n[80] Ghosh, A.K.; Bilcer, G.; Harwood, C.; Kawahama, R.; Shin, D. ; Hussain, K.A.; Hong, L.; Loy, J.A.; Nguyen, C.; Koelsch, G.;  \nErmolieff, J.; Tang, J. Structure-based design: potent inhibitors of human brain memapsin 2 ( \uf062-secretase). J. Med. Chem., 2001 , 44, \n2865-8.  \n[81] Chen, S.H.; Lamar, J.; Guo, D.; Kohn, T.; Yang, H.C.; McGee, J.; Timm, D.; Erickson, J.; Yip, Y.; May, P.; McCarthy, J. P3  cap \nmodified Phe*-Ala series BACE inhibitors. Bioorg. Med. Chem. Lett., 2004 , 14, 245-50.  \n[82] Lamar, J.; Hu, J.; Bueno, A.B.; Yang, H.C.; Guo, D. ; Copp, J.D.; McGee, J.; Gitter, B.; Timm, D.; May, P.; McCarthy, J.; C hen, S.H. \nPhe*-Ala-based pentapeptid e mimetics are BACE inhibitors: P2 and P3 SAR. Bioorg. Med. Chem. Lett., 2004 , 14, 239-43.  \n[83] Hu, B.; Fan, K.Y.; Bridges,  K.; Chopra, R.; Lovering,  F.; Cole, D.; Zhou, P.; Ellingboe, J.; Jin, G.; Cowling, R.; Bard, J . Synthesis and \nSAR of bis-statine based peptides as BACE 1 inhibitors. Bioorg. Med. Chem. Lett., 2004 , 14, 3457-3460.  \n[84] Hom, R.K.; Fang, L.Y.; Mamo, S.; Tung, J.S.; Guinn, A.C.; Walker, D.E.; Davis, D. L.; Gailunas, A.F.; Thorsett, E.D.; Sinh a, S.; \nKnops, J.E.; Jewett, N.E.; Anderson, J.P.; J ohn, V. Design and synthesis of statine-ba sed cell-permeable pept idomimetic inhibit ors \nof human \uf062-secretase. J. Med. Chem., 2003 , 46, 1799-802.  \n[85] Hom, R.K.; Gailunas, A.F.; Mamo, S.; Fang, L.Y.; Tung, J.S.; Walker, D.E.; Davis, D.; Thorsett, E.D.; Jewett, N.E.; Moon, J.B.; John, \nV. Design and synthesis of hydroxyethylene- based peptidomimetic inhibitors of human \uf062-secretase. J. Med. Chem., 2004 , 47, \n158-64.  \n[86] Maillaird, M.; Hom, C.; Gailunas, A. ; Jagodzinska, B.; Fang, L.Y.; John, V.; Fr eskos, J.N.; Pulley, S.R.; Beck, J.P.; Tenb rink, R.E. \nPreparation of substituted amines to treat  Alzheimer's disease. WO 0202512, 2002.  \n[87] Beck, J.P.; Gailunas, A.; Hom, R.; Jagodzinska, B.; John, V. ; Maillaird, M. Compounds to treat Alzheimer\u2019s disease. WO 020 2520, \n2002.  \n[88] Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C.W.; Y on, J. Apo and Inhibitor Complex Structures of BACE ( \uf062-secretase). J. Mol. Biol., \n2004 , 343, 407-416.  \n[89] Uchikawa, O.; Aso, K.; Koike, T.; Tarui, N.; Hirai, K. Preparation of benzamide derivatives as \uf062-secretase inhibitors. WO 2004014843, \n2004.  \n[90] Demont, E.H.; Faller, A.; MacPherson, D.T.; Milner, P.H.; Naylor, A.; Redshaw, S. ; Stanway, S.J.; Vesey, D.R.; Walter, D.S . \nPreparation of hydroxethylamine derivatives for the tr eatment of Alzheimer's disease. WO 2004050619, 2004.  \n[91] Pulley, S.R.; Beck, J.P.; Tenbrink, R.E.; Jacobs, J.S. Prepar ation of macrocycles useful in the treatment of Alzheimer's d isease. \nWO 2002100399, 2002.  \n[92] Reeder, M.R. Processes for the synthe sis of amino acid-related benzyl epoxides used in the production of pharmaceutical ag ents. \nWO 2002085877, 2002.  \n[93] Tenbrink, R.; Maillard, M.; Warpehoski, M. Pr eparation of substituted hydroxyethylamines as \uf062-secretase inhibitors. WO 0350073, \n2003.  \n[94] Fang, L.Y.; Hom, R.; John, V.; Mailla ird, M. Preparation of substituted amines  for treating Alzheimer's disease. WO 020250 5, 2002.  \n[95] Fang, L.Y.; John, V. Compounds to treat Alzheimer's disease. WO 0202506, 2002.  \n[96] Fobian, Y.M.; Freskos, J.N.; Jagodz inska, B. A preparation of 1,3-diamino-2- hydroxypropane derivatives as \uf062-secretase enzyme \ninhibitors. WO 2004022523, 2004.  \n[97] Vuillard, L.M.M.; Patel, S.J.; Yon, J.R.; Cleasby, A.; Hamilt on, B.J.; Shah, A. Crystal structure of human _-secretase mut ants and drug \ndiscovery applications. WO 2004011641, 2004.  \n[98] Yang, W. Preparation of amino carboxamide derivativ es as aspartyl protease inhibitors. WO 2004147454, 2004.  \n[99] Brockhaus, M.; Doebeli, H.; Grueninger, F.; Huguenin, P. ; Kitas, E.A.; Nelboeck-Hochste tter, P. Fluorescence and competiti ve \nradioligand binding assays for identifying \uf062-secretase inhibitors and for screening agents  for treatment of Alzheimer's disease and \ncerebrovascular amyloidosis. WO 2003125257, 2003.  \n[100] Brockhaus, M.; Doebeli, H.; Grueninger, F.; Huguenin, P.; Kitas, E.A.; Nelboeck-Hochstetter, P. Assay for identifying \uf062-secretase \ninhibitors. WO 20030125257, 2003.  \n[101] Miyamoto, M.; Matsui, J.; Fukumoto, H.; Tarui, N. Preparation of 2-[2-amino- or 2-( N-heterocyclyl) ethyl]-6-(4-biphenylylmethoxy)-\ntetralin derivatives as \uf062-secretase inhibitors. WO 0187293, 2001.  \n[102] Qiao, L.; Etcheberrigaray, R. Preparation of phosphinylme thyl and phosphorylmethyl succinic and glutaric acid analogs as \uf062-secretase \ninhibitors useful in the treatment of Alzheimer's disease. WO 2002096897, 2002.  \n[103] Ramakrishna, N.V.S.; Kumar, E.K.S.V.; Kulkarni, A.S.; Jain , A.K.; Bhat, R.G.; Parikh, S.; Quadros, A.; Deuskar, N.; Kalak oti, B.S. \nScreening of natural products for new leads as inhibitors of \uf062-amyloid production: Latifolin from Dalbergia sissoo. Ind. J. Chem. \nSect. B. Org. Chem. Incl. Med. Chem., 2001 , 40B, 539-540.  \n[104] Bhisetti, G.R.S.J.O.; Murcko, M.A.; Lepre, C.A.; Britt, S.D.; Come, J.H.; De ninger, D.D.; Wang, T. Preparation of \uf062-carbolines and \nother inhibitors of BACE-1 aspartic proteinase useful agai nst Alzheimer's and other BACE-m ediated dieseases. WO 2002088101, \n2002.  \n[105] Park, H.; Lee, S. Determination of the active site protonation state of \uf062-secretase from molecular dynamics simulation and docking \nexperiment: implications for st ructure-based inhibitor design. J. Am. Chem. Soc., 2003 , 125, 16416-22.  \n[106] Boss, C.; Bur, D.; Fischli, W.; Jenck, F.; Weller, T. Prep aration of piperidines for the treatment of central nervous sys tem disorders. \nWO 2004009549, 2004.  \n[107] Boss, C.; Bur, D.; Fischli, W.; Jenc k, F.; Weller, T. Preparation of substitute d 3- and 4-(aminomethyl) piperidines for u se as \n\uf062-secretase inhibitors in the treatment of  Alzheimer's disease. WO 2004002483, 2004.  \n[108] Coburn, C.A.; Stachel, S.J.; Vacca, J.P. Pr eparation of phenylcarboxamide derivatives as \uf062-secretase inhibitors for the treatment of \nAlzheimer's disease. WO 2004043916, 2004.  \n[109] Coburn, C.A.; Stachel , S.J.; Vacca, J.P. Preparation of macrocyclic \uf062-secretase inhibitors for treatment of Alzheimer's disease. \nWO 2004062625, 2004.  \n[110] Holloway, M.K.; Culberson, J.C.; Shpungin, J.; Munshi, S.; Coburn, C.A.; Stachel, S.J.; Jones, K.G.; Loutzenhiser, E.; Gr egro, A.R.; \nLai, M.-T.; Crouthamel, M.-C.; Pietrak, B. L. Evaluating scoring functions  for docking and designing \uf062-secretase inhibitors. \nAbstracts of Papers, 228th ACS National Meeting, Philadelphia, PA, United States, August 22-26, 2004 .  \n[111] Rajamani, R.; Reynolds, C.H. Modeling the pr otonation states of the catalytic aspartates in \uf062-secretase. J. Med. Chem., 2004 , 47, \n5159-66.  \n[112] Tounge, B.A.; Reynolds, C.H. Calculation of the Binding Affinity of \uf062-Secretase Inhibitors Using th e Linear Interaction Energy \nMethod. J. Med. Chem., 2003 , 46, 2074-2082.  \n[113] Coburn, C.A.; Stachel, S.J.; Li, Y.-M.; Rush, D.M.; Steele,  T.G.; Chen-Dodson, E.; Holloway, M.K.; Xu, M.; Huang, Q.; Lai , M.-T.; \nDiMuzio, J.; Crouthamel, M.-C.; Shi, X.-P.; Sardana, V.; Chen, Z.; Munshi, S.; Kuo, L.; Makara, G.M.; Annis, D.A.; Tadikonda, \nP.K.; Nash, H.M.; Vacca, J.P. Identification of a Small Molecule Nonpeptide Active Site \uf062-Secretase Inhibitor That Displays a \nNontraditional Binding Mode for Aspartyl Proteases. J. Med. Chem., 2004 , 47, 6117-6119.   \n 51[114] Stachel, S.J.; Coburn, C.A.; Steele, T.G.; Jones, K.G.; Lout zenhiser, E.F.; Gregro, A.R.; Rajapakse, H.A.; Lai, M.-T.; Cr outhamel, \nM.-C.; Xu, M.; Tugusheva, K.; Lineberger, J.E.; Pietrak, B.L.; Espeseth, A.S.; Shi, X.-P.; Chen-Dodson, E.; Holloway, M.K.; \nMunshi, S.; Simon, A.J.; Kuo, L.; Vacca, J. P. Structure-Based Design of Potent and Se lective Cell-Permeable Inhibitors of Human  \n\uf062-Secretase (BACE-1) J. Med. Chem., 2004 , 47, 6447-6450.  \n[115] Willems, H. Preparation of piperazines as \uf062-amyloid converting enzyme (BACE) inhibitors  for the treatment of Alzheimer's disease. \nWO 2004020422, 2004.  \n[116] Willems, H.; Gordon, R. Protected am ino acid derivatives for the treatment of  Alzheimer's disease. GB 2392443, 2004.  \n[117] Willems, H.; Harris, W.; John, D.E. A preparati on of triazinoindole derivatives as inhibitors of \uf062-secretase (BACE), useful in the \ntreatment of Alzheimer's disease. WO 2004063196, 2004.  \n[118] Willems, H.; Harris, W.H. Preparation of N-sulfonyl amino acid derivatives for the treatme nt of Alzheimer's di sease. WO 2004020402, \n2004.  \n[119] De Strooper, B.; Annaert, W. Where not ch and Wnt signaling meet: the presenilin hub. J. Cell Biol., 2001 , 152, F17-F19.  \n[120] Herreman, A.; Serneels, L.; Ann aert, W.; Collen, D.; Schoonjans, L.; De  Strooper, B. Total inactivation of \uf067-secretase activity in \npresenilin-deficient embryonic stem cells. Nat. Cell Biol., 2000 , 2, 461-2.  \n[121] Figueroa, D.J.; Morris, J.A.; Ma , L.; Kandpal, G.; Chen, E.; Li, Y.M. ; Austin, C.P. Pr esenilin-dependent \uf067-secretase activity modulates \nneurite outgrowth. Neurobiol. Dis., 2002 , 9, 49-60.  \n[122] Kopan, R.; Ilagan, M.X. \uf067-Secretase: proteasome of the membrane? Nat. Rev. Mol. Cell Biol., 2004 , 5, 499-504.  \n[123] Shirotani, K.; Edbauer, D.; Prokop, S.; Haass, C.; Steiner, H. Identification of distinct \uf067-secretase complexes with different APH-1 \nvariants. J. Biol. Chem., 2004 , 279, 41340-5.  \n[124] Cousin, E.; Hannequin, D.; Mace, S.; D ubois, B.; Ricard, S.; Genin, E.; Brun, C.; Chansac, C.; Pradier, L.; Frebourg, T.;  Brice, A.; \nCampion, D.; Deleuze, J.F. No replicati on of the association between the Nicastrin gene and familial early-onset Alzheimer's \ndisease. Neurosci. Lett., 2003 , 353, 153-5.  \n[125] Edbauer, D.; Winkler, E.; Regula, J.T.; Peso ld, B.; Steiner, H.; Haass, C. Reconstitution of \uf067-secretase activity. Nat. Cell Biol., 2003 .  \n[126] Turner, R.T.; Loy, J.A.; Nguyen, C.; Devasamudram, T.; Ghosh, A.K.; Koelsch, G.; Tang, J. Specificity of memapsin 1 and i ts \nimplications on the design of memapsin 2 ( \uf062-secretase) inhibitor selectivity. Biochemistry, 2002 , 41, 8742-6.  \n[127] Farmery, M.R.; Tjernberg, L.O.; Pursglove, S.E.; Bergman, A.; Winblad, B.; Naslund, J. Partial Purification and Character ization of \uf067-\nSecretase from Post-mortem Human Brain. J. Biol. Chem., 2003 , 278, 24277-24284.  \n[128] Weihofen, A.; Binns, K.; Lemberg, M.K.; Ashman, K.; Martogl io, B. Identification of signal peptide peptidase, a presenili n-type \naspartic protease. Science, 2002 , 296, 2215-8.  \n[129] Lichtenthaler, S.F.; Wang, R.; Grimm, H.; Uljon, S.U.; Ma sters, C.L.; Beyreuther, K. Mech anism of the cleavage specifity of \nAlzheimer's disease \uf067-secretase identified by phenylala nine-scanning mutagenesis of the tr ansmembrane domain of the amyloid \nprecursor protein. PNAS, 1999 , 96, 3053-3058.  \n[130] Kaether, C.; Capell, A.; Edbauer, D.; Winkler, E. ; Novak, B.; Steiner, H.; Haass, C. The presenilin C-terminus is required for \nER-retention, nicastrin-binding and \uf067-secretase activity. Embo J., 2004 , 23, 473848.  \n[131] Wolfe, M.S.; Xia, W.; Osta szewski, B.L.; Diehl, T.S.; Kimberly, W.T.; Sel koe, D.J. Two transmembrane aspartates in presen ilin-1 \nrequired for presenilin endoproteolysis and \uf067-secretase activity. Nature, 1999 , 398, 513-7.  \n[132] Kimberly, W.T.; Xia, W.; Rahmati, T.; Wolfe, M.S.; Selkoe , D.J. The Transmembrane Aspartat es in Presenilin 1 and 2 Are Ob ligatory \nfor \uf067-Secretase Activity and Amyloid \uf062-Protein Generation. J. Biol. Chem., 2000 , 275, 3173-3178.  \n[133] Paris, D.; Mullan, M.J. Anti-angiogenic and anti-tumoral properties of \uf062- and \uf067-secretase inhibitors. WO 2004073630, 2004.  \n[134] Kan, T.; Tominari, Y.; Rikimaru, K.; Morohashi, Y.; Natsugari, H.; Tomita, T.; Iwatsubo, T.; Fukuyama,  \nT. Parallel synthesis of DAPT derivatives and their \uf067-secretase-inhibitory activity. Bioorg. Med. Chem. Lett., 2004 , 14, 1983-1985.  \n[135] Shearman, M.S.; Beher, D.; Clarke, E.E.; Lewis, H.D.; Harri son, T.; Hunt, P.; Nadin, A.; Smith, A.L.; Stevenson, G.; Cast ro, J.L. \nL-685,458, an Aspartyl Protease Transition State Mimic, Is a Potent Inhibitor of Amyloid \uf062-Protein Precursor \uf067-Secretase Activity. \nBiochemistry, 2000 , 39, 8698-704.  \n[136] Nadin, A.J.; Stevenson, G.I. Preparation of peptides as \uf067-secretase inhibitors. WO 0177144, 2001.  \n[137] Nadin, A.; Owens, A.P.; Castro, J.L.; Harrison, T.; Shearman, M.S. Synthesis and \uf067-secretase activity of APP substrate-based \nhydroxyethylene dipeptide isosteres. Bioorg. Med. Chem. Lett., 2003 , 13, 37-41.  \n[138] Nadin, A.; L\u00f3pez, J.M.S. ; Neduvelil, J.G.; Thomas, S.R. A stereocontrolled synthesis of 2 R-benzyl-5 Stert-butoxycarbonylamino-4 R-\n(tert-butyldimethylsilanyloxy)-6-phenyl-hexanoic acid (Phe-Phe hydroxyethylene dipeptide isostere). Tetrahedron, 2001 , 57, 1861-\n1864.  \n[139] Moore, C.L.; Leatherwood, D.D.; Diehl, T.S.; Selkoe, D.J. ; Wolfe, M.S. Difluoro Ketone Peptidomimetics Suggest a Large S1  Pocket \nfor Alzheimer's \uf067-Secretase: Implications for Inhibitor Design. J. Med. Chem., 2000 , 43, 3434-3442.  \n[140] Wolfe, M.S. __Secretase inhibitors as molecular pr obes of presenilin function. J. Mol. Neurosci., 2001 , 17, 199-204.  \n[141] Campbell, W.A.; Iskandar, M.K.; Reed, M.L.; Xia, W.  Endoproteolysis of presenilin  in vitro: inhibition by \uf067-secretase inhibitors. \nBiochemistry, 2002 , 41, 3372-9.  \n[142] Petit, A.; Bihel, F.; Alves da Cost a, C.; Pourquie, O.; Checler, F.; Kraus,  J.-L. New protease inhibitors prevent \uf067-secretase-mediated \nproduction of A \uf06240/42 without affecting Notch cleavage. Nat. Cell Biol., 2001 , 3, 507-511.  \n[143] Zhang, L.; Song, L.; Terracina, G.; Liu, Y.; Praman ik, B.; Parker, E. Biochemi cal Characterization of the \uf067-Secretase Activity That \nProduces \uf062-Amyloid Peptides. Biochemistry, 2001 , 40, 5049-5055.  \n[144] Berezovska, O.; Jack, C.; McLean, P.; Aster, J.C.; Hicks, C.; Xia, W.; Wolfe, M.S.; Kimberly, W.T.; Weinmaster, G.; Selko e, D.J.; \nHyman, B.T. Aspartate mutations in presenilin and \uf067-secretase inhibitors both impair Notch1 proteolysis and nuclear translocation \nwith relative preservation of Notch1 signaling. J. Neurochem., 2000 , 75, 583-593.  \n[145] Wolfe, M.S.; Xia, W.; Moore, C.L.; Leatherwood, D.D.; Osta szewski, B.; Rahmati, T.; Donkor, I.O.; Selkoe, D.J. Peptidomim etic \nprobes and molecular modeling suggest that Alzheimer's \uf067-secretase is an intramembrane-cleaving aspartyl protease. Biochemistry, \n1999 , 38, 4720-7.  \n[146] Wolfe, M.S.; Citron, M.; Diehl, T.S.; Xia, W.; Donkor, I.O. ; Selkoe, D.J. A Substrate-Based Difluoro Ketone Selectively I nhibits \nAlzheimer's \uf067-Secretase Activity. J. Med. Chem., 1998 , 41, 6-9.  \n[147] Doerfler, P.; Shearman, M.S.; Pe rlmutter, R.M. Presenilin-dependent \uf067-secretase activity modulates thymocyte development. PNAS, \n2001 , 98, 9312-9317.  \n[148] Roncarati, R.; Sestan, N.; Scheinfeld , M.H.; Berechid, B.E.; Lopez, P.A.; Meucci, O.; McGlade, J.C.; Rakic, P.; D'Adamio,  L. The \n\uf067-secretase-generated intracellular domain of \uf062-amyloid precursor protein binds Numb and inhibits Notch signaling. PNAS, 2002 , \n99, 7102-7107.  \n[149] Das, C.; Wolfe, M.S.; Tsai, J.-Y.; Diehl, T.S. Designed helical peptides as \uf067-secretase inhibitors. Abstracts of Papers, 223rd ACS \nNational Meeting, Orlando, FL, United States, April 7-11, 2002 , MEDI-011.  \n[150] Wolfe, M.S. Helical pep tidomimetics as inhibitors of \uf062-amyloid production, and therapeutic use thereof. WO 2003068168, 2003.   \n 52 [151] Bihel, F.; Das, C.; Bowman, M.J.; Wolfe, M.S. Discove ry of a Subnanomolar Helical D-Tridecapeptide Inhibitor of \uf067-Secretase. J. \nMed. Chem., 2004 , 47, 3931-3933.  \n[152] Bakshi, P.; Wolfe, M.S. Stereochemical Analysis of (Hydroxyethyl)urea Peptidomimetic Inhibitors of \uf067-Secretase. J. Med. Chem., \n2004 , 47, 6485-6489.  \n[153] McLendon, C.; Xin, T.; Ziani-Cherif, C.; Murphy, M.P.; Findl ay, K.A.; Lewis, P.A.; Pinnix, I.; Sambamurti, K.; Wang, R.; Fauq, A.; \nGolde, T.E. Cell-free assays for \uf067-secretase activity. FASEB J., 2000 , 14, 2383-6.  \n[154] Esler, W.P.; Kimberly, W.T.; Ostaszew ski, B.L.; Ye, W.; Diehl, T.S.; Selkoe, D. J.; Wolfe, M.S. Activity dependent isolati on of the \npresenilin- \uf067-secretase complex reveals nicastrin and a \uf067 substrate. PNAS, 2002 , 99, 2720-5.  \n[155] Kukar, T.L.; Ladd, T.B.; Bann, M.A.; Fraering, P.C.; Narlaw ar, R.; Maharvi, G.M.; Healy, B.; Chapman, R.; Welzel, A.T.; P rice, \nR.W.; Moore, B.; Rangachari, V.; Cusack, B. ; Eriksen, J.; Jansen-West, K.; Verbeeck, C. ; Yager, D.; Eckman, C.; Ye, W.; Sagi, S .; \nCottrell, B.A.; Torpey, J.; Rosenbe rry, T.L.; Fauq, A.; Wolfe, M.S.; Schmidt, B.; Walsh, D.M.; Koo, E.H.; Golde, T.E. Substrate -\ntargeting \uf067-secretase modulators. Nature, 2008 , 453, 925-9.  \n[156] Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; de Sain t Andrieu, P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach , E.; \nHolsztynska, E.J.; Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops, J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I. M.; Motter, R.N.; Mutter, L. C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L. ; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D. ; \nTung, J.S.; Wu, J.; Yang, S.; Yi n, C.T.; Schenk, D.B.; May, P. C.; Altstiel, L.D.; Bender, M.H. ; Boggs, L.N.; Britton, T.C.; Cle mens, \nJ.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; L ittle, \nS.P.; Mabry, T.E.; Miller, F. D.; Audia, J.E. Functional \uf067-secretase inhibitors reduce \uf062-amyloid peptide levels in brain. J. \nNeurochem., 2001 , 76, 173-81.  \n[157] Audia, J.E.; Britton, T.C.; Droste, J. J.; Folmer, B.K.; Huffman, G.W.; Varghese, J.; Latimer, L.H.; Mabry, T.E.; Nissen, J.S.; Porter, \nW.J.; Reel, J.K.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Eid,  C.N.; Scott, W.L. Methods and compounds for inhibiting \uf062-amyloid peptide \nrelease and/or its synthesis. WO 6191166, 2001.  \n[158] Audia, J.E.B.T.C.; Droste, J.J.; Folmer, B.K.; Huffman, G.W.; John, V.; Latimer, L.H.; Mabry, T.E.; Nissen, J.S.; Porter,\n W.J.; Reel, \nJ.K.; Thorsett, E.D.; Tung, J.S.; Eid, C.N.; Scott, W.L. Preparation of N(phenylacetyl)di- and tripeptid e derivatives for inhibiting \n\uf062-amyloid peptide release. WO 9822494, 1998.  \n[159] Larbig, G.; Zall, A.; Schmidt, B. I nhibitors Designed for Presenilin 1 utilizing by Means of Aspartic  Acid Activation. Helv. Chim. \nActa, 2004 , 87, 2334-2340.  \n[160] Garofalo, A.W.; Wone, D.W.G.; Phuc, A.; Audia, J.E.; Bales,  C.A.; Dovey, H.F.; Dressen, D. B.; Folmer, B.; Goldbach, E.G.;  Guinn, \nA.C.; Latimer, L.H.; Mabry, T.E.; Nissen, J.S.; Pleiss, M.A.; Sohn, S.; Thorsett, E.D.; Tung, J.S.; Wu, J. A Series of C-Termin al \nAmino Alcohol Dipeptide A \uf062 Inhibitors. Bioorg. Med. Chem. Lett., 2002 , 12, 3051-3053.  \n[161] Hutton, M.; Lewis, J.; Dickson, D.; Yen, S.H.; McGo wan, E. Analysis of tauopa thies with transgenic mice. Trends Mol. Med., 2001 , 7, \n467-470.  \n[162] Hadland, B.K.; Manley, N.R.; Su, D.-M.; Longmore, G.D.; Moore, C.L.; Wolfe, M.S.; Schroeter, E.H.; Kopan, R. \uf067-Secretase \ninhibitors repress thymocyte development. PNAS, 2001 , 98, 7487-7491.  \n[163] Fuwa, H.; Takahashi, Y.; Konno, Y.; Watanabe, N.; Miyashita , H.; Sasaki, M.; Natsugari, H.; Kan, T.; Fukuyama, T.; Tomita , T.; \nIwatsubo, T. Divergent Synthesis of Mu ltifunctional Molecular Probes To Elucidate the Enzyme Specificity of Dipeptidic \n\uf067-Secretase Inhibitors. ACS Chem. Biol., 2007 , 2, 408-418.  \n[164] Wong, G.T.; Manfra, D.; Poulet, F.M.; Zhang, Q.; Josien, H.; Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J.S.; Lee, H .J.; Zhang, \nL.; Higgins, G.A.; Parker, E.M. Chronic treatment with the \uf067-secretase inhibitor LY-411,575 inhibits \uf062-amyloid peptide production \nand alters lymphopoiesis and in testinal cell differentiation. J. Biol. Chem., 2004 , 279, 12876-82.  \n[165] Fleisher, A.S.; Raman, R.; Siemers, E.R.; Becerra, L.; Clar k, C.M.; Dean, R.A.; Farlow, M.R.; Galvin, J.E.; Peskind, E.R. ; Quinn, J.F.; \nSherzai, A.; Sowell, B.B.; Aisen, P.S.; Thal, L.J. Phase 2 safety trial targeting amyloid- \uf062 production with a \uf067-secretase inhibitor in \nAlzheimer disease. Arch. Neurol., 2008 , 65, 1031-8.  \n[166] Iwata, N.; Saido, T.C. Catabolism of \uf062-amyloid peptide in brain. Dementia Jpn., 2000 , 14, 80-88.  \n[167] Iwata, N.; Tsubuki, S.; Takaki, Y.; Wata nabe, K.; Sekiguchi, M.; Hos oki, E.; Kawashima-Morishima, M.; Lee, H.-J.; Hama, E .; \nSekine-Aizawa, Y.; Saido, T.C. Identification of the major A \uf0621-42-degrading catabolic pathway in brain parenchyma: Suppression \nleads to biochemical a nd pathological deposition. Nat. Med., 2000 , 6, 143-150.  \n[168] Abraham, C.R.; McGraw, W.T.; Slot, F.; Yamin, R. a1-antichymot rypsin inhibits A \uf062 degradation in vitro and in vivo. Ann. N.Y. Acad. \nSci., 2000 , 920, 245-248.  \n[169] Smith, D.W.; Munoz, B.; Srinivasan, K.; Bergstrom, C.P.; Chaturvedula, P.V.; Des hpande, M.S.; Keavy, D.J.; Lau, W.Y.; Par ker, \nM.F.; Sloan, C.P.; Wallace, O.B.; Wang, H.H. Preparation of sulfonamide derivs. as amyloid \uf062 production inhibitors useful in \ntreating or preventing diseases related to A \uf062. WO 2000050391, 2000.  \n[170] Rishton, G.M.; Retz, D.M.; Tempest, P.A.; Novotny, J.; Ka hn, S.; Treanor, J.J.S.; Lile, J. D.; Citron, M. Fenchylamine Su lfonamide \nInhibitors of Amyloid Peptide Production by the \uf067-Secretase Proteolytic Pathway: Potential Small-Molecule Ther apeutic Agents for \nthe Treatment of Alzheimer's Disease. J. Med. Chem., 2000 , 43, 2297-2299.  \n[171] Belanger, P.C.; Collins, I.J.; Hannam,  J.C.; Harrison, T.; Lewis, S.J.; Madin,  A.; McIver, E.G.; Nadin, A.J.; Neduvelil, J.G.; Shearman, \nM.S.; Smith, A.L.; Sparey, T.J.; Stevenson, G.I.; Teall, M.R. Synthesis of sulfonami do-substituted bridged bi cycloalkyl derivat ives \nas \uf067-secretase inhibitors. WO 20010170677, 2001.  \n[172] Olson, R.E.; Maduskuie, T.P.; Thomas , L.A. Preparation of succinoylaminoazepinone s and related compounds as inhibitors of  A\uf062-\npeptide production. WO 0007995, 2000.  \n[173] Seiffert, D.; Bradley, J.D.; Rominger,  C.M.; Rominger, D.H.; Yang, F.; Meredith , J.E., Jr.; Wang, Q.; Roach, A.H.; Thomps on, L.A.; \nSpitz, S.M.; Higaki, J.N.; Prakash, S.R.; Combs, A.P.; Copeland, R.A.; Arneric, S.P.; Hartig, P.R.; Robertson, D.W.; Cordell, B .; \nStern, A.M.; Olson, R.E.; Zaczek, R. Presenilin1 and -2 are molecular targets for \uf067-secretase inhibitors. J. Biol. Chem., 2000 , 275, \n34086-91.  \n[174] Thompson, L.A. Amino lactam sulfonamides as inhibitors of A \uf062 protein production. WO 0127091, 2001.  \n[175] Thompson, L.A.; Han, A.Q. Preparation of amino lactam sulfonamides as inhibitors of A \uf062-protein production. WO 0127108, 2001.  \n[176] Teall, M.R. \uf067-secretase inhibitors. WO 20020013315, 2002.  \n[177] Fuchs, K.; Romig, M.; Mendla, K.; Briem, H.; Fe chteler, K. Preparation of novel imidazopyridines as \uf062-amyloid formation inhibitors. \nWO 2002014313, 2002.  \n[178] Himmelsbach, F.; Fuchs, K.; Briem, H. ; Fechteler, K.; Kostka, M.; Dorner-Ciossek,  C.; Bornemann, K.; Klinder, K. Preparat ion of \ndiaminopyrimidines as inhibitors of \uf062-amyloid formation or its release. WO 2003032994, 2003.  \n[179] Otto, M.; Cepek, L.; Ratzka, P.; Doeh linger, S.; Boekhoff, I.; Wiltf ang, J.; Irle, E.; Pergande , G.; Ellers-Lenz, B.; Win dl, O.; \nKretzschmar, H.A.; Poser,  S.; Prange, H. Efficacy of flupi rtine on cognitive function in pati ents with CJD: A double-blind stud y. \nNeurology, 2004 , 62, 714-8.  \n[180] Churcher, I.; Williams, S.; Kerrad, S.; Harrison, T.; Castro, J.L.; Shearman , M.S.; Lewis, H.D.; Clarke, E.E.; Wrigley, J .D.; Beher, D.;  \n 53Tang, Y.S.; Liu, W. Design and synt hesis of highly potent benzodiazepine \uf067-secretase inhibitors: preparation of (2 S,3R)-3-(3,4-\ndifluorophenyl)-2-(4-fluorophenyl)-4-hydroxy- N((3S)-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1 H-benzo[e][1,4 ]-diazepin-3-\nyl)butyramide by use of an asymme tric Ireland-Claisen rearrangement. J. Med. Chem., 2003 , 46, 2275-8.  \n[181] Churcher, I.; Ashton, K.; Butcher, J. W.; Clarke, E.E.; Harrison, T.; Lewis, H.D. ; Owens, A.P.; Teall, M.R.; Williams, S.;  Wrigley, \nJ.D.J. A new series of potent benzodiazepine \uf067-secretase inhibitors. Bioorg. Med. Chem. Lett., 2003 , 13, 179-183.  \n[182] Lewis, H.D.; Perez Revuelta, B.I.; Na din, A.; Neduvelil, J.G.; Harrison, T.; Po llack, S.J.; Shearman, M.S. Catalytic site -directed \n\uf067-secretase complex inhibitors do not discrimi nate pharmacologically between Notch S3 and \uf062-APP cleavages. Biochemistry, 2003 , \n42, 7580-6.  \n[183] Bowers, S.; Garofalo , A.W.; Hom, R.K.; Konradi, A.W.; Mattson, M.N.; Neitzel, M.L.; Semko, C.M.;  Truong, A.P.; Wu, J.; Xu , Y.-Z. \nPreparation of bridged N-cyclic sulfonamide compounds as inhibitors of \uf067-secretase. WO 2007022502, 2007.  \n[184] Konradi, A.W.; Mattson, M.N.; Semko, C.M.; Ye, X.M. Preparation of bridged N-bicyclic sulfonamides as inhibitors of \uf067-secretase. \nWO 2007024651, 2007.  \n[185] Barten, D.M.; Guss, V.L.; Corsa, J.A.; Loo, A.; Hansel, S.B.; Zheng, M.; Munoz, B.; Srinivasan, K.; Wang, B.; Robertson, B.J.; \nPolson, C.T.; Wang, J.; Roberts, S.B.; Hendrick, J.P.; Anderson, J.J.; Loy, J.K.; Denton, R.; Verdoorn, T.A.; Smith, D.W.; \nFelsenstein, K.M. Dynamics of \uf062-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of \uf062-Amyloid Precursor Protein \nTransgenic Mice Treated with a \uf067-Secretase Inhibitor. J. Pharmacol. Exp. Ther., 2005 , 312, 635-643.  \n[186] Josien, H.B.; Clader, J.W.; Bara , T.A.; Xu, R.; Li, H.; Pissarnitski, D. ; Zhao, Z. Preparation of substituted N-arylsulfonylheterocyclic \namines as \uf067-secretase inhibitors. WO 2006004880, 2006.  \n[187] Zhao, B.; Yu, M.; Neitzel, M.; Marugg, J.; Jagodzinski, J.; Lee, M.; Hu, K.; Schenk, D.; Yednock, T.; Basi, G. Identifica tion of \n\uf067-secretase inhibitor potency determinants on presenilin. J. Biol. Chem., 2008 , 283, 2927-38.  \n[188] Beher, D.; Bettati, M.; Checksfield, G.D.; Churcher, I.; Doughty, V.A.; Oakley, P.J.; Quddus, A.; Teall, M.R.; Wrigley, J .D. \nPreparation of tetrahydrocarb azole-1-alkanoic acids for the treatment of Alzheimer's disease and related conditions. \nWO 2005013985, 2005.  \n[189] Wilson, F.; Reid, A.; Reader, V.; Harrison, R.J.; Sunose, M.; Hernandez-Perni, R.; Major, J.; Boussard, C.; Smelt, K.; Ta ylor, J.; \nLeformal, A.; Cansfield, A.; Burckhardt, S.  Preparation of biphenylacetic acids as \uf067\uf02dsecretase modulators for the treatment of \nAlzheimer's disease. WO 2006045554, 2006.  \n[190] Ramsden, N.; Wilson, F. Use of S-enantiomers of \uf067-substituted aryl acetic acids for the prevention of alzheimer's disease. \nWO 2006048219, 2006.  \n[191] Narlawar, R.; Perez Revuelta, B.I.; Baumann, K.; Schubenel, R.; Haass, C.; Steiner, H.; Schmidt, B. N-Substituted carbazolyloxyacetic \nacids modulate Alzheimer associated \uf067-secretase. Bio. Med. Chem. Lett., 2007 , 17, 176-82.  \n[192] Serradji, N.; Bensaid, O.; Martin, M.; Kan, E.; Dereuddre-Bo squet, N.; Redeuilh, C.; Huet, J.; Heymans, F.; Lamouri, A.; Clayette, P.; \nDong, C.Z.; Dormont, D.; Godfroid, J.J. Structure-activity relati onships in platelet-activating factor (PAF). 10. From PAF \nantagonism to inhibition of HIV-1 replication. J. Med. Chem., 2000 , 43, 2149-54.  \n[193] Weggen, S.; Eriksen, J.L.; Das, P.; Sagi, S.A.; Wang, R. ; Pietrizik, C.U.; Findlay, K.A.; Smith, T.E.; Murphy, M.P.; Bult er, T.; Kang, \nD.E.; Marquez-Sterling, N.; Golde, T.E.; Koo, E.H. A subset of NSAIDs lower amyloidogenic A \uf06242 independently of \ncyclooxygenase activity. Nature, 2001 , 414, 212-216.  \n[194] Weggen, S.; Eriksen, J.L.; Sagi, S.A.; Pietrzik, C.U.; Golde, T.E.; Koo, E.H. A \uf06242-lowering Nonsteroidal Anti-inflammatory Drugs \nPreserve Intramembrane Cleavage of th e Amyloid Precursor Protein (APP) and Er bB-4 Receptor and Signaling through the APP \nIntracellular Domain. J. Biol. Chem., 2003 , 278, 3074830754.  \n[195] in 't Veld, B.A.; Ruitenberg, A.; Ho fman, A.; Launer, L.J.; van Duijn, C.M.; S tijnen, T.; Breteler, M.M.B.; Stricker, B.H .C. \nNonsteroidal Antiinflammatory Drugs a nd the Risk of Alzheimer's Disease. N. Engl. J. Med., 2001 , 345, 1515-1521.  \n[196] Zhou, Y.; Su, Y.; Li, B.; Liu, F.; Ry der, J.W.; Wu, X.; Gonzalez-DeWhitt, P.A.; Gelfanova, V.; Hale, J.E.; May, P.C.; Pau l, S.M.; Ni, \nB. Nonsteroidal Anti-Inflammatory  Drugs Can Lower Amyloidogenic A \uf06242 by Inhibiting Rho. Science, 2003 , 302, 1215-1218.  \n[197] Lanz, T.A.; Hosley, J.D.; Adams, W.J.; Merchant, K.M. Studies of A \uf062 pharmacodynamics in the brain, cerebrospinal fluid, and plasma \nin young (plaque-free) Tg2576 mice us ing the _-secretase inhibito r N2[(2S)-2-(3,5-difluorophenyl )-2-hydroxyethanoyl]-N1-[(7S)-5 -\nmethyl-6-oxo-6,7-dihy dro-5Hdibenzo[b,d]azepin-7-y l]-L-alaninamide (LY-411575) . J. Pharmacol. Exp. Ther., 2004, 309, 49-55.  \n[198] Eriksen, J.L.; Sagi, S.A.; Smith, T.E.; Weggen, S.; Das,  P.; McLendon, D.C.; Ozols, V.V.; Jessing, K.W.; Zavitz, K.H.; Ko o, E.H.; \nGolde, T.E. NSAIDs and enantiomers of fl urbiprofen target g-secretase and lower A \uf06242 in vivo. J. Clin. Invest., 2003 , 112, 440-449.  \n[199] Beher, D.; Clarke, E.E.; Wrigley, J.D.J.; Martin, A.C.L.; Nadin, A.; Churcher, I.; Shearman, M.S. Selected Non-steroidal Anti-\ninflammatory Drugs and Th eir Derivatives Target \uf067-Secretase at a Novel Site: Evidence for an allosteric mechanism. J. Biol. Chem., \n2004 , 279, 43419-43426.  \n[200] Geerts, H. Drug evaluation: (R)-flurb iprofen-an enantiomer of flurbiprofen fo r the treatment of Alzheimer's disease. IDrugs, 2007 , 10, \n121-33.  \n[201] Page, R.M.; Baumann, K.; Tomioka, M.; Perez-Revuelta, B.I.; Fukumori, A.; Jacobsen, H.; Flohr, A.; Luebbers, T.; Ozmen, L .; \nSteiner, H.; Haass, C. Generation of A \uf06238 and A\uf06242 is independently and di fferentially affected by familial Alzheimer disease-\nassociated presenilin mutations and \uf067-secretase modulation. J. Biol. Chem., 2008 , 283, 677-83.  \n[202] Eckert, G.P.; Wood, W.G.; Muller, W.E.  Statins: drugs for Alzheimer's disease? J. Neural. Transm., 2005 , 112, 1057-71.  \n[203] Cucchiara, B.; Kasner, S.E. Us e of statins in CNS disorders. J. Neurol. Sci., 2001 , 187, 81-89.  \n[204] Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lu tjohann, D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; Von Be rgmann, K.; \nHennerici, M.; Beyreuther, K.; Hartmann, T. Simvasta tin strongly reduces levels of Alzheimer's disease \uf062-amyloid peptides A \uf06242 \nand A\uf06240 in vitro and in vivo. PNAS, 2001 , 98, 5856-5861.  \n[205] Simons, M.; Keller, P.; Dichgans, J.; Schulz, J.B. Cholesterol and Alzheimer's disease: Is there a link? Neurology, 2001 , 57, \n1089-1093.  \n[206] Riddell, D.R.; Christie, G.; Hussain, I.; Dingwall, C. Compartmentalization of \uf062-secretase (Asp2) into low-buoyant density, \nnoncaveolar lipid rafts. Curr. Biol., 2001 , 11, 1288-1293.  \n[207] Kojro, E.; Gimpl, G.; Lammich, S.; Marz, W.; Fahrenholz, F. Low cholesterol stimulates th e nonamyloidogenic pathway by it s effect \non the \uf061-secretase ADAM 10. PNAS, 2001 , 98, 5815-5820.  \n[208] George, A.J.; Holsinger, R.M.D.; McLean, C.A.; Laughton, K .M.; Beyreuther, K.; Evin, G.; Ma sters, C.L.; Li, Q.-X. APP int racellular \ndomain is increased and soluble A \uf062 is reduced with diet-induced hypercholesterole mia in a transgenic mouse model of Alzheimer \ndisease. Neurobiol. Dis., 2004 , 16, 124132.  \n[209] Eckert, G.P.; Kirsch, C.; Leutz, S.; Wood, W.G.; Muller, W.E. Cholesterol modulates amyloid \uf062-peptide's membrane interactions. \nPharmacopsychiatry, 2003 , 36 Suppl 2 , S136-43.  \n[210] Refolo, L.M.; Pappolla, M.A.;  LaFrancois, J.; Malester, B.; Schmidt, S.D.; Thomas-Bryant, T.; Tint, G.S.; Wang, R.; Merck en, M.; \nPetanceska, S.S.; Duff, K.E. A cholesterol-lowering drug reduces \uf062-amyloid pathology in a transgenic mouse model of Alzheimer's \ndisease. Neurobiol. Dis., 2001 , 8, 890-9.   \n 54 [211] Bayer, T.A.; Schaefer, S.; Simons, A.; Kemmling, A.; Ka mer, T.; Tepest, R.; Eckert, A.; Schuessel, K.; Eikenberg, O.; \nSturchler-pierrat, C.; Abramowski, D.; Staufenbiel, M.; Multhaup, G. Dietary Cu stabilizes brain superoxide dismutase 1 activit y \nand reduces amyloid A \uf062 production in APP23 transgenic mice. PNAS, 2003 , 100, 14187-14192.  \n[212] Regland, B.; Lehmann, W.; Abedini, I.; Blennow, K.; Jonsson, M.; Karlsson, I. ; Sjoegren, M.; Wallin, A.; Xilinas, M.; Got tfries, C.-G. \nTreatment of Alzheimer's Disease with Clioquinol. Dement. Geriatr. Cogn., 2001 , 12, 408-414.  \n[213] Melov, S.`\u2026 and C is for Clioquinol' - the A \uf062Cs of Alzheimer's disease. Trends. Neurosci., 2002 , 25, 1214.  \n[214] Treiber, C.; Simons, A.; Strauss, M.; Hafner, M.; Cappai, R.; Bayer, T.A.; Multhaup, G. Clioquinol mediates copper uptake  and \ncounteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J. Biol. Chem., 2004 , 279, 51958-64.  \n[215] Barnham, K.J.; Gautier, E.C.L.; Kok,  G.B.; Krippner, G. Preparation of 8-hydroxyquinolines for treatment of neurological conditions. \nWO 2004007461, 2004.  \n[216] Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C.L.; Targum, S.; Bush, A.I.; Mu rdoch, R.; \nWilson, J.; Ritchie, C.W. Safety, efficacy, a nd biomarker findings of PBT2 in targeting A \uf062 as a modifying therapy for Alzheimer's \ndisease: a phase IIa, double-blind, ra ndomised, placebo-controlled trial. Lancet Neurol., 2008 , 7, 779-786.  \n[217] Marksteiner, J.; Hinterhuber, H.; Humpel, C. Cerebrospi nal fluid biomarkers for diagnos is of Alzheimer's disease: \uf062-amyloid(1-42), \ntau, phospho-tau-181 and total protein. Drugs Today, 2007 , 43, 423-431.  \n[218] Brys, M.; Mosconi, L.; De Santi, S.; Rich, K.; de Leon, M.J . Cerebrospinal fluid biomarkers  for mild cognitive impairment . Aging \nHealth, 2006 , 2, 111-121.  \n[219] Parnetti, L.; Lanari, A.; Silvestrelli, G.; Saggese, E.; Re boldi, P. Diagnosing prodromal Alzheimer's disease: Role of CS F biochemical \nmarkers. Mech. Ageing Dev., 2006 , 127, 129-132.  \n[220] Mosconi, L.; Sorbi, S.; de Leon, M.J.; Li, Y.; Nacmias, B.; Myoung, P.S.; Tsui, W.; Ginestroni, A.; Bessi, V.; Fayyazz, M .; Caffarra, \nP.; Pupi, A. Hypometabolism exceeds atrophy in presym ptomatic early-onset familial Alzheimer's disease. J. Nucl. Med., 2006 , 47, \n1778-1786.  \n[221] Devanand, D.P.; Pradhaban, G.; Liu, X.; Khandji, A.; De Sa nti, S.; Segal, S.; Rusinek, H. ; Pelton, G.H.; Honig, L.S.; May eux, R.; \nStern, Y.; Tabert, M.H.; de Leon, M.J. Hippocampal and entorhinal  atrophy in mild cognitive impairment: prediction of Alzheimer  \ndisease. Neurology, 2007 , 68, 828-36.  \n[222] Strassner, B. Coherences between cereb ral glucose metabolism (F-18-FDG-PET), genetic marker (APOE) and biomarkers (TAU an d \uf062 \n-Amyloid in liquor cerebro spinalis) in patients with Alzheimer's disease (AD)  and patients with (mild cognitive impairment MCI) . \n2008.  \n[223] Ng, S.; Villemagne, V.L.; Berlangieri, S.; Lee, S.-T.; Ch erk, M.; Gong, S.J.; Ackermann,  U.; Saunder, T. ; Tochon-Danguy, H.; Jones, \nG.; Smith, C.; O'Keefe, G.; Masters, C.L.; Rowe, C.C. Visual assessment versus quantitative assessment of 11C-PIB PET and \n18F-FDG PET for detection of Alzheimer's disease. J. Nucl. Med., 2007 , 48, 547-552.  \n[224] Shoghi-Jadid, K.; Small Gary, W.; Agdeppa Eric, D.; Kepe, V.; Ercoli Linda, M.; Siddarth, P.; Read, S.; Satyamurthy, N.; Petric, A.; \nHuang, S.-C.; Barrio Jorge, R. Loca lization of neurofib rillary tangles and \uf062-amyloid plaques in the brains of living patients with \nAlzheimer disease. Am. J. Geriatr. Psychiatry, 2002 , 10, 24-35.  \n[225] Klunk, W.E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.; Holt, D.P.; Bergstrom, M.; Savitcheva, I.; Huang, G.-f.; Estrada, S.; \nAusen, B.; Debnath, M.L.; Barletta, J.; Pric e, J.C.; Sandell, J.; Lopresti, B.J.; Wall,  A.; Koivisto, P.; Antoni, G.; Mathis, C .A.; \nLangstrom, B. Imaging brain amyloid in Alzh eimer's disease with Pittsburgh compound-B. Ann. Neurol., 2004 , 55, 306-319.  \n[226] Verhoeff Nicolaas, P.L.G.; Wilson Alan, A.; Takeshita, S.; Tr op, L.; Hussey, D.; Singh, K.; Kung Hank, F.; Kung, M.-P.; H oule, S. \nIn-vivo imaging of Alzheimer disease \uf062-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry, 2004 , 12, 584-95.  \n[227] Mathis, C.; Lopresti, B.; Mason, N.; Price, J.; Flatt, N.; Bi, W.; Ziolko, S.; DeKosky, S.; Klunk, W. Comparison of the a myloid \nimaging agents [F-18]3'-F-PIB and [C-11]PIB in  Alzheimer's disease and control subjects. In 2007 , Vol. 48, pp 56P-b.  \n[228] Kudo, Y.; Okamura, N.; Furumoto, S.; Tashiro, M.; Furukawa , K.; Maruyama, M.; Itoh, M.; Iwata, R.; Yanai, K.; Arai, H. 2- (2-[2-\ndimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole : a novel PET agent for in vivo detection of dense amyloid \nplaques in Alzheimer's disease patients. J. Nucl. Med., 2007 , 48, 553-561.  \n[229] Rowe, C.; Ackerman, U.; Browne, W.; Mu lligan, R.; Pike, K.L.; O'Keefe, G.; Tochon -Danguay, H.; Chan, G.; Berlangieri, S.U .; Jones, \nG.; Dickinson-Rowe, K.L.; Kung, H.P.; Zhang, W.; Kung, M.P.; Skovronsky, D.; Dyrks, T.; Hall, G.; Krause, S.; Friebe, M.; \nLehman, L.; Lindemann, S.; Dinkelborg, L.M.; Masters, C.L.; Ville magne, V.L. Imaging of amyloid beta in Alzheimer's disease \nwith 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol., 2008 , 7, 129-135.  \n[230] Seneca, N.; Cai, L.; Liow, J.-S.; Z oghbi Sami, S.; Gladding Robert, L.; Hong, J.; Pike Victor, W.; Innis Robert, B. Brain  and \nwhole-body imaging in nonhuman primates with [11C]MeS-IMPY, a candidate radioligand for \uf062-amyloid plaques. Nucl. Med. Biol., \n2007 , 34, 681-9.  \n[231] Cai, L.; Liow, J.-S.; Zoghbi, S.S.; Cuevas, J.; Baetas, C. ; Hong, J.; Shetty, H.U.; Seneca,  N.M.; Brown, A.K.; Gladding, R.; Temme, \nS.S.; Herman, M.M.; Innis, R.B.; Pike, V.W. Synthesis and Evalua tion of N-Methyl and S-Methyl 11C-Labeled 6-Methylthio-2-(4'-\nN,N-dimethylamino)phenylimidazo[1,2a]pyridines as Radioligands for Imaging \uf062-Amyloid Plaques in Alzheimer's Disease. J. Med. \nChem., 2008 , 51, 148-158.  \n[232] Braak, H.; Braak, E. Stagi ng of Alzheimer's disease-rela ted neurofibrilla ry changes. Neurobiol. Aging, 1995 , 16, 271-8; discussion \n278-84.  \n[233] Klunk, W.E.; Lopresti, B.J.; Ikonomovic, M.D.; Lefterov, I.M.; Koldamova, R.P.; Abrahamson, E.E.; Debnath, M.L.; Holt, D. P.; \nHuang, G.-f.; Shao, L.; DeKosky, S.T.; Pr ice, J.C.; Mathis, C.A. Binding of the positron emission tomogr aphy tracer pittsburgh \ncompound-B reflects the amount of amyloid- \uf062 in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci., 2005 , \n25, 10598-10606.  \n[234] Engler, H.; Forsberg, A.; Almkvist, O.; Blomquist, G.; La rsson, E.; Savitcheva, I.; Wall, A.; Ringheim, A.; Langstrom, B. ; Nordberg, \nA. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 2006 , 129, 2856-66.  \n[235] Forsberg, A.; Engler, H.; Almkvist, O.; Blomquist, G.; Ha gman, G.; Wall, A.; Ringheim, A.; Langstrom, B.; Nordberg, A. PE T \nimaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging, 2008 , 29, 1456-65.  \n[236] Kemppainen, N.M.; Aalto, S.; Wilson, I.A.; Naagren, K.; Helin, S.; Brueck, A.; Oikonen, V.; Kailajaervi, M.; Scheinin, M. ; Viitanen, \nM.; Parkkola, R.; Rinne, J.O. PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology, 2007 , 68, \n1603-1606.  \n[237] Pike Kerryn, E.; Savage, G.; Villemagne Victor, L.; Ng, S. ; Moss Simon, A.; Maruff, P.; Mathis Chester, A.; Klunk William , E.; \nMasters Colin, L.; Rowe Christopher, C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical \nAlzheimer's disease. Brain, 2007 , 130, 2837-44.  \n[238] Rabinovici, G.D.; Furst, A.J.; O'Neil, J.P.; Racine, C.A.; Mormino, E.C.; Baker, S.L.; Chetty, S.; Patel, P.; Pagliaro, T .A.; Klunk, \nW.E.; Mathis, C.A.; Rosen, H.J. ; Miller, B.L.; Jagust, W.J. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar \ndegeneration. Neurology, 2007 , 68, 1205-12.  \n[239] Engler, H.; Santillo Alexander, F.; Wang Shu, X.; Lindau, M.; Savitcheva, I.; Nordberg, A.; Lannfelt, L.; Langstrom, B.; Kilander, L. \nIn vivo amyloid imaging with PE T in frontotemporal dementia. Eur. J. Nucl. Med. Mol. Imaging, 2008 , 35, 100-6.   \n 55[240] Drzezga, A.; Grimmer, T.; Henriksen,  G.; Stangier, I.; Perneczky, R.; Diehl-Sc hmid, J.; Mathis Chester, A.; Klunk William , E.; Price, \nJ.; DeKosky, S.; Wester, H.-J.; Schwaiger, M.; Kurz, A. Imagi ng of amyloid plaques and cerebral glucose metabolism in semantic \ndementia and Alzheimer's disease. Neuroimage, 2008 , 39, 619-33.  \n[241] Nordberg, A. Amyloid imaging in Alzheimer's disease. Neuropsychologia, 2008 , 46, 1636-41.  \n[242] Fein, J.A.; Sokolow, S.; Miller, C.A.; Vinters, H.V.; Yang, F.; Cole, G.M.; Gylys, K.H. Co-localization of amyloid beta a nd tau \npathology in Alzheimer's disease synaptosomes. Am. J. Pathol., 2008 , 172, 16831692.  \n[243] Oddo, S.; Caccamo, A.; Kitazawa, M.; Tseng, B.P.; LaFerla,  F.M. Amyloid deposition precedes tangle formation in a triple transgenic \nmodel of Alzheimer's disease. Neurobiol. Aging, 2003 , 24, 1063-1070.  \n[244] Ono, M.; Wilson, A.; Nobrega, J.; Westaway, D.; Verhoeff, P.; Zhuang, Z.-P.; Kung, M.-P.; Kung Hank, F. 11C-labeled stilbene \nderivatives as Abeta-aggregate-specific PET imaging agents for Alzheimer's disease. Nucl. Med. Biol., 2003 , 30, 565-71.  \n[245] Kung, M.-P.; Hou, C.; Zhuang, Z.-P.;  Skovronsky, D.; Kung Hank, F. Binding of tw o potential imaging agents targeting amyl oid \nplaques in postmortem brain tissues of  patients with Alzheimer's disease. Brain Res., 2004 , 1025 , 98-105.  \n[246] Henriksen, G.; Yousefi Behrooz, H.; Drzezga, A.; Wester, H.-J. Development a nd evaluation of compounds for imaging of \uf062-amyloid \nplaque by means of positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging, 2008 , 35 Suppl 1 , S75-81.  \n[247] Zhang, W.; Oya, S.; Kung, M.-P.; H ou, C.; Maier, D.L.; Kung, H. F. F-18 stilbenes as PET imaging agents for detecting \uf062-amyloid \nplaques in the brain. J. Med. Chem., 2005 , 48, 5980-5988.  \n[248] Rowe, C.C.; Ng, S.; Ackermann, U.; Gong, S.J.; Pike, K.; Sa vage, G.; Cowie, T.F.; Dickinson, K.L.; Maruff, P.; Darby, D.;  Smith, C.; \nWoodward, M.; Merory, J.; Tochon-Danguy, H.; O'Keefe, G.; Klunk, W.E.; Mathis, C.A.; Pr ice, J.C.; Masters, C.L.; Villemagne, \nV.L. Imaging \uf062-amyloid burden in aging and dementia. Neurology, 2007 , 68, 1718-1725.  \n[249] Lopresti, B.J.; Klunk, W.E.; Mathis, C.A.; Hoge, J.A.; Ziol ko, S.K.; Lu, X.; Meltzer, C.C.; Schimmel, K.; Tsopelas, N.D.;  DeKosky, \nS.T.; Price, J.C. Simplified quantifica tion of Pittsburgh Compound B amyloid imagi ng PET studies: a comparative analysis. J. Nucl. \nMed., 2005 , 46, 1959-1972.   \n 56  \n 573.2 Die \uf067-Sekretase als ein interessantes Target  f\u00fcr die Behandlung der \nAlzheimer-Demenz  \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentlicht:  \nStefanie Baumann, Nicole H\u00f6ttecke, Boris Schmidt, \u201c \uf067-Secretase as a target for AD\u201c, in \nMedicinal Chemistry of Alzheimer Diseas e, ed. A. Martinez, Research Signpost, 2008 . \nMit freundlicher Genehmigung von Res earch Signpost/Transworld Research.  \n \nNicole H\u00f6ttecke, Stefanie Baumann Bioforum  2008 , 6, 32-34. \u201cAlzheimer-Demenz: Ein \nPla(qu)e mit Hoffnung auf Besserung?\u201c \n \nDie \uf067-Sekretase ist ein interessantes Target  in der Behandlung der Alzheimer-Demenz, da das \nzur Aggregation neigende amyloide- \uf062-Peptid freigesetzt wird. Dies e Aspartylprotease ist ein \nin der Membran eingelagerter Enzymkompl ex, der in der aktiven Form aus vier \nUntereinheiten besteht. Durch die Memb ranst\u00e4ndigkeit dieses Komplexes hat die \uf067-Sekretase \nden ungew\u00f6hnlichen Spaltungsmechanismus einer \u201e regulated intermembrane proteolysis \u201c, da \nf\u00fcr eine Spaltung der Substrate in der li pophilen Membran ein Wasseraustausch mit dem \nextrazellull\u00e4ren Raum oder dem Cytosol notwendig ist.  \nIn den letzten Jahren wurde eine Vielzahl verschiedener \uf067-Sekretase-Inhibitoren identifiziert, \nwelche in klinischen Te st aber zum Teil schwere Nebenwirkungen zeigten. Diese \nNebenwirkungen sind auf die gleichzeitige Inhib ition des Notch-Stoffwechsel, eines weiteren \nSubstrates der \uf067-Sekretase, zur\u00fcckzuf\u00fchren. Da Notch auch eine wichtige Rolle in der \nZelldifferenzierung spielt k\u00f6nnen bei dauerhafter Inhibition des Notch Stoffwechselweges \ntoxische Nebenwirkungen auftreten. Seit 2001 ist der Forschungsschwerpunkt eher auf einer \nModulation der \uf067-Sekretase fokussiert, bei der das Schnittmuster der \uf067-Sekretase von dem \ntoxischen A \uf06242 zu dem ungef\u00e4hrlichen A \uf06238 hin verschoben wird. \n \n    \n \n  \n 58  \n 59Transworld Research Network 37/661 (2), Fort P.O., Trivandrum-695 023, Kerala, India  \nMedicinal Chemistry of Alzheimer\u2019s Disease, 2008: ISBN: 978-81-7895-\n342-7 Editor: Ana Mart\u00ednez Gil  \n  \n\u03b3-Secretase as a target for \nAD  \nStefanie Baumann, Nicole H\u00f6ttecke,  Raj Narlawar and Boris Schmidt  \nClemens Sch\u00f6pf-Institute for Organic Chemistr y and Biochemistry, Technische Universit\u00e4t \nDarmstadt, Petersenstrasse 22, D-64287 Darmstadt, Germany  \nAbstract  \n   Most gene mutations associ ated with Alzheimer\u2019s disease \npoint to the metabolism of am yloid precursor protein as \npotential cause. The \u03b2- and \u03b3-secretases are two \nexecutioners of amyloid precursor protei n processing resulting in amyloid \u03b2. \nSignificant progress has been made in the selective inhibition of \u03b3-secretase, \nregardless of structural information for \u03b3secretase. Several peptidic and \nnon-peptidic leads were identified and  several drug candidates are in \nclinical trials for Alzheimer\u00b4s di sease. This review focuses on the \ndevelopments in the field of \u03b3-secretase inhibition and modulation since \n2003.  \nCorrespondence/Reprint request: Dr. Boris Schmidt, Clemens Sch\u00f6pf-Institute for Organic Chemistry and Biochemistry, \nTechnische Universit\u00e4t Darmst adt, Petersenstrasse 22, D-64287 Darmstadt, Ge rmany E-mail: Schmidt_Boris@t-online.de  \n \n  \n 60 1. Introduction  \n Alzheimer's disease (AD) is the mo st common progressive and currently \nirreversible form of demen tia with symptoms like memory loss, pe rsonality changes, \nimpaired judgment, disorienta tion and loss of language skills. Despite great efforts to \nunderstand the causes, there remains the challenge to develop novel agents for AD \ntherapy. Approved drugs such as ac etylcholinesterase inhibitors or \nN-methyl- D-aspartate (NMDA) receptor antagoni sts offer symptoma tic treatment and \ndelay memory impairment but they do not a ddress the basic pathology of the disease \nwhich is deposition of extrac ellular amyloid plaques and formation of intracellular \nneurofibrillary tangles (NFT) in the brain.  \nThe aggregation of \u03b2-amyloid (A \u03b2) peptide, which is the major componen t of these \namyloid plaques, exerts a decisive ro le in the neuropathology of AD. The A \u03b2 peptides, \nwhich differ in length fro m 38 to 42 amino acids, are generated from the amyloid \nprecursor protein (APP, chromosome 21) by processing of two aspartic proteases: \u03b2- \n(BACE-1) and \u03b3-secretase. Both secretases have  multiple substrates and cause \ndifferent APP cleavages. The membrane loca lization of both enzymes is crucial for \nselectivity, as cell free conditions shift the cleavage pattern or result in additional \ncleavage sites. Usually 90% of  APP is degraded by the \u03b1-secretase pathway and only \n10% by the consecutive cleavages of \u03b2- and \u03b3-secretase, which results in aggregation \nof insoluble extracellular A \u03b2 deposits of approximately 4 kDa. Neither the \npathological consequences of deposited or soluble A \u03b2 are established beyond doubt, \nnor does plaque formation adequately correlate  to the progress of AD. A definite proof \nof the A\u03b2 hypothesis is still missi ng for humans. Furthermore \u03b3-secretase inhibition \nmay be utilized to control cell proliferati on, and thus be a ta rget for oncology.  \nHerein, we report the relevance of \u03b3-secretase involved in AD and give an \noverview of the research efforts in this field. \u03b3-Secretase inhibitors and modulators are \npresented as well as their mode of action, if available.  \n1.1 Established therapies fo r AD and novel approaches  \nCurrent pharmacological approaches relate d to AD treatment include antioxidant \ntherapy, acetylcholine esterase (AChE) inhi bitors, nicotinic and muscarinic agonists, \nnerve growth factor (NGF), low molecular lipophilic activ ators of the neurotrophic \nfactor signaling pathway, anti-inflammatory  drugs such as cyclooxygenase-1 (COX-1) \nand COX-2 inhibitors, drugs which interfere with A \u03b2 formation and deposition, as \nwell as food dietary compon ents. Approximately 500 co mpounds are in development \nfor the treatment of neurodegen erative diseases and at least 10% of these are related to \nAD. The targets derive from a whole range of receptors and enzymes like \u03b2-and \n\u03b3-secretase, glycogen synthase kinase 3 (GSK-3), phosphodies terase 4 (PDE 4) and the \nmuscarinic M1 receptor.  \nnACh modulators, AChE in hibitors, nMDA receptor an tagonists, 5-HT agonists \nand several vaccination projects (e.g. Elan , Cytos Biotechnology ) are in advanced 1.1 \nstages of development [1]. Plaque forma tion was seen as a major cause for AD and \ntheir removal was one of the therapy goal s until 2001. Today, Tau derived paired \nhelical filaments (PHFs), soluble A \u03b2 and its low molecular weight oligomers (A \u03b2*56) \nare seen as the main causes of A \u03b2 pathology. AChE inhibitors like galantamine, \ntacrine, donepezil and rivastigmine ( Scheme 1 ) produce small improvements in \ncognitive abilities of patients in the early stages of AD by suppressing the hydrolysis  \n 61of acetylcholine, an essential neurotransmitte r which is diminished in AD, but they do \nnot address the severe mortality in the fi nal stages nor did they improve upon the \nprimary endpoint of clinical trials: hos pitalisation. Meman tine hydrochloride \n(Scheme 1 ), a nMDA receptor antagonist, is ab le to modulate th e influx of Calcium \nions, which forms the basis of neuronal excitotoxicity; it was approved for the \ntreatment of moderate to severe AD in 2002 as first of its class. Nevertheless, a causal \ntherapy is still in demand, since no approved  therapy effectively stops or cures AD.  \n \nNOO\nH\nHO\n1GalantamineNNH2\n2Ta cri neNO\nOO\n3Donezepil\nN\nO NO\nH\n4Ri vasti gmine 5MemantineNH2\n \n \nScheme 1.  Current used drugs for symptomatic therapies.  \n \n1.2 APP processing  \nAmyloid plaques are processed via two different pathways: the amyloidogenic and \nthe non-amyloidogenic pathway.  \nThe non-amyloidogenic pathway involves membrane located \u03b1-secretase \n(Figure 1 ) [2]. The \u03b1\u2212secretase belongs to the family of metalloproteases, e.g. \nAdam10, and cleaves APP within the A \u03b2 sequence at amino acid 17 [3]. \nNon-amyloidogenic processing of APP generates p3 peptides which do not aggregate \nand do not display amyloid a ssociated pathology. Amyloi dogenic processing of APP \nresults in the pr oduction of A \u03b2 and involves sequential cleavage by \u03b2- and \u03b3-secretase \n(Figure 1 ). This requires traffick ing of APP from the membra ne to the endosomes and \nfinally to the lysosomes [4]. \u03b2-Secretase, recently  identified as the \u03b2-site APP-cleaving \nenzyme (BACE-1) [5], cleaves APP ther eby generating an extracellular soluble \nfragment called s-APP \u03b2 and an intracellular C-terminal fragment called C99. \nSubsequently, \u03b3-secretase cleaves C99 at amino aci ds 38, 40 or 42 thereby generating \nA\u03b2 peptides of various lengths.  \n \n  \n 62 Figure 1.  APP processing by \u03b2- and \u03b3-secretase leads to aggregated amyloid plaques and is called \nthe amyloidogenic way. Initial cleavage by \u03b1- and subsequently \u03b3-secretase represents the \nnon-amyloidgenic way by generating p3 instead of A \u03b2. \n \n \n \n1.3 BACE and its inhibitors  \nCleavage of the APP by BA CE-1 is the first step in the generation of A \u03b2 . In vitro  \nand in vivo  experiments confirmed that this enzy me is mainly responsible for initiating \nthe amyloidogenic processing of APP [6]. Par ticularly, brains of BACE knockout mice \nhad no detectable levels of A \u03b2 and did not show accumulation of APP C-terminal \nfragments (CTF) C99 and C89 [7]. Brains of  BACE transgenic mice are characterized \nby increased levels of A \u03b2 and amassing of the CTF [6].  BACE was identified as an \naspartic protease [8]. The key features are th e mobile flap region and the flexible 10s \nloop, which are crucial for substrate docking [9]. The kinetics of statine-based inhibitors revealed a two state mechanism with structural reorganisation and activity \nmodulation [8,10]. The two states: open and closed, contribute to selectivity and \nactivity of the enzyme  [8,11]. The flexibility of free and inhibitor b ound BACE was \ninvestigated in silico  and revealed several novel aspect s of BACE, which are useful for \nstructure-based, computer-aided inhibitor de sign [8,12]. The protonation states of the \ntwo active site residues Asp3 2 and Asp228 were calculated  by several groups with \ndifferent results [8,12-15]. Two \u03b2-secretases are known: BACE1 (ASP2 or memapsin \n2) and BACE2 (ASP1 or memaps in 1) with high homology, yet subtle differences in \nthe active site and an additional disulfid e bridge for BACE1 [8,16]. BACE2 causes \nadditional cleavages close to Ph e20, which are reminiscent of \u03b1-secretase activity \n[17,18]. BACE1 is anchored to the membrane via its transmembrane domain (TMD, \n455-480) and under native conditions BACE exists as a homodimer [19]. Several \nreviews on secretase inhibition of BACE ha ve been published [8 ,20-23] as well as \nmodelling studies [9].   \n 632. \u03b3-Secretase complex  \n\u03b3-Secretase mediates the critical step in the liberation of A \u03b2 from the membrane. \n\u03b3-Secretase has an unusual cleav age mechanism, as the proteo lysis takes place within a \nhydrophobic environment. Ther eby different lengths of A \u03b2 peptides are generated, \nindicating a lack of sequence specificity.  \n Lichtenthaler et al. reported an \u03b1 -helical model for substr ate cleavage [24]. It is \npostulated that one turnof \u03b1-helix contains around 3.6 resi dues and thus one site of the \n\u03b1-helix carries the amino acids 40, 43, 46 and 49 an d the opposite of the \u03b1-helix the \nresidues 42, 45 and 48. The cleavage depends on the subs trate orientation in the \ncatalytic core. Cleavage at every third resi due does not correspond to a whole turn and \ntherefore compensational cleavage after a four th residue is necessary which explains \nthe existence of A \u03b238 beside A \u03b242. \u03b3-Secretase recognizes substrate \u03b1-helical substrates \nin topographically distinct manner and inte racts with them from opposite directions \nand cleaves at multiple sites [25]. \u03b3-Secretase is conformation specific since it \nselectively cleaves \u03b1-helical substrates [24].  \nThe major forms of A \u03b2 generated by  \uf067-secretase are A \u03b238, A\u03b240 and A\u03b242 [26]. \nA\u03b242, which is toxic due its trend to aggregate and thereby forming plaques, \ncorresponds to approximately 5- 10% of the total amount of A \u03b2 secreted by cultured \ncells under normal conditions. Other A \u03b2 peptides of 19, 37\u201339 and 43\u201348 amino acids \nwere also identified but these represent only minor species [27]. The longer the \npeptides, the more insoluble they are and hence they are more prone to aggregate and \nthus seed amyloid deposition. \u03b3-Secretase also mediates the release of the APP \nintracellular domain (AICD) by cleaving at the \u03b5-site, located nine amino acids close \nto the A\uf06240 cleavage site [28]. The relationship between \u03b3- and \u03b5-cleavage has been \ndiscovered recently by the isolation of A \u03b249, which is the N-terminal product of \n\u03b5-cleavage and thus may be a precursor of A \u03b2. \u03b3-Secretase processes the APP \ntransmembrane domain from its C-terminal end by sequentia l steps and each cleavage \noccurs on the same side of the \u03b1-helix. Biochemical and genetic studies have \ndemonstrated that presenilin  (PS), nicastrin (Nct), ante rior pharynx defective-1 \n(Aph-1) and presenilin enhance r-2 (Pen-2) form th e enzymatically active core of the \n\u03b3-secretase complex ( Figure 2 ) [29].   \n 64  Evidence indicates that PS comprises the catalytic moiety of the complex, while \nthe other identified subunits are necessary  for proper maturation and sub-cellular \nlocalization of the active enzyme  complex [30]. Consistent with  that hypothesis is that \nPS knockout mice exhibit significant reduction in \u03b2-amyloid production [31].  \nPS1 is a 9 (or 10) transmembrane (TM) aspartyl protease which possesses two highly \nconserved aspartic residues as a catalytic dimer. These essen tial amino acids are parts of a \nhydrophilic loop between TM6 and TM7, which re aches into the cytoplasmatic region of \nthe plasma membrane. Consequently, subs trate proteolysis takes place within the \nhydrophobic environment of the plasma memb rane and represents an unusual cleavage \nmechanism [32].  \nThe influence of detergents on \u03b3-secretase activity in rat brain isolates has been \ninvestigated by Fr\u00e5nberg et al.  [33] \u03b3-Secretase showed the high est activity at 0.4% of \nCHAPSO, a zwitterionic detergent that protects the native state of proteins, resulting in \napproximately four times more  AICD than in absence of the detergent. 1% CHAPSO \nsolubilized a substantial amount of the \u03b3-secretase components  but lowered the \nactivity. Diluting the sample to  0.4% restored the activit y. The production of AICD \nwas time dependent: \u03b3-secretase was still active after 16 h incubation at 37\u00b0C. Beside \nthe detergent concentration, the protein concentration was considered: concentrations \nhigher than 1 mg/ml led to a decrease in the relative amount of soluble active \n\u03b3-secretase in 1% CHAPSO. Therefore, a de tergent: protein ratio of at least 10:1 \nshould be used for effi cient solubilization.  \nFigure 2. \u03b3-Secretase is an aspartyl protease and requires the correct assembling of the tetrameric \nsubunits Aph-1, Nct, PS and Pen-2.  \n \n \n  \n 652.1 Presenilins  \nThe presenilins (PS1  and PS2) contro l the activity of \u03b3-secretase and are involved \nin the processing of APP and the production of A \u03b2 [34]. Mutations in the genes of \nPS1/2 (Chromosome 14, 1) account for the majo rity of the cases of inherited familial \nAD. A\u03b2 levels were dramatically decreased in animal models lacking the expression of \nPS1 but not PS2 [35]. This indicates that  among the two presenilins, PS1 exerts the \nmajor role in regulating the activity of \u03b3-secretase and hence A \u03b2 secretion. PS1 is an \naspartyl protease and its topology is ch aracterized by 9 or 10-membrane spanning \ndomains. The sixth and seventh domains bear  the aspartate residues (D257 and D385) \nwhich are crucial for the production of A \u03b2, as a mutation on eith er of these residues \nabolishes the A \u03b2 generation [36,37].  \nNevertheless, PS1 alone is not able to coor dinate all the processe s that lead to its \nown activation [38]. It has been reported th at overexpression of PS1 does not lead to \nincreased levels of its N- and C-terminal fragments [39]. Therefore, there must be \nadditional limiting factors (Nct, Aph-1, Pen- 2) which control the endoproteolysis of \nPS1.  \n2.2 Nicastrin  \nNicastrin (Nct) was the first protein of the \u03b3-secretase complex to  be identified \n[40]. It is a large type-1 transmembrane prot ein (~ 130 kDa) and exists in an immature \nand a mature form which differ in their glyc osylation [41]. It has a large extracellular \nN-terminal and a short intracellular domain. In  its partial glycosylated, immature form \nit is able to bind to PS where it is cruc ial for PS endoproteolysis and thus for \n\u03b3-secretase activity [42]. This was confir med by the experiments carried out with \ntransition-state analogue inhibitors whic h bind specifically to active PS. These \nexperiments showed that nicastrin co-purif ies with the active fo rm of PS1. This \nindicates that it is an integral part of the active \u03b3-secretase complex [43]. The \nextracellular domain of Nicastrin interacts with the N-terminal region of the substrate \nand enables them to re ach the complex [42].  \n2.3 Anterior pharynx-defective  phenotype-1 and presenilin \nenhancer-2  \n Anterior pharynx-defective phenotype 1 (Aph-1) and presenilin enhancer 2 \n(Pen-2) were isolated as part of the \u03b3-secretase complex in tw o different experiments \ncarried out in C. elegans  [44,45]. Aph-1 and Pen-2 ar e required for Notch signalling \nand A\u03b2 formation. Aph-1, a 30  kDa and 7 TM protein, forms a subcomplex with \nNicastrin and is required for st abilization of PS holoprotein [42].   \n 66 Pen-2 is a short two-membrane domain sp anning protein and it has approximately \n101 amino acids. Pen-2 knockout affects the activity of the \u03b3-secretase complex by \naltering the Notch-mediated signalling pathwa y and the processing of APP [44]. The \nphysiological significance of Aph-1 in the \u03b3-secretase complex is to stabilize the \nPS-Nicastrin subcomplex [46].  \n The C-terminal domain of Pen- 2 induces the endoproteolysis of PS which is \ncrucial for the development of the active he terodimer and also st abilizes the resulting \nC- and N-terminal fragments afterwards [47]. It was revealed that, in absence of PS, \nPen-2 is destabilized and degraded in the endoplasmic reticulum (ER) as an \nubiquitinylated protein [48].  \n2.4 Assembling  \nAn assembling model was proposed by Zhou et al . Initially Nicastrin, in its \npartially glycosylated \u201cimmature\u201d mode, forms a subcomplex with Aph-1 and this \nsubcomplex is suggested to enter the ER. Together with PS ho loprotein a trimeric \nintermediate complex is formed. This is  followed by complete glycosylation of \nNicastrin in the Golgi/transGol gi network and entry of Pen- 2 into the complex induces \nthe PS endoproteolysi s to the active \u03b3-secretase complex ( Figure 3 )[42].  \nEndoproteolysis of PS results in the formation of a N-terminal (NTF) and a \nC-terminal (CTF) fragment. These two fragm ents contain one of the two critical \naspartic residues and remain associated forming a heterodimer which comprises the \nactive PS [49]. PS1 activity resides in its ability to cleave APP within the plasma \nmembrane at the 38-, 40- and 42- sites of the A \u03b2 sequence. This process is known as \n\u201cRegulated Intra-membrane Proteolysis\u201d (RIP). It requires the exchange of water \nmolecules, which are excluded from the hydrophobic lipid bilayer of the cell \nmembrane [50].  \nFigure 3.  Simplistic model of the \u03b3-secretase complex with dimeric substrate C99.  \n \n  \n 672.5 Binding partners  \n Purification of endogenous \u03b3-secretase complex from de tergent solubilized HeLa \ncell membranes showed an add itional integral subunit, the membrane protein CD147. \nCD147 was found to have  a regulatory effect on \u03b3-secretase activity [51]. Apart from \nCD147, other transient or w eak binding partners of the \u03b3-secretase complex, such as \nGSK-3, phospholipase D1 (PLD1) and TM P21 also have been reported [42]. \nAlthough the presence of th ese binding partners is cr ucial for the activity of \n\u03b3-secretase, none of these pr oteins have been detected in purified samples of the \ncomplex. In addition to APP, the \u03b3-secretase complex processe s numerous other type I \nTM proteins including fragments of Notc h, E-cadherin, N-cadherin, CD44, ErbB4, \nLRP and nectin-1, which are involved in  many physiological and pathological \nfunctions [52]. \n \n2.6 Mode of action  \n Multhaup et al.  revealed new mechanistic aspects of \u03b3-secretase cleavage [53]. \nThey reported the dimerization of two AP P-TMSs, via G29 and G33 as a hinge for \nsubstrate dimerization, to be essential for A \u03b240 and A\u03b242 production. This hinge is a \nsterical hindrance for \uf067\uf02dsecretase processing and shifts th e cleavage to the pathological \nA\u03b2 (Figure 4 ). The mutations G29A and G32A reso lve this hindrance and favour the \n\u201cnormal\u201d cleavage to A \u03b238 and A\u03b237.  \n  \n \n  \nFigure 4.  Sterical hindrance for secretase processing by a G29, G33 cross point (see Multhaup) \n[53].   \n 68 3. Inhibition of \u03b3-secretase  \n\u03b3-Secretase inhibitors must reduce A \u03b2 secretion sufficiently to alleviate the cause \nof AD, but must neither totally  abolish secretion nor the pr ocessing of other proteins, \nwhich have important roles in neuronal structure and function. In addition to \u03b2APP, \nseveral substrates are known to be cleaved by \u03b3-secretase, which seems to be the \n\u201cproteasome of the membrane\u201d [54]. Generally , such multiple substr ates increase the \nrisk for toxic side effects by \u03b3-secretase inhibition. In fa ct, the close relation to the \nNotch pathway, which is important in embryonic development, makes \u03b3-secretase a \nrather challenging and risky drug target . The crossover to the Notch pathway \nhampered attempts towards PS -/- knockout  animals, which did not pass the embryonic \nstate, but embryonic stem cells may fill part of the gap [55]. The intracellular \ntrafficking of Notch in human  CNS neurons is reduced by PS1 inhibitors, and results \nin dramatic changes in neurite morphology. A great task will be the determination of a \ntherapeutic window between e fficacy and unacceptable t oxicity [56]. If a safe \ntherapeutic window cannot be defined,  there may remain an option to use \u03b3-secretase \ninhibitors in oncology. Several other substrates must be c onsidered in addition to APP \nand Notch: the Notch ligands Delta and Ja gged, apoER2 lipoprotein receptor, the \nlow-density lipoprotein rece ptor-related protein, ErbB4 receptor tyrosine kinase, \nCD44, p75 neurotrophin and \u03b2-subunits of voltage-gated sodium channels [57,58]. \nAdvances in the last years i ndicate the right direction: \u03b3-secretase modulators that \nmodify APP processing without genera ting unacceptable side effects.  \nSpecial features of the \u03b3-secretase complex hinder crystallisation and thus \ncrystallographic analysis of the enzyme , which is a major obstacle for rational \nstructure-based drug design. Therefore, docking and mol ecular modelling studies are \navailable for BACE, but not for \u03b3-secretase. One crude model was recently proposed \nby Fraering et al.  [59]. The information available on inhibitor binding sites has \nimproved but is still limited. He nce, most of the selective \u03b3-secretase inhibitors were \ndiscovered by high-throughput-screening (H TS) efforts. However, during the last \ndecade a number of potent \u03b3-secretase inhibitors were su ccessfully developed [60,61]. \n Wolfe et al.  explored the mechanisms of different \u03b3-secretase inhibitors in detail \n[62]. Most of them bind direc tly to the active site or alte r it through an allosteric \ninteraction. Some inhibitors, e.g. the isocoumarins and the Aib containing helical \npeptides, do not block A \u03b2-production by affecting the activ e site of the protease, thus \nthey do not target \u03b3-secretase directly. Signal Peptid e Peptidase (SPP) inhibitors can \ninhibit \u03b3-secretase too, showing that SPP and \u03b3-secretase have similar active sites and \nare likely to share the prot eolytic mechanism [63].   \n 69 Compounds inhibiting th e production of all A \u03b2 species without selectivity are \ncalled \u03b3-secretase inhibitors (GSIs), while compounds selectiv ely reducing the \nsecretion of the pathological A \u03b242 are called \u03b3-secretase modulators (GSMs). Inverse \n\u03b3-secretase modulators either downregulate A \u03b238 production without affecting A \u03b240/42 \nor increase A \u03b242 production.  \n3.1 Peptidic, semi-peptidic and non peptidic \u03b3-secretase \ninhibitors and modulators  \nPeptidic PS1 inhibitors, like Merck\u2019s L-685,458 ( 6, Scheme 2 ) display potent \n\u03b3-secretase inhibition (IC 50 = 17 nM) [64]. The all-lip ophilic sequence with 3 \nphenylalanines was somewhat anticipated, as several studies had indicated the \nlipophilic binding pockets (P 2, P 1, P 1\u2019, P 2\u2019, even P 4\u2019 and P 7\u2019) in proximity to the \ncleavage site [24]. It was suggested that compound 6 acts as a direct transition-state \nanalogue of the A \uf06240 and A\uf06242 cleavage sites. The core structure of 6 was linked to \nbiotin and photoreactive fragments attached N- or C-terminally leading to L-852,505 \n(7) and L-852,646 ( 8), which were suitable for labelling studies. Despite the \nattachment of the photoreactive benzophenones, 7 and 8 retained potent inhibition \n(IC 50 < 1 nM for \u03b3-secretase). Biotin was used to  facilitate the isolation and \nidentification of the reversibly labelled ad ducts via their streptavidin-enzyme linked \nconjugates. Photolysis in the presence of solubilized \u03b3-secretase provided a protein of \n20 kDa linked to L-852,505 ( 7) after isolation on a biotin-s pecific streptavidin-agarose \ngel, followed by partial digestion. This fragment was shown to be the C-terminal \nfragment of PS1 (PS1-CTF) by specific an tibodies. Binding to wild-type PS1 was \nnegative in a control experiment. Yet binding to the deletion construct PS1 \uf044\uf020E9, which \nlacks the cytosolic E9 loop, was positive [6 5]. Useful informatio n resulted from the \nphotolysis of L-852,646 ( 8) in the presence of solubilized \u03b3-secretase. This resulted in \nthe isolation of a 34 kDa fragment,  which was assigned to be an N-terminal fragment \nof PS1. A similar transition-st ate motif, the hydroxyethylurea 9 (III-31-C) [66], was \nutilised for activity based affinity  purification. Immobilisation of 9 (IC 50 < 300 nM) on \naffigel 102 allowed isolation and identifi cation of PS1-CTF, PS1 -NTF and Nicastrin \nfrom solubilized \u03b3-secretase preparations [67]. Initial attempts to free active \n\u03b3-secretase from the affinity gel failed. Yet,  a delicate combination of Brij-35 and \nCHAPSO resulted in the isolation of active \u03b3-secretase. The co-precipitation of the \ninhibited \u03b3-secretase with its substrates C83 and C99 gave rise to speculations about \nadditional binding sites, where the substrate is  recognised prior to transfer to the active \nsite.  \nSemi-peptidic inhibitors have also been  comprehensively utilized in a range of \ndiscoveries from the Elan group [68]. DAPT ( 10, IC 50 = 20 nM; HEK) was developed \nfrom a N-dichlorophenylalanine lead and structure activity relationships  \n  \n 70 OHNHN\nNHNH2\nOOH\nOO\nOOHNHN\nNHNH\nOOH\nOO\nOO\nHN\nOS\nHNNH\nO\nHNHN\nNHNH\nOOH\nOO\nOHN\nOS\nHNNH\nOO6 L-685,458            \nIC50 = 17 nM7  L-852,505 \nIC50 < 1 nM\n8 L-852,646  \n  IC50 < 1 nM\n10 DAPT LY374973 \nIC50 = 20 nMOHNO\nNHOO\nFF\nOHNO\nNH\nFFOH\nN\nO\n11 LY 411575 \nIC50 < 1 nM\nOHNO\nNH\nFFNN\nOS\nOHNO\nNHNN\nO ON\nO\n14 DuPont 13 Scios/DuPont  \nIC50 = 0.3 nMOHN NHN\nNHO\nOOH\nOO\nO\n9 III-31-C   \nIC50 < 300 nM\n12 LY450139OHNO\nNHN\nOHO\n \nScheme 2.  Peptidic and semi-peptidic \u03b3-secretase inhibitors.  \n(SAR) studies revealed difluorophenylacetic ac id and phenylglycine to be crucial for \nactivity [69]. DAPT has demons trated robust efficacy in vivo  at relatively high doses. \nThe subcutaneous application to mice in  a dosage of 100 mg/kg resulted in a 50% \nreduction of cortical A \u03b2 levels within 3 hours. A 40% A \u03b2 reduction was observed at \nthe dosage of 100 mg/kg orally , again after 3 hours, but no brain levels of DAPT were \nreported for the latter study [70]. A setbac k came from several preclinical studies, \nwhich revealed in vivo  toxicity, mainly because DAPT  effects the Notch pathway at \nhigher levels (100 \u2013 1000 fold) [8,71,72]. \n Extensive in vivo  studies have been carried out with the more potent \ndibenzoazepine-type analogue LY-411575 ( 11, DBZ). The stereoselective placement \nof the hydroxyl group and the locked spatial arrangement of two phenyl rings in a \ncaprolactam increased the activity 20fold (IC 50 < 1 nM). Oral dosing of 1 mg/kg of 11 \nto 3 to 5 month-old Tg2576 mice halved plasma and cortical A \u03b2 levels within 3 hours \n[73]. A lesser active diastereomer was admi nistered orally to C57BL/6 and TgCRND8 \nAPP mice for 15 days at 1-10 mg/kg per day and resulted in reduction of A \u03b2 levels \n[74]. This was accompanied by  atrophy of the thymus and deterioration of the  \n 71intestinal epithelium.  The Notch/APP selectivity was determined in cellular assays: \nIC50 (A\u03b240) = 0.082 nM, Notch IC 50 = 0.39 nM. This small toxicity window and the \nhigh potency made DAPT and LY-411575 unlik ely candidates to enter clinical trials. \nNevertheless, E. Siemers et al . went on and reported the results of the phase I and \nphase II studies of the \u03b3-secretase inhibitor LY450139 ( 12), which is less potent than \n11 [75]. LY450139 ( 12) is moderately selective for APP cleavage over the Notch \npathway. The oral application of 12 to healthy volunteers re sulted in reduced plasma \nlevels of A \u03b2total to 74.3% of the initial baseline at 40  mg/d after 14 days. The sampling \ntime point was crucial, as a single dos e resulted in significant reduction of A \u03b2total 3-6 h \nafter dosage but also in recovery and overs hoot within 12 h. However, cerebrospinal \nfluid (CSF) levels were constant. Furtherm ore the results of phase IIa were reported \n[76]: The application of 30-40 mg/d over  6 weeks to AD 70 patients led to 38% \nplasma A \u03b2 reduction: again no changes in CS F were observed. Moreover, there \nappeared one severe case of Barrett oes ophagus, but biopsy excluded Notch mediated \nprocesses. Recently, the resu lts of the phase IIb clinic al study of LY450139 were \nreported at the 2nd International Conferen ce on Prevention of Dementia by Fleisher et \nal. (Washington, 2007), testing the effect of  LY450139 on 51 par ticipants with AD for \n14 weeks with randomized doses (100 mg, 140 mg) or a plac ebo. Three adverse events \nwere observed during this clinical study: 1) small bowel obstruction, 2) haemoglobin \npositive stool, and 3) diarrhoea. Th e study recorded reduced plasma A \u03b240 by 58.2% for \nthe 100 mg group and 64.6% for the 140 mg group, but no  significant reduction of \nCSF A\u03b240 (100 mg = 20%, 140 mg = 11%, Pla cebo = 6%). During this trial a t 1/2 of \n2.59 h with a T max of 1.68 h at 140 mg was observed.  No differences were seen in \ncognitive or functional measures of any group.  \nDuPont Pharmaceuticals and Scio s described a highly potent \ndifluorophenacyl-caprolactam derivative ( 13, IC 50 = 0.3 nM) [77]. 13, better known as \nCompound E is a potent, selective, non-tr ansition state and non-competitive inhibitor \nof \u03b3-secretase and Notch processing. Bristol-Me yers Squibb and Du Pont continued to \nelaborate this caprolactam motif. Some efforts were dedicated to modify the \nN-terminus to create non-infringing structures  to the Elan patents. The synthesis of \noxazolylsulfonamide 14 is one such example [78].  \n \n  \n 72 FCOOH\nNSF\nFClOO\n 18 BMS-299897                       \n   IC 50 = 7.1 nM\nS\nSHNO\nO\n24 MSDO OClS\nFO ONH\nNHSO\nOSO\nONH\nOHNS\nClOOO\nNH 2\nN\nS\nClO ONBoc15 Amgen        \n IC50 = 1.8 \u00b5M\n23 MSD16 Wyeth 17 BMS            \n  IC50 < 50 nM\n19 ScheringN\nS\nClO O ONN\nO\nOH\n20 ScheringN\nS\nClO OO\nON\nN\n21 Schering            \nIC50 = 0.2 nM\nF\nFN\nS\nClO OO\nO\nO\n22 ScheringF\nFNNOHSHN\nSOO\nOO\nF3CF\nF\n25 MSD  \nScheme 3.  Non-peptidic \u03b3-Secretase inhibitors I.  \nDespite tremendous research efforts, th e molecular mechanis m of DAPT and Co. \nstill remain unclear. Fuwa et al.  presented the synthesis of multifunctional probes for \nthe identification and characteriz ation of molecular domains in \u03b3-secretase or signal \npeptide peptidase (SPP). A ph otoaffinity as cross-linking unit like benzophenone or \nphenyldiazirine and biotin as re porter were attached to DAPT, 11 and 13 via the \nazide/alkyne fusion process. The affinity  probes displayed strong inhibition of A \u03b2 \nsecretion comparable to the parent co mpounds, suggesting affinity towards \n\u03b3-secretase. Photoaffinity labelli ng experiments revealed that 11 and 13 directly target \nPS1 N-terminal fragments (NTF), while DAPT targets C-terminal fragments (CTF) of \nPS1. A competition assay was performed and th e results suggest that the binding site \nfor 11 and 13 is functionally overlapping wi th the DAPT binding site. The C-terminal \nstructure of these compounds might determin e the final target region in PS1 and the \nmode of action on \u03b3-secretase activity. Furthermore, 11 and 13 directly and \nspecifically target signal peptide pep tidase while DAPT does not. The authors \nproposed a speculative mode of binding: PS1 harbours a binding pocket for dipeptidic \n\u03b3-secretase inhibitors that is composed for difluorobenzene, phenylglycine and \ncaprolactam binding sites. The phenylglycine  and caprolactam binding sites reside on \nPS1 CTF and PS1 NTF, while the caprolactam  binding site resides on SPP. DAPT, 11 \nand 13 initially bind to the difluorobenzene bi nding site in PS1 and subsequently the \ncompounds target the secondary site , forming a stable complex with \u03b3-secretase, \neventually inhibiting the proteolytic activity . The authors argue, that these results do \nnot allow a final conclusion as  they cannot rule  out an allosteric  effect caused by \naffinity ligands [79].   \n 73Apart from the previously described pe ptidic and semi-peptidic inhibitors, \nlipophilic scaffolds based on  sulfonamide moieties have been explored in recent \ndiscoveries. The Amgen group exploited fe nchylamine sulfonamides as moderately \npotent inhibitors (e.g. 15, IC 50 = 1.8 \u00b5M, HEK293-cells) ( Scheme 3 ) [80]. \nWyeth/Arqule reported sulfonamides ( 16) which were prepared from amino alcohols \n[81]. Acetamide derivatives such as 17 have been reported  by BMS. Compound 17 \ndisplayed potent inhibition of A \uf062 secretion with an IC 50 < 50 nM in H4-cells. \nBMS-299897 ( 18) [56] was found to reduce A \u03b2 in brain, cerebrospinal fluid (CSF) and \nplasma in young transgenic  mice in a dose and time dependent manner with a \nsignificant correlation be tween brain and CSF A \u03b2 levels. Transgenic mice were used \nto examine potential side effects related to  Notch inhibition whic h is a crucial issue \nwith \u03b3-secretase inhibitors. 18 was 15-fold more effective and selective at preventing \nthe cleavage of APP than of Notch in vitro  (APP IC 50 = 7.1 nM, Notch \nIC50 = 105.9 nM). No changes in the maturation of CD8+ thymocytes or of intestinal \ngoblet cells were observed in mice treated with 18. In a series of closely related \ndisclosures, the Schering-Plough group empl oyed a variety of sulfonamides, such as \npiperidine 19, tetrahydroquinoline 20 (IC 50 = 30-535 nM, DKF167 cells expressing \nC99) and the 2,6-dis ubstituted piperidine 21 (IC 50 = 0.2 nM). Replacement of the \nsulfonamides by a sulfone moiety resulte d in corresponding series. Substituted \nN-arylsulfonyl heterocyclic amines ( 22) displayed IC 50 values in the range of 1 nM to \n1 \u00b5M [82]. The Merck group employed an unusual bicyclo-[4.2.1]-sulfonamide scaffold characterized by  the toluyl sulfonamide 23 [83]. Other aryl cyclohexyl \nsulfones like 24 (IC50 < 100 nM, SH-SY5Y cells) [84] and 25 [no data shown] were \nalso claimed by Merck Sharp & Dohme (MSD) as \u03b3-secretase inhibitors [85,86].  \n  \n 74 NS ClO\nOHN O\nOO\n28 Elan\nIC50 < 25 nM\nF\nF\nF NONN\nS\nClHNO\nOO\n29 ElanS\nN\nNHNOO\nOO OCl\n30 ElanS\nClO OF\nFO\nONNO\nS\nClO OF\nF\n26 Bayer 27 Daiichi      \nIC50 < 50 nM\nN\nS\nN\nNHOO OBr\n31 Elan\nS\nNNO O\nOCl\nHN N\n32 Elan             \nIC50 < 100 nMNHO\nFFNSFF MeO\nO\nO\nCl\n34 Roche\nIC50 = 0.2 nMNHO\nNSF MeO\nO\nO\nS\nCl\n33 Roche\nIC50 < 300 nM \nScheme 4: Non-peptidic \uf020\uf067-Secretase inhibitors II. \nFollowing this initial discovery of cy clohexyl sulfones, additional compounds \nsuch as 26 ( Scheme 4)  have been claimed by the Ba yer AG [87]. Various related \nsulfones were claimed by Da iichi Pharm Co. (e.g. 27, IC 50 < 50 nM, H4-cells). The \nElan patent application reported three general synthetic schemes and about 700 \ntabulated examples [88]. Selected N-(oxoazepanyl) benzenesulfonamides showed \npromising activities, fo r example, compound 28 inhibits \u03b3-secretase with an IC 50 \nwithin the range of 0.1-25 nM. However, the activities of compound 29 and 30 are not \nreported. Another related Elan pa tent described the synthesis of N-substituted \nheterocyclic sulfonamides like  31 as potent inhibitors of A \u03b2 synthesis with minimal \ninhibition of Notch si gnalling [89]. Furt hermore, Elan identifie d bridged N-bicyclic \nsulfonamides for \u03b3-secretase inhibition [90, 91]. Compound 32 exhibited an IC 50 value \nfor A\u03b2 secretion of less than 100 nM in 293sw cells.  \nRoche presented sulfonamides (e.g. 33) and preferred compounds display IC 50 \nvalues < 0.3 \u00b5M [92]. Rela ted fluoro-substituted 2-oxo-azepanes were prepared as \n\u03b3-secretase inhibitors for the treatment of AD or cancer. Synthesis and activities in \nHEK293 are given as well as formulati ons as tablets and capsules. Preferred \ncompounds exert an IC 50 of < 10 nM, e.g. compound 34 inhibits A \u03b2 secretion with an \nIC50 of 2 nM [93]. Additionally, Roche presented malonamide derivatives ( 35), where \nseveral compounds display IC 50 values of <10 nM ( Scheme 5 ) [88,94]. Roche\u2019s \n1,4-benzoxazepin-3-one 36 was prepared by a cyclocondensation of \n(formylaryloxy)-alkanoic acid, amin es and isonitrile [95]. Compound 36 inhibits \n\u03b3-secretase with an IC 50 value of 0.18 (no units give n). Astra Zeneca claimed novel  \n 75molecular probes for the det ection, characterisation and lo calization and isolation of \n\u03b3-secretase. They presente d biotinylated and bodipy-labeled compounds (e.g. 37) and \ndetermined the inhibition of A \u03b240 production in HEK cells, but did not reveal assay \ndata [96]. Gleevec ( 38) inhibits A \uf062\uf020production but not Notch cleavage [97]. Recently, \nFraering et al. reported IC 50 values for A \u03b240, A\u03b242 and AICD generation of ~75 \u00b5M. \nGeneration of the N-terminal intracellular domain-Fl ag (NICD) was not inhibited, \neven at >10-fold concentra tions. The authors proposed a potential nucleotide-binding \ndomain on \u03b3-secretase, because ATP wa s able to recover the \u03b3-secretase activity \ninhibited by a Gleevec formulation. There is strong support for this hypothesis: \n\u03b3-secretase binds to ATP acr ylamide resin through the \u03b3-phosphate [98].  \nTorrey Pines Therapeutics (formerly name d Neurogenetics) disclosed a large \nnumber of aminothiazole derivatives (e.g. 39) with A\u03b242/A\u03b240-lowering activities at \nconcentrations of about 30 \u00b5M [99]. The compounds derived from \u03b1-halogenated \nketones and appropriate thioureas or ureas. Approximately 60 of these structures were \nclaimed to display good inhibition (activ ity < 0.2 \u00b5M). Furthermore, Torrey Pines \ndelivered interesting news: the results of the phase I study for the company's lead AD \ncandidate, NGX267 ( 40), were presented by M. Mu rphy (Salzburg 2007, 8th \nInternational Conference on Alzheime r\u2019s and Parkinson\u2019s Diseases). 40 is a \nmuscarinic or M1 receptor agonist which has also been  linked to a decrease in \nA\uf06242-production. The double-blind, placebo- controlled, multiple-d ose trial enrolled 90 \nhealthy males, between the ages of 18 and 55, in sequential cohort s. Doses of 10, 20, \n30, and 35 mg were evaluated. Evidence of  cholinergic stimulation was detected by \nincrease in salivary flow, and there were no clinically notable adverse events. NGX267 \nor ( S)-2-ethyl-8-methyl-1-thia-4 ,8-diazaspiro-[4.5]-decan- 3-one is identical with \nAF267b, claimed by Abraham Fisher [100]. Pr eclinical data support a dual mechanism \nof action. NGX267 has been shown to stimul ate M1 receptors in a mode analogous to \nacetylcholine. Additionally, NGX267  lowered brain levels of A \u03b242 in studies in mice \nand rabbits [101]. Furthermore, the compan y has two preclinical candidates targeted \nfor the treatment of AD in the pipeline: fi rst, the follow-on M1  agonist, NGX292, a \ndesmethyl derivative of NGX267. Second, NGX97555 (structure not disclosed), a \n\u03b3-secretase modulator presente d by S. Wagner in Salzburg 2007. According to the \nworking hypothesis, series555 compounds bind to, and allo sterically modulate, the \n\u03b3-secretase complex, causing a shift in the \u03b3-site cleavage preference from A\u03b240/42 to \nA\u03b237/38, without inhibiting the overall catalytic activity of the comp lex. The changed \nratio of A \u03b2 isoforms and A \u03b2total (IC 50 (A\u03b242) = 10 nM, IC 50 (A\u03b240) = 64 nM, SY5Y \ncells), and the retained Notc h and E-cadherin processing supports classification of \nNGX97555 as a \u03b3-secretase modulator. Similar A \u03b2 isoform changes have been \nobserved in vivo . A 3-day oral dosing revealed the minimum efficacious dose of 25-50 \nmg/kg to lower brain A \u03b242 in Tg mice. NGX97555 is likel y to be a close analogue of \nthe very lipophilic compound 39 (Scheme 5 ) and Pen-2 has been advanced as a \npotential binding site. The unusually high lipophilicity  (clogP = 6.8) makes 39 and \nanalogues thereof to potent bi nders to protein aggregates such as tau derived PHFs and \nA\u03b2 fibrils. These poor pharmacokinetic properties in comb ination with the \nmetabolically labile and noto rious hepatotoxic arythiazole fragment (Pfizer disclosed \ntwo clinical trials failures) will be severe obstacles in the further clinical development \nof analogues.   \n 76  Substituted thiazolamides ( 41), which resemble the Torrey Pines compounds, \nwere coupled to a redox chemical delivery system (RCDS) and may feature enhanced \npharmacokinetic properties [102]. A dihyd ropyridine RCDS was introduced to \nimprove the blood brain barrier (BBB) permeation. The compounds exhibited EC 50 \nvalues ranging from 0.1 to 1.0 \u00b5M  in cell free assays. Compound 41 displayed an ED 50 \nvalue of 0.2 \u00b5M for A \u03b2total in cellular assays using APP transfected HEK293 cells. An \napplication by Pfizer contains 7 genera l synthetic schemes and more than 350 \ntabulated imidazolylamides, e.g. 42, inhibiting the generation of A \u03b2-peptide (no data \nshown) [103].  \nN\nOOClONHO\nO\nN\nOOClONHO\nO\n36 RocheF\nFF\nNNHN\nNHN\nONN\n38 GleevecNS\nNHN\nN\n39 Torrey Pines\nIC50 < 0.2 \u00b5M\nOHNO\nNHNS\nNH\nO\nNF\nF\n41 Kraus et al.\nED50 = 0.2 \u00b5MN35 Roche\nIC50 < 10 nM\n40 NGX267S NH\nNON\nOO\nNHO\nNH OFFF\nFF\nHNO\nNHNN NHHO\nF\nF 42 PfizerNO\nONH\nO\nNHO\nHN\nO\nOHN\nO\nN\nNB\nFF\n37 Astra Zeneca\n \nScheme 5.  Non-peptidic \u03b3-Secretase inhibitors III.  \nA selective GSM ( 43, Scheme 6 ) was reported by MSD [104]. The carboxylic \nacid seems to be important to achieve the desired ratio of A \u03b238/A\u03b240/A\u03b242. This \nmodulation is distinctly different from inhibition as the A \u03b2total load may be \nunaffected. Tetrahydroin dole derivatives like 44 and 45 [105] as well as arylacetic \nacids (e.g. 46) [106] developed by MSD were te sted using a cell-based (human \nSH-SY5Y cells) assay. These co mpounds exhibit selective inhibition (modulation) of \nA\u03b242 production. The IC 50 values of the most potent compounds are at least 2-fold \nlower than for A \u03b240, typically at least 5-fold lower and in the preferred cases 50-fold \nlower (data not shown). Closely related S-enantiomers of \u03b1-substituted aryl acetic \nacids and biphenylacetic acids ( 47 and 48) have been reported by Cellzome. Potent \nmodulators (e.g. 48) display an IC 50 < 1 \u00b5M in SKN neuroplast cells [107,108].  \nN-Sulfonylated and N-alkylated carbazolyloxyacetic acids have been presented as \npotent modulators of \u03b3-secretase [109]. Introduction of  a lipophilic substituent, which \nmay vary from arylsulfone to alkyl, turned  2-carbazolyloxyacetic acids into potent  \n 77\u03b3-secretase modulators (e.g. 49, IC 50 (A\u03b242) = 7.5 \u00b5M). This resulted in the selective \nreduction of A \u03b242 and an increase of the less aggregatory A \u03b238 fragment. Introduction \nof an electron donating gr oup at position 6 and 8 of N-substituted carbazolyloxyacetic \nacids either decreased the ac tivity or inversed modulation.  The most active compounds \ndisplayed activity in the low micromolar  range and little or no effect on the \u03b3-secretase \ncleavage at the \u03b5-site. Furthermore, N-sulfonylated and N-alkylated carprofen \nderivatives displayed modulatory effects on \u03b3-secretase. The introduction of a \nlipophilic substituent transformed the C OX-2 inhibitor carprof en into a potent \n\u03b3-secretase modulator (e.g. 50, IC 50 (A\u03b242) = 2.9 \u00b5M). Several compounds selective \nreduced A \u03b242 secretion and increased A \u03b238 secretion.  \nNCOOHCl\nF3CNCOOH\nF3C\n44 MSD 45 MSDCOOHF3C\n46 MSD\nCF3COOH\n47 Cellzome \nIC50 < 50 \u00b5MCOOH\nCF3OF3C\n48 Cellzome \nIC50 < 1 \u00b5MNCO2H\nF3C\n43 MSD\nNOCOOH\nSOO\n49 Schmidt\nIC50 (A\uf06242) = 7.5 \u00b5MNCOOH\nCl\n50 Schmidt\nIC50 (A\uf06242) = 2.9 \u00b5M \nScheme 6.  Non-peptidic \u03b3-secretase inhibitors IV.  \n \nThe lipophilic substituents cause amphiphilic  properties of the carboxylic acids, \nwhich may interact with membra nes. The authors favour the N-alkylated derivatives \nfor the investigation of potential memb rane interactions, as they allow the \nincorporation of phospholip ids analogues and membrane disrupting fragments. If \naffected at all, the \uf065\uf02dcleavage of \u03b3-secretase was inhibited at much higher compound \nconcentrations than those determ ined to be modulatory at the \u03b3-site. The compounds \nare therefore expected to have little or no impact on \u03b3-secretase mediated signalling \nvia the AICD or via intracellular domains of other \u03b3-secretase substrates. However, the \ninteraction site of these compound s has not been reported yet.   \n 78 3.2 Non-steroidal anti -inflammatory drugs as \u03b3-secretase \nmodulators  \nBrains of AD patients show  a number of pathological  abnormalities such as a \nprofound loss of synapses, profuse reactive glyosis, microglial proliferation and ultimately indication of infl ammatory processes [110]. In creasing evidence suggests \nthat a large number of inflammatory  mediators are elements of the AD \nneuropathology. Several inflammatory fact ors were identified in the brains of AD \npatients which include activated complement  proteins, cytokines, chemokines, acute \nphase reactants, proteases and their inhibi tors, proteoglycans, growth factors and \nvarious other enzymes. Due to these obs ervations, different inflammation based \nhypothesis for AD have been proposed. One of  these postulates that neurodegeneration \nin AD brain is secondary to an inflammatory  response to plaques and NFTs rather than \nto these hallmarks themselves. Moreove r, inflammation initiates the formation of \nplaques and NFTs and their progressive ac cumulation, which in sequence activates \nimmune reactions that force a self-sustain ing \u201cauto destructive\u201d process. Thus, these \nhypotheses propose that in both circ umstances chronic inflammation has a \nfundamental role in AD pathoge nesis. This hypothesis is fu rther supported by several \ngenetic studies indicating that polymorphisms  of inflammatory genes (i.e., interleukin \n(IL)-1\u03b1; IL-1\u03b2; tumour necrosis factor (TNF)- \u03b1; \u03b12-macroglobulin, \na1-antichimotrypsin)  increase the risk of AD [111 ]. Epidemiological studies \ndemonstrated that use of non-steroidal an ti-inflammatory drugs (NSAIDs) may delay \nor prevent the onset of AD.  They slow AD progression and reduce the severity of \ncognitive symptoms [1 12,113]. The duratio n of the treatment is critical for the \noutcome as long-term treatment is more bene ficial compared to short-term treatment \n[112]. Moreover, the type of NSAIDs is crucial for the outcome e.g. ibuprofen, \nsulindac, indomethacin offer the best prot ection, whereas naproxen does not. This \nprovided the rationale for clinical trials  of different NSAIDs in AD patients.   \n 793.2.1 APP metabolism by NSAIDs  \nIt is well documented that NSAIDs can modulate the secretion of s-APP \u03b2 in \ndifferent neuronal cell lines , astrocytes and neurons via a protein kinase C \n(PKC)-mediated mechanism [114]. Weggen et al . reported three NSAIDs which \ndisplay selective A \u03b242-lowering activity in a variety of  stable transfected cell lines \n[115]. Two structurally clos ed compounds, sulindac sulfid e and indomethacin lowered \nA\u03b242 secretion (IC 50 = 25-50 \u00b5M), whereas ibuprofen lowered A \u03b242 secretion with an \nIC50 of around 250 \u00b5M. At maximal non- toxic concentrations, 70\u201380% A \u03b242 secretion \ninhibition was observed withou t significant reduction of A \u03b240 levels. Interestingly, this \nactivity was not associated with all NSAIDs  and negative results  were observed with \nother commonly prescribed NSAIDs  such as naproxen and Aspirin\u00ae \nas they did not \naffect either  A\u03b240 or A\u03b242 levels [115]. Later Eriksen et al.  identified other NSAIDs \nwith A\u03b242-lowering activity such as fenoprofen 55, flurbiprofen 51 and meclofenamic \nacid 56 (Scheme 7 ) [116].  \nFOH\nO\n51 R-Flurbiprofen\nIC50 (A\uf06242) = 307 \u00b5MOOH\nSF\n52 Sulindac sulfide\nIC50 (A\uf06242) = 34 \u00b5MNO\nO\nClOOH\n53 Indomethacin\nIC50 (A\uf06242) = 25-50 \u00b5MOH\nO\n54 Ibuprofen\nIC50 (A\uf06242) = 200 \u00b5M\nO OH\nO\n55 FenoprofenCl\nCl NH\nO OH\n56 Mechlofenamic acidNN F\nFFSOOH2N\n57 Celecobix\nEC50 (A\uf06242) = 10 \u00b5M \nScheme 7.  NSAIDs that modulate \u03b3-secretase activity. \n \nSome cyclooxygenase-2 (C OX-2) specific inhibito rs, including celecoxib 57 and other \nstructurally related compounds such as the peroxisome pro liferator-activated receptor-\n\u03b3 (PPAR-\u03b3) antagonist fenofibrate 58 were found to increase A \u03b242 levels selectively \n[117,118]. Furthermore, cell based studies with A \u03b242-lowering compounds have \nrevealed that \uf067-secretase modulators do not a ffect the cleavage of other \u03b3-secretase \nsubstrates such as Notch a nd others [115,118-122]. Assays  with APP-transfected cell \nlines revealed that A \u03b242-lowering NSAIDs do not change APP expression, turnover, \ninternalization or release of the APP ecto domain. Significantly, in contrast to the \nconventional \u03b3-secretase inhibitors NSAIDs do not cause accumulation of APP \nC-terminal fragments [115,118,121]. Some NSAIDs may display their A \u03b2-lowering \neffect by inhibiting the small GTP-binding protein Rho and its  effector, Rho associated \nkinase (Rock) [123]. Remarkab le, some NSAIDs shift the in vitro \u03b2-APP metabolism \ntowards shorter and less fibrillogenic forms of the A \u03b2 peptides. Ibuprofen 54, sulindac \n52 and indomethacin 53 (Scheme 7 ) modulate APP metabolism to explicitly generate  \n 80 less A\u03b242 and more soluble A \u03b238 by interfering directly  with the activities of \n\u03b3-secretase. Furthermore, treat ment with sulindac sulfide 52, indomethacin 53 and \nibuprofen 54 did neither impair \u03b3-secretase-mediated Notch receptor cleavage and \nNICD formation nor the generation of th e ICDs of APP and the ErbB-4 receptor \n[115,118,119,122]. This consistently unaffected ICD-generation of several \u03b3-secretase \nsubstrates indicate that \u03b3-secretase modulators and improved compounds may avoid \nthe toxicity associated with \u03b3-secretase inhibitors. Substantial progress has been made \nto determine the mech anism of action of A \u03b242-lowering compounds. However, several \narguments rule out any involvement of COX in the A \u03b242-lowering activity such as: \nonly a few NSAIDs display A \u03b242-lowering activity, whereas all NSAIDs inhibit COX \n[115], the A \u03b242-lowering activity of sulindac su lfide was not impaired in COX-\n1/2-deficient cells [115], and NSAID deri vatives have been reported which lower A \u03b242 \ndevoid of their COX inhibitory ac tivity [116,121,124 ,125]. Peretto et al.  reported \nnovel cyclopropylated flurbipr ofen analogues with potent  and selective inhibitory \nactivity on A \u03b242 [125]. \n Compared to flurbiprofen, the compounds 59, 60  (Scheme 8 ) exert improved \npotency on A \u03b242-secretion. Moreover, introduction of  the cyclopropyl substituent at \nthe alpha position caused almost complete  loss of COX-1 inhi bition. In rats, \ncompounds 59, 60  showed good oral bioavailability and long elimination half-life. \nShort-term studies in transgenic  mice showed that compounds 59, 60  decreased plasma \nA\u03b242 concentrations significantly. Carprofen 61, a COX-2 inhibitor approved for the \nuse in dogs, cows and horse s is a weak inhibitor of \u03b3-secretase. The geminal dimethyl \nderivatives of carprofen  and flurbiprofen ( 62, 63 ) display 40% and 67% inhibition of \nA\u03b242 production respectively in HEK cells at  100 \u00b5M concentration [126].  \n \nClClFOH\nO\n58 IC50 (A\uf06242) = 41 \u00b5MOFOH\nO\nF FF\n59 IC50 (A\uf06242) = 20 \u00b5MNHClO\nOH\n60 Carprofen\nNHClO\nOH\n61FOH\nO\n62  \nScheme 8.  NSAIDs derivatives that modulate \u03b3-secretase activity.  \n  \n 813.2.2 Long-term and short term  treatment studies with A \u03b242-lowering NSAIDs  \nSeveral long-term and short-term treatme nt studies in APP- transgenic mouse \nmodels of AD have b een performed with A \u03b242-lowering NSAIDs. Even before the \nA\u03b242-lowering activity of certai n NSAIDs was reported, Lim et al. demonstrated that \nchronic treatment with high doses of ibuprofen for 6 m onths strongly reduced both \namyloid pathology and inflammatory res ponses in Tg2576 mi ce [127]. In animals \ntreated with ibuprofen, the total number and area of A \u03b2 plaques was reduced by 50% \nwhile the soluble and insoluble A \u03b2 in the brain was reduced  by 30\u201340%. This was \naccompanied by reductions in the number of plaque-associated activated microglia \ncells and lowered levels of pro-inflamma tory markers. Indome thacin was found to \nreduce amyloid pathology in Tg2576 mous e model but celecoxib and nimesulide did \nnot show significant reductions in amyloid pathology [128,129]. Short-term treatments \nhave demonstrated that A \u03b242-lowering NSAIDs can lower A \u03b242 levels in the brains of \nyoung, plaque-free APP-transgenic mice. In the initial experiments, 3-month-old \nTg2576 mice were orally do sed for 3 days with 50 mg /kg/day of ibuprofen or \nnaproxen [115]. Treatment with ibuprofen re sulted in a 39% decrea se in SDS-soluble \nA\u03b242 without any changes in A \u03b240 levels, whereas naproxe n displayed no effect. \nFurther short term studies have confirmed in vivo A\u03b242-lowering activity for sulindac \nsulfide, indomethacin and flurbi profen  [67]. Only a few clin ical trials with NSAIDs in \nAD patients have been conduc ted to date. A slowing of  the cognitive decline was \nobserved in the first trial with indomethacin [130]. Severe side effects caused by the long-term use of NSAIDs hamper the clinical  use of NSAIDs, espe cially in elderly AD \npatients. Another promising strategy may be the application of specific NSAID \nenantiomers devoid of COX-1/2 inhibition. A particular interesting compound is the \n(R)-enantiomer of flurbiprofen, which la cks COX-1 inhibitory activity, but is \nequipotent in reducing A \u03b2\n42 in vitro  and in vivo  compared to ( S)-flurbiprofen \n[116,121]. Recently, a phase II clinical trial with ( R)-flurbiprofen ( 51, Flurizan\u00ae, \ndeveloped by Myriad Pharmaceuticals) w ith duration of 12 months has been \ncompleted. According to the company website, a significant fraction of study \nparticipants with mild AD who took 800 mg of ( R)-flurbiprofen twice daily declined \nless than did patients on placebo. As meas ured by the MMSE test, 42 percent of \npatients on ( R)-flurbiprofen remained stable or ev en improved compar ed to 14 percent \nof patients on placebo. On the ADAS-Cog set of  tests and other test batteries, one in \nfour patients on ( R)-flurbiprofen stayed stable or im proved slightly, while none of the \npatients on placebo did. If the two ongoing phase 3 trials replicate these data, \n(R)-flurbiprofen would appear to be able to not only slow a person\u2019s decline but also \nhalt progression of the disease, at least for a period of time. So far, this was true in \nsome but not all people. Last year, the co mpany reported that patients who responded \nto (R)-flurbiprofen also had fewer psychiatric complic ations. However, a related \n(R)-flurbiprofen dosage of 5 mg/kg per day was reported to interfere with COX-2 \nmRNA synthesis [131]. Thus AD therapy with ( R)-flurbiprofen may cause an increase \nof thrombotic events. This potential cardiovascular risk s till requires evaluation against \nthe therapeutic benefit in AD.   \n 82 4. Models for \u03b3-secretase modulation  \nUntil now, there is no sa tisfactory explanation for the binding site of the \n\u03b3-secretase-modulators. To solve this dile mma the authors suggest two models for \nmodulation versus inhibition ( Figure 5 ). Potent active site dir ected inhibitors display \nmodulatory action at concentrations below their IC 50 concentration. This supports two \nbinding sites ( Figure 5a ) of the active complex where one site is responsible for \nsubstrate recognition, the other for cleavage [132]. This observation is in accordance \nwith the activity of partia l PS1 Asp mutants by C. Haa ss and H. Steiner [36]. The \nhypothesis is that o ccupation of one site only results in a tilt of the dimeric substrate, \nwhich is subsequently cleaved at the A \u03b238 site. On the contrary the occupation of both \nsites is predicted to result in full \u03b3-secretase inhibition. The distance between the two \nsites is an important aim of  ongoing investigation for future studying. In the second \nmodel ( Figure 5b ) it is hypothesized, th at GSMs such as NSAI Ds do not target the \n\uf067-secretase-complex directly but rather bind to  its substrate APP, thereby changing the \ncleavage pattern. The dimerization of APP may be influenced by this NSAIDs binding. \nA further possibility for the inhibition of APP cleavage was repor ted by D\u00b4Adamio et \nal. [133]. They discovered BRI2 and BRI3, type II membrane proteins, which inhibit \nthe production of A \u03b2 from APP. BRI2 inte racts with APP and regulates the processing \nof APP resulting in reduced A \u03b2 and AICD levels. 17 amino acids of BRI2 \ncorresponding to the NH 2-terminal portion of A \u03b2, have been found to be essential for \nthis interaction. \na) \n \nb) \n \n \nFigure 5 . a) Simplistic model of the secretase modulation by occupation of one or two sites in the \n\u03b3-secretase complex. Low inhibitor concentrations result in single occupation of the binding site, \nwhich tilts dimeric C99 substrate to result in a novel cleavage pattern. b) Substrate binding of \nGSMs leads to modulation. \n \n  \n  \n 835. Outlook  \nThe availability of peptidic and peptidomimetic inhibitors for \u03b3-secretase \ninhibitors made a huge impact on the re search area. But th ese potent compounds \ncome with costly price tags : oral availability cost of goods and blood-brain barrier \npenetration impose severe obstacles on drug development. Finally, the first results of \nbrain penetrating secretase i nhibitors in phase I or II were reported. Despite the \nextremely rapid progress in the field, th ere are no reports of a brain penetrating \nsecretase inhibitor free of undesired activi ties in phase III in AD treatment. The \nselective modulation of \u03b3-secretase by NSAIDs is poin ting in the right direction: \nallosteric modulation of the active site, which can be identified by additional cleavage \nsites of PS1. Models for the mode of actio n of GSMs have been suggested, but the \nultimate proof of concept for \u03b3-secretase inhibition has not been revealed yet. \nHowever, the Notch associated anti-prolifer ative effects stimulat ed major companies \n(MSD and others) to switch the GSI programmes to oncology.   \n 84 6. References  \n1. Schmidt, B., Narlawar R., Braun H.A. 2005. Current Medicinal Chemistry, 12, 1677.  \n2. Parvathy, S., Karran E.H., Turner A.J., Hooper N.M. 1998. FEBS letters, 431, 63.  \n3. Nunan, J., Small David H. 2002. Essays Biochem., 38, 37.  4. Perez, R.G., Soriano S., Hayes J.D., Ostaszewski, B., Xia, W., Selkoe, D.J., Chen, X., Stokin, \nG.B., Koo, E.H.. 1999. J. Biol. Chem., 274, 18851.  \n5. Vassar, R., Bennett B.D., Babu-Khan S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., \nRoss, S., Amarante, P., Loeloff, R., Luo, Y., Fisher, S., Fuller, J., Edenson, S., Lile, J., \nJarosinski, M.A., Biere, A.L., Curran, E., Burge ss, T., Louis, J.C., Collins, F., Treanor, J., \nRogers, G., Citron, M. 1999. Science, 286, 735.  \n6. Bodendorf, U., Danner S., Fischer F., Stefani, M., Sturchler-Pierrat, C., Wiederhold, K.H., \nStaufenbiel, M., Paganetti, P. 2002. J. Neurochem., 80, 799.  \n7. Pastorino, L., Ikin A.F., Lamprianou S., Vacare sse, N., Revelli, J.P., Platt, K., Paganetti, P., \nMathews, P.M., Harroch, S., Buxbaum, J.D. 2004, Molecular and Cellular Neuroscience, 25, 642.  \n8. Capell, A., Steiner H., Willem M., Kaiser, H., Meyer, C., Walter, J., Lammich, S., Multhaup, \nG., Haass, C. 2000, J. Biol. Chem., 275, 30849.  \n9. Limongelli, V., Marinelli L., Cosconati S., Braun, H.A., Schmidt, B., Novellino, E. 2007. \nChemMedChem, 3, 667.  \n10. Marcinkeviciene, J., Luo Y., Graciani N.R., Combs A.P., Copeland R.A. 2001. J. Biol. Chem., \n276, 23790.  \n11. Leung, D., Abbenante G., Fairlie D.P. 2000. J. Med. Chem., 43, 305.  \n12. Gorfe, A.A., Caflisch A. 2005. Structure (Camb), 13, 1487.  \n13. Park, H., Lee S. 2003. J. Am. Chem. Soc., 125, 16416.  14. Rajamani, R., Reynolds C.H. 2004. J. Med. Chem., 47, 5159.  \n15. Polgar, T., Keserue G.M. 2005. J. Med. Chem., 48, 3749.  \n16. Chou, K.C. 2004. J. Proteome Res., 3, 1069.  \n17. Farzan, M., Schnitzler C.E., Vasilieva N ., Leung D., Choe H. 2000, PNAS, 97, 9712.  \n18. Yan, R., Munzner J.B., Shuck M.E., Bienkowski M.J. 2001. J. Biol. Chem., 276, 34019.  19. Westmeyer, G.G., Willem M., Lichtenthaler S.F., Lurman, G., Multhaup, G., Assfalg-\nMachleidt, I., Reiss, K., Saftig, P., Haass, C. 2004. J. Biol. Chem., 279, 53205.  \n20. Roggo, S. 2002. Curr. Top. Med. Chem., 2, 359.  \n21. Ishiura, S. 2000. Dementia Jpn., 14, 236.  \n22. John, V., Beck J.P., Bienkowski M.J., Sinha S., Heinrikson R.L. 2003. J. Med. Chem., 46, \n4625.  \n23. Schmidt, B., Baumann S., Narlawar R., Braun H.A., Larbig G. 2006, Neurodegen. Dis., 3, \n290.  \n24. Lichtenthaler, S.F., Wang R., Grimm H., Uljon, S.N., Masters, C.L., Beyreuther, K. 1999, \nPNAS, 96, 3053.  \n25. Qi-Takahara, Y., Morishima-Kawashima M., Tanimura Y., Dolios, G., Hirotani, N., \nHorikoshi, Y., Kametani, F., Maeda, M., Saido, T.C., Wang, R., Ihara, Y. 2005, J. Neurosci., \n25, 436.  \n26. Beher, D., Wrigley J.D.J., Owens A.P., Shearman M.S. 2002. J. Neurochem., 82, 563.  \n27. Esh, C., Patton L., Kalback W., Kokjohn, T.A., L opez, J., Brune, D., Newell, A.J., Beach, T., \nSchenk, D., Games, D., Paul, S., Bales, K., Ghetti, B., Castano, E.M., Roher, A.E. 2005, \nBiochemistry, 44, 13807.  \n28. Weidemann, A., Eggert S., Reinhard Friedrich B.M., Vogel, M., Paliga, K., Baier, G., \nMasters, C.L., Beyreuther, K., Evin, G. 2002, Biochemistry, 41, 2825.  \n29. Wolfe, M.S. 2006, Biochemistry, 45, 7931.  30. De Strooper, B. 2003, Neuron, 38, 9.  \n31. Annaert, W.G., Levesque L., Craessaerts K ., Dierinck, I., Snellings, G., Westaway, D., \nGeorge-Hyslop, P.S., Cordell, B., Fraser, P., De Strooper, B. 1999, J. Cell Biol., 147, 277.   \n 8532. Lazarov, V.K., Fraering P.C., Ye W., Wolfe, M.S., Selkoe, D.J., Li, H. 2006, PNAS, 103, \n6889.  \n33. Franberg, J., Welander H., Aoki M., Winbl ad, B., Tjernberg, L.O., Frykman, S. 2007, \nBiochemistry, 46, 7647.  \n34. Brunkan, A.L., Goate A.M. 2005, J. Neurochem., 93, 769.  \n35. Mastrangelo, P., Mathews P.M., Chisti M.A., Sc hmidt, S.D., Gu, Y., Yang, J., Mazzella, M.J., \nCoomaraswamy, J., Horne, P., Strome, B., Pelly, H., Levesque, G., Ebeling, C., Jiang, Y., Nixon, R.A., Rozmahel, R., Fraser, P.E., St George-Hyslop, P., Carlson, G.A., Westaway, D. \n2005, PNAS, 102, 8972.  \n36. Yu, G., Chen F., Nishimura M., Steiner, H., Tandon, A., Kawarai, T., Arawaka, S., Supala, A., \nSong, Y.Q., Rogaeva, E., Holmes, E., Zhang, D.M., Milman, P., Fraser, P., Haass, C., St \nGeorge-Hyslop, P. 2000, Acta Neurol. Scand. Suppl. , 176, 6.  \n37. Kimberly, W.T., Xia W., Rahmati T., Wolfe M.S., Selkoe D.J. 2000, J. Biol. Chem., 275, \n3173.  \n38. Selkoe, D., Kopan R. 2003, Annual Review of Neuroscience, 26, 565.  \n39. Thinakaran, G., Borchelt D.R., Lee M.K., Slunt, H.H., Spitzer, L., Kim, G., Ratovitsky, T., \nDavenport, F., Nordstedt, C., Seeger, M., Hardy, J., Levey, A.I., Gandy, S.E., Jenkins, N.A., Copeland, N.G., Price, D.L., Sisodia, S.S. 1996, Neuron, 17, 181.  \n40. Yu, G., Nishimura M., Arawaka S., Levitan, D., Zhang, L., Tandon, A., Song, Y.Q., Rogaeva, \nE., Chen, F., Kawarai, T., Supala, A., Levesque, L., Yu, H., Yang, D.S., Holmes, E., Milman, \nP., Liang, Y., Zhang, D.M., Xu, D.H., Sato, C., Rogaev, E., Smith, M., Janus, C., Zhang, Y., \nAebersold, R., Farrer, L.S., Sorbi, S., Bruni, A., Fraser, P., St George-Hyslop, P. 2000, Nature, 407, 48.  \n41. Esler, W.P., Das C., Campbell W.A., Kimberly, W.T., Kornilova, A.Y., Diehl, T.S., Ye, W., \nOstaszewski, B.L., Xia, W., Selkoe, D.J., Wolfe, M.S. 2002, Nat. Cell Biol., 4, E110.  \n42. Zhou, S., Zhou H., Walian P.J., Jap B.K. 2007, Biochemistry, 46, 2553.  \n43. Esler, W.P., Kimberly W.T., Ostaszewski B.L., Diehl, T.S., Moore, C.L., Tsai, J.Y., Rahmati, \nT., Xia, W., Selkoe, D.J., Wolfe, M.S. 2000, Nat. Cell Biol., 2, 428.  \n44. Francis, R., McGrath G., Zhang J., Ruddy, D.A., Sym, M., Apfeld, J., Nicoll, M., Maxwell, \nM., Hai, B., Ellis, M.C., Parks, A.L., Xu, W., Li, J., Gurney, M., Myers, R.L., Himes, C.S., \nHiebsch, R., Ruble, C., Nye, J.S., Curtis, D. 2002, Dev. Cell, 3, 85.  \n45. Goutte, C., Tsunozaki M., Hale V.A., Priess J.R. 2002, PNAS, 99, 775.  46. Steiner, H., Winkler E., Edbauer D., Prokop, S ., Basset, G., Yamasaki, A., Kostka, M., Haass, \nC. 2002, J. Biol. Chem., 277, 39062.  \n47. Luo, W.-j., Wang H., Li H., Kim, B.S., Shah, S., Lee, H.J., Thinakaran, G., Kim, T.W., Yu, \nG., Xu, H. 2003, J.Biol. Chem., 278, 7850.  \n48. Bergman, A., Hansson E.M., Pursglove S.E., Farmery, M.R., Lannfelt, L., Lendahl, U., \nLundkvist, J., Naslund, J. 2004, J.Biol. Chem., 279, 16744.  \n49. Capell, A., Grunberg J., Pesold B., Diehlmann, A., Citron, M., Nixon, R., Beyreuther, K., \nSelkoe, D.J., Haass, C. 1998, J.Biol. Chem., 273, 3205.  \n50. Brown, M.S., Ye J., Rawson R.B., Goldstein J.L. 2000, Cell (Cambridge, Massachusetts), \n100, 391.  \n51. Zhou, S., Zhou H., Walian P.J., Jap B.K. 2005, PNAS, 102, 7499.  \n52. Kimberly, W.T., LaVoie M.J., Ostaszewski B.L., et al 2003, PNAS, 100, 6382.  \n53. Munter, L.-M., Voigt P., Harmeier A., Kaden, D., Gottschalk, K.E., Weise, C., Pipkorn, R., \nSchaefer, M., Langosch, D., Multhaup, G. 2007, EMBO Journal, 26, 1702.  \n54. Kopan, R., Ilagan M.X. 2004, Nat. Rev. Mol. Cell Biol., 5, 499.  55. Herreman, A., Serneels L., Annaert W., Collen, D., Schoonjans, L., De Strooper,  \nB. 2000, Nat. Cell Biol., 2, 461  \n56. Barten, D.M., Guss V.L., Corsa J.A., Loo, A., Hansel, S.B., Zheng, M., Munoz, B., \nSrinivasan, K., Wang, B., Robertson, B.J., Polson, C.T., Wang, J., Roberts, S.B., Hendrick, \nJ.P., Anderson, J.J., Loy, J.K., Denton, R., Verdoorn, T.A., Smith, D.W., Felsenstein, K.M. 2005, J. Pharmacol. Exp. Ther., 312, 635.   \n 86 57. Wong, H.-K., Sakurai T., Oyama F., Kaneko, K ., Wada, K., Miyazaki, H., Kurosawa, M., De \nStrooper, B., Saftig, P., Nukina, N. 2005, J. Biol. Chem., 280, 23009.  \n58. Beglopoulos, V., Sun X., Saura C.A., Lemere, C.A., Kim, R.D., Shen, J. 2004, J. Biol. Chem., \n279, 46907.  \n59. Fraering, P.C., LaVoie M.J., Ye W., Strub, J.M., Dolios, G., LaVoie, M.J., Ostaszewski, B.L., \nvan Dorsselaer, A., Wang, R., Selkoe, D.J., Wolfe, M.S. 2004, Biochemistry, 43, 323.  \n60. Pissarnitski, D. 2007, Curr. Opin. Drug Discov. Devel., 10, 392.  61. Schmidt, B., Baumann S., Braun H.A., Larbig G. 2006, Curr. Top. Med. Chem. , 6, 377.  \n62. Kornilova, A.Y., Das C., Wolfe M.S. 2003, J. Biol. Chem., 278, 16470.  \n63. Weihofen, A., Lemberg M.K., Friedmann E., Rueeger, H., Schmitz, A., Paganetti, P., Rovelli, \nG., Martoglio, B. 2003, J. Biol. Chem., 278, 16528.  \n64. Shearman, M.S., Beher D., Clarke E.E., Lewis, H.D., Harrison, T., Hunt, P., Nadin, A., Smith, \nA.L., Stevenson, G., Castro, J.L. 2000, Biochemistry, 39, 8698.  \n65. McLendon, C., Xin T., Ziani-Cherif C., Murphy, M.P., Findlay, K.A., Lewis, P.A., Pinnix, I., \nSambamurti, K., Wang, R., Fauq, A., Golde, T.E. 2000, Faseb J, 14, 2383.  \n66. Castro Pineiro, J.L., Smith A.L., Stevenson G.I. (Merck Sharp & Dohme Limited, UK). \nWO2001066564, 2001, 34 pp.  \n67. Esler, W.P., Kimberly W.T., Ostaszewski B.L., et al 2002, PNAS, 99, 2720.  \n68. Audia, J.E., Mabry T.E., Nissen J.S., McDaniel  S.L. (Elan Pharmaceuticals, Inc., USA; Eli \nLilly and Company). WO9932453, 1999, 114 pp.  \n69. Dovey, H.F., John V., Anderson J.P., Chen, L.Z., de Saint Andrieu, P., Fang, L.Y., Freedman, \nS.B., Folmer, B., Goldbach, E., Holsztynska, E.J., Hu, K.L., Johnson-Wood, K.L., Kennedy, S.L., Kholodenko, D., Knops, J.E., Latimer, L.H., Lee, M., Liao, Z., Lieberburg, I.M., Motter, \nR.N., Mutter, L.C., Nietz, J., Quinn, K.P., Sacchi, K.L., Seubert, P.A., Shopp, G.M., Thorsett, \nE.D., Tung, J.S., Wu, J., Yang, S., Yin, C.T., Schenk, D.B., May, P.C., Altstiel, L.D., Bender, \nM.H., Boggs, L.N., Britton, T.C., Clemens, J.C., Czilli, D.L., Dieckman-McGinty, D.K., \nDroste, J.J., Fuson, K.S., Gitter, B.D., Hyslop , P.A., Johnstone, E.M., Li, W.Y., Little, S.P., \nMabry, T.E., Miller, F.D., Audia, J.E. 2001, J. Neurochem., 76, 173.  \n70. Lanz, T.A., Himes C.S., Pallante G., Adams, L., Yamazaki, S., Amore, B., Merchant, K.M. \n2003, J. Pharm. Exp. Ther., 305, 864.  \n71. Geling, A., Steiner H., Willem M., Bally-Cuif L., Haass C. 2002, EMBO reports, 3, 688.  \n72. Hadland, B.K., Manley N.R., Su D., Longmore, G.D., Moore, C.L., Wolfe, M.S., Schroeter, \nE.H., Kopan, R. 2001, PNAS, 98, 7487.  \n73. Lanz, T.A., Hosley J.D., Adams W.J., Merchant K.M. 2004, J. Pharm. Exp. Ther., 309, 49.  \n74. Wong, G.T., Manfra D., Poulet F.M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., \nPinzon-Ortiz, M., Fine, J.S., Lee, H.J., Zhang, L., Higgins, G.A., Parker, E.M. 2004, J. Biol. \nChem., 279, 12876.  \n75. Siemers, E., Skinner M., Dean R.A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., May, \nP.C. 2005, Clin. Neuropharmacol., 28, 126.  \n76. Siemers, E.R., Quinn J.F., Kaye J., Farlow, M.R., Porsteinsson, A., Tariot, P., Zoulnouni, P., \nGalvin, J.E., Holtzman, D.M., Knopman, D.S., Satterwhite, J., Gonzales, C., Dean, R.A., May, \nP.C. 2006, Neurology, 66, 602.  \n77. Seiffert, D., Bradley J.D., Rominger C.M., Rominger, D.H., Yang, F., Meredith, J.E. Jr, \nWang, Q., Roach, A.H., Thompson, L.A., Spitz, S.M., Higaki, J.N., Prakash, S.R., Combs, \nA.P., Copeland, R.A., Arneric, S.P., Hartig, P.R., Robertson, D.W., Cordell, B., Stern, A.M., \nOlson, R.E., Zaczek, R. 2000, J. Biol. Chem., 275, 34086.  \n78. Zaczek, R., Olson R.E., Seiffert D.A., Thompson L.A. (Bristol-Myers Squibb Company, \nUSA). US6737038, 2004, 45 pp.  \n79. Fuwa, H., Takahashi Y., Konno Y., Watanabe, N., Miyashita, H., Sasaki, M., Natsugari, H., \nKan, T., Fukuyama, T., Tomita, T., Iwatsubo, T. 2007, ACS Chem. Biol., 2, 408.  \n80. Rishton, G.M., Retz D.M., Tempest P.A., Novotny, J., Kahn, S., Treanor, J.J., Lile, J.D., \nCitron, M. 2000, J. Med. Chem., 43, 2297.   \n 8781. Kreft, A.F., Cole D.C., Woller K.R., Stock,  J.R., Diamanitis, G., Kurbrak, D.M., Kutterer, \nK.M., Moore, W.J., Casebier, D. (Wyeth, John, and Brother Ltd., USA; Arqule, Inc.). WO2002057252, 2002, 133 pp.  \n82. Josien, H.B., Clader J.W., Bara T.A., et al.  (Schering Corporation, USA). WO2006004880, \n2006, 147 pp.  \n83. Belanger, P.C., Collins I.J., Hannam J.C., et al.  (Merck Sharp & Dohme Limited, UK; Merck \nFrosst Canada + Co.). WO0170677, 2001, 199 pp.  \n84. Churcher, I., Harrison T., Kerrad S., et al. (Merck Sharp & Dohme Limited, UK). \nWO2004031137, 2004, 78 pp.  \n85. Lewis, H.D., Harrison T., Shearman M.S. (Merck Sharp & Dohme Limited, UK). \nWO2006123184, 2006, 44 pp.  \n86. Brands, K.M.J., Brewer S.E., Davies A.J., et al.  (Merck Sharp & Dohme Limited, UK). \nGB2427193, 2006, 23 pp.  \n87. Hendrix, M., Baumann K., Grosser R., et al.  (Bayer Aktiengesellschaft, Germany). \nWO2003059335, 2003, 181 pp.  \n88. Flohr, A., Galley G., Jakob-Roetne R., et al. (Switz.). WO2005075327, 2005, 38 pp.  \n89. Neitzel, M. (Elan Pharmaceuticals,  Inc., USA). WO2006078753, 2006, 111 pp.  \n90. Konradi, A.W., Mattson M.N., Semko C.M., Ye X.M. (Elan Pharmaceuticals, Inc., USA). \nWO2007024651, 2007, 102 pp.  \n91. Bowers, S., Garofalo A.W., Hom R.K., et al.  (Elan Pharmaceuticals, Inc., USA). \nWO2007022502, 2007, 141 pp.  \n92. Galley, G., Kitas E.A., Jakob-Roetne R. (F. Hoffmann-La Roche AG, Switz.). \nWO2006005486, 2006, 107 pp.  \n93. Flohr, A., Galley G., Jakob-Roetne R., Kitas E.A., Wostl W. (Switz.). WO2007020190, 2007, \n18 pp.  \n94. Flohr, A., Jakob-Roetne R., Wostl W. (Hoffmann-La Roche Inc., USA). WO2006061136, \n2006, 58 pp.  \n95. Galley, G., Goodnow R.A., Peters J.-U. (Hoffmann-La Roche Inc., USA). WO2004235819, \n2004, 27 pp.  \n96. Greenberg, B., Hill D.C., Jacobs R., Sisodia S.S. (AstraZeneca AB, Swed.; University of \nChicago). WO2006065218, 2006, 60 pp.  \n97. Netzer, W.J., Dou, F., Cai, D., Veach. D., Jean, S., Li, Y., Bornmann, W.G., Clarkson, B., Xu, \nH., Greengard, P. 2003, PNAS, 100, 12444.  \n98. Fraering, P.C. 2005, J. Biol. Chem., 280, 41987.  \n99. Cheng, S., Comer D.D., Mao L., Balow G.P., Pleynet D. (Neurogenetics, Inc., USA). \nWO2004110350, 2004, 178 pp.  \n100. Fisher, A., Bar-Ner N., Karton Y. (Israel Institute for Biological Research, Israel). \nWO2003092580, 2003, 102 pp.  \n101. Caccamo, A., Oddo S., Billings L.M., Green, K.N., Martinez-Coria, H., Fisher, A., LaFerla, \nF.M. 2006, Neuron, 49, 671.  \n102. Laras, Y., Quelever G., Garino C., Pietrancosta, N., Sheha, M., Bihel, F., Wolfe, M.S., \nKraus, J.L. 2005, Biol. Org. Chem., 3, 612.  \n103. Brodney, M.A., Coffman K.J., Kleinman E.F., O'Neill B.T., Chen Y.L. (Pfizer Inc, USA). \nWO2007034326, 2007, 137 pp.  \n104. Beher, D., Bettati M., Checksfield G.D., et al.  (Merck Sharp & Dohme Limited, UK). \nWO2005013985, 2005, 74 pp.  \n105. Burkamp, F., Checksfield G.D., Fletcher S.R., et al . (Merck Sharp & Dohme Ltd., UK). \nWO2007054739, 2007, 42 pp.  \n106. Blurton, P., Burkamp F., Churcher I., Harrison T., Neduvelil J. (Merck Sharp & Dohme \nLimited, UK). WO20 06008558, 2006, 58 pp.  \n107. Wilson, F., Reid A., Reader V., et al.  (Cellzome A.-G., Germany). WO2006045554, 2006, \n57 pp.  \n108. Ramsden, N., Wilson F. (Cellzome A.-G., Germany). WO2006048219, 2006, 35 pp.   \n 88 109. Narlawar, R., Perez Revuelta B.I., Baumann K., Schubenel, R., Haass, C., Steiner, H., \nSchmidt, B. 2007, Bioorg. Med. Chem. Lett., 17, 176.  \n110. Pratico, D., Trojanowski J.Q. 2000, Neurobiol. Aging, 21, 441.  \n111. McGeer, P.L., McGeer E.G. 2001, Archives of Neurology, 58, 1790.  \n112. in 't Veld, B.A., Ruitenberg A., Hofman A ., Launer, L.J., van Duijn, C.M., Stijnen, T., \nBreteler, M.M., Stricker, B.H. 2001, N. Engl. J. Med., 345, 1515.  \n113. Etminan, M., Gill S., Samii A. 2003, BMJ, 327, 128.  114. Avramovich, Y., Amit T., Youdim M.B.H. 2002, J. Biol. Chem., 277, 31466.  \n115. Weggen, S., Eriksen J.L., Das P., Sagi, S.A., Wang, R., Pietrzik, C.U., Findlay, K.A., Smith, \nT.E., Murphy, M.P., Bulter, T., Kang, D.E., Marquez-Sterling, N., Golde, T.E., Koo, E.H. \n2001, Nature, 414, 212.  \n116. Eriksen, J.L., Sagi S.A., Smith T.E., Weggen, S., Das, P., McLendon, D.C., Ozols, V.V., \nJessing, K.W., Zavitz, K.H., Koo, E.H., Golde, T.E. 2003, J. Clin. Investigation, 112, 440.  \n117. Kukar, T., Murphy M.P., Eriksen J.L., Sagi, S.A., Weggen, S., Smith, T.E., Ladd, T., Khan, \nM.A., Kache, R., Beard, J., Dodson, M., Merit, S., Ozols, V.V., Anastasiadis, P.Z., Das, P., \nFauq, A., Koo, E.H., Golde, T.E. 2005, Nature Med., 11, 545.  \n118. Gasparini, L., Rusconi L., Xu H., del Soldato P., Ongini E. 2004, J. Neurochem., 88, 337.  119. Takahashi, Y., Hayashi I., Tominari Y., Rikimaru, K., Morohashi, Y., Kan, T., Natsugari, H., \nFukuyama, T., Tomita, T., Iwatsubo, T. 2003, J. Biol. Chem., 278, 18664.  \n120. Beher, D., Clarke E.E., Wrigley J.D.J., Martin, A.C., Nadin, A., Churcher, I., Shearman, \nM.S. 2004, J. Biol. Chem., 279, 43419.  \n121. Morihara, T., Chu T., Ubeda O., Beech W., Cole G.M. 2002, J. Neurochem., 83, 1009.  122. Weggen, S., Eriksen J.L., Sagi S.A., Pietrzik, C.U., Ozols, V., Fauq, A., Golde, T.E., Koo, \nE.H. 2003, J. Biol. Chem., 278, 30748.  \n123. Zhou, Y., Su Y., Li, B., Liu, F., Ryder, J.W., Wu, X., Gonzalez, D.,Whitt, P.A., Gelfanova, \nV., Hale, J.E., May, P.C., Paul, S.M., Ni, B. 2003, Science, 302, 1215.  \n124. Narlawar, R., PerezRevuelta B.I., Haass C., Steiner, H., Schmidt, B., Baumann, K. 2006, J. \nMed. Chem., 49, 7588.  \n125. Peretto, I., Radaelli S., Parini C., Zandi, M., Raveglia, L.F., Dondio, G., Fontanella, L., \nMisiano, P., Bigogno, C., Rizzi, A., Riccardi, B., Biscaioli, M., Marchetti, S., Puccini, P., \nCatinella, S., Rondelli, I., Cenacchi, V., Bolzoni, P.T., Caruso, P., Villetti, G., Facchinetti, F., \nDel Giudice, E., Moretto, N., Imbimbo, B.P. 2005, J. Med. Chem., 48, 5705.  \n126. Stock, N., Munoz B., Wrigley J.D., Shearman, M.S., Beher, D., Peachey, J., Williamson, \nT.L., Bain, G., Chen, W., Jiang, X., St-Jacques, R., Prasit, P. 2006, Bioorg. Med. Chem. Lett., \n16, 2219.  \n127. Lim, G.P., Yang F., Chu T., Chen, P., Beech, W., Teter, B., Tran, T., Ubeda, O., Ashe, K.H., \nFrautschy, S.A., Cole, G.M. 2000, J. Neurosci., 20, 5709.  \n128. Sung, S., Yang H., Uryu K., Lee, E.B., Zhao, L., Shineman, D., Trojanowski, J.Q., Lee, \nV.M., Pratico, D. 2004, Am. J. Path., 165, 2197.  \n129. Jantzen, P.T., Connor K.E., DiCarlo G., Wenk,  G.L., Wallace, J.L., Rojiani, A.M., Coppola, \nD., Morgan, D., Gordon, M.N. 2002, J. Neurosci., 22, 2246.  \n130.Rogers, J., Kirby L.C., Hempelman S.R., Berry, D.L., McGeer, P.L., Kaszniak, A.W., \nZalinski, J., Cofield, M., Mansukha ni, L., Willson, P.1993, Neurology, 43, 1609.  \n131. Wechter, W.J. (Loma Linda University  Medical Center, US A). WO2000013684, 2000, 10 \npp.  \n132. Clarke, E.E., Churcher I., Ellis S., Wrigley, J.D., Lewis, H.D., Harrison, T., Shearman, M.S., \nBeher, D. 2006, J. Biol. Chem., 281, 31279.  \n133. D'Adamio, L., Matsuda S. (Albert Einstein College of Medicine of Yeshiva University, \nUSA). WO2006138355, 2006, 39 pp.   \n 89\n  \n 90 \n \n 91\n  \n 92  \n 933.3 Untersuchungen der Membrananker-Eig enschaften von NSAID-abgeleiteten \n\uf067-Sekretase Modulatoren  \n \nDer Inhalt dieses Kapitels wurde bereits ver\u00f6ffentlicht:  \nStefanie Baumann, Nicole H\u00f6ttecke, Robert Schubenel, Karlheinz Baumann, Boris Schmidt  \nBioorg. Med. Chem. Lett.  2009 , 19, 6986-6990. \u201cNSAID-derived \uf067-secretase modulators. Part \nIII: Membrane anchoring.\u201d \n Durch die Synthese von 7 Carbazol-Derivaten unter Variation des lipophilen Restes wurde \nuntersucht, ob dieser Rest als Membrananker fungieren kann.  \n \nChloressigs\u00e4ure\ntert-Butylester\nK2CO3, Aceton\n16h, rf1) NaH, R-X, THF,\n     0\u00b0C-rt, 16h\n2) CH 2Cl2, TFA\n    rt, 16h\nN\nHOH\nN\nHOOtBu\nONOOH\nO\nR\nNOOH\nO\nSO2\nR\nNOOH\nO\nRO1) DCC, R-CO 2H, CH 2Cl2,\n     0\u00b0C-rt, 16h\n2) CH2Cl2, TFA\n    rt, 16h1) NaH, R-SO 2Cl, THF,\n     0\u00b0C-rt, 16h\n2) CH 2Cl2, TFA\n    rt, 16h\n \nAbb. 21:  Synthese der Carbazol-Derivate, um die Membrananker-Eigenschaft zu untersuchen. \n \nDer lipophile Rest konnte unter Aufbau eines terti\u00e4ren Amins, eines Carbons\u00e4ureamids oder \nSulfonamids an das Carbazol-Gr\u00fcndger\u00fcst subs tituiert werden. Durch das Einf\u00fchren einer \nDoppelbindung in den lipophilen Alkylrest (\u00d6ls\u00e4u re- bzw. Elaidins\u00e4ure-Derivat) konnte eine \num Faktor zwei gesteigerte Aktivit\u00e4t (IC 50(A\uf06242) = 13 \u00b5M) im Vergleich mit dem ges\u00e4ttigten \nOctadecan-Derivat (IC 50(A\uf06242) = 26 \u00b5M) beobachtet werden.  \nEine m\u00f6gliche Erkl\u00e4rung dieser Aktivit \u00e4tssteigerung ist die Lokalisierung des \nAlkyl-Substituenten in der Membran, da eine Doppelbindung den Alkyl-Rest rigider werden \nl\u00e4sst und die Inkorporation in die Membran ve reinfacht.  Es ist \u00fcberraschenderweise \nirrelevant, ob die Doppelbindung cis- oder trans -konfiguriert vorliegt, denn Beide zeigen die \ngleiche modulatorische Aktivit\u00e4t auf die A \uf062-Sekretion (IC 50(A\uf06242) = 13 \u00b5M). Die Vermutung, \ndass ein rigider lipophil er Rest das Einlagern in die Me mbran erleichtert und somit eine \nSteigerung der modulatorischen Eigenschaft zu r Folge hat, konnte durch Derivatisierung des  \n 94 Grundger\u00fcstes mit einem para -substituierten Azofarbstoff (IC 50(A\uf06242) = 9 \u00b5M) best\u00e4tigt \nwerden. Im Gegensatz dazu zeigen in m-Position substituierte Arom aten als lipophiler Rest \nkeine Aktivit\u00e4t auf die A \uf062-Sekretion mehr.  \nDurch diese Untersuchungen wurde die Verm utung erh\u00e4rtet, dass de r lipophile Rest als \nMembrananker agiert. Ein rigider linearer lipophiler Rest erleic htert die Einlagerung in die \nMembran wo hingegen eine Verzweigung de s lipophilen Substituenten diese Einlagerung \nerschwert, was zu einem vollst\u00e4ndigen Verl ust der modulatorischen Aktivit\u00e4t f\u00fchrt. \n \nListe der von Nicole H\u00f6ttecke von 2 006-2009 synthetisierten Verbindungen: \nBSc3770 \nBSc3853 \nBSc3854 BSc3915 BSc3955 Bsc3956 BSc3984   \n \n  \n 95NSAID-derived \uf067-secretase modulators. Part III. \nMembrane anchoring  \nStefanie Baumann,a Nicole H\u00f6ttecke,a Robert Schubenel,b Karlheinz \nBaumann,b Boris Schmidta* \naClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry , Technische Universit\u00e4t Darmstadt, Petersenstr. 22, \nD-64287 Darmstadt, Germany, Fax: (+49) 6151-163278, E-mail: schmidt_boris@t-online.de \nbF. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Preclinical Research CNS, Bldg. 70/345, CH-4070 \nBasel, Switzerland \nThis is where the receipt/accepted da tes will go; Received Month XX, 2000; A ccepted Month XX, 2000 (BMCL RECEIPT) \nAbstract \u2014 Selective lowering of A \uf06242 levels with small-molecule substrate targeting \uf067-secretase modulators (sGSMs), such \nas some non-steroidal anti -inflammatory drugs, is a promisi ng therapeutic approach for Alzheimer\u2019s disease. In the present \narticle we have synthesized N-substituted carbazole- and O-substituted fenofibrate-derived sGSMs and present the activity \ndata. Out of 19 screened compounds, 7 exhibited promising activity against A \uf06242 secretion at a low micromolar level. We \npresume, that the sGSMs interact with lys624 next to the me mbrane and that the lipophilic substituents anchor the compound \norientation in the membrane. \n\uf067-Secretase is one of two aspartyl proteases held \nresponsible for the generation of the Alzheimer\u2019s disease causing pathology; amyloid \uf062-peptide \n(A\uf062) aggregation to amyloid plaques. The \nunderstanding of the precise mechanism of A \uf062 \ngeneration is crucial for the development of \ndrugs targeting the disease. Small-molecule \nsubstrate targeting \uf067-secretase modulators \n(sGSMs) have shown promise in therapeutic \ntreatment of Alzheimer\u2019s disease.1 These sGSMs \nseem to interfere with substrate recognition/cleavage and shift the precision of \n\uf067-secretase cleavage from the beta-amyloid 42 to \nthe beta-amyloid 38 site to generate more A \uf062\n38 \nand less A \uf06242. This activity is summarized as \nstraight modulation of \uf067-secretase. The \ndevelopment of modulators will benefit from precise information on the binding site(s), but up \nto now this information is rather limited.  \nSelected NSAIDs, e.g. ibuprofen, sulindac sulfide, and flurbiprofen were found to modulate \nthe secretion of A \uf062 in vitro  and in vivo .\n2,3,4 Some \ncyclooxygenase-2 (COX-2) specific inhibitors, e.g. celecoxib, and the pe roxisome proliferator-\nactivated receptor- \uf067 (PPAR- \uf067) antagonist, \nfenofibrate ( 3, Figure 1)  were found to increase \nA\uf062\n42 levels selectively, resulting in inverse \nmodulation of \uf067-secretase activity.5,6  \nWe recently described N-substituted carprofen \nderivatives and carbozolyloxyactetic acids as \n\uf067-secretase modulators (Figure 1).7,8 The \nintroduction of a lipophilic substituent, which may vary from arylsulfone to alkyl, turned \n2-carbazolyloxyacet ic acids into \uf067-secretase \nmodulators (e.g., 4: IC\n50 (A\uf06242) = 7.5 \u00b5M, 5: IC 50 \n(A\uf06242) = 2.9 \u00b5M). The most active compounds \ndisplayed activity in the low micromolar range and little or no effect on the \uf067-secretase cleavage \nat the \uf065-site. Furthermore, cell-based studies with \nA\uf06242-lowering compounds have revealed that \nsGSMs do not affect the cleavage of other \n\uf067-secretase substrates, such as Notch and \nothers.3,6,9-12 \nN\nHClOOH\nNClOOH1 Carprofen\n4 BSc2912decylNO\nSOH\nO\nO\nON\nHOOO\nCl\nO\n3 Fenofibrate 2 Carbazole\n5 BSc3041\n \nFigure 1. Carprofen ( 1), carbazole ( 2), fenofibrate ( 3) and the \nmost active derivatives BSc2912 ( 4) and BSc3041 ( 5). \n \nBiotinylated, photoactivatable probes were \ndeveloped to identify the target of flurbiprofen- \nand fenofibrate-derived sGSMs.11 Surprisingly, \nthese photoprobes did not label the core proteins \nof the \uf067-secretase complex, but instead labelled \nthe \uf062-amyloid precursor protein (APP), APP \ncarboxy-terminal fragments (CTFs) and A \uf062 \npeptide in human neuroglioma H4-cells. sGSM \ninteraction was localized to the residues 29\u201336 of A\uf062, a region critical for aggregation. This \nsubstrate targeting by sGSMs results in alteration \nof A\uf062\n42 production and inhibition of A \uf062 \naggregation.13 Substrate labeling has been \ncompeted by other sGSMs, and labeling of an \nAPP \uf067-secretase substrate was more efficient than \nof a Notch substrate. The established binding site  \n 96 of flurbiprofen-derived sGSMs resides close to \nthe membrane surface, and implies high \nlipophilicity in combination with an acidic \nfunctional group is necessary for binding. This combination is unusual for a therapeutic drug, \nbut common to amphiphilic surfactants, thus \ncreating an obstacle for drug development.  \nFenofibrate ( 3) is used as lipid-regulating agent \nin humans. In H4-cells, 3 raises A \uf062\n42 by over \n300% and decreases A \uf06238 by up to 60% in a \ndose-dependent fashion, while A \uf06240 levels are \nnot altered.5,14 At these concentrations, \nfenofibrate did not show toxic effects in the \nlactose dehydrogenase (LDH) and 3-(4,5-\ndimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Notably, the active \nmetabolite of fenofibrate, the corresponding \nfenofibric acid, did not raise A \uf062\n42 at doses up to \n250 \u03bcM.  \nThe results with the N-substituted carprofen \nderivatives and carbazolyloxyacetic acids prompted us to investigate the detailed effects of \nthe lipophilic substituents of N-substituted \ncarbazolyloxyacetic acids. Therefore, lipophilic substituents like trans - and cis-oleic acid were \nintroduced. cis-Configurated oleic acid is a \ncomponent of biological lipid bilayers and should incorporate into the cellular membrane readily. \nSterically more demandi ng substituents like aza-\nbenzene, naphthalene, or biphenyl were linked to the carbazolic backbone testing space \navailability. These carbazolyloxyacetic acid \nderivatives have been synthesized according to Scheme 1 and are summarized in Table 1. One \nderivative ( 8h) features a compact photoreactive \nsububunit aiming to minimize the tether used in previous crosslinking experiments. Such probes \ncan be useful to identify binding sites on proteins \neither by mass spectrometry or via additional labeling. The synthesis is outlined in Scheme 2  \nand described in the supplement.  N\nHOH\nNHOO\nNOO\nR1OHOt-Bu\n6 7\n8a\uf02dga\nb, c\n \nScheme 1.  Synthesis of carbazole-derived sGSMs.  Reagents and \nconditions : a) t-butyl 2-bromoacetate, K 2CO 3, acetone, reflux; b) \nKOt-Bu, R1X, THF, 0 \u00b0C to r.t.; c) 20% TFA, CH 2Cl2. \n \nCF3HN NH\nCF3NNCF3NOTs\nCF3O\nCF3NOH\nCF3NN\nBr\nNO\nOt-BuO\nF3CN\nNNO\nOHO\nF3CN\nN\n8hab\ne d\nf\ngc9 1011\n12 1314\n15  \n \nScheme 2.  Synthesis of a carbazole-derived sGSM 8h equipped \nwith a photoreactive unit. Reagents and conditions : a) \nNH 2OH*HCl, py, EtOH, reflux; b) TsCl, DIEA, DMAP, CH 2Cl2, \n0 \u00b0C to r.t.; c) NH 3, Et 2O -78\u00b0C to r.t.; d) I 2, MeOH, Et3N, pH > \n7; e) NBS, AIBN, CCl 4, reflux; f) 7, KO t-Bu, THF, 0 \u00b0C to r.t., \n12 h, g) TFA, CH 2Cl2, 0 \u00b0C to r.t., 2-8 h. \n \nIn addition, we tried to convert the inverse \uf067-secretase modulating effects of fenofibrate into \nstraight  \nmodulation. The corresponding O-alkylated \noximes (Table 1)  were readily accessible by \nstraightforward synthesis (Scheme 3, 11a-g) \nOCl OOO\nNCl OOHO\nNOHOOO\nCl\nO\nHOONCl OOHO\nO\nR3\nO\nNO\nR2Clab , c\nd,c e,c\nNCl OOHO\nN3 16 17a\uf02dg\n18a\uf02dc19R4\n \nScheme 3. Synthesis of fenofibrate derived sGSMs . Reagents and conditions : a) NH 2OH\u00b7HCl, py, EtOH, 80 \u00b0C, 4 h; b) NaH, R2X, DMF, 0 \n\u00b0C to r.t., 6 \uf02d12 h; c) 2 N NaOH, MeOH, r.t., 4 \uf02d12 h; d) 2,4-dinitrophenylhydrazine, H 2SO 4, MeOH, r.t, 2 h; e) NaH, X \uf02dR3\uf02dX (0.5 equiv), \nDMF, 0 \u00b0C to r.t., 6 \uf02d12 h.  \n 97 \nTable 1 . Compounds 8\u201319 . \nEntry Compds BSc number R Substituent \n1 8a 3770 R1 octadecyl \n2 8b 3853 R1 trans -oleic acid \n3 8c 3854 R1 decacarbonyl \n4 8d 3915 R1 cis-oleic acid \n5 8e 3955 R1 8-(N,N-dimethyl)-4-\nsulfonylnaphthalene \n6 8f 3956 R1 4\u00b4-(N,N-dimethyl)-1-\nsulfonylazabenzene \n7 8g 3984 R1 4'-methylbiphenyl-3-\ncarbonitrile \n8 8h 3958 R1 3-(3-methylphenyl)-3-\n(trifluoromethyl)-3 H-\ndiazirine \n9 17a 3934 R2 Octyl \n10 17b 3935 R2 Nonyl \n11 17c 3936 R2 Decyl \n12 17d 3937 R2 Undecyl \n13 17e 3938 R2 Dodecyl \n14 17f 3939 R2 tetradecyl \n15 17g 3940 R2 hexadecyl \n16 18a 3941 R3 Octyl \n17 18b 3942 R3 Nonyl \n18 18c 3943 R3 Decyl \n19 19 3989 R4 2,4-\ndinitrophenylhydrazyl \n \nThe ongoing discussion on the existence of two \n(or even more) bind ing sites in the \uf067-secretase \ncomplex advocates for an investigation into the potential distance between these sites. Two \nmodulating monomer units linked by a variable \nspacer may form a more active dimer interacting with the two potential binding sites. \nThe length of these spacers would thus provide \ninformation about the distance between both binding sites. Fenofibrate dimers with variable \nalkyl tethers offer access to such distance \nmapping. The conversion of the fenofibrate with 2,4-dinitrophenylhydrazine provided the \nhydrazone 13 (Scheme 3). The UV-activity and \nintrinsic color of 13 may be exploited in \ncellular mechanistic studies of \uf067-secretase \nmodulation.  \n \nTo evaluate the compounds 8a\uf02dh, 17a\uf02dg, 18a\uf02dc, \n19 for their potency to modulate \uf041\uf062\uf020secretion, \nwe used the A \uf062 liquid phase \nelectrochemiluminescence (LPECL) assay to measure A \uf062 isoforms.7 Cell viability was \nmeasured by a colorimetric cell proliferation \nassay (CellTiter 96TM AQ assay, Promega) utilizing the bioreduction of MTS (Owen\u2019s \nreagent) to formazan. The results are summarized \nin Table 2  and the dose-dependent curves of the \nmost active compounds are shown in Figure 2. \nIntroduction of a double bond by substitution \nwith cis- and trans- configurated oleic acid did \nnot show any differences in potency. Both \nisomers, E (8b) and Z (8d) inhibited A \uf062\n42 \nsecretion with an IC 50 of 13 \u00b5M. Remarkably, \nthere is a 2-fold increase in potency compared to \nthe saturated analogue 8a (BSc3770). The \nintroduction of an E- or Z-double bond seems to stabilize the membrane orientation of the lipophilic anchor resulting in increased potency. \nIn addition linear lipophilic alkyl chains, even \namides ( 8c) and sulfonamides are tolerated. We \nsuggest that linear, lipophilic substituents are \nuseful anchors, given that para -substituted \nbenzenes ( 8f) are modulators in contrast to meta -\nsubstituted benzenes ( 8e,g,h ) showing no activity \nat all. \nThe activities of the fenofibrate derivatives have been determined at an in itial concentr ation of 40 \n\u00b5M (see Supporting Information). As expected, \nfenofibrate (BSc3931) and the oxime 16 showed \ninverse modulation, the fenofibrate acid \n(BSc3932) displayed no activity at all (data not \nshown). The O-substituted compounds 17a \n(BSc3934) and 17c (BSc3936) displayed \nmodulating effects. At a concentration of 40 \uf06dM \nthe A\uf062\n\uf034\uf032 level was reduced by 60%, while the \nA\uf06238 level was increased. The modulating effects \nof the dimers 18a,b are not as strong, but still \nsignificantly stronger than those of flurbiprofen or indomethacin (see Supporting Information), \nwhich are benchmarks for GSM activity. The \nC12 dimer 18c (BSc3943) does not show any \neffect on A \uf062 secretion.  \n \nTable 2 . Modulation and cell toxicity results for compounds  \n8\u201319 . \nEntry CompdsBSc \nnumberCell  \ntoxicity  \n(\u00b5M) EC 50 \n\uf041\uf062 38 \n(\u00b5M) IC50 \n\uf041\uf062 40 \n(\u00b5M) IC50 \n\uf041\uf062 42 \n(\u00b5M)\n1 8a 3770 - 1.4 >80 26.0 \n2 8b 3853 n.t.a 9.3 >40 13.0 \n3 8c 3854 n.t. 12.6 >40 22.4 \n4 8d 3915 - 9.2 >40 13.1 \n5 8e 3955 80 >40 >40 >40 \n6 8f 3956 n.t. 7.6 >80 9.0 \n7 8g 3984 - >80 >80 >80 \n8 8h 3958 - >80 >80 >80 \n9 17a 3934 80 16.1 47.6 36.2 \n10 17b 3935 - >40 >40 >40 \n11 17c 3936 - >80 >80 36.1 \n12 17d 3937 - >40 >40 >40 \n13 17e 3938 80 >40 >40 >40 \n14 17f 3939 - >80 >80 >80 \n15 17g 3940 - >80 >80 >80 \n16 18a 3941 - 47.6 37.3 23.7 \n17 18b 3942 80 >40 >40 >40 \n18 18c 3943 80 >40 >40 >32.6\n19 19 3989 80 47.6 37.3 17.0 \na n.t. = not tested. \n \nTwo out of eleven fenofibrate derivatives showed \nmodulating effects at low concentrations with the most active being the O-alkylated C8 derivative  \n17a (BSc3934). The modulating tendency is \nvisible with all other alkylated derivatives 17b\uf02dg, \nhowever, only at high er concentrations. \nHydrazone 19 (BSc3989) inhibited total A \uf062. The \ndimers 18a\uf02dc showed modulatory effects at high \nconcentrations. Some compounds showed \ncellular toxicity at a concentration of 80 \u00b5M in \nH4-cells. As fenofibrate is an approved drug, the in silico  parameters are established and adequate. \nThe introduction of the lipophilic substituent  \n 98 caused a dramatic increase of the clogP value \n(fenofibrate: tPSA: 52.6, clogP: 5.2; fenofibrate-\nC8-oxime: tPSA: 57.1, clogP: 10.2). We \npresume, that the lipophilic anchor of the compounds is essential for orientation within the \nmembrane. The maximum alkyl chain length \nshould therefore not ex ceed the length of a \nnatural phospholipid (see 8a\uf02dd, Table 2). The \nresults of the fenofibrate dimers indicate that the \nmaximum chain length has been reached with C12. Furthermore, our results do not indicate an \ninteraction with more than one binding site.  \nWe compared the structures of highly active compounds (see supplement of ref. 13) to \nrationalize the binding mode of straight sGSMs. \nApparently, a carboxylic acid moiety is essential for potency. We assume, that this functionality \ninteracts with a lysine (maybe lys624) of the \nsubstrate APP, which is located next to the membrane interface. Thereby, the lipophilic \nsubstituents of the sGSMs serve as membrane \nanchors. Binding to the substrate may avoid substrate dimerization involving the GAIIG \nmotif (see Supporting Information), thereby \ndriving the cleavage shift away from \uf041\uf062\n42.  \n \n-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.00255075100125150175\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150200\nconc. / log MA\uf062 / %a)b)\nc) d)\ne)\n-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.00255075100125150175\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150200\nconc. / log MA\uf062 / %a)b)\nc) d)\ne)-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7 -6 -5 -40100200300\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.00255075100125150175\nconc. / log MA\uf062 / %\n-7.0 -6.5 -6.0 -5.5 -5.0 -4.5 -4.0050100150200\nconc. / log MA\uf062 / %a)b)\nc) d)\ne)\n \nFigure 2. Dose\u2013response curves for the most \nactive N-substituted carbazolyloxyacetic acid and \nfenofibrate derivatives; \uf041\uf062 (% of control). (A) \nCompound 8d. (B) Compound 8c. (C) \nCompound 8f. (D) Compound 17a (E) \nCompound 18c. \n \nIn summary, the introduction of a lipophilic \nsubstituent turned fenof ibrate- and carbazole-\nderived carboxylic acids into sGSMs, which \ndisplay selective reduction of \uf041\uf062 42 and an \nincrease of the less aggregatory \uf041\uf062 38 fragment. \nThe most active compounds display activity on \nAPP overexpressing cell lines in the low \nmicromolar range. Some of these sGSMs do not target the \uf067-secretase complex directly, but rather \nbind to its substrate APP, thereby changing the \ncleavage pattern. The dimerization of APP may \nbe influenced by this sGSM binding. The lipophilic substituents anchor the compound in \nthe membrane. \n \nAcknowlegements:  \n \nWe thank the DFG (B.S. and S.B., SPP1085 (SCHM1012-3-1/2), the EU (B.S. and S.B., \nAPOPIS contract LSHM-CT-2003-503330) \nBMBF (N.H., KNDD) for support of this work..  \nReferences and notes:  \n1. Schmidt, B.; Baumann, S.; Narlawar, R.; Braun, \nH. A.; Larbig, G. Neurodegen. Dis . 2006 , \n3, 290-297. \n2.Avramovich, Y.; Amit, T.; Youdim, M. B. H. J. \nBiol. Chem.  2002 , 277, 31466. \n3. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; \nWang, R.; Pietrizik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. Nature  2001 , 414, 212. \n4. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, \nS.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. J. Clin. Invest.  2003 , 112, \n440. \n5. Kukar, T.; Murphy Michael, P.; Eriksen Jason, \nL.; Sagi Sarah, A.; Weggen, S.; Smith Tawnya, E.; Ladd, T.; Khan Murad, A.; Kache, R.; Beard, J. ; Dodson, M.; Merit, \nS.; Ozols Victor, V.; Anastasiadis Panos, Z.; Das, P.; Fauq, A.; Koo Edward, H.; Golde Todd, E. Nature Med.  2005 , 11, \n545. \n6. Gasparini, L.; Rusconi, L.; Xu, H.; del \nSoldato,P.; Ongini, E. J. Neurochem.  \n2004 , 88, 337. \n7. Narlawar, R.; Perez Revuelta, B. I.; Baumann, \nK.; Schubenel, R.; Haa ss, C.; Steiner, H.; \nSchmidt, B. Bioorg. Med. Chem. Lett.  \n2007 , 17, 176. \n8. Narlawar, R.; PerezRevuelta, B. I.; Haass, C.; \nSteiner, H.; Schmidt, B.; Baumann, K. J. \nMed. Chem.  2006 , 49, 7588. \n9. Takahashi, Y.; Hayashi, I.; Tominari, Y.; \nRikimaru, K.; Morohashi, Y.; Kan, T.; Natsugari, H.; Fukuyama, T.; Tomita, T.; Iwatsubo, T. J. Biol. Chem.  2003 , 278, \n18664. \n10. Beher, D.; Clarke, E. E.; Wrigley, J. D. J.; \nMartin, A. C. L.; Nadin, A.; Churcher, I.; Shearman, M. S. J. Biol. Chem.  2004 , 279, \n43419. \n11. Morihara, T.; Chu, T.; Ubeda, O.; Beech, W.; \nCole, G. M. J. Neurochem.  2002 , 83, 1009.  \n 9912. Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, \nC. U.; Golde, T. E.; Koo, E. H. J. Biol. \nChem. 2003 , 278, 30748. \n13. Kukar, T. L.; Ladd, T. B.; Bann, M. A.; \nFraering, P. C.; Narlaw ar, R.; Maharvi, G. \nM.; Healy, B.; Chapman, R.; Welzel, A. T.; Price, R. W.; Mo ore, B.; Rangachari, \nV.; Cusack, B.; Erikse n, J.; Jansen-West, \nK.; Verbeeck, C.; Yager, D.; Eckman, C.; Ye, W.; Sagi, S.; Cottrell, B. A.; Torpey, J.; Rosenberry, T. L.; Fauq, A.; Wolfe, M. S.; Schmidt, B.; Walsh, D. M.; Koo, E. H.; Golde, T. E. Nature  2008 , 453, 925. \n14. Gebel, T.; Arand, M.; Oesch, F. FEBS Letters  \n1992 , 309, 37.  \n 101Supporting Information \n \nNSAID-derived \uf067-secretase modulators. Part III. \nMembrane anchoring  \nStefanie Baumann,a Nicole H\u00f6ttecke,a Karlheinz Baumann,b Robert Schubenel,b \nBoris Schmidta* \naClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry , Technische Universit\u00e4t Darmstadt, Petersenstr. 22, \nD-64287 Darmstadt, Germany, Fax: (+49) 6151-163278, E-mail: schmidt_boris@t-online.de \nbF. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Preclinical Research CNS, Bldg. 70/345, CH-4070 \nBasel, Switzerland \n \n \n \nTable of Content: \n1. General comments  \n2. Experimental methods and spectral data of N-substituted carbazole-derived sGSMs \n3. Experimental methods and spectral data of 8h \n4. Experimental methods and spectral data of O-substituted fenofibrate-derived sGSMs \n5. Figure_SI: Binding mode of sGSMs. \n \n       \n \n       \n 102 1. General Comments \nThe 1H NMR spectra were recorded on a Bruke r AC 300 spectrometer at 300 Hzand Bruker \nAC 500 spectrometer at 500 Hz. The 13C NMR spectra were recorded on a Bruker AC 300 \nspectrometer at 75 Hzand Bruker AC 500 spect rometer at 125 Hz. Chemical shifts are \nreported as ppm downfield from Me 4Si. Mass spectrometry was performed on a \nBruker-Franzen Esquire LC ma ss spectrometer. Flash column  chromatography was carried \nout using Merck silica gel 60 (40 \uf02d63 and 15 \uf02d40 \u03bcm) and 60G (5 \uf02d40 \u03bcm). Thin-layer \nchromatography (TLC) was carried out using al uminum sheets precoated with silica gel 60 \nF254 (0.2 mm; E. Merck). Chromatographic spot s were visualized by UV and/or spraying \nwith an acidic, ethanolic solu tion of p-anisaldehyde or an ethanolic solution of ninhydrin \nfollowed by heating. For preparative TLC, plates  precoated with silica gel 60 F254 (2.0 mm; \nE. Merck) were used.   \n \n2. Experimental methods and spectral data of N-substituted carbazole-derived sGSMs \n \ntert-Butyl 2-(9 H-carbazol-2-yloxy)acetate (7): \nAnhydrous K 2CO 3 (4.53 g, 32.75 mmol) was added to a stirred solution of 2-hydroxy \ncarbazole (2.00 g, 10.92 mmol) in acetone (25 mL) and stirred at ambient temperature for \n30 min. tert-Butyl chloroacetate (1.870 mL, 13.10 mmol) was added and the reaction \nmixture was heated at 60\u201370 \u00b0C for 12 h. The mi xture was cooled to room temperature and \nfiltered. The residue was washed with acet one (3\u00d7). Combined organic extract was \nevaporated in vacuo and purified by flash column chromatography (CH 2Cl2) to yield the title \ncompound as a yellow solid (2.63 g, 99%) \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.99 (s, 1H, H-9), 7.92-7.85 (m, 2H, H-4/5), 7.28-7.26 (m, \n2H, H-7/8), 7.19-7.12 (m, 1H, H-6), 6.81-6.76 (m, 2H, H-1/3) , 4.52 (s, 2H, H-14), 1.45 (s, \n9H, H-16) ppm.  \n9 123 4\n5\n6\n7\n8101112\n1314\n15 16\nNHO OO\n \nGeneral procedure for N-alkylation of tert-butyl 2-(9 H-carbazol-2-yloxy)acetate \nderivatives \nKOt-Bu (1.2 equiv) was added to a stirre d solution of THF (5 mL/mmol) tert-butyl 2-(9 H \ncarbazol-6-yloxy)acetate ( 7) (1.0 equiv) at 0 \u00b0C. After 30 minutes alkyl halide (1.5 equiv) \ndissolved in THF was added. The reaction mixt ure was stirred at ambient temperature for \n6-24 h. The heterogeneous reactio n mixture was quenched with NH 4Cl (sat. aq), diluted with \nCH 2Cl2 and then washed sequentially with H 2O and brine. The organic extract was dried \nover anhydrous Na 2SO 4 and evaporated in vacuo to give crude compound. The crude \ncompound was purified by flash column chromatography (CH 2Cl2\uf02dhexane, 1:100). \n \ntert-Butyl 2-(9-octadecyl-9 H-carbazol-2-yloxy)acetate (BSc4022): \nReactants:  0.241 g (1.00 mmol) 7, 0.516 mL (1.50 mmol) 1-bromooctadecan, 0.135 g \n(1.20 mmol) KO t-Bu, 3 mL THF. \nYield:  0.076 mg (14%) as a colourless solid \nMp: 62\u00b0C \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.02-7.96 (m, 2H, H-4/5), 7.43-7.34 (m, 2H, H-6/7), \n7.23-7.18 (m, 1H, H-3), 6.91 (d, 4J = 2.1 Hz, 1H, H-1), 6.84 (dd, 3J = 8.5 Hz, 4J = 2.3 Hz, \n1H, H-8), 4.65 (s, 2H), 4.22 (t, 3J = 7.3 Hz, 2H), 1.85 (q, 4J = 7.5 Hz, 2H), 1.53 (s, 9H), \n1.28-1.26 (m, 30H), 0.90 (t, J = 6.8 Hz, 3H) ppm.  \n 10313C NMR (75 MHz, CDCl 3): \uf064 = 168.2 (C-15), 157.2 (C-2), 141.6 (C-13), 130.7 (C-12), \n124.5 (C-4), 122.9 (C-10), 121.0 (C-7), 119.6 (C-5), 118.9 (C-6 ), 117.6 (C-11), 108.4 (C-8), \n107.0 (C-3), 94.7 (C-1), 82.3 (C-16), 66.4 (C -14), 43.1 (C-18), 31.9 , 29.7, 29.6, 29.5, 29.4, \n29.3, 27.3 (CH 2), 28.1 (C-17), 22.7 (C-34), 14.1 (C-35) ppm. \nMS: (m/z, 70eV, EI) = 549 (M+), 493, 254, 196, 180. \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n1617\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35NO\nOO\n \n \ntert-Butyl 2-(9-((2'-cyanobiphenyl-4-yl)methyl)-9 H-carbazol-2-yloxy)acetate (BSc4023) \nReactants:  0.150 g (0.51 mmol) 7, 0.206 mL (0.76 mmol) 4'-bromomethyl \nbiphenyl-2-carbonitrile, 0.068 g (0.61 mmol) KO t-Bu, 3 mL THF. \nYield:  0.170mg (69%) as a colourless solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.98\u20138.05 (m, 2H H-24/25), 7.70\u20137.75 (m, 1H, H-27), \n7.59 (m, 1H, H-26), 7.21\u20137.46 (m, 7H, H-4/5/6/ 7/8/21/20), 6.83\u20136.89 (m, 2H, H-1/3), 5.49 \n(s, 2H, H-14), 4.59 (s, 2H, H-18), 1.45 (s, 9H, H-17) ppm. \n13C NMR  (75 MHz, CDCl 3): \uf064 = 168.1 (C-18), 157.5 (C-2), 144.9 (C-22), 141.8 (C-13), \n140.9 (C-23), 137.6 (C-12), 137.4 (C-19), 133.8 (C-25), 132.8 (C-28), 130.0 (C-27), 129.2 \n(C-20), 127.6 (C-24), 126.7 (C-26), 124.9 (C-2 1), 123.2 (C-22), 121.2 (C-4), 119.7 (C-7), \n119.6 (C-5), 118.7 (C-29), 117.8 (C -10), 111.2 (C-11), 108.7 (C-6), 107.8 (C-3/8), 94.8 \n(C-1), 82.3 (C-16), 66.4 (C-14), 46.2  (C-18), 28.0 (C-17) ppm. \nMS: (m/z, 70eV, EI): 489 (M)+, 433, 192. \n9123 4\n5\n6\n7\n8101112\n1314\n15\n16\n1718\n1920\n21\n22\n2324\n25\n26272829NO\nOO\nN \n \n \nGeneral procedure for amidation of tert-butyl 2-(9 H-carbazol-2-yloxy)acetate \nderivatives \nKOt-Bu (1.2 equiv) was added to a stir red solution of THF (5 mL/mmol) tert-butyl \n2-(9Hcarbazol-6-yloxy)acetate ( 7) (1 equiv) at 0 \u00b0C. After 30 minutes acid chloride (1.5 \nequiv) was added. The reaction mixture was stirred at ambi ent temperature for 6\u201324 h. The \nheterogeneous reaction mixture was quenched with NH 4Cl (sat. aq), diluted with CH 2Cl2 and \nthen washed sequentially with H 2O and brine. The organic ex tract was dried over anhydrous \nMgSO 4 and evaporated in vacuo to give crude compound. The crude compound was purified \nby flash column chromatography (CH 2Cl2\uf02dhexane, 1:50).  \n 104 tert-Butyl 2-(9-decanoyl-9 H-carbazol-2-yloxy)acetate (BSc4024): \nReactants:  0.200 g (0.83 mmol) 7, 0.258 mL (1.25 mmol) decanonyl chloride, 0.112 g \n(1.00 mmol) KO t-Bu, 6 mL THF. \nYield:  0.158 g, (42%) as a yellow solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.04 (d, 3J = 7.7 Hz, 1H, H-4), 7.96 (d, 4J = 2.2 Hz, 1H, \nH-1), 7.92-7.87 (m, 1H, H-5), 7.85 (d, 3J = 8.5 Hz, 1H, H-8), 7.43-7.31 (m, 2H, H-6/7), 7.00 \n(dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, H-3), 4.64 (s, 2H, C-14), 3.10 (t, 3J = 7.3 Hz, 2H, H-19), \n1.96-1.84 (m, 2H, H-20), 1.52 (s, 9H, H-17), 1.47-1.19 (m, 12H, CH 2), 0.97-0.82 (m, \n3J = 6.8, 3H, H-27). \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.2 (C-18), 167.7 (C-15), 157.7 (C-2), 139.7 (C-13), \n138.2 (C-12), 126.3 (C-10), 125.8 (C-7), 123.3 (C-4), 120.2 (C-11), 120.2 (C-5), 119.0 \n(C-6), 115.7 (C-8), 111.6 (C-3 ), 102.8 (C-1), 82.2 (C-16), 66.0 (C-14), 38.9 (C-19), 31.7, \n29.3, 29.2, 29.1 (CH 2), 27.9 (C-17), 24.2, 22.4 (CH 2), 13.9 (C-26) ppm. \n \nNO\nOO\nO9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n1718\n19\n20\n21\n22\n2324\n25\n26\n27 \n \nGeneral procedure for the amidation of tert-butyl 2-(9 H-carbazol-2-yloxy)acetate \nderivatives \nDCC  (1.5 equiv) was added to a stirred solution of THF (5 mL/mmol) tert-butyl \n2-(9Hcarbazol- 6-yloxy)acetate ( 7) (1 equiv), carboxylic acid (1.5 equiv) and catalytic \namount of DMAP at 0 \u00b0C. The reaction mixture was stirred at ambient temperature for 6\u201324 \nh. The heterogeneous reaction mi xture was quenched with NaHCO 3 (sat. aq), diluted with \nCH 2Cl2 and then washed sequentially with H 2O and brine. The organic extract was dried \nover anhydrous MgSO 4 and evaporated in vacuo to give crude compound. The crude \ncompound was purified by flash column chromatography (CH 2Cl2\uf02dhexane, 1:5). \n \n (E)-tert-Butyl 2-(9-(octadec-9-enyl)-9 H-carbazol-2-yloxy)acetate (BSc4018): \nReactants:  0.200 g (0.83 mmol) 7, 0.469 mL (1.66 mmol) elaidi c acid, 0.258 g (1.25 mmol) \nDCC, catalytic amount DMAP, 6 mL CH\n2Cl2. \nYield:  0.231 g, (50%) as a yellow solid. \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.04 (d, 3J = 7.8 Hz, 1H, H-4), 7.97 (d, 4J = 2.2 Hz, 1H, \nH-1), 7.91-7.89 (m, 1H, H-7), 7.86 (d, 3J = 8.5 Hz, 1H, H-5), 7.43-7.32 (m, 2H, H-6/7), 7.01 \n(dd, 3J = 8.5 Hz, 4J =2.2 Hz, 1H, H-3), 5.42-5.34 (m, 2H, H26/27), 4.64 (s, 2H, H-14), 3.10 \n(t, J = 7.3 Hz, 2H, H19), 2.03-1.86 (m, 6H, H-20/ 25/28), 1.52 (s, 9H, H-17), 1.45-1.20 (m, \n20H, CH 2), 0.87 (t, J = 6.7 Hz, 3H, H-35) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.4 (C-16), 167.9 (C-15) ,157.9 (C-2), 139.9 (C-13), \n138.4 (C-12), 130.5 (C-26), 130.2 (C-27), 126.5 (C-10), 126.0 (C-7 ), 123.5 (C-4),120.4 \n(C-11), 120.2 (C-5), 119.2 (C -6), 115.9 (C-8), 111.8 (C-3),  103.0 (C-1), 82.4 (C-16), 66.1 \n(C-14), 39.1, 32.6, 31.9, 29.7, 29.6,  29.5, 29.4, 29.3, 29.2, 29.1, 29.0 (CH 2), 28.0 (C-17), \n24.6, 22.7 (CH 2), 14.1 (C-35) ppm. \n  \n 1059 123 4\n5\n6\n7\n8101112\n1314\n15\n16 17\n18\n19\n20\n21\n22\n23\n24\n25NO\nOO\nO\n26\n27\n28\n29\n30\n31\n32\n33\n34\n35  \n \n(Z)-tert-Butyl 2-(9-oleoyl-9 H-carbazol-2-yloxy)acetate (BSc4025)  \nReactants:  0.100 g (0.42 mmol) 7, 0.234 mL (0.83 mmol) oleic acid, 0.130 mg (0.63 mmol) \nDCC, catalytic amount DMAP, 3 mL CH 2Cl2. \nYield:  0.070 mg, (30%) as a colourless oil. \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.04 (d, 3J = 8.4 Hz, 1H, H-5), 7.97 (d, 4J = 2.2 Hz, 1H, \nH-1), 7.90 (dd, 3J = 7.4 Hz, 4J = 1.2 Hz, 1H, H-8), 7.86 (d, 3J = 8.5 Hz, 1H, H-4), 7.44-7.31 \n(m, 2H, H-6/7), 7.01 (dd, 3J = 8.5 Hz, 4J =2.3 Hz, 1H, H-3), 5.41-5.30 (m, 2H, H-26/27), \n4.64 (s, 2H, H-14), 3.11 (t, 3J = 7.3 Hz, 2H, H-19), 2.11-1.85 (m , 6H, H-20/25/28), 1.58-1.48 \n(s, 9H, H-17), 1.37 (m, 20H, CH 2), 0.94-0.83 (m, 3H, H-35) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.4 (C-18), 167.9 (C-15), 157.9 (C-2), 139.9 (C-13), \n138.4 (C-12), 130.0 (C-26), 129.8 (C-27), 126.5 (C-10), 126.0 (C-7),  123.5 (C-4), 120.4 \n(C-11), 120.2 (C-5), 119.3 (C -6), 116.0 (C-8), 111.8 (C-3),  103.0 (C-1), 82.5 (C-16), 66.1 \n(C-14), 39.1, 31.9, 29.8, 29.7, 29.6, 29.5, 29.4, 29.2 (CH 2), 28.1 (C-17), 27.2, 24.7, 22.7 \n(CH 2), 14.1 (C-35) ppm. \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n161718\n19\n20\n21\n22\n23\n24\n25\n26\n272829\n3031\n3233NO\nOO\nO\n34 35  \n \nGeneral procedure for N-sulfonylation of carbazole derivatives \nNaH (60% dispersion, 1.2 equiv) was combined with THF (5 mL/mmol) and cooled to 0 \u00b0C. \ntert-butyl 2-(9 H-carbazol-6-yloxy)acetate ( 7) (1 equiv) was added to  the stirring slurry in \nportions. After 30 minutes R-sulfonyl chloride (1.2 equiv) dissolved in THF was added and \nthe reaction was stirred at ambient temper ature for 6\u201324 h. The heterogeneous reaction \nmixture was quenched with NH 4Cl (sat. aq.), diluted with CH 2Cl2 and then washed \nsequentially with H 2O and brine (2\u00d7). The organic ex tract was dried over anhydrous Na 2SO 4 \nand evaporated in vacuo to give crude compound. The cr ude compound was purified by flash \ncolumn chromatography using (CH 2Cl2\uf02dhexane, 2:3) to afford  the desired product. \n  \n 106 tert-Butyl 2-(9-(5-(dimethylami no)naphthalen-1-ylsulfonyl)-9 H-carbazol-2-\nyloxy)acetate (BSc4027): \nReactants:  0.100 g (0.42 mmol) 7, 0.134 mL (0.50 mmol) dansyl chloride, 0.020 g \n(0.50 mmol) NaH, 3 mL THF. Yield:  0.060 g (99%) as a green solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.88 (d, 3J = 8.5 Hz, 1H, H-4), 7.67 (d, 3J = 8.7 Hz, 1H, \nCH), 7.54-7.52 (m, 1H, CH), 7.30-7.19 (m, 4H , CH), 6.85-6.68 (m, 4H, CH), 6.50-6.42 (m, \n2H, CH), 4.02 (s, 2H, H-14), 2.21 (m, 6H, H-28), 0.90 (s, 9H, H-17) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 167.7 (C-15), 157.9 (C-2), 151.7 (C-22), 139.8 (C-18), \n138.6 (C-13), 134.6 (C-26), 131.2 (C-23), 129.9 (C-12) 128.6 (C-20), 128.5 (C-24), 127.5 \n(C-10) 126.1 (C-25), 125.5 (C-11), 123.6 (C -7), 122.8 (C-19), 120.8 (C-4), 119.6 (C-27), \n119.4 (C-5), 118.7 (C-6), 115.5 (C-21), 114.7 (C-8 ), 112.7 (C-3), 100.2 (C-1), 82.5 (C-16), \n66.1 (C-14), 45.2 (C-28), 28.0 (C-17) ppm. \nMS: (m/z, 70eV, ESI) = 553 (M + Na).  \n \n9123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17 18 19\n20\n2122\n232425\n26\n27\n28NO\nOO\nSOO\nN\n \n \n(E)-tert-Butyl 2-(9-(4-((4-(dimethylamino )phenyl)diazenyl)phenylsulfonyl)-9 H-\ncarbazol-2-yloxy)acetate (BSc4027) \nReactants:  0.050 g (0.19 mmol) NH01, 0.072 mL (0.22 mmol) dabsyl chloride, 0.015 g \n(0.38 mmol) NaH, 2 mL THF. Yield:  0.064 g, (58%) as a red solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.29 (d, 3J = 8.3 Hz, 1H, CH), 7.93 (d, 4J = 2.3 Hz, 1H, \nCH), 7.87 (dt, 3J = 8.8 Hz, 4J = 2.0 Hz, 2H, CH), 7.81-7.73 (m, 4H, CH), 7.72-7.65 (m, 2H, \nCH), 7.41 (dt, 3J = 8.2 Hz, 4J = 1.3 Hz, 1H, CH), 7.31 (t, J = 7.4 Hz, 1H, CH), 7.01 (dd, \n3J = 8.6, Hz., 4J = 2.3 Hz, 1H, CH) 6.67 (d, 3J = 8.54 Hz, 2H, H-24), 4.68 (s, 2H, H-14), \n3.04 (s, 6H, H-26), 1.56 (s, 9H, H-17) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 167.8 (C-15), 158.0 (C-21), 157.3 (C-2), 143.5 (C-25), \n139.5 (C-22), 138.4 (C-18), 136.6 (C-3), 127.5 (C -19), 126.5 (C-12), 125.5 (C-23), 124.8 \n(C-7), 124.2 (C-20), 122.5 (C-4 ), 120.7 (C-5), 1 19.7 (C-11), 119.3 (C-6), 115.2 (C-8), 113.0 \n(C-24), 111.4 (C-3), 100.8 (C-1 ), 82.6 (C-16), 66.2 (C-14), 40.2 (C-26), 28.1 (C-17) ppm. \nMS: (m/z, 70eV, ESI) = 607 (M + Na). \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n1617\n18\n19\n20\n21\n22\n23\n24\n25\n26NO\nOO\nSOO\nN\nN\nN \n  \n 107General procedure for tert-butyl ester cleavage of N-substituted tert-butyl 2-(9 H-\ncarbazol-2-yloxy)acetates \nA solution of t-butyl ester in 20% tr ifluoroacetic acid in CH 2Cl2 (5 mL/mmol) was stirred at \nambient temperature for 4 to 12 h. After completion of reaction (TLC), solvent was evaporated in vacuo to get crude product. The crude acid was purified by crystallization \n(CH\n2Cl2\uf02dhexane) to afford the desired product. \n  \n2-(9-Octadecyl-9 H-carbazol-2-yloxy)acetic acid (8a , BSc3770) \nReactants:  0.102 g (0.186 mmol) BSc4022 , 0.500 mL TFA, 2 mL (CH 2Cl2). \nYield : 0.040 g, (44%) as a colourless solid \nMp: 118.6\u00b0C \n1H NMR (300 MHz, Acetone): \uf064 = 7.99 (d, 3J = 7.8 Hz, 1H, H-4), 7.98 (d, 3J = 8.5 Hz, 1H, \nH-5), 7.45 (d, 3J = 8.2 Hz, 1H, H-7), 7.32 (d, 3J = 8.2 Hz, 1H, H-6), 7.13 (d, 3J = 7.8 Hz, 1H, \nH-3), 7.09 (d, 4J = 2.2 Hz, 1H, H-1), 6.85 (dd, 4J = 2.2 Hz, J = 8.5 Hz, 1H, H-8),4.80 (s, 2H, \nH-14), 4.34 (t, 3J = 7.2 Hz, 2H, H-16), 1.85 (q, 3J = 7.3 Hz, 2H, H-17), 1.20-1.41 (m, 3H, \nCH 2), 0.86 (t, 3J = 6.6 Hz, 3H, H-33) ppm. \n13C NMR (75 MHz, Acetone): \uf064 = 164.2 (C-15), 155.4 (C-2), 142.6 (C-13), 141.6 (C-12), \n125.3 (C-4), 123.8 (C-10), 121.7 (C-7), 120.2 (C-5), 119.7 (C-6 ), 118.0 (C-11), 109.6 (C-8), \n100.9 (C-3), 95.3 (C-1), 66.0 (C- 14), 43.4 (C-16), 32.6, 27.8, 23.3 (CH 2), 14.3 (C-33) ppm. \nMS: (m/z, 70eV, EI) = 493 (M+), 436, 254, 196, 167. \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33NO\nOHO\n \n \n2-(9-((2'-cyanobiphenyl-4-yl )methyl)-9H-carbazol-2-yloxy )acetic acid (8g, BSc3984) \nReactants:  0.020 g (0.04 mmol) BSc4023 , 0.500 mL TFA, 2 mL (CH 2Cl2). \nYield:  0.010g, (57%) as a colourless solid \n1H NMR  (500 MHz, CDCl 3) \uf064 = 8.03 (m, 2H, CH), 7.71 (d, 3J = 7.6 Hz, 1H, CH), 7.61 (t, \n3J = 7.9 Hz, 1H, CH), 7.47-7.37 (m, 6H,CH), 7.31- 7.21 (m, 3H,CH), 6.91-6.87 (m, 1H, CH), \n6.77 (3J = 10.1 Hz, 2J = 2.2 Hz, 1H, CH), 5.51 (s, 2H, H-14), 4.2 (s, 2H, H-16) ppm.  \n  \n9123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17 18\n19\n20\n2122\n23\n24252627NO\nOHO\nN  \n 108 2-(9-Decanoyl-9 H-carbazol-2-yloxy)acetic acid (8c, BSc3854)  \nReactants:  0.050 g (0.11 mmol) BSc4024 , 0.250 mL TFA, 1 mL (CH 2Cl2). \nYield:  0.035 g (80%) as a yellow solid \n1H NMR (500 MHz, acetone- d6): \uf064 = 8.08 (d, 3J = 8.0 Hz, 1H, H-4), 7.88-7.92 (m, 3H, \nH-3/6/7), 7.25-7.37 (m, 2H, H-1/5), 6.97 (dd, 4J = 2.3 Hz, 3J = 8.4 Hz, 1H, H-8), 4.72 (s, 2H, \nH-14), 3.61-3.48 (m, 2H, H-17), 3.12 (t, 3J = 7.2 Hz, 2H, H-18), 2.27-1.93 (m, 2H, H-19), \n1.86-1.76 (m, 2H, H-20), 1.80-1.90 (m, 2H, H-21), 1.41-1.51 (m, 2H, H-22),1.11-1.31 (m, \n4H, H-23/24) 0.82 (3J = 6.7 Hz, H, H-25) ppm. \n13C NMR (125 MHz, acetone- d6): \uf064 = 173.0 (C-16), 157.7 (C- 15), 139.5 (C-13), 138.2 \n(C-12), 126.0 (C-10),125.8 (C-7 ), 123.2 (C-4), 120.1 (C-11), 119.9 (C-5), 118.9 (C-6), 115.8 \n(C-8), 111.2 (C-3), 103.0 (C-1), 72. 2 (C-14), 65.1, 61.0, 38.6, 31.5,30.0, 28.8, 24.3 (CH 2), \n14.0 (C-27) ppm. MS: (m/z, 70eV, EI) = 395 (M\n+), 241, 196, 182, 166, 154. \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25NO\nOHO\nO\n \n \n(E)-2-(9-(Octadec-9-enyl)-9 H-carbazol-2-yloxy)acetic acid (8b, BSc3853) \nReactants:  0.050 g (0.09 mmol) BSc4018 , 0.250 mL TFA, 1 mL (CH 2Cl2). \nYield:  0.027 mg (60%) as a colourless solid \n1H NMR (300 MHz, acetone- d6): \uf064 = 7.66 (d, J = 8.0 Hz, 1H, H-4), 7.55-7.44 (m, 3H, \nH-3/6/7), 6.96-6.84 (m, 2H, H-1/5), 6.56 (dd, J = 8.5, J = 2.3 Hz, 2H, H-8), 4.92-4.89 (m, \n2H, H-24/25), 4.30 (s, 2H, H-14), 3.23-3.10 (m, 2H, H-17), 2.70 (t, J = 7.28 Hz, 2H, H-18), \n1.51-1.38 (m, 6H, H-23/36/32), 1.07-0.79 (m, 20H, CH 2), 0.41-0.37 (m, 3H, H-33) ppm. \n13C NMR (75 MHz, acetone- d6): \uf064 = 173.2 (C-16), 169.4 (C-15), 157.9 (C-2), 139.6 (C-13), \n138.3 (C-12), 130.2 (C-24), 130.0 (C-25), 126.1 (C-10), 125.9 (C-7),  123.3 (C-4), 120.2 \n(C-11), 120.1 (C-5), 119.0 (C-6 ), 116.0 (C-8), 111.3 (C-3),  103.1 (C-1), 65.1 (C-14), 61.1, \n38.8, 32.4, 31.7, 30.2, 30.0, 29.7, 29.4, 29.2, 29.1, 29.0, 28.8, 28.7, 24.4, 22.4 (CH 2), 13.7 \n(C-33) ppm. MS: (m/z, 70eV, EI) = 506(M\n+), 241, 196, 182, 154. \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n25\n26\n27\n28\n29\n30\n31\n32\n33NO\nOHO\nO\n \n  \n 109(Z)-2-(9-Oleoyl-9H-carbazol -2-yloxy)acetic acid (8d, BSc3915) \nReactants:  0.070 g (0.13 mmol)  BSc4025 , 0.250 mL TFA, 1 mL (CH 2Cl2). \nYield:  0.034 g (54%) as colourless solid \nMp: 101.1 \u00b0C \n1H NMR (500 MHz, acetone- d6): \uf064 = 8.03 (d, J = 2.0 Hz, 1H, H-1), 7.97 (d, J = 8.3 Hz, 1H, \nH-4), 7.89 (d, J = 7.6 Hz, 1H, H-8), 7.85 (d, J = 8.5 Hz, 1H, H-5), 7.42-7.39 (m, 1H, H-7), \n7.34 (t, J = 7.4 Hz, 1H, H-6), 7.01 (dd, J = 8.5, J = 2.1 Hz, 1H, H-3), 5.36-5.34 (m, 2H, \nH-24/25), 4.78 (s, 2H, H-14), 3.08 (t, J = 7.3 Hz, 2H, H-17), 2.05-1.99 (m, 2H, H-23), 1.90 \n(q, J = 7.4 Hz2H, H-26), 1.52-1.44 (m, 2H , H-32), 1.41-1.26 (m, 22H, CH 2), 0.89-0.85 (m, \n3H, H-33) ppm. \n13C NMR (125 MHz, acetone- d6): \uf064 = 173.5 (C-16), 172.1 (C -15), 157.3 (C-2), 139.9 \n(C-13), 138.3 (C-12), 130.0 (C-24), 129.7 (C -25), 126.3 (C-7), 123.6 (C-4), 120.9 (C-10), \n120.4 (C-5), 119.4 (C-6), 115.8 (C-8), 112.5 (C- 11), 111.8 (C-3), 103.5 (C-1), 65.5 (C-14), \n39.1, 31.9, 29.8, 29.7, 29.5, 29.4, 29.3, 29.2, 29.1, 29.0, 28.9, 27.2, 27.1, 26.6 (CH 2), 14.1 \n(C-33) ppm. MS: (m/z, 70eV, EI) = 505 (M\n+), 423, 269, 241, 182. \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23\n24\n252627\n2829\n3031\n32\n33NO\nOHO\nO\n \n \n2-(9-(5-(Dimethylamino)naphthalen-1-ylsulfonyl)-9 H-carbazol-2-yloxy)acetic acid \n(8e, BSc3955) \nReactants:  0.070 g (0.13 mmol) BSc4027 , 0.500 mL TFA, 2 mL (CH 2Cl2). \nYield:  0.055g (89%) as a green solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 9.34 (s, 1H, OH), 8.36 (d, 3J = 8.5 Hz, 1H, CH), 8.14 (d, \n3J = 8.7 Hz, 1H, CH), 8.06 (d, 3J = 8.2 Hz, 1H, CH), 7.86 (d, J = 7.3 Hz, 1H,CH), 7.76-7.57 \n(m, 3H, CH), 7.40-7.15 (m, 4H, CH ), 7.06-6.76 (m, 1H, CH), 6.96 (d, 3J = 7.6 Hz, 1H, CH), \n6.85 (d, 3J = 8.5 Hz, 1H, CH) 4.61 (s, 2H, C-14), 2.70 (s, 6H, H-26) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.0 (C-15), 157.4 (C-2), 150.5 (C-20), 139.5 (C-16), \n138.7 (C-13), 134.6 (C-24), 131.0 (C-21), 129.9 (C-12), 129.5 (C-10), 129.0 (C-18), 128.5 \n(C-22), 126.3 (C-23), 125.4 (C-25), 123.7 (C -7), 123.3 (C-17), 120.9 (C-4), 119.9 (C-11), \n119.5 (C-5), 119.3 (C-6), 115.8 (C-19), 114.7 (C-8 ), 112.4 (C-3), 110.5 (C-1), 65.5 (C-14), \n45.4 (C-26) ppm. MS: (m/z, 70eV, EI) = 474 (M\n+), 430, 366, 307, 240, 182, 170. \n \n9123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n1920\n212223\n2425\n26NO\nOHO\nSOO\nN\n  \n 110 (E)-2-(9-(4-((4-(Dimethylamino)phenyl)diazenyl)phenylsulfonyl)-9 H-carbazol-2-yloxy)-\nacetic acid (8f, BSc3956) \nReactants:  0.060 g (0.10 mmol) BSc4027 , 0.500 mL TFA, 2 mL (CH 2Cl2). \nYield:  0.045 g, (85%) as a red solid \n1H NMR (500 MHz, DMSO): \uf064 = 8.11 (d, 3J = 8.4 Hz, 1H, CH), 7.91 (d, 3J = 8.5 Hz, 2H, \nCH), 7.83 (d, 3J = 8.7 Hz, 2H, CH), 7.69-7.58 (m, 5H, CH), 7.39 (t, 3J = 7.3, 1H, CH), 7.29 \n(t, 3J = 7.5, 1H, CH), 6.95 (dd, 3J = 8.6 Hz, 4J = 2.2 Hz, 1H, CH), 6.69 (d, 3J = 9.3 Hz, 2H, \nCH), 4.76 (s, 2H, H-14), 2.94 (s, 6H, H-25) ppm.  \n13C NMR (125 MHz, DMSO): \uf064 = 169.8 (C-15), 157.6 (C-2), 155.6 (C-23), 153.1 (C-19), \n142.3 (C-20), 138.2 (C-16), 137.1 (C-13), 135.1 (C-12), 127.4 (C-17), 126.3 (C-21), 125.3 \n(C-7), 124.2 (C-18), 122.1 (C-4 ), 121.2 (C-5), 1 19.7 (C-6), 114.3 (C-8),  112.6 (C-23), 111.3 \n(C-3), 99.8 (C-1), 64.8 (C-14) ppm. MS: (m/z, 70eV, EI) = 528 (M\n+), 484, 396, 241, 224. \nUV: 449 nM \n \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n2122\n23\n24\n25NO\nOHO\nSOO\nN\nN\nN \n \n3. Experimental methods and spectral data of 8h:  2,2,2-Trifluoro-1- m-tolylethanone oxime (10) \nA solution of trifluoracetophenone (2.00 g, 10.60 mmol) and hydroxylamine hydrochloride \n(745 mg, 10.60 mmol) in dry EtOH (10 mL) und pyr idine (22 mL) was heated at 80 \u00b0C for \n4 h. The solvent was evaporated and the residu e was diluted with diethyl ether (70 mL) and \nthen washed sequentially with H\n2O (3x 30 mL). The combined or ganic extracts were dried \nover anhydrous Na 2SO and evaporated in vacuo to give crude compound. The crude \ncompound was purified by flash co lumn chromatography (hexane \uf02dEtOAc, 4:3). \nYield:  1.98 g (92%) as colourless solid \n1H NMR (500 MHz, CDCl 3): \uf064 = 9.00 (s, OH), 7.30-7 .27 (m, 2H, H-4/-6), 7.23-7.18 (m, 2H, \nH-2/-3), 2.31 (d, J = 7.9, 3H, H-9) ppm \n13C NMR (125 MHz, CDCl 3): \uf064 = 172.2 (C-7), 138.8 (C-1), 131.8 (C-5), 129.4 (C-2) 128.8 \n(C-6), 126.4 (C-3), 122.1 (C-4), 1 19.9 (C-8), 117.7 (C-8),  21.8 (C-9) ppm.  \nMS (EI):  m/z = 203 (M+). \n1\n2\n3456\n7CF389N10 OH11\n  \n 1112,2,2-Trifluoro-1- m-tolylethanone- O-tosyloxime (11)  \n4-TsCl (937 mg, 4.93 mmol) was added portio nwise to a solution of 2,2,2-trifluoro-1- m-\ntolylethanone oxime (1.0 g, 4.93 mmol), DIEA (943 \u00b5L, 5.52 mmol) and DMAP (46 mg, 0.37 mmol) in CH\n2Cl2 (8 mL) at 0 \u00b0C. After 40 min the cooling was removed and the \nsolution was stirred for 2 h at r.t. Then  the reaction mixture was washed with H 2O (3 \nx 30 mL). The organic phase  was dried over anhydrous Na 2SO and evaporated in vacuo \nto give crude compound. The crude compound was purified by flash column \nchromatography (CH 2Cl2\uf02dpetroleum ether, 3:4).  \nYield:  1.23 g (70%) as colourless solid  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.83-7.80 (m, 2H, H-11), 7.32-7.09 (m, 6H, H-2/-3/-\n4/-6/-12), 2.40 (d, J = 9.2 Hz, 3H, H-14), 2.31 (d, J = 8.6 Hz, 3H, H-9) ppm.  \n3C NMR (125 MHz, CDCl 3): \uf064 = 168.8 (C-7), 146.5 (C-10), 139.1 (C-13), 132.8 (C-1), \n131.9 (C-5), 130.3 (C-2), 129.8 (C-1 2), 129.1 (C-6), 129.0 (C-3),  126.4 (C-11), 125.0 (C-4), \n114.4 (C-8), 22.2 (C-14), 21.8 (C-9) ppm.  \nMS (EI):  m/z = 357 (M)+.  \n1\n2\n3456\n7CF389N10\nO11\nS121314\nO O\n \n3-m-Tolyl-3-(trifluoromethyl)diaziridine (12)  \nTo a solution of 2,2,2-trifluoro-1- m-tolylethanone- O-tosyloxime (1.0 g, 2.80 mmol) in \ndiethyl ether (7 mL), liquid ammonia (6 mL , distilled over sodium) was added at \u201378 \u00b0C. \nThe tube was capped and the solution was stirred for 2 h at -78 \u00b0C in the dark. Under warming to r.t. the ammonia was allowed to ev aporate. The etheric solution was filtered and \nwashed with H\n2O (3x 20 mL). The organic phase was dried over anhydrous Na 2SO and \nevaporated in vacuo to give crude compound. The crude  compound was purified by flash \ncolumn chromatography (hexane \uf02dCH 2Cl2, 20:1).  \nYield:  504 mg (89%) as colourless oil \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.34-7.26 (m, 2H, H-3/-6),  7.25-7.17 (m, 2H, H-2/-4), 2.69 \n(d, J = 8.5 Hz, 1H), 2.31 (s, 3H, H-9), 2.14 (d, J = 9.0 Hz, 1H) ppm.  \n13C NMR (125 MHz, CDCl 3): \uf064 = 132.8 (C-5), 131.3 (C-1), 130.3 (C-8), 129.7 (C-6), 129.1 \n(C-3), 126.9 (C-2), 125.6 (C-4),  80.8 (C-7), 21.8 (C-9) ppm.  \nMS (EI):  m/z = 203 (M+H)+.  \n \n1\n2\n3456\n7CF3\n89HN10NH11\n \n3-m-Tolyl-3-(trifluoromethyl)-3 H-diazirine (13)  \n3-m-Tolyl-3-(trifluoromethyl)diaziridine (300 mg, 1.48 mmol) was solved in CH 2Cl2 (8 mL) \nand Et 3N (0.6 mL, 4.33 mmol) was added. The solu tion was cooled to 0 \u00b0C and iodine \n(413 mg, 1.63 mmol) was added in small portions. The solution was stirred for 2 h at r.t. and \nthen washed with 1M NaOH (2 x 25 mL), dest. H 2O (2 x 25 mL) and sat. NaCl (25 mL). The \norganic phase was dried over anhydrous MgSO 4 and evaporated in vacuo to give crude \ncompound. The crude compound was purifie d by flash column chromatography \n(hexane\uf02dCH 2Cl2, 20:1).  \nYield:  198 mg (67%) as colourless oil  \n 112 1H NMR (500 MHz, CDCl 3): \uf064 = 7.22-7.18 (m, 2H), 7.15 (d, J = 7.6 Hz, 1H), 6.95 (d, \nJ = 7.7 Hz, 1H), 2.28 (s, 3H, H-9) ppm.  \n13C NMR (125 MHz, CDCl 3): \uf064 = 139.2 (C-5), 130.8 (C-1), 129.5 (C-8), 129.1 (C-6), 127.4 \n(C-3), 124.0 (C-2), 123.7 (C-4), 84.0 (C-7), 32.0 (C-8, CF), 23.0 (C-8, CF), 21.8 (C-9), 14.5 \n(C-8, CF) ppm.  \nMS (EI):  m/z = 200 (M)+.  \n \n1\n2\n3456\n7CF389NN\n \n \n3-(3-(Bromomethyl)phenyl)-3-(trifluoromethyl)-3 H-diazirine (14)  \nA solution of 3- m-Tolyl-3-(trifluoromethyl)-3 H-diazirine  (100 mg, 0.50 mmol) in CCl 4 \n(4 mL) was heated to 70 \u00b0C and NBS (80 mg, 0.45 mmol) was added. After 10 min AIBN \n(8 mg, 0.05 mmol) was added and the reaction mixture was stirred for 2 h under reflux. The \nformed precipitate was filtered and the solvent was evaporated carefully. The crude \ncompound was purified by flash co lumn chromatography (hexane \uf02dCH 2Cl2, 20:1). \nYield:  73 mg (52%) as colourless oil \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.40-7.31 (m, 2H, H-3/-6), 7.19-7.08 (m, 2H, H-2/-4), 4.38 \n(s, 2H, H-9) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 138.8 (C-5), 130.3 (C-1), 129.8 (C-8), 129.4 (C-6), 128.9 \n(C-3), 126.9 (C-2), 123.8 (C-4), 79.8 (C-7), 32.1 (C-9), 31.6 (C-8, CF), 22.6 (C-8, CF), 14.1 \n(C-8, CF) ppm.   \n1\n2\n3456\n7CF389NN\nBr\n \ntert-Butyl-2-(9-(3-(3-(trifluoromethyl)-3 H-diazirine-3-yl)benzyl)-9 H-carbazol-2-yloxy)-\nacetate (15)  \n7 (25 mg, 0.084 mmol) was solved at 0 \u00b0C in THF (5 mL) and KO t-Bu (12 mg, 0.101 mmol) \nwas added. After 30 min 3-(3-(bro momethyl)phenyl)-3-(trifluoromethyl)-3 H-diazirine \n(35 mg, 0.126 mmol) was added in the dark. The reaction mixture wa s stirred for 12 h at r.t. \nThe heterogeneous reaction mixture was dilu ted with EtOAc (20 mL) and then washed \nsequentially with H 2O (3x 15 mL) and brine. The organi c extract was drie d over anhydrous \nMgSO 4 and evaporated in vacuo to give crude compound. The crude compound was purified \nby flash column chromatography (hexane \uf02dCH 2Cl2, 5:4).  \nYield:  18 mg (43%) as colourless solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.05-7.99 (m, 2H, H-4/-5), 7.37-7.35 (m, 1H, H-8), \n7.27-7.24 (m, 3H, H-6/-7/-21), 7.09 (d, J = 4.02 Hz, 1H, H-24), 6.89 (m, 2H, H-20/22), 6.86 \n(d, J = 6.1 Hz, 1H, H-3), 6.79 (d, J = 6.5 Hz, 1H, H-1), 5.44 (s, 2H, H-18), 4.58 (s, 2H, \nH-14), 1.45 (s, 9H, H-17) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 174.6 (C-15), 157.5 (C-2), 142.6 (C-13), 138.7 (C-23), \n129.8 (C-12), 129.5 (C-19), 127.5 (C-25), 125.7 (C -4/24), 125.0 (C-21), 124.4 (C-22/-20), \n123.2 (C-7/-10), 121.3 (C-5), 119.8 (C-6), 117.6 (C-11), 108.5 (C-8), 107.8 (C-3), 94.7 \n(C-1), 84.2 (C-26), 82.4 (C-16), 66.3, (C- 14), 46.2 (C-18), 28.0 (C-17) ppm.  \nMS (ESI):  m/z = 495(M)+. \n  \n 113123 4\n5\n6\nN7\n8910912\n13O\n14 15\n16O\n17O\n18\n19\n20\n21222324\n2526\nF3CN\nN\n \n \n2-(9-(3-(3-(Trifluoromethyl)-3 H-diazirine-3-yl)benzyl)-9 H-carbazol-2-yloxy)acetic acid  \n(8h, BSc3958)  \ntert-Butyl-2-(9-(3-(3-(trifluoromethyl)-3 H-diazirine-3-yl)benzyl)-9 H-carbazol-2-yloxy)-\nacetate (12 mg, 0.024 mmol) was solved in CH 2Cl2 (2 mL) and TFA (0.4 mL) was added. \nThe solution was stirred for 6 h at r.t., filtered, and the solvent was evaporated. The crude \ncompound was purified by flash co lumn chromatography (hexane \uf02dCH 2Cl2, 5:4).  \nYield:  8 mg (76%) as colourless solid \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.05-7.98 (m, 2H, H-4/-5), 7.45-7.33 (m, 1H, H-8), \n7.27-7.24 (m, 3H, H-6/-7/-21), 7.197.17 (m, 1H , H-24), 6.97-6.94 (m, 2H, H-20/22), 6.88 (d, \nJ = 6.1 Hz, 1H, H-4), 6.76 (d, J = 6.5 Hz, 1H, H-1), 5.36 (s, 2H , H-18), 4.65 (s, 2H, H-14) \nppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 169.4 (C-15), 154.5 (C-2), 139.8 (C-13), 138.7 (C-21), \n129.8 (C-12), 129.5 (C-17), 126.2 (C-24), 125.7 (C -4/-22), 125.0 (C-19), 123.7 (C-18/-20), \n122.5 (C-7/-10), 121.3 (C-5), 119.8 (C-6), 117.0 (C-11), 108.3 (C-8), 107.4 (C-3), 94.3 \n(C-1), 84.2 (C-23), 66.3, (C-14), 46.2 (C-16) ppm.  \nMS (ESI):  m/z = 440 (M+H)+. \n \n123 4\n5\n6\nN7\n89101112\n13O\n14 15\n16OH\n17O\n18\n19202122\n23\n24F3CN\nN\n \n \n4. Experimental methods and spectral data of O-substituted fenofibrate-derived sGSMs \n \nIsopropyl 2-(4-((4-chlorophenyl)(hydroxyi mino)methyl)phenoxy)-2-methylpropanoate \n(16, BSc3933) \nFenofibrate (2.000 g, 5.54 mmol), hydroxylam ine hydrochloride (0.962 g, 13.86 mmol), and \npyridine (22 mL) were dissolved in ethanol (10 mL) and the reaction mixture was stirred \novernight at 80 \u00b0C. Solvent was evaporat ed, and the residue was diluted with CH 2Cl2 and \nthen washed with H 2O (3x 30 mL) and brine (1x 30 mL). The organic extract was dried over \nanhydrous Na 2SO 4 and evaporated in vacuo . The crude compound was purified by flash \ncolumn chromatography using (CH 2Cl2\uf02dMeOH, 15:1) to yield the title compound as \ncolourless solid (1.46 g, 70.2%) \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.6 (s, OH), 7.27-7.44 (m, 4H), 7.26 (dd, J = 8.9 Hz, \nJ = 2.2 Hz, 2H), 6.75 (dd, J = 9.0, 2.2 Hz, 2H), 5.09 (m, 1H), 1.6 (d, J = 12.8 Hz, 6H), 1.15 \n(dd, J = 11.9, 5.6 Hz, 6H) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.5 (C-12), 156.4 (C-9), 135.3 (C-5), 134.9 (C-1), 131.2 \n(C-4), 130.7 (C-3), 129.4 (C -7), 129.3 (C-2), 125.1 (C-6), 117.9 (C-8 ), 79.2 (C-10), 69.1 \n(C-13), 25.4 (C-11), 21.5 (C-14) ppm. MS (ESI): m/z = 376\n.(M+).  \n 114 OOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nHO  \n \nGeneral procedure for O-alkylation of Isopropyl 2-(4-((4-clorophenyl)-hydroxy-\nimino)ethyl) henoxy) -2-methylpropanoate \nIsopropyl 2-(4-((4-clorophenyl)hydroxyimi no)ethyl)phenoxy)-2-methylpropanoate ( 10, \n1 equiv) was added to a stirred suspension of NaH (1.2 equiv) in DMF (5 mL/mmol) at 0 \u00b0C. \nAfter 30 minutes alkyl halide (1.2 equiv) diss olved in DMF was added. The reaction mixture \nwas stirred at ambient temperature for 6\u201324 h. The heterogeneous reaction mixture was \nquenched with NH 4Cl (sat. aq), diluted with EtOAc and the solution was washed with water. \nThe aqueous solution was extracted with EtOAc (3x 50 mL). The combined organic extract was washed with H\n2O, brine and dried over anhydrous Na 2SO 4 and rotary evaporated. The \ncrude compound was purified by flash column chromatography using ethyl acetate and cyclohexane mixtures.  \nIsopropyl 2-(4-((4-chlorphenyl)octyloxyi mino)methyl)phenoxy)-2-methylpropanoat \n(BSc3974) \nReactants:  0.300 g (0.80 mmol) 10, 0.038 g NaH (0.96 mmol), 0.230 g 1-iodooctane \n(0.96 mmol), 4 mL DMF. Yield:  0.190 g, 52%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.32-7.18 (m, 4H), 6.78 (dd, J = 8.8, 2.0 Hz, 2H), 6.71 \n(dd, J = 8.8 Hz, J = 2.2 Hz, 2H), 4.98 (m, 1H), 4.06 (t, J = 10 Hz, 2H, H-15), 1.59-1.52 (m, \n8H), 1.18-1.12 (m, 16H), 0.79 (t, J = 6.6 Hz, 3H; H-22) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.5 (C-12). 156.7 (C-9), 154.8 (C-5), 134.5 (C-1), 132.0 \n(C-4), 130.8 (C-3), 129.8 (C -6), 129.4 (C-7), 128.7 (C-2), 118.3 (C-8 ), 79.2 (C-10), 74.8 \n(C-15), 69.0 (C-13), 31.9 (C -20), 29.6 (C-19), 29.5 (C-18) , 29.4 (C-17), 25.9 (C-16), 25.5 \n(C-11), 22.7 (C-21), 21.5 (C -14), 14.1 (C-22) ppm.  \nESI-MS : m/z (%) = 510 (M+Na). \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 16 \nIsopropyl 2-(4-((4-chlorophenyl)(nonyloxyi mino)methyl)phenoxy)-2-methylpropanoate  \n(BSc3975) \nReactants:  0.300 g (0.80 mmol) 10, 0.038 g NaH (0.96 mmol), 0.200 g 1-bromononane \n(0.96 mmol), 4 mL DMF. Yield:  0.190 g, 50%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.33-7.17 (m, 4H), 6.78 (d, J = 8.8 Hz, 2H), 6.71 (d, \nJ = 8.9 Hz, 2H), 5.00 (m, 1H), 4.08 (m, 2H, H-15), 1.58-1.51 (m, 8H), 1.18-1.12 (m, 18H), \n0.80 (t, J = 6.5 Hz, 3H; H-23) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 172.5 (C-12). 155.7 (C-9), 153.8 (C-5), 134.7 (C-1), 130.9 \n(C-4), 129.9 (C-3), 128.8 (C -6), 128.4 (C-7), 127.7 (C-2), 117.3 (C-8 ), 78.1 (C-10), 73.8 \n(C-15), 68.1 (C-13), 30.9 (C -21), 28.7 (C-20), 28.5 (C-19) , 28.4 (C-18), 28.2 (C-17), 24.9 \n(C-16), 24.4 (C-11), 21.7 (C-22), 20.5 (C-14), 13.1 (C-23) ppm.  \nESI-MS : m/z (%) = 524 (M+Na). \n  \n 115OOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n \n \nIsopropyl 2-(4-((4-chlorophenyl)(decyloxyi mino)methyl)phenoxy)-2-methylpropanoate   \n(BSc3976) \nReactants:  0.200 g (0.53 mmol) 10, 0.024 g NaH (0.64 mmol), 0.141 g 1-bromodecane \n(0.64 mmol), 3 mL DMF. \nYield:  0.170 g, 68%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.43-7.24 (m, 4H), 6.94 (d, J = 8.9 Hz, 2H), 6.85 (d, \nJ = 8.9 Hz, 2H), 5.10 (m, 1H), 4.16 (m, 2H, H-15), 1.86 (m, 2H), 1.68-1.60 (m, 8H), \n1.27-1.21 (m, 18H), 0.80 (t, J = 6.8 Hz, 3H; H-24) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.5 (C-12). 156.7 (C-9), 154.8 (C-5), 135.7 (C-1), 131.9 \n(C-4), 129.8 (C-3), 128.4 (C -6), 128.7 (C-7), 128.3 (C-2), 118.3 (C-8 ), 79.2 (C-10), 74.8 \n(C-15), 69.0 (C-13), 34.0 (C -22), 32.9 (C-21), 31.9 (C20) , 29.6 (C-19), 29.5 (C-18), 29.4 \n(C-17), 25.9 (C-16), 25.7 (C-11), 21.5 (C-23), 21.5 (C-14), 14.1 (C-24) ppm.  \nESI-MS : m/z (%) = 538 (M+Na). \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n24 \nIsopropyl 2-(4-((4-chlorophenyl )(undecyloxyimino)methyl)phenoxy)-2-\nmethylpropanoate (BSc3977) \nReactants:  0.050 g (0.13 mmol) 10, 0.024 g NaH (0.16 mmol), 0.038 g 1-bromoundecane \n(0.16 mmol), 1 mL DMF. Yield:  0.048 g, 70%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.41-7.32 (m, 4H), 6.86 (d, J = 9 Hz, 2H), 6.79 (d, \nJ = 9 Hz, 2H), 5.08 (m, 1H), 4.14 (m, 2H, H-15 ), 3.41 (m, 2H), 1.91-1.84 (m, 2H), 1.67-1.60 \n(m, 8H), 1.27-1.20 (m, 18H), 0.80 (t, J = 6 Hz, 3H; H-25) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.5 (C-12). 155.7 (C-9), 154.8 (C-5), 135.0 (C-1), 131.9 \n(C-4), 130.8 (C-3), 129.4 (C -6), 128.7 (C-7), 128.3 (C-2), 118.3 (C-8 ), 79.2 (C-10), 74.8 \n(C-15), 69.0 (C-13), 34.0 (C -23), 32.9 (C-21), 31.9 (C20) , 29.6 (C-19), 29.5 (C-18), 29.4 \n(C-17), 29.3 (C-22), 25.9 (C- 16), 25.5 (C-11), 22.7 (C-24), 21.5 (C-14), 14.1 (C-24) ppm.  \nESI-MS : m/z (%) = 552 (M+Na).  \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n2425\n  \n 116 Isopropyl 2-(4-((4-chlorophenyl)(dodecy loxyimino)methyl)phenoxy)-2-methyl-propan-\noate (BSc3978) \n \nReactants:  0.050 g (0.13 mmol) 10, 0.024 g NaH (0.16 mmol), 0.040 g 1-bromododecane \n(0.16 mmol), 1 mL DMF. Yield:  0.056 g, 79%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.32-7.19 (m, 4H), 6.78 (d, J = 8.8 Hz, 2H), 6.71 (d, \nJ =8.6 Hz, 2H), 5.01 (m, 1H), 4.08 (m, 2H, H-15), 3.33 (m, 2H), 1.79-1.76 (m, 2H), \n1.56-1.53 (m, 4H), 1.36-1.33 (m, 6H ), 1.24-1.13 (m, 18H), 0.81 (t, J = 6.7 Hz, 3H; H-26) \nppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 176.0 (C-12). 156.7 (C-9), 155.8 (C-5), 134.2 (C-1), \n134.9 (C-4), 133.2 (C-3), 131.7 (C-6), 131.1 (C-7 ), 130.6 (C-2), 120.6 (C-8), 81.5 (C-10), \n77.1 (C-15), 71.5 (C-13), 36.3 (C-24), 35.13 (C -23), 34.2 (C22), 31.9 (C-21), 31.9 (C-20), \n31.8 (C-19), 31.7 (C-18), 31.6 (C-17), 28.2 (C- 11), 27.6 (C-25), 25.0 (C-16), 23.8 (C-14), \n16.4 (C-24) ppm.  ESI-MS : m/z (%) = 567 (M+Na).  \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n2425\n26 \nIsopropyl 2-(4-((4-chlorophenyl)(tet radecyloxyimino)methyl)phenoxy)-2-\nmethylpropanoate (BSc3979) \n \nReactants:  0.050 g (0.13 mmol) 10, 0.024 g NaH (0.16 mmol), 0.044 g 1-bromotetradecane \n(0.16 mmol), 1 mL DMF. Yield:  0.042 g, 56%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.33-7.18 (m, 4H), 6.78 (d, J = 8.8 Hz, 2H), 6.71 (d, \nJ =8.7 Hz, 2H), 5.01 (m, 1H), 4.08 (m, 2H, H-15), 3.34 (m, 2H), 1.79-1.77 (m, 4H), \n1.59-1.52 (m, 8H), 1.34-1.26 (m, 22H), 0.81 (t, J = 6.7 Hz, 3H; H-28) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 174.4 (C-12). 157.0 (C-9), 156.3 (C-5), 136.0 (C-1), \n134.8 (C-4), 132.2 (C-3), 131.2 (C-6), 131.1 (C-7 ), 129.7 (C-2), 118.6 (C-8), 79.5 (C-10), \n75.1 (C-15), 69.3 (C-13), 34.3 (C-26), 33.2 (C- 25), 33.2 (C-24), 30.0 (C-23), 29.9 (C-22), \n29.9 (C21), 29.8 (C-20), 29.7 (C-19), 29.4 (C-1 8), 29.1 (C-17), 28.4 (C-11), 28.3 (C-16), \n23.0 (C-27), 21.8 (C-14), 14.4 (C-28) ppm.  ESI-MS : m/z (%) = 594 (M+Na).  \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n2425\n26 2827\n  \n 117Isopropyl 2-(4-((4-chlorophenyl)(h exadecyloxyimino)methyl)phenoxy)-2-\nmethylpropanoate (BSc3980) \nReactants:  0.050 g (0.13 mmol) 10, 0.024 g NaH (0.16 mmol), 0.049 g 1-bromohexadecane \n(0.16 mmol), 1 mL DMF. Yield:  0.057 g, 73%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.40-7.28 (m, 4H), 6.79 (d, J = 8.8 Hz, 2H), 6.76 (d, \nJ =8.7 Hz, 2H), 5.06 (m, 1H), 4.16 (m, 2H, H-15), 3.41 (m, 2H), 1.88-1.84 (m, 4H), \n1.64-1.60 (m, 8H), 1.44-1.42 (m, 4H ), 1.27-1.20 (m, 22H), 0.81 (t, J = 6.7 Hz, 3H; H-30) \nppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.5 (C-12). 157.0 (C-9), 156.3 (C-5), 136.0 (C-1), 134.8 \n(C-4), 130.8 (C-3), 129.4 (C -6), 128.7 (C-7), 128.3 (C-2), 118.3 (C-8 ), 78.4 (C-10), 74.2 \n(C-15), 69.1 (C-13), 34.0 (C -28), 32.9 (C-27), 31.9 (C-26) , 29.7 (C-25), 29.5 (C-24), 29.4 \n(C23), 29.3 (C-22), 29.1 (C-21), 28.8 (C-20) , 28.6 (C-19), 28.5 (C-18), 28.2 (C-17), 28.3 \n(C-16), 25.5 (C-11), 22.7 (C29), 21.5 (C-14), 14.1 (C-30) ppm.  \nESI-MS : m/z (%) = 623 (M+Na). \n \nOOO\nCl\nN12\n3\n4\n56\n7910\n1112\n13\n814\nO1521 19 17\n18 20 22 1623\n2425\n26 2827\n3029\n \n \n \nGeneral procedure for isopropyl ester cleavage of O-substituted isopropyl 2-(4-((4-\nchlorophenyl)(hydroxyimino)meth yl)phenoxy)-2-methylpropanoates \nA solution of isopropyl ester in 2N NaOH in methanol (5 mL/mmol) was stirred at 70 \u00b0C \novernight. After completion of reacti on (TLC), solvent was evaporated in vacuo to get crude \nproduct. The heterogeneous reaction mixture diluted with EtOAc, acified with 2N HCl \n(pH ~ 4) and the solution was washed with water. The aqueous solution was extracted with EtOAc (3x 50 mL). The combined organic extract was washed with H\n2O, brine and dried \nover anhydrous Na 2SO 4 and rotary evaporated. If necessary, the crude compound was \npurified by flash column chromatography us ing ethyl acetate and hexane mixtures.  \n \n2-(4-((4-Chlorophenyl)(octyloxyimino)me thyl)phenoxy)-2-methylpropanoic acid \n(17a, BSc3934) \n \nReactants:  0.190 g (0.43 mmol) BSc3974, 0.36 mL 2N NaOH (4.3mmol), 5 mL MeOH. \nYield:  0.170 g, 98%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.44-7.21 (m, 4H), 6.94 (d, J = 9 Hz, 2H), 6.85 (d, \nJ = 9 Hz, 2H), 4.11 (m, 2H, H-13), 3.31 (m, 2H), 1.64-1.58 (m, 6H), 1.33-1.21 (m, 10H), \n0.89 (t, J = 6 Hz, 3H, H-20) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 178.6 (C-12), 158.3 (C-9), 158.4 (C-5), 137.0 (C-1), 135.6 \n(C-4), 133.6 (C-3), 131.7 (C -6), 129.7 (C-7), 129.3 (C-2), 119.7 (C-8 ), 75.6 (C-10), 75.5 \n(C-13), 32.9 (C-18), 30.4 (C -17), 30.2 (C-16), 30.1 (C-14) , 27.1 (C-15), 25.8 (C-11), 23.7 \n(C-19), 14.5 (C-20) ppm.  ESI-MS : m/z (%) = 446 (M\n+). \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 2016   \n 118 2-(4-((4-Chlorophenyl)(nonyloxyimino)meth yl)phenoxy)-2-methylpropanoic acid  \n(17b, BSc3935)  \nReactants:  0.270 g (0.60 mmol) BSc3975, 1.5 mL 2N  NaOH (6.00 mmol), 7 mL MeOH. \nYield:  0.240 g, 97%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.43-7.21 (m, 4H), 6.94 (d, J = 9 Hz, 2H), 6.85 (d, \nJ = 9 Hz, 2H), 4.11 (m, 2H, H-13), 3.31 (m, 2H), 1.65-1.58 (m, 6H), 1.27-1.21 (m, 12H), \n0.89 (t, J = 6 Hz, 3H, H-20) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 178.6 (C-12). 158.4 (C-9), 158.4 (C-5), 135.6 (C-1), 135.6 \n(C-4), 131.9 (C-3), 131.7 (C -6), 130.5 (C-7), 129.7 (C-2), 119.6 (C-8 ), 75.6 (C-10), 75.5 \n(C-13), 33.1 (C-19), 30.7 (C -18), 30.4 (C-17), 30.3 (C-16) , 30.1 (C-14), 27.1 (C-15), 25.9 \n(C-11), 23.7 (C-20), 14.5 (C-21) ppm.  ESI-MS : m/z (%) = 460 (M\n+). \n \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n \n \n2-(4-((4-Chlorophenyl)(decyloxyimino)meth yl)phenoxy)-2-methylpropanoic acid  \n(17c, BSc3936)  \nReactants:  0.115 g (0.23 mmol) BSc3976, 0.36 mL 2N  NaOH (2.30 mmol), 4.8 mL MeOH. \nYield:  0.085 g, 78%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.43-7.21 (m, 4H), 6.91 (d, J = 9 Hz, 2H), 6.85 (d, \nJ = 9 Hz, 2H), 4.11 (m, 2H, H-13), 3.31 (m, 2H), 1.65-1.58 (m, 6H), 1.27-1.21 (m, 14H), \n0.89 (t, J = 6 Hz, 3H, H-20) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 177.6 (C-12). 158.2 (C-9), 156.4 (C-5), 135.6 (C-1), 133.6 \n(C-4), 132.0 (C-3), 131.7 (C -6), 131.1 (C-7), 129.4 (C-2), 119.7 (C-8 ), 80.3 (C-10), 75.5 \n(C-13), 33.1 (C-20), 30.7 (C -19), 30.6 (C-18), 30.5 (C-17) , 30.4 (C-16), 30.2 (C-14), 27.1 \n(C-15), 25.8 (C-11), 23.8 (C -21), 14.5 (C-22) ppm.  \nESI-MS : m/z (%) = 474 (M+). \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n22 \n \n2-(4-((4-Chlorophenyl)(undecyloxyimino)m ethyl)phenoxy)-2-methylpropanoic acid  \n(17d, BSc3937)  \nReactants:  0.030 g (0.06 mmol) BSc3977, 0.09 mL 2N  NaOH (0.60 mmol), 1 mL MeOH. \nYield:  0.022 g, 75%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.37-7.12 (m, 4H), 6.93 (d, J = 9 Hz, 2H), 6.82 (d, \nJ = 9 Hz, 2H), 4.04 (m, 2H, H-13), 3.25 (dd, J = 3.24, 1.63 Hz, 2H), 1.74-1.40 (m, 6H), \n1.37-1.02 (m, 16H), 0.84 (t, J = 6.6 Hz, 3H, H-20) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 177.1 (C-12). 158.3 (C-9), 156.4 (C-5), 137.4 (C-1), 133.8 \n(C-4), 132.5 (C-3), 131.2 (C -6), 131.0 (C-7), 129.9 (C-2), 119.7 (C-8 ), 81.7 (C-10), 76.3 \n(C-13), 33.6 (C-21), 31.3 (C -20), 31.2 (C-19), 31.0 (C-18) , 30.7 (C-17), 30.7 (C-16), 27.6 \n(C-14), 27.0 (C-15), 27.0 (C-11) , 24.3 (C-22), 15.4(C-23) ppm. \nESI-MS : m/z (%) = 488 (M+).  \n 119OOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n2223\n \n \n2-(4-((4-Chlorophenyl)(dodecyloxyimino)m ethyl)phenoxy)-2-methylpropanoic acid \n(17e, BSc3938)  \nReactants:  0.033 g (0.06 mmol) BSc3978, 0.09 mL 2N  NaOH (0.60 mmol), 1 mL MeOH. \nYield:  0.020 g, 66%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.41-7.13 (m, 4H), 6.89 (d, J = 8.8 Hz, 2H), 6.77 (d, \nJ = 8.5 Hz, 2H), 4.10-3.96 (m, 2H), 3.23 (m, 2H ), 1.64-1.38 (m, 6H), 1.36-1.13 (m, 18H), \n0.79 (t, J = 6.63 Hz, 3H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 =178.9 (C-12), 159.1 (C-9), 157.3 (C-5), 138.2 (C-1), 137.4 \n(C-4), 132.4 (C-3), 130.1 (C -6), 130.1 (C-7), 129.7 (C-2), 119.0 (C-8 ), 88.2 (C-10), 65.4 \n(C-13), 33.5 (C-22), 31.2, 31.2, 30.9, 27.6, 27.5, 27.1, 27.0, 24.2, 24.1, 20.5 (C-23), 15.2 (C-24) ppm.  ESI-MS : m/z (%) = 502 (M\n+). \n \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n2223\n24 \n \n2-(4-((4-Chlorophenyl)(tetradecyloxyimino )methyl)phenoxy)-2-methylpropanoic acid  \n(17f, BSc3939) \n \nReactants:  0.034 g (0.06 mmol) BSc3979, 0.09 mL 2N  NaOH (0.60 mmol), 1 mL MeOH. \nYield:  0.024 g, 75%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.43-7.12 (m, 4H), 6.87 (d, J = 8.3 Hz, 2H), 6.77 (d, \nJ = 8.1 Hz, 2H), 4.10-4.05 (m, 2H), 3.32-3.30 (m , 2H), 1.77-1.47 (m, 6H), 1.21-1.35 (m, \n20H), 0.80 (t,  J = 6.5 Hz, 3H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 177.6 (C-12), 158.4 (C-9), 156.9 (C-5), 140.4 (C-1), \n137.3 (C-4), 132.9 (C-3), 132.5 (C-6), 131.1 (C-7 ), 130.4 (C-2), 119.5 (C-8), 81.0 (C-10), \n74.7 (C-13), 35.3 (C-24), 34.5, 33.6, 31.3, 31.1, 31.1, 31.0, 30.4, 29.8, 26.9, 26.7, 24.3 (C-11), 22.9 (C-25), 15.4 (C-26) ppm. ESI-MS : m/z (%) = 530 (M\n+). \n \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n2223\n24 2625\n \n  \n 120 Isopropyl 2-(4-((4-chlorophenyl)(h exadecyloxyimino)methyl)phenoxy)-2-\nmethylpropanoate (17g, BSc3940) \n \nReactants:  0.036 g (0.06 mmol) BSc3979, 0.09 mL 2N  NaOH (0.60 mmol), 1 mL MeOH. \nYield:  0.026 g, 78%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.73-7.15 (m, 4H), 6.80 (d, J = 8.5 Hz, 2H), 6.73 (d, \nJ = 8.3 Hz, 2H), 4.06-3.99 (m, 2H), 3.34-3.32 (m , 2H), 1.76-1.73 (m, 2H), 1.57-1.48 (m, \n2H), 1.34-1.31 (m, 6H), 1.19-1.12 (m, 22H), 0.78 (t,  J = 6.5 Hz, 3H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 178.2 (C-12), 158.9 (C-9), 158.9 (C-5), 139.2 (C-1), \n138.7(C-4), 135.2 (C-3), 135.1 (C-6 ), 133.0 (C-7), 132.6 (C-2), 122.8 (C-8), 83.5 (C-10), \n78.9 (C-13), 37.2 (C-26), 37.0, 36.2, 34.0, 33.8, 33.5, 33.4, 33.2, 32.8, 32.5, 31.2, 30.3, 29.7, 27.0 (C-11), 25.8 (C-27), 18.5 (C-28) ppm. \nESI-MS : m/z (%) = 558 (M\n+). \n \nOOHO\nCl\nN12\n3\n4\n56\n7910\n1112\n138\n14O15 19 17\n18 201621\n2223\n24 2625\n282712\n3\n4\n56\n7910\n1112\n138\n1415 19 17\n18 201621\n2223\n24 2625\n2827\n \n \nGeneral procedure for N-alkylation and dimerization of Isopropyl 2-(4-((4-\nclorophenyl)hydroxyimino)ethyl ) henoxy) -2-methylpropanoate \nIsopropyl 2-(4-((4-clorophenyl)hydroxyi mino)ethyl)phenoxy)-2-methylpropanoate \n(2.2 equiv) was added to a stirred suspension of  NaH (2.2 equiv) in DMF (5 mL/mmol) at 0 \n\u00b0C. After 30 minutes alkyl halide (1 equiv)  dissolved in DMF was added. The reaction \nmixture was stirred at ambien t temperature for 6\u201324 h. The he terogeneous reaction mixture \nwas quenched with NH 4Cl (sat. aq), diluted with EtOAc and the solution was washed with \nwater. The aqueous solution was extracted wi th EtOAc (3x 50 mL). The combined organic \nextract was washed with H 2O, brine and dried over anhydrous Na 2SO 4 and rotary evaporated. \nThe crude compound was purified by flash column  chromatography using ethyl acetate and \ncyclohexane mixtures.  \n \n Isopropyl 2,2'-(4,4'-(1,14-bis(4-chloro phenyl)-3,12-dioxa-2,13-diazatetradeca-1,13-\ndiene-1,14-diyl)bis(4,1-phenylene))bis( oxy)bis(2-methylpropanoate) (BSc3981) \n \nReactants:  0.100 g (0.26 mmol) 10, 0.011 g NaH (0.26 mmol), 0.033 g 1,8-dibromooctane \n(0.12 mmol), 1 mL DMF. Yield:  0.064 g, 62%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.31-7.18 (m, 8H), 6.77-6.71 (m, 8H), 5.08-4.97 (m, 2H), \n4.07 (m, 4H, H-15, H-22), 1.59-1.52 (m , 16H), 1.24-1.12 (m, 20H) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 172.5 (C-12), 155.7 (C-9), 153.8 (C-5), 134.0 (C-1), 132.0 \n(C-4), 130.8 (C-3), 129.8 (C-6), 129.4 (C-7 ), 128.7 (C-2), 117.3, 116.6, 116.3 (C-8), 78.2, \n78.1, (C-10), 73.8, 73.7 (C-15, C-22), 68.1, 68.3 (C-13), 28.7, 28.3, 28.1, 24.9, 24.5, 24.1, 20.5 (C-14) ppm. ESI-MS : m/z (%) = 862 (M\n+).  \n 12112\n3\n4\n56\n7910\n1112\n13\n814\n15 19 17\n18 20 1621\n22NCl OOO\nOON\nCl O\nOO\n \n \nIsopropyl 2,2'-(4,4'-(1,16-bis(4-chloro phenyl)-3,14-dioxa-2,15-diazahexadeca-1,15-\ndiene-1,16-diyl)bis(4,1-phenylene)) bis(oxy)bis(2-methylpropanoate)  (BSc3982)  \n \nReactants:  0.100 g (0.26 mmol) 10, 0.011 g NaH (0.26 mmol), 0.036 g 1,10-dibromodecane \n(0.12 mmol), 1 mL DMF. Yield:  0.056 g, 52%, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.39-7.27 (m, 8H), 6.89-6.68 (m, 8H), 5.03-4.98 (m, 2H), \n4.16-4.14 (m, 4H, H-15, H-24), 1.70-1.56 (m , 16H), 1.26-1.21 (m, 24H) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.4 (C-12), 157.8 (C-9), 154.9 (C-5), 134.0 (C-1), 132.0 \n(C-4), 131.6 (C-3), 129.8 (C-6 ), 129.6 (C-7), 128.7 (C-2),  118.4, 116.6 (C-8), 78.4 (C-10), \n73.8, 73.7 (C-15, C-24), 68.3 (C-13), 29.7, 29.1, 28.8, 26.4, 25.9, 25.5, 24.5, 24.1, 20.4 \n(C-14) ppm. ESI-MS : m/z (%) = 912 (M+Na). \n \nNCl OOO\nOON\nCl O\nOO12\n3\n4\n56\n7910\n1112\n13\n814\n15 19 17\n18 20 1621\n2223\n24\n \n \nIsopropyl 2,2'-(4,4'-(1,18-bis(4-chlorophe nyl)-3,16-dioxa-2,17-diazao ctadeca-1,17-diene-\n1,18-diyl)bis(4,1-phenylene))bis (oxy)bis(2-methylpropanoate)  (BSc3983) \n \nReactants:  0.100 g (0.26 mmol) 10, 0.011 g NaH (0.26 mmol), 0.040 g \n1,12-dibromododecane (0.12 mmol), 1 mL DMF. Yield:  0.0 g, %, colourless oil.  \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.46-7.24 (m, 8H), 6.82-6.79 (m, 8H), 5.20-5.01 (m, 2H), \n4.11-4.04 (m, 4H, H-15, H-26), 1.62-1.52 (m , 16H), 1.19-1.12 (m, 28H) ppm. \n13C NMR (75 MHz, CDCl 3): \uf064 = 174.5 (C-12), 156.6 (C-9), 153.9 (C-5), 132.8 (C-1), 132.0 \n(C-4), 131.2 (C-3), 130.8 (C-6), 128.9, (C-7 ), 128.7 (C-2), 118.4, 119.6, 118.3 (C-8), 77.6 \n(C-10), 74.8, 74.8 (C-15, C-26), 69.1 (C-13), 29.6, 29.4, 29.1, 28.8, 26.4, 25.9, 25.5, 25.3, 24.5, 24.1, 21.5 (C-14) ppm. ESI-MS : m/z (%) = 940 (M+Na).  \n 122 NCl OOO\nOON\nCl O\nOO12\n3\n4\n56\n7910\n1112\n13\n814\n15 19 17\n18 20 1621\n2223\n24 2625\n \n \nGeneral procedure for isopropyl ester cleavage of dimeric O-substituted isopropyl 2-(4-\n((4 chlorophenyl)(hydroxyimino)meth yl)phenoxy)-2-methylpropanoates \nA solution of isopropyl ester (1 equiv) in 2N NaOH (20 equiv) in methanol (5 mL/mmol) \nwas stirred at 70 \u00b0C overnight.  After completion of reaction (TLC), solvent was evaporated \nin vacuo to get crude product. The heterogeneous reaction mixture diluted with EtOAc, \nacified with 2N HCl (pH ~ 4) and the solution was washed with water. The aqueous solution \nwas extracted with EtOAc (3x 50 mL). The combined organic extract was washed with H 2O, \nbrine and dried over anhydrous Na 2SO 4 and rotary evaporated. If necessary, the crude \ncompound was purified by flash column chroma tography using ethyl acetate and hexane \nmixtures.  \n \n2,2'-(4,4'-(1,18-Bis(4-chlorophenyl)-3,16- dioxa-2,17-diazaoctadec a-1,17-diene-1,18-\ndiyl)bis(4,1-phenylene))bis(oxy)bis(2 -methylpropanoic acid) (18a, BSc3941) \n \nReactants:  0.050 g (0.06 mmol) BSc3981, 0.09 mL 2N NaOH (1.2 mmol), 1 mL MeOH. \nYield:  0.043 g, 92%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.29-7.16 (m, 8H), 6.82-6.73 (m, 8H), 4.68-4.01 (m, 4H, \nH-13, H-20), 1.57-1.50 (m, 16H), 1.24-1.67 (m, 8H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 178.2 (C-12), 158.8 (C-9),  158.4 (C-5), 137.3, 136.3 \n(C-1), 133.7, 133.7 (C-4), 132.9, 132.5 (C-3), 131.6, 131.1 (C -6), 130.5, 130.3 (C-7), 130.0, \n129.9 (C-2), 119.9, 119.3 (C-8), 80.8 (C-10) , 76.3, 76.2 (C-13, C-20), 31.3, 30.9, 30.7, 30.7, \n27.5, 26.8, 26.7 (C-11) ppm.  ESI-MS : m/z (%) = 777 (M\n+). \n \n12\n3\n4\n56\n7910\n1112\n138\n1415 19 17\n18 20 16NCl OOHO\nOON\nCl O\nOOH\n \n \n2,2'-(4,4'-(1,16-Bis(4-chlorophenyl)-3,14- dioxa-2,15-diazahexadeca-1,15-diene-1,16-\ndiyl)bis(4,1-phenylene))bis(oxy)bis(2-me thylpropanoic acid) (18b, BSc3942) \nReactants:  0.053 g (0.06 mmol) BSc3982, 0.09 mL 2N NaOH (1.2 mmol), 1 mL MeOH. \nYield:  0.047 g, 88%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.31-7.18 (m, 8H), 6.87-6.74 (m, 8H), 4.07-4.03 (m, 4H, \nH-13, H-22), 1.60-1.51 (m, 16H), 1.27-1.20 (m, 12H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 178.2 (C-12), 158.4 (C-9), 157.7, 157.0 (C-5), 137.3, \n136.8 (C-1), 133.8, 133.7 (C-4),  132.9, 132.5 (C-3), 131.6, 1 31.1 (C-6), 130.4, 130.3 (C-7), \n130.0, 129.9 (C-2), 119.9, 119.4 (C-8), 80.8, 80.8 (C-10), 76.4, 76.3 (C-13, C-22), 31.3, 31.1, 31.0, 30.9, 30.7, 30.7, 27.6, 26.8, 26.7 (C-11) ppm.   \n 123ESI-MS : m/z (%) = 806 (M+). \n222112\n3\n4\n56\n7910\n1112\n138\n1415 19 17\n18 20 16NCl OOHO\nOON\nCl O\nOOH\n \n \n2,2'-(4,4'-(1,18-Bis(4-chlorophenyl)-3,16- dioxa-2,17-diazaoctadec a-1,17-diene-1,18-\ndiyl)bis(4,1-phenylene))bis(oxy)bis(2-me thylpropanoic acid) (18c, BSc3943) \n \nReactants:  0.055 g (0.06 mmol) BSc3983, 0.09 mL 2N NaOH (1.2 mmol), 1 mL MeOH. \nYield:  0.045 g, 88%, colourless oil.  \n1H NMR (500 MHz, CDCl 3): \uf064 = 7.39-7.18 (m, 8H), 6.80-6.69 (m, 8H), 4.08-4.04 (m, 4H, \nH-13, H-24), 1.58-1.46 (m, 16H), 1.20-1.14 (m, 16H) ppm. \n13C NMR (125 MHz, CDCl 3): \uf064 = 178.4 (C-12). 155.7, 155.2 (C-9), 154.2, 154.2 (C-5), \n134.6, 133.7 (C-1), 131.2, 131.0 (C-4), 129.9, 129.9 (C-3), 129.0, 128.5 (C-6), 127.9, 127.7 \n(C-7), 127.5, 127.4 (C-2), 116.9, 116.5 (C-8), 78.4 (C-10), 73.9, 73.8 (C-13, C-24), 32.4, \n32.1, 28.8, 28.7, 28.2, 27.7, 27.1, 25.0, 24.4, 24.3, 20.5 (C-11) ppm.  ESI-MS : m/z (%) = 850 (M\n+). \n \nNCl OOHO\nOON\nCl O\nOOH12\n3\n4\n56\n7910\n1112\n8\n2423\n2221 13\n1415 19 17\n18 20 16\n \nIsopropyl 2-(4-((4-chlorophenyl)(2-(2,4-di nitrophenyl)hydrazono)methyl)phenoxy)-2-\nmethylpropanoate  (BSc3899)  \nTo a solution of 2,4-Dinitrophenyl)hydrazine (0.160 g, 0.82 mmol) and conc. H 2SO 4 \n(0.1 mmol) in methanol (8 mL) a solution of fenofibrat e (0.200 g, 0.55 mmol) in methanol \n(5 mL) was added dropewise. The reaction mi xture was stirred at 50 \u00b0C for 2 h. The \nprecipitate was filtered, washed with cold methanol, H 2O and KHCO 3 (3%) and dried in \nvacuo to yield the title compound.  \nYield:  0.205 g, 70% as a red solid  \n1H NMR (300 MHz, CDCl 3): \uf064 = 9.07 (d, J = 2.6 Hz, 1H, H-19), 8.16 (d, J = 9.6 Hz, 1H, \nH-17), 8.36 (d, J = 9.6, 1H, H-16), 7.66-7.51 (m, 2H, H-3) , 7.40-7.20 (m, 2H, H-7), 7.11 (d, \nJ = 8.8 Hz, 2H, H-2), 6.855 (d, J = 9.0 Hz, 2H, H-8), 5.14-5.05 (m, 1H, H-13), 1.73-1.53 (m, \n6H, H-11), 1.31-1.18 (m, 6H, H-13) ppm.  \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.3 (C-12), 157.4 (C-9), 155.6 (C-5), 145.2 (C-15), \n138.8 (C-18), 136.6 (C-1), 131.0 (C-17), 130.8 (C-4 ), 130.6 (C-3), 129.8 (C -7), 128.9 (C-2), \n129.0 (C-20), 124.5 (C-6), 123.4 (C-19), 116.6 (C-16), 114.5 (C-8), 79.4 (C-10), 69.4 \n(C-13), 25.4 (C-11), 21.5 (C-14) ppm.  MS (ESI):  m/z = 539 (M\n+). \n  \n 124 OOO\nCl\nNNH\nNO2\nNO212\n3\n4\n5678\n9 10\n1112\n13\n15\n16\n17\n181914\n \n \n2-(4-((4-chlorophenyl)(2-(2,4-dinitrophenyl)hydrazono)methyl)phenoxy)-2-\nmethylpropanoic acid (19, BSc3898) \nA solution of BSc3899 (0.141 g, 0.26 mmol) in 2 N NaOH (2.6 mmol) in methanol (5 mL) \nwas stirred at 70 \u00b0C overnight.  After completion of reaction (TLC), solvent was evaporated \nin vacuo to get crude product. The heterogeneous reaction mixture diluted with EtOAc, \nacified with 2N HCl (pH ~ 4) and the solution was washed with water. The aqueous solution \nwas extracted with EtOAc (3x 50 mL). The combined organic extract was washed with H 2O, \nbrine and dried over anhydrous Na 2SO 4 and rotary evaporated vacuo. The crude compound \nwas purified by flash column chromatography (CH 2Cl2\uf02dMeOH, 10:1 ) to yield the title \ncompound.  \nYield:  0.036 g, 28% as a red solid  \n1H-NMR (500 MHz, DMSO): \uf064 = 8.88 (d, J = 3.2 Hz, 1H, H-17), 8.16 (d, J = 9.6 Hz, 1H, \nH-15), 8.36 (d, J = 9.6 Hz, 1H, H-14), 7.66-7.51 (m, 2H, H- 3), 7.40-7.20 (m, 2H, H-7), 7.11 \n(d, J = 8.8 Hz, 2H, H-2), 6.855 (d, J = 9.0 Hz, 2H, H-8), 1.53 (s, 6H, H-11) ppm.  \n13C-NMR (75 MHz, CDCl 3): \uf064 = 175.2 (C-12), 157.4 (C-9), 155.6 (C-5), 144.8 (C-13), \n138.8 (C-16), 136.4 (C-1), 131.0 (C-4), 130.3  (C-3), 130.0 (C-15), 129.6 (C-2), 129.0 \n(C-18), 124.4 (C-6), 123.4 (C -17), 116.6 (C-14), 114.8 (C-8),  79.3 (C-10), 69.4 (C-13), 25.7 \n(C-11) ppm. MS (ESI):  m/z = 497 (M+). \n \nOOHO\nCl\nNNH\nNO2\nNO212\n3\n4\n5678\n9 10\n1112\n13\n15\n161714\n \n \n \n    \n   \n 1255. Figure_SI: Binding mode of sGSMs. \n \n \nC99Lys624\nG\nA\nI\nI\nG\nPen-2 PS-NTFPS-CTFAph-1\nNct\nAsp Asp\nNOOH\nO\nC99Lys624\nG\nA\nI\nI\nG\nC99Lys624\nG\nA\nI\nI\nG\nC99Lys624Lys624\nG\nA\nI\nI\nG\nPen-2 PS-NTFPS-CTFAph-1\nNct\nAspAsp AspAsp\nNOOH\nO\nC99Lys624\nG\nA\nI\nI\nG\nC99Lys624Lys624\nG\nA\nI\nI\nG\n \nFigure_SI:  Binding mode of sGSMs.  \n \nWe compared the structures of highly active compounds to rationalize the binding mode of sGSMs. Apparently, a carboxylic acid moiety is essential for potency. We assume, that this functionality interacts with a lysine (maybe lys624) of the substrate APP which is located next to the membrane interface. Thereby, the lipophilic substituents of the sGSMs serve as membrane anchors. \n \n. \n \n \n \n  \n 126  \n 1273.4 Untersuchung der Bindungstasch e von NSAID-abgeleiteten \n\uf067-Sekretase-Modulatoren durch  Derivatisierung der Seit enkette und Austausch der \nCarbons\u00e4urefunktion durch S\u00e4ureisostere. \n \nDer Inhalt dieses Kapitels wird im Januar 2010 bei J.Med.Chem  zur Ver\u00f6ffentlichung \neingereicht: Es handelt sich hi er um ein vorl\u00e4ufiges Manuskript, aufgrund der fehlenden \nexperimentellen Daten der Koautoren. Nicole H\u00f6ttecke, Andrea Zall, Daniel Kies er, Eva Fuchs, Katrin Schneider, Dirk \nSteinbacher, Robert Schubenel, Karlheinz Baumann, Boris Schmidt \u201cNSAID-derived \n\uf067-secretase modulators: PartIV: The isosteric replacement of a carboxylic acid on a carbazole \nscaffold.\u201d \n Durch eine Struktur-Aktivit\u00e4ts-Analyse von 16 synthetisierten Carbazol-Derivaten wurde die \nBedeutung der Carbons\u00e4urefunktion f\u00fcr die \uf067-Sekretase-Modulation untersucht. \n \nNO\nOHO\noctylNO\nOHO\noctyl\nNO\nS\noctylO\nOOH\nNOH\noctyl\nNO\noctylBr\nNO\noctylOHNO\nORO\noctylNO\nP\noctylOEtOEt\nON\noctylO\nOR\nNO\noctylOHCF3N\noctylOHBSc3030\n \nAbb. 22:  \u00dcbersicht der Carbazol-Derivate zur Untersuchung der Seitenkette. \n \nEine Dimethylierung der Methyl engruppe der Seitenkette zeigte  keine signifikante \u00c4nderung \nauf die A \uf062-Sekretion. Bei Kettenverl\u00e4ngerung und Austausch der Carbons\u00e4urefunktion \ndurch eine Sulfons\u00e4ure, konnte eine modulatorische Aktivit\u00e4t beobachtet werden. Diese  \n 128 Aktivit\u00e4t f\u00fchrte bei einer Konzentration von 80 \u00b5M jedoch nur zu einer Erniedrigung der \nA\uf06242-Sekretion auf 70% und somit konnte kein IC 50-Wert ermittelt werden. Die noch \nvorhandene, aber reduzierte modulatorische Ak tivit\u00e4t deutet darauf hin, dass nur ein Linker \nvon 2-3 Atomen zwischen dem arylischen Gr undger\u00fcst und dem anscheinend notwendigen \naziden H-Atom der S\u00e4ure zu einer signifikan ten modulatorischen Aktivit\u00e4t f\u00fchrt. Ein \nk\u00fcrzerer Linker wie im N-Octyl-2-hydroxycarbazol zeigte keine modulatorische Aktivit\u00e4t. \nDer Ersatz der Carbons\u00e4urefunktion durch Derivate mit einem Bromid oder einer \nAlkoholfunktion f\u00fchrte zu keiner modulatorische Aktivit\u00e4t auf die \uf067-Sekretase, was darauf \nhindeutet, dass das azide H-Atom essentiell f\u00fc r die modulatorische Aktivit\u00e4t ist. Durch \nSubstitution der die Alkoholfunktion-tragende n Seitenkette mit einer Methyl- oder \nTrifluormethylgruppe wurden \u00fcberrasche nderweise inverse GSMs erhalten. \nInteressanterweise zeigten sowohl ein Methyl- (IC 50(A\uf06242) = 27 \u00b5M) als auch ein Ethylester \n(IC 50(A\uf06242) = 31 \u00b5M) modulatorische Aktivit\u00e4t auf die A \uf062-Sekretion, bei nur geringer \nPotenzminderung verglichen mit de r freien Carbons\u00e4urefunktion (IC 50(A\uf06242) = 19 \u00b5M). \nDieses l\u00e4sst ein cellul\u00e4res Pr odrug-System vermuten, wobei die aktive Carbons\u00e4urefunktion \nim Gehirn freigesetzt werden k\u00f6nnte. Wir verm uten, dass der Transporter mit einer Esterase \nassoziiert ist, die kurzkettige, unverz weigte Ester hydrolysieren kann, denn die \nmodulatorische Aktivit\u00e4t nimmt mit der L\u00e4nge und dem Grad der Verzweigung des Esters \nab. Ebenso zeigen kurzkettige Ester, die an einer \uf061-verzweigten Seitenkette lokalisiert sind, \nkeine modulatorische Aktivit\u00e4t. \n \nListe der von Nicole H\u00f6ttecke von 2 006-2009 synthetisierten Verbindungen: \nBSc3985 \nBSc3986 BSc4004 BSc4006 BSc4021 BSc4029 BSc4030 BSc4051 BSc4052 BSc4053 BSc4056 BSc4057 BSc4058 BSc4062 BSc4079  \n  \n 129NSAID-derived \uf067-secretase modulators: Part IV: \nThe isosteric replacement of a carboxylic acid on a \ncarbazole scaffold \nNicole H\u00f6tteckea, Andrea Zalla, Daniel Kiesera, Eva C. Fuchsa, Katrin Schneidera, Dirk T. \nSteinbachera, Robert Schubenelb, Karlheinz Baumannb, Boris Schmidt.a* \n \naClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry, Technische Universit\u00e4t \nDarmstadt, Petersenstr. 22, D-64287 Darmstadt, Germany. \nbF. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Preclinical Research CNS, Bldg. \n70/345, CH-4070 Basel, Switzerland. \nE-mail: schmidt_boris@t-online.de   \n \n \n  \n[*] Prof. Dr. Boris Schmidt  \nTel: (+49) 6151-163075 \nFax: (+49) 6151-163278 \nE-Mail: schmidt_boris@t-online.de\n  \n  \n 130 ABSTRACT: Modulation of \uf067-secretase activity holds potential for the treatment of \nAlzheimer\u2019s disease. Most NSAID-derived \uf067-secretase modulators feature a carboxylic acid, \nwhich may impair blood brain barrier perm eation. Therefore the structure activity \nrelationship of 33 carbazoles featuring di verse carboxylic acid isosteres or metabolic \nprecursors therefore was establis hed in a cellular am yloid secretion assay. The activity was \nlinked to either the acidity of the carboxylic acid  isostere or the ability to undergo metabolic \nactivation. \nKEYWORDS: Alzheimer\u2019s disease, \uf067-secretase modulation, carboxy lic acid isosteres, \nCarprofen. \nAlzheimer\u2019s disease (AD) is the most co mmon neurodegenerative disease, it is a \ndevastating illness effecting more than 20 million patients globally. The brain atrophy \nassociated with AD is accompanied by the hallma rk amyloid plaques and fibrillary tangles. \nThe plaques consist of aggr egated oligomeric amyloid- \uf062-peptides (A \uf062) of various lengths \nwherein A \uf06242 is more prone to aggregate than A \uf06240 or A\uf06238.1 These A \uf062-peptides are \ngenerated by sequential processing of the amyloid precursor protein (APP) by \uf062- and \n\uf067-secretase. The \uf067-secretase catalyses the critical st ep in the liberation of these A \uf062 isoforms, \nand is thus a promising target in the prevention of AD. The membrane located \n\uf067-secretase-complex consists of four proteins: Nicastrin (Nct), Aph-1, Pen-2 and presenilin \n(PS1 or PS2).2 PS1 is a 9 transmembrane domain (TMD ) protein which bears two catalytic \naspartates Asp257 and Asp385 in the transmembrane domains 6 and 7.3-5 These catalytic \ndomains cleave APP within the membrane, impl icating an unusual re gulated intramembrane \nproteolysis (RIP) in the lipophilic membrane.6-8  \nSeveral inhibitors for this pro cess have been reported recently.7 However, most of these \ninhibit the cleavage of other \uf067-secretase substrates such as Notch, which is responsible for  \n 131cell proliferation. Some NSAIDs (non-steroida l anti inflammatory drugs) show a partial \ninhibition, the so called modulation of the \uf067-secretase cleavage, which is characterised by \nincreased A \uf06238 secretion and decreased A \uf06242 secretion.9 Photoaffinity labelling experiments \nwith a R-flurbiprofen derivative indicate a binding site for NSAID-derived \uf067-secretase \nmodulators directly on the substrat e APP close to the GxxxG region,10-11 which is \nresponsible for substrate dimerizati on and may control the processing by \uf067-secretase. We \nsuggested an interaction of th e NSAID\u2019s carboxylic acid with  a basic amino acid, perhaps \nlysine624, on APP, which is located in vicinity  of the GxxxG motif, at the membrane \ninterface.12  \nWe recently reported on N-alkylated carprofen-d erivatives with lipophi lic side chains and \nN-sulfonylated or N-alkylated carbazolyloxyacetic aci ds to be substrate targeting \uf067-secretase \nmodulators (sGSMs).13-14 The N-alkyl chain strongly enhances the modulator activity; this \nmay be partially due to modulat or orientation via a membrane anchoring effect. (Scheme 1) \nScheme 1. Carprofen ( 1) is the sGSM-lead structure of 2 and 3. \nNO\nOH\nCl\nNO\noctylO\nOH\nN\nHOHO\nCl\n1 Carprofen 3 BSc3030 2 BSc3039octyl\n \nHerein we report the replacement of the carboxylic acid of sGSMs  2 (IC 50 (A\uf06238) = not \ndetermined, IC 50 (A\uf06240) > 40 \u00b5M, IC 50 (A\uf06242) = 6.9 \u00b5M) and  3 (EC 50 (A\uf06238) = 24 \u00b5M, \nIC50 (A\uf06240) > 40 \u00b5M, IC 50 (A\uf06242) = 19 \u00b5M) by several carboxylic acid isosteres. This \nreplacement aimed to reduce the topological polar surface area and the amphiphilicity of the \nlipophilic acids. This was expected to improve potential blood brain barrier (BBB) \npermeation.13-14 Carboxylic acid isosteres require rela ted chemical environments as the \ncarboxylic acid for target bindin g and thus some of them were expected to display \n\uf067-secretase modulatory effects. We  chose several well establis hed carboxylic acid isosteres  \n 132 such as tetrazole, sulfonic acid, sulfone am ides and tetronates, alcohols or amino \nfunctionalities to obtain either straight or inverse \uf067-secretase modulators. In addition, we \nexplored the available space at the modulator binding site by th e introduction of sterically \ndemanding groups. The synthesis was carried out according to scheme 2. (explicit synthesis: \nsee supporting information) \n \nScheme 2.a General synthesis of carboxylic isosteres on a carbazole backbone. \nN\nHO\nOH\nCl\nNO\nOBn\nCl\noctyla, b\n14NO\nOR\nCl\noctyl\n6\nN\nHOH\nNOH\noctyl\n7 8c\nNR1\noctyl11R2\nR35\n9\n10\n1312\n \naReagents: (a) benzylbromide, K 2CO 3, acetone, rf; (b) octylbromide, NaH, THF, 0\u00b0C-rt; (c) \noctylbromide, NaH, THF, 0\u00b0C-rt. \n \nWe kept the length of the supposed lipid an chor at 8 carbon atoms, making a compromise \nbetween lipophilicity and activity although this anc hor is not the most active sGSM. The side \nchain of 3 (BSc3030) bears a methylene group which is an important structur al feature as an \nadditional methylene group diminished activit y. This effect was observed for the carboxylic \nacid 10a and to a lesser extent for the sulfonic acid 10b. Surprisingly, the dimethylation \n(11a) of the unsubstituted methylene diminish ed activity although moderately potent \n\uf067-secretase activity modulating fenofibrat e-derivatives have been described.12 However, the \nreplacement by a salicylic acid ( 10c) displayed a modulator y effect with an \nIC50 (A\uf06242) = 38 \u00b5M. The salicylic acid lock s the extended carbon chain in a Z-configuration \nresulting in sufficiently close pos itioning of the carboxylic acid.   \n 133Equipotent modulatory activity as 10c was achieved by a tetronic- ( 10d) and tetramic acid \n(10e), which are rarely employed as carboxylic  acid isosteres. Only  a sterically more \ndemanding tetronate ( 10f) turned into a full inhibitor. (Scheme 3) \nScheme 3. a Synthesis of the higher substituted tetronate 10f.\uf020\nOO\nNH2OO\nNH\nO\nOOO\nN\nO\nOBr\nO\nNO\nNO\nOOO\nO\noctylNO\noctylNO\nOOa b\nc d14 15 16\n17 10f  \naReagents: (a) piperonal, Na(AcO) 3BH, DCE, rt, 5h; (b) bromoacetyl bromide, TEA, \nDCM, rt, 2,5h; (c) 8, K2CO 3, acetone, rf; (d) KO tBu, THF, rt.  \n \nOn the contrary, established isosteres like the tetrazoles ( 10h) or the  2,2,2-trifluoroethanol \n(9a) did not exert \uf067-secretase modulatory activity until a co ncentration of 20 \u00b5M or turned \nout to be inverse GS M. The linear alcohol 10g and bromide 9b were inactive. However, the \n\uf061-branched alcohol 6a acted as an inverse GSM. \nThe amines 10i, 11b-d  did not show modulatory ac tivity. Whereas the nitrile 9c displayed \ninverse modulation and the acidic sulfonimide 6b showed straight i nhibition. These results \nindicate the necessity of an acidic proton fo r modulatory activity on this scaffold. This \nconfirmed our hypothesis that modulators inte ract with a basic amine on the substrate, \nbecause all sGSMs of this series e xhibit a pKa value in the range 2-5.  \n \n \n  \n 134 Scheme 4.  Synthesis of C3-substituted carbazole 13a. \nN\nHOH\nN\noctylO\nOO\nN\noctylO\nOOO\nN\noctylO\nOO7a\nb\n9d 10l\n19c\ne f\nN\noctylO\nOHO\n13aN\noctylO\nOOdOO O\nOO\nOH\n18  aReagents: (a) octyliodide, NaH, THF, DMF, -70\u00b0C-rt, 12h; (b) bromoacetic acid \nmethylester, K 2CO 3, acetone, rf. 12h; (c) N,N.diisopropylformamide, POCl 3, H 2O, DCE, \n80\u00b0C, 2-5d; (d) phosphonium salt, NaOEt, EtOH, 80\u00b0C, 20h; (e) Pd/C, H 2, EtOH, HCl, rt, \n24h; (f) KOH, MeOH, rt/64\u00b0C, 2d. \n \nAdditional substituents in the C-3 position of 3 revealed a tolerance for small functional \ngroups like an aldehyde ( 11e), but an additional acetic acid side chain ( 13a) diminished \nactivity. (Scheme 4) These findings suggest a defined binding pocket for the modulators. \n \nTable 1.  Activity report of N-octylcarprofen and N-octylcarbazole carboxylic acid isosteres. \n[%] Entry Compd. Compd. \nCode R1 R2 R3 \nA\u03b238 A\u03b240 A\u03b242 \n1 5a BSc4053  H Cl XX XX 50a \n2 6a BSc4021 OH H Cl XX XX 21a \n3 6b BSc4056 H\nN\nOSO\n2 H Cl XX XX 32 \n4 8 BSc4029 -OH H H XX XX >80 \n5 9a BSc4062 OCF3\nOH H H XX XX 12a \n6 9b BSc4004 OBr H H >40 >40 >40 \n7 9c BSc3891 ON H H 74b 105b 252b \n8 10a BSc4005 \nO OHO\n H H >80 >80 >80 \n9 10b BSc4079 OSOHO\nO H H XX XX >80  \n 13510 10c BSc4003 O\nO HO  H H 23a >80 38 \n11 10d BSc3972 OO\nOHO\n H H 21a >80 37 \n12 10e BSc3990 ONH\nOHO\n H H 8a 72 28 \n13 10f BSc3966 NHO\nO\nOOO\n H H 31 32 24 \n14 10g BSc4030 OOH H H XX XX >40 \n15 10h BSc3892 O\nHN NNN\n H H 165b 102b 113b \n16 10i BSc4019 ONH2 H H >80 >80 >80 \n17 11a BSc3985 OOH\nO H H >40 >40 >40 \n18 11b BSc4122 ON H H XX XX >10 \n19 11c BSc4124 ONCO H H XX XX >80 \n20 11d BSc4123 ONO\nCF3\nOCF3\n H H XX XX >80 \n21 11e BSc4041 OOH\nO O H XX XX 32 \n22 13a BSc4050 OOH\nO OH\nO H XX XX >80 \n23 13b BSc4048 OOH OH H XX XX 80 \n[a] EC 50 values are displayed. \n[b] Tested at 20 \u00b5M. \n \nThe methyl ester 9d displayed unexpected modul atory activity with an \nIC50 (A\uf06242) = 27 \u00b5M, a marginal loss in activity compared to the carboxylic acid 3 with an \nIC50 for A\uf06242 of 19 \u00b5M. Further investig ation confirmed the tolerance of short linear esters. \nHowever, the activity decreased with increasi ng length of the ester. The ethyl ester ( 11f) \nshowed modulatory activity (IC 50 (A\uf06242) = 31 \u00b5M), but iso-propyl ( 11g) or iso-butyl ester \n(10j) did not show modulatory activity. On the contrary, the tertiary butyl ester 9e acted as \nan inverse GSM and increased A \uf06242 levels at EC 50 = 19 \u00b5M. Equally the phosphoric diethyl \nester showed inverse modul atory effects with an EC 50 (A\uf06242) = 13 \u00b5M. These findings  \n 136 suggest metabolic activation, e.g. an esterase  releasing the active carboxylic acid. This \nesterase seems to tolerate short linear esters as substrates. This presumption was confirmed \nby investigation of the \uf061-branched side chain of Carprofen-esters ( 4, 5b, c ) which did not \nshow modulatory activity. Consequently, short \uf061, \uf061\u00b4-linear esters fulfil criteria for a prodrug \nsystem in this cellular assay. This potential prodrug system is still under investigation. \nFinally, an additional aldehyde in the C-3 position ( 10l) of the methyl ester is not tolerated \nand resulted in straight \uf067-secretase inhibition. \nTable 2.  Activity report of N-octylcarbazole and N-octylcarpofen esters. \n[%] \nEntry Compd. Compd. \nCode R1 R2 R3 \nA\u03b238 A\u03b240 A\u03b242 \n1 4 BSc3018 O\nOH Cl XX XX >80 \n2 5b BSc4051 O\nO H Cl XX XX 15a \n3 5c BSc4052 O\nO  H Cl XX XX 21a \n4 9d BSc4028 OO\nO H H XX XX 27 \n5 9e BSc3029 OO\nO  H H XX XX 19a \n6 10j BSc3986 OO\nOH H XX XX >80 \n7 10k BSc4006 \nOPOO\nO H H XX XX 13a \n8 10l BSc4038 OO\nO O H XX XX 89 \n9 11f BSc4057 OO\nO  H H XX XX 31 \n10 11g BSc4058 OO\nO  H H XX XX 49a \n[a] EC 50 values are displayed. \n \nAs none of the acid isosteres displaye d improved potency of the lead acid 3, a closely \nrelated compound ( 20, BSc3040) was selected for further investigations. Se rendipitously, the \nC-9-derivative 20 showed a remarkable BBB permeation in APP swe Tg mice at a single \n10 mg/kg oral dosage suspended in NaCl and ge latine. The plasma and brain concentration  \n 137of the modulator were monitored over a peri od of 5 hours. The brain concentration was \nfound to continuously increase to a plasma/bra in ration of approximately 2:1. (Figure 1) \nHowever, no significant A \uf06242 changes were observed at this timepoint. These unchanged A \uf062 \nlevels were recently linked to the double tr ansgenic mice exhibiting NSAID-resistant PS1 \nmutations.15-16 The remarkable brain permeation reduc es the need for a potential prodrug \nsystem. However, the significan t brain levels of the acid 20 do not imply localisation of the \ncompound at the site required for modulatory activity.  \nBSc3040; brain uptake; mouse C57/BL6\n020004000600080001000012000\n0123456\nTime (hrs)Plasma (ng_ml) and brain (ng_g) \nconcentrationsPlasma\nBraina) b)\nNO\nOH\nCl\nnonyl\n20, BSc3040BSc3040; brain uptake; mouse C57/BL6\n020004000600080001000012000\n0123456\nTime (hrs)Plasma (ng_ml) and brain (ng_g) \nconcentrationsPlasma\nBraina) b)\nNO\nOH\nCl\nnonyl\n20, BSc3040\n \nFigure 1.  BSc3040 ( 20) penetrates the BBB in C57/BLg mice at an oral dosage of 10 mg/kg. \nWe were able to replace the carboxylic acid  by isosteres preservi ng modulatory activity. \nThese finding confirm the necessity of an acidic proton on this class of \uf067-secretase \nmodulators. Most sGSMs are f ound in a pKa-range of 2-5. Th is small pKa-range supports \nour hypothetical interaction with lysine624. The location of this lysine, directly at the \nmembrane interface close to the GxxxG di merization motif, suggests a modulation \nmechanism as an APP dimerization inhibitor, sh ifting the cleavage site to the less toxic A \uf06238. \nThe optimum spacer length between the arylic backbone and carboxylic acid was determined \nto be 2-3 carbon or oxygen atoms. However, in troduction of a rigid aryl spacer allowed an \nelongation of up to 4 atoms. We  identified a potential prodrug sy stem based on short linear \nesters, which complements the remarkab le BBB penetrations of the free acid 20. \n  \n 138 ACKNOWLEDGMENT: We thank the BMBF (B .S., N.H., A.Z. KNDD) for support of \nthis work.  \nSUPPORTING INFORMATION: Synthetic proce dure and spectral data of the tested \ncompounds and method of the in vivo  mouse experiment.  \n \nREFERENCES \n1. Beher, D.; Wrigley, J. D.; Owens, A. P.; Shearman, M. S., Generation of C-\nterminally truncated A \uf062 peptides is dependent on \uf067-secretase activity. J. Neurochem. 2002,  \n82 (3), 563-575. \n2. Wolfe, M. S., The \uf067-secretase complex: membrane-embedded proteolytic ensemble. \nBiochemistry 2006,  45 (26), 7931-7939. \n3. Kaether, C.; Haass, C.; Steiner, H ., Assembly, trafficking and function of \uf067-secretase. \nNeurodegener. Dis. 2006,  3 (4-5), 275-283. \n4. Brunkan, A. L.; Goate, A. M., Presenilin function and \uf067-secretase activity. J. \nNeurochem. 2005,  93 (4), 769-792. \n5. Kimberly, W. T.; Xia, W.; Rahmati, T.; Wolfe, M. S.; Selkoe, D. J., The \nTransmembrane Aspartates in Presenilin 1 and 2 Are Obligatory for \uf067-Secretase Activity and \nAmyloid \uf062-Protein Generation. J. Biol. Chem. 2000,  275 (5), 3173-3178. \n6. Steiner, H.; Fluhrer, R.; Haass, C., Intramembrane proteolysis by \uf067-secretase. J. Biol. \nChem. 2008,  283 (44), 29627-29631. \n7. Baumann, S.; Hoettecke, N.; Narlawar, R.; Schmidt, B., \uf067 -Secretase as a target for \nAD. Med. Chem. Alzheimer's Dis. 2008 , 193-224. \n8. Brown, M. S.; Ye, J.; Rawson, R. B.; Goldstein, J. L., Regulated intramembrane \nproteolysis: a control mechanism c onserved from bacteria to humans. Cell 2000,  100 (4), \n391-398. 9. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S.  A.; Wang, R.; Pietrzik, C. U.; Findlay, K. \nA.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Ka ng, D. E.; Marquez-Sterling, N.; Golde, T. E.; \nKoo, E. H., A subset of NSAIDs lower amyloidogenic A \uf062\n42 independently of \ncyclooxygenase activity. Nature 2001,  414 (6860), 212-216. \n10. Kukar, T. L.; Ladd, T. B.; Bann, M. A.; Fraering, P. C.; Narlawar, R.; Maharvi, G. M.; Healy, B.; Chapman, R.; Welzel, A. T.; Pr ice, R. W.; Moore, B.; Rangachari, V.; \nCusack, B.; Eriksen, J.; Jansen-West, K.; Ve rbeeck, C.; Yager, D.; Eckman, C.; Ye, W.; \nSagi, S.; Cottrell, B. A.; Torpey, J.; Rosenberry , T. L.; Fauq, A.; Wolfe, M. S.; Schmidt, B.; \nWalsh, D. M.; Koo, E. H.; Golde,  T. E., Substrate-targeting \uf067-secretase modulators. Nature \n2008,  453 (7197), 925-929. \n11. Munter, L. M.; Voigt, P.; Harmeier, A.; Kaden, D.; Gottschalk, K. E.; Weise, C.; Pipkorn, R.; Schaefer, M.; Langosch, D.; Mult haup, G., GxxxG motifs within the amyloid \nprecursor protein transmembrane sequence are critical for the etiology of A \uf062\n42. Embo J. \n2007,  26 (6), 1702-1712. \n12. Baumann, S.; Hoettecke, N.; Schubenel, R.; Baumann, K.; Schmidt, B., \nNSAID-derived \uf067-secretase modulators. Part III: Membrane anchoring. Bioorg. Med. Chem. \nLett. 2009,  19 (24), 6986-6990.  \n 13913. Narlawar, R.; Perez Revuelta, B. I.; Baumann, K.; Schubenel, R.; Haass, C.; Steiner, \nH.; Schmidt, B., N-Substituted carbazolyloxyacetic acids  modulate Alzheimer associated \n\uf067\uf02dsecretase. Bioorg. Med. Chem. Lett. 2007,  17 (1), 176-182. \n14. Narlawar, R.; Perez Revuelta, B. I.; Haass,  C.; Steiner, H.; Schmidt, B.; Baumann, \nK., Scaffold of the cyclooxygenase-2 (COX-2)  inhibitor carprofen provides Alzheimer \n\uf067-secretase modulators. J. Med. Chem. 2006,  49 (26), 7588-7591. \n15. Czirr, E.; Leuchtenberger, S.; Dorner-Cio ssek, C.; Schneider, A.; Jucker, M.; Koo, E. \nH.; Pietrzik, C. U.; Baumann, K.; Weggen, S., Insensitivity to A \uf06242-lowering nonsteroidal \nanti-inflammatory drugs and \uf067-secretase inhibitors is comm on among aggressive presenilin-1 \nmutations. J. Biol. Chem. 2007,  282 (34), 24504-24513. \n16. Page, R. M.; Baumann, K.; Tomioka, M.; Perez-Revuelta, B. I.; Fukumori, A.; \nJacobsen, H.; Flohr, A.; Luebbers, T.; Ozmen, L. ; Steiner, H.; Haass, C., Generation of A \uf06238 \nand A\uf06242 is independently and differentially a ffected by familial Alzheimer disease-\nassociated presenilin mutations and \uf067-secretase modulation. J. Biol. Chem. 2008,  283 (2), \n677-683.  \n 140  \n 141Supporting Information \n \nNSAID-derived \uf067-secretase modulators: Part IV: \nThe isosteric replacement of a carboxylic acid on a \ncarbazole scaffold \nNicole H\u00f6tteckea, Andrea Zalla, Daniel Kiesera, Eva C. Fuchsa, Katrin \nSchneidera, Dirk T. Steinbachera, Karlheinz Baumannb, Robert Schubenelb, \nBoris Schmidt.a* \naClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry , Technische Universit\u00e4t Darmstadt, Petersenstr. 22, \nD-64287 Darmstadt, Germany, Fax: (+49) 6151-163278, E-mail: schmidt_boris@t-online.de \nbF. Hoffmann-La Roche Ltd., Pharmaceuticals Division, Preclinical Research CNS, Bldg. 70/345, CH-4070 \nBasel, Switzerland \n \n \n Table of Content: \n1. General comments  \n2. Experimental methods and spectral data of carboxylic acid isosteres on a carbazolic \nscaffold. 3. in vivo  mouse experiment. \n  \n 142 1. General comments: \nThin-layer chromatography (TLC) was carried out using aluminium sheets precoated with \nsilica gel 60 F254 (0.2 mm; E. Merck). Chro matographic spots were visualized by UV \nand/or spraying with a metha nolic solution of vanillin/H 2SO 4 or aq. KMNO 4 solution \nfollowed by heating. Silica gel chromatography wa s carried out using Me rck silica gel 60 \n(0.063-0.2 mm). Melting Points were determined on a Mettler FP 51 melting point apparatus \nand are uncorrected. The 1H and 13C spectra were recorded on a Bruker AC 300 (300 MHz) \nand AC 500 spectrometer (500 MHz). Chemical shifts are reported as  % values (ppm) and \nadjusted at the central line of th e deuterated solvent (MeOD, CDCl 3). Mass spectrometry was \nperformed on a Bruker-Franzen Esquire LC mass spectrometer (ESI) and a double focused \nMAT 95 (EI).  HPLC analysis was carried out using: an Agile nt 1100 with a reversed phase column (Zorbax \nEclipse XDB-C8; 4.6*150 mm) and a 254 nm detector. The eluent is composed of H\n2O (1% \nTFA) (A) and acetonitrile (B) w ith a gradient: 30 to 100% B within 15 min (Nicole.M). The \npurity is given in area [%]. All reagents and solvents (THF, DMF, CH 2Cl2, ethyl acetate, \nMeOH) were purchased at ABCR,  Acros and Alfa Aesar, TC I, Sigma Aldrich and VWR. \nMethanol abs. was additionally dried over magnesium.  \n \n2. Experimental methods and spectral data of carboxylic acid isosteres on a carbazolic \nscaffold:  \n2.1 General procedure for ether/ester formation: \nTo a suspension of anhydrous K\n2CO 3 (3.0 eq.) in acetone or  DMF was added 2-hydroxy-\nN-octyl-carbazole (BSc4029) or a correspond ing carboxylic acid (BSc3030/BSc3039) (1 eq.) \nand the alkylhalogenide (1.5 eq.). The reaction mixture wa s heated under reflux until the \nreaction was completed. (TLC control) The mixture was cooled to room temperature and filtered. The residue was washed with acetone (3\u00d7). The combined organic extract was evaporated in vacuo and purified by silica gel chromatogr aphy to yield the title compound. \n \n2.2 General procedure for reduction with LiAlH\n4:  \nTo a solution of the corresponding ester (1 eq.) in THF at -78\u00b0C was added LiAlH 4 (2.5 eq.). \nThe reaction mixture was stirred at -78\u00b0C until  the reaction was completed (TLC control) \nand quenched by sequential addition of H 2O (1 mL by usage of 1 g LiAlH 4), 1M NaOH \n(2 mL by usage of 1 g LiAlH 4), H 2O (3 mL by usage of 1 g LiAlH 4). After stirring for \n30 min the mixture was filtered through Celite, concentrated in vacuo  and purified by silica \ngel chromatography to yield the title compound.       \n 143N\nHO\nOO\nNHOH\nNO\nOHO\noctylK2CO3, Br-R\nacetone, rf1) KOtBu, octyl-Br\n    THF, 0\u00b0C-rt\n2) CH 2Cl2/TFA \n    rt\nBSc39852-Hydroxycarbazole 21 \nScheme SI1: Detailed synthesis of Bsc3985  \n \ntert-Butyl 2-(9 H-carbazol-2-yloxy)-2-me thylpropanoate (21) \n9 123 4\n5\n6\n7\n8101112\n1314\n1516\n17\n18NHO\nOO\n \nAccording to general procedure 2.1: 2-Hydroxycarbazole (1.500 g, 8.19 mmol), K 2CO 3 \n(3.395 g, 24.56 mmol),  tert .-butyl-2-bromo-2-methylpropanoate (1.834 mL, 9.83 mmol), \nacetone (20 mL). Yield: 0.395 g (18%), colourless solid. \nHPLC: 8.6 min (95%);  \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.01 (s, 1H, H-9), 7.97 (d,  3J = 7.7 Hz, 1H), 7.90 (d, \n3J = 8.5 Hz, 1H), 7.40-7.30 (m, 2H), 7.24-7.16 (m, 1H), 6.94 (d, 4J = 1.8 Hz, 1H), 6.83 (dd, \n3J = 8.5, 4J = 2.2 Hz, 1H), 1.62 (s, 6H, H-15), 1.46 (s, 9H, C-18). \n13C NMR (75 MHz, CDCl 3): \uf064 = 173.6 (C-16), 154.8 (C-2),140.3 (C-13), 139.7 (C-12), \n124.8 (C-7) 123.3 (C-10), 220.5 (C-4), 119.6 (C-5), 119.5 (C-6), 118.2 (C-11), 112.4 (C-8), \n110.3 (C-3), 100.9 (C-1), 81.5 (C-14), 80.0 (C-17), 27.8 (C-18), 25.5 (C-15). \n \ntert.-Butyl 2-methyl-2-(9-octyl-9 H-carbazol-2-yloxy)propanoate (22) \n9 123 4\n5\n6\n7\n8101112\n1314\n16\n19\n20\n21\n22\n23\n24\n25\n26NO\nOO\n1718\n15\n \nKOtBu (0.043 g, 0.38 mmol) was added to  a stirred solu tion of THF (1  mL) 21(0.050 g, \n0.19 mmol) at 0 \u00b0C. After 30 min octyliodi de (0.067 g, 0.28 mmol) was added and the \nreaction mixture was allowed to stir at rt for 16 h. The heterogeneous reaction mixture was \nquenched by addition of NH 4Cl (sat. aq), extracted with CH 2Cl2 (3x 10 mL). The combined \norganic layers were seque ntially washed with H 2O and brine, dried over MgSO 4, \nconcentrated in vacuo and purified by silica gel chromatography (CH 2Cl2\uf02dhexane, 1:3) to \ngive 0.027 g (27%) of 22 as yellow oil. \nHPLC: 11.1 min (98%) \n1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf064: = 8.02-7.97 (m, 1H, H-5), 7.92 (d, 3J = 8.5 Hz, 1H, \nH-4), 7.43-7.32 (m, 2H, H-6/7), 7.19 (m, 1H, H-8), 6.93 (d,4 J = 2.0 Hz, 1H, H-1), 6.81 \n(dd,3J = 8.5 Hz, 4 J = 2.2 Hz, 1H, H-3), 4.20 (t, 3J = 7.3 Hz, 1H, H-19), 1.84 (pen, \n3J = 7.2 Hz, 2H, H-20), 1.64 (s, 6H, H-15), 1.48 (s, 9H, H-17), 1.43-1.21 (m, 10H, 21-25), \n0.87 (t, J = 6.7 Hz, 3H, H-26). \n13C NMR  (75 MHz, CDCl 3) ppm\uf020\uf064: = 173.6 (C-16), 154.7 (C-2), 141.4 (C-13), 140.7 \n(C-12), 124.6 (C-7), 122.8 (C-10), 120.4 (C-5), 119.6 (C-4), 118.8 (C-6), 117.8 (C-11), \n111.6 (C-8), 108.4 (C-3), 99.4 (C -1), 81.5 (C-14), 80.0 (C-17), 43.1 (C-19), 31.8 (C-20), \n29.4, 29.2 (CH 2), 28.9 (C-18), 27.9, 27.4 (CH 2), 25.5 (C-15), 22.6 (C-25), 14.0 (C-26).  \nMS (m/z, 70 eV) = 437 (M+), 336, 295, 196.  \n 144 2-Methyl-2-(9-octyl-9 H-carbazol-2-yloxy)propanoic acid (BSc3985) \n9 123 4\n5\n6\n7\n8101112\n1314\n16\n17\n18\n19\n20\n21\n22\n23\n24NO\nOHO\n15\n \nA solution of 22 (0.027 g, 0.06 mmol) in a mixture of  20% trifluoroacetic acid in CH 2Cl2 \n(2 mL) was stirred at ambient temperature for 12h. After completion of reaction (TLC) the \nsolvent was evaporated in vacuo . The obtained crude acid was purified by crystallization \n(CH 2Cl2\uf02dhexane) to give 0.010 g (44%) of BSc3985  as a colourless solid. \nHPLC: 9.4 min (91%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.02 (d, 3J = 7.6 Hz, 1H, H-5), 7.95 (d, 3J = 8.4 Hz, \n1H, H-4), 7.45-7.40 (m, 1H, H-7), 7.35 (d, 3J = 8.2 Hz 1H, H-8), 7.25-7.20 (m, 1H, H-6), \n7.01 (d, 4J = 1.9 Hz, 1H, H-1), 6.87 (dd, 3J = 8.4 Hz, 4J = 2.0 Hz, 1H, H-3), 4.19 (t, \n3J = 7.2 Hz, 2H, H-17), 1.86-1.79 (m, 2H, H-18 ), 1.68 (s, 6H, H-15), 1.39-1.20 (m, 10H, \nH-19/20/21/22/23), 0.87 (t, 3J = 7.0 Hz, 3H, H-24). \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 178.4 (C-16), 153.0 (C-2), 141.2 (C-13), 140.8 \n(C-12), 125.1 (C-7), 122.6 (C -10), 120.6 (C-4), 119.9 (C-5 ), 119.0 (C-11), 118.9 (C-6) 112.8 \n(C-8), 108.6 (C-2), 101.5 (C -1), 80.3 (C-11), 43.1 (C- 17), 31.7 (C-18), 29.3, 29.1, 28.8, 27.3 \n(CH 2), 25.1 (C-17), 22.5 (C-23) 14.3 (C-24).  \nMS (m/z, 70 eV) = 381 (M+), 295, 196. \n  \nN\nHOH NaH, Br-octyl\nTHF, 0\u00b0C-rt NOH\noctyl\nBSc4029NO\noctylK2CO3, Br(CH 2)2Br\nacetone, rf Br\nNO\noctylS\nOO\nOH\nNO\noctylPO\nOEtEtOP(OEt)3\nMW, 160\u00b0CNa2SO3\nH2O/dioxane\nMW, 160\u00b0C\nBSc4079\nBSc4006BSc4004\nNO\noctylOHCF3\nBSc4062K2CO3, BrCH 2CF3OH\nacetone, rf2-Hydroxycarbazole\n \nScheme SI2: Detailed synthesis of BSc4004, BSc400 6, BSc4029, BSc4062 and BSc4079. \n  \n 1452-Hydroxy- N-octylcarbazole (BSc4029) \n9 123 4\n5\n6\n7\n8101112\n13\n14\n15\n16\n17\n18\n19\n20\n21NOH\n \nTo a suspension of NaH (0.820 g, 20.48 mmol) in THF (20 mL) under argon atmosphere was \nadded 2-hydroxycarbazole (1.50 g, 8.19 mmol) at a temperature of  0\u00b0C. After 30 min stirring \noctylbromide (1.500 g, 7.78 mmol) was added and the reaction mixture was allowed to warm \nto rt. After 12h the reaction mixture wa s quenched by drop wise addition of H 2O until gas \nformation ceased. The obtained mixtur e was extracted three times with CH 2Cl2 (30 mL). The \ncombined organic layers were wa shed with brine, dried over MgSO 4, concentrated in vacuo  \nand purified by silica gel column chromatogra phy (gradient starting with cyclohexane to \ncyclohexane: CH 2Cl2 1:2) to give 1.580 g (74%) of BSc4029  as a colourless solid. \nHPLC: 9.2 min (96%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.96 (d, 3J = 8.3 Hz, 1H, H-5), 7.90 (d,3J = 8.3 Hz, \n1H, H-4), 7.36 (m, 1H, H-8), 7.34 (m, 1H, H-7), 7.19 (td, 3J = 7.0 Hz, 4J = 1.2 Hz, 1H, H-6), \n6.82 (d, 4J = 2.2 Hz, 1H, H-1), 6.72 (dd, 3J = 8.3 Hz, 4J = 2.2 Hz, 1H, H-3), 4.81\u20135.43 (b.s., \n1H, OH), 4.18 (t, 3J = 7.5 Hz, 2H, H-14), 1.82 (q, 3J = 7.5 Hz, 2H, H-15), 1.20\u20131.41 (m, \n10H, H-16-H-20), 0.86 (t, 3J = 6.8 Hz, 3H, H-21). \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 154.7 (C-2), 141.9 (C-12) 140.6 (C-13), 124.4 (C-8), \n123.0 (C-10), 121.2 (C-5), 119.4 (C-6), 118.9 (C-7 ), 116.9 (C-11), 108.4 (C -4), 108.0 (C-3), \n95.0 (C-1), 43.1 (C-14), 31.8 (C-15), 29.4, 29.2, 28.8, 27.31, 22.6 (CH 2), 14.1 (C-21). \nMS (m/z, 70 eV, ESI) = 318.4 [M+Na] \n \n2-(2-Bromoethoxy)-9-octyl-9 H-carbazole  (BSc4004) \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23NO\nBr\n \n \nAccording to general procedure 2.1: BSc4029 (0.100 mg, 0.34 mmol), 1,2-dibromoethane \n(3.180 mg, 16.93 mmol), K 2CO 3 (0.141 g, 1.02 mmol), acetone (30 mL). \nYield: 80 mg (51%), colourless solid \nHPLC:  10.8 min (98%) \n1H NMR (300 MHz, CDCl 3): \uf064 = 8.01 (d, 3J = 7.7 Hz, 1H, H-5), 7.97 (d, 3J = 8.5 Hz, 1H, \nH-4), 7.44-7.35 (m, 2H, H-6/7), 7.24-7.19 (m, 1H, H-8), 6.90 (d, 4J = 2.2 Hz, 1H, H-1), 6.85 \n(dd, 3 J = 8.5 Hz, 4J = 2.2 Hz,1H, H-3), 4.43 (t, 3J = 6.3 Hz, 2H, H-14), 4.23 (t, 3J = 7.3 Hz, \n2H, H-16), 3.74-3.69 (m, 2H, H-15), 1.90-1.8 2 (m, 2H, H-17), 1.44-1.23 (m, 10H, CH 2), \n0.89 (t, 3J = 7.0 Hz, 3H, H-23).  \n13C NMR (75 MHz, CDCl 3): \uf064 = 157.3 (C-2), 141.6 (C-13), 140.7 (C-12), 124.6 (C-7), \n122.9 (C-11), 121.1 (C-5), 119.6 (C-4), 118.9 (C-6 ), 117.5 (C-12), 109.5 (C -8), 107.3 (C-3), \n94.8 (C-1), 68.6 (C-22), 43.1 (C-14), 31.8, 29.4, 29.3, 29.2, 28.8, 27.3, 22.6 (CH 2), 14.0 \n(C-23).   \n 146  \n2-(9-Octyl-9H-carbazol-2-yloxy)ethanesulfonic acid  (BSc4079) \n22\n239 123 4\n5\n6\n7\n8101112\n13\n14\n15\n16\n17\n18\n19\n20\n21NO\nSOOOH\n \nTo a solution of BSc4004 (0.020 g, 0.05 mmol) in a mixture of H 2O (0.050 mL) and dioxane \n(0.050 mL) was added Na 2SO 3 (0.032 g, 0.25 mmol) and the resulting mixture was heated at \n160\u00b0C under microwave irradiation until the r eaction was completed. (TLC control) The \nreaction mixture was concentrated in vacuo , the resulting solid dissolved in EtOH abs. and \nconcentrated in vacuo  to give 0.007 g (35%)of BSc 4079 as a colourless solid. \nHPLC: 7.0 min (93%) \n1H NMR  (500 MHz, MeOD) ppm \uf020\uf064: = 7.97-7.94 (m, 1H, H-5), 7.93 (d, 3J = 8.5 Hz, 1H, \nH-4), 7.41 (d, 3J = 8.2 Hz, 1H, H-6), 7.37-7.30 (m, 1H, H-7), 7.18-7.10 (m, 1H, H-8), 6.84 \n(dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, H-3), 7.04 (d, 4J = 2.1 Hz, 1H, H-1), 4.32 (t, 3J = 7.1 Hz, \n2H, H-14), 4.53-4.47 (m, 2H, H-22), 3.38-3.33 (m , 2H, H-23), 1.89-1.81 (m, 2H, H-15), 0.86 \n(m, 10H), 1.32-1.24 (t, 3J = 7.0 Hz, 3H, H-21).  \n13C NMR  (125 MHz, MeOD) ppm \uf020\uf064: = 143.1 (C-2), 142.0 (C-13), 125.3 (C-7), 124.3 \n(C-12), 121.8 (C-5), 120.2 (C-4), 119.8 (C-6) 118.2 (C-10), 109.7 (C-8), 109.1 (C-3), 100.5 \n(C-11), 95.2 (C-1), 65.3 (C-22), 51.9 (C -23), 43.7 (C-14), 32.9, 30.7, 30.3, 29.9, 28.2, 23.6 \n(CH 2), 14.4 (C-21).  \nMS (m/z, 70 eV, ESI) = 402 (M-). \n \nDiethyl 2-(9-octyl-9 H-carbazol-2-yloxy)ethylphosphonate  (BSc4006) \n24\n259 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n1718\n19\n20\n21\n22\n23NO\nPOOO\n \nBSc4004 (0.020 g, 0.05 mmol) was dissolved in triethylphosphite (0.012 g, 0.08 mmol) and \nheated at 160\u00b0C under microwave irradiatio n until the reaction was completed. (TLC \ncontrol) The reaction mixture was concentrated in vacuo  to give 0.025 mg (99%) of \nBSc4006 as colourless oil. HPLC:  9.8 min (97%) \n1H NMR (300 MHz, CDCl 3): \uf064 = 7.99 (d, 3J = 7.7 Hz, 1H, H-5), 7.95 (d, 3J = 8.5 Hz, 1H, \nH-4), 7.42-7.33 (m, 2H, H-6/7), 7.20 (dt, 3J = 7.9 Hz, 4J = 1.7 Hz, 1H, H-8), 6.87 (d, \n4J = 2.1 Hz, 1H, H-1), 6.83 (d, 3J = 8.5 Hz, 4J = 2.1 Hz, 1H, H-3), 4.42-4.33 (m, 2H, H-18), \n4.27-4.12 (m, 6H, H-14/16), 2.39 (td, 2J = 18.7 Hz, 3J = 7.5 Hz, 2H, H-15), 1.85 (quin., \n3J = 7.2 Hz, 2H, H-19), 1.39 (t, 3J = 7.1 Hz, 6H, H-17), 1.31-1.24 (m, 10H, CH 2), 0.87 (t, \n3J = 6.7 Hz, 3H, H-25). \n13C NMR (75 MHz, CDCl 3): \uf064 = 157.5 (C-2), 141.7 (C-13), 140.6 (C-12), 124.4 (C-7), \n122.9 (C-10), 121.1 (C-4), 119.5 (C-)5, 118.9 (C-6), 117.2 (C-11), 108.5 (C-7), 107.5 (C-3) \n94.2 (C-1), 62.6, 61.9, 43.1, 31.8, 29 .4, 29.2, 28.8, 27.7, 27.3, 25.9, 22.6 (CH 2), 16.4 (C-25), \n14.0 (C-17), MS (m/z, 70 eV, EI) = 460 (M+), 361, 196, 165, 137.  \n 1471,1,1-Trifluoro-3-(9-octyl-9 H-carbazol-2-yloxy)propan-2-ol (BSc4062) \n22\n23\n249 123 4\n5\n6\n7\n8101112\n1314\n1516\n17\n18\n19\n20\n21NO\nOHFFF\n \nAccording to general procedure 2.1: BSc4029 (0.030 g, 0.10 mmol), 3-bromo-1,1,1-\ntrifluro-2-propanol (0.032 mL, 0.30 mmol), K 2CO 3 (0.084 mg, 0.060 mmol), acetone (2 mL). \nYield: 0.028 g (69%), colourless solid \nHPLC: 9.8 min (97%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.02 (d, 3J = 7.7 Hz, 1H, H-5), 7.98 (d, 3J = 8.5 Hz, \n1H, H-4), 7.44-7.40 (m, 1H, H-6), 7.37 (d, 3J = 8.1 Hz, 1H, H-8), 7.24-7.21 (m, 1H, H-7), \n6.90 (d, 4J = 2.0 Hz, 1H, H-1), 6.86 (dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, H-3), 4.45 (deca, \n4J = 3.4 Hz, 1H, H-15), 4.39 (dd, 3J = 9.9 Hz, 4J =3.0 Hz, 1H, H-14), 4.30 (dd, 3J = 9.9 Hz, \n4J = 6.4 Hz, 1H, H-14), 4.23 (t, 3J = 7.3 Hz, 2H, H-16), 3.15-2.77 (m, 1H, OH), 1.90-1.82 \n(m, 2H, H-17), 1.45-1.20 (m , 10H, H-18-H-22), 0.88 (t, 3J = 6.8 Hz, 3H, H-23).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 157.0 (C-2), 141.5 (C-13), 140.7 (C-12), 124.8 \n(C-7), 122.8 (C-10), 121.2 (C -4), 119.7 (C-5), 119.0 (C-6), 117.9 (C-1 1), 108.6 (C-8), 107.1 \n(C-3), 94.6 (C-1), 69.4 (C-15), 66.6 (C-14), 43.1 (C-16), 31.8, 29.4, 29.2, 28.8, 27.3, 22.6 (CH\n2), 14.0 (C-23).  \nMS (m/z, 70 eV, EI) = 407 [M+], 308, 294, 196, 167. \n \nNO\noctylOONO\noctylOHLiAlH4\nTHF, -20\u00b0C\nBSc4028BSc4030\nDIBAl\nTHF, rt NO\noctylOO\nBSc3986NOH\noctylK2CO3, BrCH2CO2Me\nacteone, rf\nBSc4029\n \nScheme SI3: Detailed synthesis of BSc3986, BSc4028, BSc4030. \n  \n 148 2-(9-Octyl-9 H-carbazol-2-yloxy)ethanol  (BSc4030) \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n16\n17\n18\n19\n20\n21\n22\n23NO\nOH\n \nAccording to general procedure 2.1:  BSc4028 (0.020 mg, 0.05 mmol), LiAlH 4 (0.012 mg \n(0.25 mmol), THF (2 mL). \nYield : 9 mg (53%), colourless oil \nHPLC:  9.2 min (96%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.00 (d, 3J = 7.7 Hz, 1H, H-5), 7.96 (d, 3J = 8.5 Hz, \n1H, H-4), 7.41-7.37 (m, 1H, H-7), 7.36 (d, 3J = 7.7 Hz, 1H, H-6), 7.22-7.18 (m, 1H, H-8), \n6.90 (d, 4J = 2.1 Hz, 1H, H-1), 6.86 (dd, 3J = 8.5 Hz, 4J = 2.1 Hz, 1H, H-3), 4.25-4.20 (m, \n4H, H-14/16), 4.05-4.02 (m, 2H, H-15), 1.88- 1.82 (m, 2H, H-17), 0.89-0.83 (m, 10H, CH 2), \n1.28 (t, 3J = 7.0 Hz, 3H, H-23).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 157. 9 (C-2), 141.7 (C-13), 140.6 (C-12), 124.5 \n(C-7), 122.9 (C-10), 121.1 (C -4), 119.5 (C-5), 118.9 (C-6), 117.2 (C-1 1), 108.4 (C-8), 107.3 \n(C-3), 94.2 (C-1), 69.7 (C-14), 61.7 (C-15), 43.1 (C-16), 31.9, 29.7, 29.2, 28.8, 27.3, 22.6 (CH\n2), 14.1 (C-23).  \nMS = (m/z, 70 eV, EI): 339 (M+), 295, 240, 196, 167. \n \n2-(9-Octyl-9 H-carbazol-2-yloxy)ethyl isobutyrate  (BSc3986) \n9 123 4\n5\n6\n7\n8101112\n1314\n15\n19\n20\n21\n22\n23\n24\n25\n26NO\nOO\n1617\n18\n \nTo a solution of BSc4028 (0.060 g, 0.17 mmol) in toluene (1.5 mL) was added DIBAl \n(0.407 mL, 0.50 mmol) After stirring for 12h 2M  HCl was added to the reaction mixture \nuntil the salts had dissolved. The obtained so lution was extracted with ethyl acetate (3x \n10 mL). The combined organic layers were wa shed with brine (20 mL), dried over MgSO 4 \nand concentrated in vacuo  to give 0.058 g (96%) of BSc3986  as a yellow solid. \nHPLC:  10.7 min (96%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.00 (d, 3J = 7.6 Hz, 1H, H-5), 7.97 (d, 3J = 8.5 Hz, \n1H, H-4), 7.44-7.33 (m, 2H, H-6/7), 7.20 (dt, 3J = 7.9 Hz, 3J = 1.1 Hz, 1H, H-8), 6.92 (d, \n4J = 2.2 Hz, 1H, H-1), 6.85 (dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, H-3), 4.77 (s, 2H, H-14), 4.22 \n(t, 3J = 7.3, Hz, 1H, H-19), 4.03 (d, 3J = 6.7 Hz, 1H, H-16), 2.02-1.94 ( m, 1H,H-17), \n1.89-1.80 (m, 2H, H-20), 1.42-1.22 (m, 10H, CH 2), 0.90-0.84 (m, 6H, H-18), 0.95-0.90 (m, \n3H, H-26).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 169.5 (C-15), 157.2 (C-2), 141.6 (C-13), 140.7 \n(C-12), 124.6 (C-4), 122.8 (C-10), 121.1 (C-7), 119.6 (C-5), 118.9 (C-6), 117.8 (C-11), \n108.5 (C-8), 106.9 (C-3), 94.9 (C-1), 71.3, 66.1, 43.1, 31.8, 29.4, 29.2, 28.8 (CH 2), 27.7 \n(C-17), 27.3 (C-16), 22.6 (C-18), 14.03 (C-26).  \nMS (m/z, 70 eV) = 409 (M+), 310, 294, 254. 196, 180.  \n 149 \nNLiAlH 4\nTHF, -20\u00b0CO\nO\nCl\noctyl\nBSc3018NOH\nCl\noctyl\nBSc4021  \nScheme SI4: Detailed synthesis of BSc4021. \n \n2-(3-Chloro-9-octyl-9H-carbazo l-7-yl)propan-1-ol (BSc4021) \n1415\n169 123 4\n5\n6\n7\n8101112\n13\n17\n18\n19\n20\n21\n22\n23\n24NOHCl\n \n \nAccording to general procedure 2.2: BSc3018 (0.050 g, 0.10 mmol), LiAlH 4 (0.009 g, \n0.22 mmol), THF (3 mL). Yield:  0.038 g = 97% colourless solid \nHPLC: 9.9 min (97%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.01-8.00 (m, 1H, H-5), 7.99 (d, 3J = 8.0 Hz, 1H, \nH-4), 7.38-7.37 (m, 2H, H-7/8), 7.25 (t, 4J = 1.9 Hz, 1H, H-1), 7.12 (dd, 3J = 8.1 Hz, \n4J = 1.4 Hz, 1H, H-3), 4.70 (s, 1H, OH), 4.26 (t, 3J = 7.3 Hz, 2H, H-17), 3.81 (d, \n3J = 6.8 Hz, 1H, H-15), 3.16 (sex, 3J = 6.9 Hz, 1H, H-14), 1.88-1.81 (pen, 3J = 7.3Hz, 1H, \nH-17), 1.39 (d, J = 7.0 Hz, 3H, H-16), 1.29-1.21 (m, 10H, H-19-23), 0.88 (t, 3J = 6.7 Hz, \n3H, H-24). \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: =  142.3 (C-2), 141.3 (C-10),138.9 (C-11), 125.4 \n(C-5), 124.4 (C-6), 123.8 (C- 13), 120.8 (C-7), 120.7 (C-12) , 110.8 (C-4), 118.5 (C-3), 109.6 \n(C-8), 107.9 (C-1), 68.9 (C-23), 43.1 (C -14), 31.7 (C-15), 19.3, 20.1, 28.9, 27.3, 22.6 (CH 2), \n18.0 (C-24), 14.0 (C-21). MS (m/z, 70 eV) = 371 (M\n+), 340, 272, 240, 209. \n \nNO\noctylOHO\nBSc3030K2CO3, Br-R\nDMF, 65\u00b0C NO\noctylOHO\nBSc4057: R = Et\nBSc4058: R = iPr  \nScheme SI5: Detailed synthesis of BSc4057, BSc4058. \n  \n 150 Ethyl 2-(9-octyl-9 H-carbazol-2-yloxy)acetate  (BSc4057)   \n22\n23\n24\n259 123 4\n5\n6\n7\n8101112\n1314151617\n18\n19\n20\n21NOO\nO\n \nAccording to general procedure 2.1: BSc3030 (0.020 g, 0.06 mmol), ethylbromide \n(0.010 g, 0.09 mmol), K 2CO 3 (0.025 g, 0.18 mmol), DMF (2 mL). \nYield: 0.010 g (44%), colourless solid \nHPLC: 10.2 min (99%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.00 (d, 3J = 7.7 Hz, 1H, H-8), 7.97 (d, 3J = 8.5 Hz, \n1H, H-4), 7.42-7.37 (m, 1H, H-6), 7.35 (d, 3J = 8.0 Hz, 1H, H-5), 7.22-7.17 (m, 1H, H-7), \n6.92 (d, 4J = 2.1 Hz, 1H, H-1), 6.84 (dd, 3J = 8.5 Hz, 4J =2.2 Hz, 1H, H-3), 4.75 (s, 2H, \nH-14), 4.31 (q, 3J = 7.1 Hz, 2H, H-18), 4.22 (t, 3J = 7.3 Hz, 2H, H-16), 1.88-1.80 (m, 2H, \nH-19), 1.32 (m, 13H, H-17/H-20-24), 0.87 (t, 3J = 6.9 Hz, 3H, H-25).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 169.1 (C-15), 157.1 (C-2), 141.6 (C-13), 140.8 \n(C-12) 124.6 (C-4), 122.8 (C -10), 121.1 (C-7), 119.6 (C-5),  118.9 (C-6), 117.8 (C-11), 108.5 \n(C-8), 106.9 (C-3), 95.0 (C-1), 66.3 (C-14), 61.4 (C-16), 43.2 (C-18), 31.8, 29.4, 29.2, 28.8, \n27.3, 22.6 (CH 2), 14.2 (C-17), 14.1 (C-25).  \nMS (m/z, 70 eV, EI) = 381 (M+), 352, 282, 254, 196. \n \nIsopropyl 2-(9-octyl-9 H-carbazol-2-yloxy)acetate  (BSc4058)   \n22\n23\n24\n259 123 4\n5\n6\n7\n8101112\n1314151617\n18\n19\n20\n21NOO\nO\n \nAccording to general procedure 2.1: BSc3030 (0.028 g, 0.08 mmol), isopropylbromide \n(0.015 g, 0.12 mmol), K 2CO 3 (0.033 g, 0.24 mmol), DMF (2 mL). \nYield: 0.024 g (76%), colourless solid \nHPLC: 10.4 min (100%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 8.00 (d, 3J = 7.7 Hz, 1H, H-8), 7.97 (d, 3J = 8.5 Hz, \n1H, H-4), 7.44-7.32 (m, 1H, H-7), 7.36 (d, 3J = 8.0 Hz, 1H, H-6), 7.19-7.21 (m, 1H, H-5), \n6.92 (d, 4J = 2.1 Hz, 1H, H-1), 6.84 (dd, 3J = 8.5 Hz, 4J = 2.2 Hz, 1H, H-3), 5.18 (hept, \n3J = 6.2 Hz, 1H, H-16), 4.72 (s, 2H, H-14) 4.22 (t, 3J = 7.3 Hz, 2H, H-18), 1.90-1.79 (m, 2H, \nH-19), 1.45-1.19 (m, 16H, H-17/H-20-24), 0.87 (t, 3J = 6. 9 Hz, 3H, H-25).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 168.7 (C-15), 157.2 (C-2) 141.6 (C-13), 140.7 \n(C-12) 124.6 (C-4), 122.8 (C-10), 121.0 (C-7 ), 119.6 (C-5), 118.9 (C-6), 117.7 (C-11) \n108.46 (C-8), 107.0 (C-3), 94.9 (C-1), 69.1 (C -16), 66.4 (C-14), 43.1 (C-18), 31.8, 29.4, \n29.2, 28.8, 27.3, 22.6 (CH 2), 21.8 (C-17), 14.0 (C-25).  \nMS (m/z, 70 eV, EI) = 395 (M+), 381,296, 282, 254. \n  \n 151NO\nO\nCl\noctylHCl conc.\nR-OH, rt\nNO\nOR\nCl\noctyl\nBSc3018BSc4051: R = Me\nBSc4052: R = Et  \nScheme SI6: Detailed synthesis of BSc4051, BSc4052. \n \nMethyl-2-(6-chloro-9-octyl- carbazol-2-yl)propanoate  (BSc4051) \n22\n23\n24\n259 123 4\n5\n6\n7\n8101112\n1314\n151617\n18\n19\n20\n21NOO\nCl\n \nTo a solution of BSc3018 (0.025 g, 0.057 mmol) in methanol (2 mL) was added catalytic \namount of HCl conc.. After stirring for 12h at  rt the reaction was ne utralized with 1M NaOH  \nand extracted with CH 2Cl2 (3x 10 mL). The combined or ganic layers were dried over \nMgSO 4, concentrated in vacuo  to give 0.015 g (72%) of BSc4051  as a colourless solid. \nHPLC:  10.8 min (92%) \n1H NMR  (500MHz, CDCl 3) ppm \uf064: = 7.93 (d, 4J = 1.8 Hz, 1H, H-5), 7.89 (d, 3J = 7.9 Hz, \n1H, H-4), 7.31 (dd, 4J = 2.0 Hz, 3J = 6.6 Hz, 1H, H-7), 7.23-7.10 (m, 2H H-3/8), 7.09 (d, \n4J = 1.4 Hz, 1H, H-1), 4.18 (t, 3J = 7.3 Hz, 2H, H-18), 3.84 (q, 3J = 7.2 Hz, 1H, H-14), 3.60 \n(s, 3H, H-17), 1.75 (m, 2H, H-19), 1.53 (d, 3J = 7.2 Hz, 3H, H-15), 1.29-1.16 (m, 10H, CH 2), \n0.79 (t, 3J = 6.8 Hz, 3H, H-25).  \n13C NMR  (500MHz, CDCl 3) ppm \uf064: = 175.6 (C-16), 145.4 (C-13), 141.5 (C-12), 139.5 \n(C-10), 126.0 (C-7), 124.7 (C-6), 124.1 (C-10), 121.5 (C-11), 121.1 (C-5), 120.3 (C-4), \n119.3 (C-3), 110.0 (C-8), 108.1 (C-1), 52.5 (C -17), 46.4 (C-14), 43.6 (C-18), 32.1, 29.7, \n29.5, 29.3, 27.7, 23.0 (CH 2), 19.5 (C-15), 14.4 (C-25).  \nMS (EI): m/z (%) = 401 (M+), 340, 300, 240. \nIR (cm-1): \uf06e\uf020 = 2928 (m), 2857 (s), 1723 (w), 1460 (w), 1266 (s), 895 (s), 746 (m).  \n \nEthyl-2-(6-chloro-9-octyl-carb azol-2-yl)propanoate (BSc4052) \n23\n24\n25\n269 123 4\n5\n6\n7\n8101112\n1314\n151617\n19\n20\n21\n22NOO\nCl18\n \nTo a solution of BSc3018 (0.025 g, 0.057 mmol) in  ethanol (2 mL) was added a catalytic \namount of HCl conc.. After stirring for 12h at rt the reaction was neut ralized with 1M NaOH \nand extracted with CH 2Cl2 (3x 10 mL). The combined organic layers were dried over MgSO 4 \nand concentrated in vacuo  to give 0.011 g (51%) of BSc4052  as a colourless solid. \nHPLC:  11.0 min (91%)  ~  \n 152 1H NMR  (500MHz, CDCl 3) ppm \uf064: = 8.01 (d, 4J = 2.0 Hz, 1H, H-5), 7.97 (d, 3J = 8.0 Hz, \n1H, H-4), 7.38 (dd, 3J = 6.8 Hz, 4J = 1.8 Hz, 1H, H-7), 7.33-7.40 (m, 1H, H-1), 7.29 (d, \n3J = 8.7 Hz, 1H, H-8), 7.18 (dd, J = 38.1 Hz, 4J = 1.4 Hz, 1H, H-3), 4.26 (t, 3J = 7.3 Hz, 2H, \nH-17), 4.21-4.08 (m, 2H, H-19), 3.90 (q, 3J = 7.1 Hz, 1H, H-14), 1.88-1.80 (m, 2H, H-20), \n1.62 (d, 3J = 7.2 Hz, 3H, H-15), 1.38-1.24 (m, 10H, CH 2), 1.21 (t,  3J = 7.0 Hz, 3H, H-18) \n0.79 (t,  3J = 7.0 Hz, 3H, H-26).  \n13C NMR  (500MHz, CDCl 3) ppm \uf064: = 175.1 (C-16), 141.5 (C-13), 140.0 (C-12), 139.5 \n(C-2), 125.9 (C-7), 124.7 (C-6), 124.2 (C- 10), 121.4 (C-11), 121.0 (C -5), 120.3 (C-4), 119.3 \n(C-3), 110.0 (C-8), 108.1 (C-1), 61.2 (C- 17), 46.6 (C-14), 43.6 (C-19), 32.2, 30.1, 29.8, 29.5, \n29.3, 23.0 (CH 2), 19.5 (C-15), 14.5 (C-18), 14.4 (C-26).  \nMS (EI): m/z (%) = 413 (M+), 340, 314, 240, 177. \nIR (cm-1):\uf020\uf06e\uf020= \uf0202928 (s), 1723 (m), 1462 (m), 1274 (s), 895 (s), 750 (s).  \n \nNClOHO\noctylMeSO2NH2, CDI, DBU\nCH2Cl2, rt\nBSc3030NClNHO\noctylSO\nO\nBSc4056  \nScheme SI7: Detailed synthesis of Bsc4056. \n \n2-(6-Chloro-9-octyl-9H-carbazol-2-yl)- N-(methylsulfonyl)propanamide  (BSc4056) \n24\n259 123 4\n5\n6\n7\n8101112\n1314\n151617\n18\n19\n20\n21N\n22\n23O\nNHSOO\nCl\n \n \nTo a solution of BSc3030 (0.035 g, 0.09 mmol) in CH 2Cl2 (2 mL) was added CDI (0.015 g, \n0.09 mmol). After 20 min stirring at rt was added DBU (0.017 g, 0.11 mmol) and methylsulfonamide. After additional 2h s tirring at rt was added Amberlyst\nacidic, stirred for \n10 min and the mixture was filtered. The filtra te was diluted with water, extracted with \nCH 2Cl2, dried over MgSO 4, concentrated in vacuo  and purified by silica gel chromatography \n(CH 2Cl2: acetone; 5: 1) to give 0.038 g (83%) of BSc4056  as a colourless solid. \nHPLC: 9.450 min (94%) \n1H NMR  (500 MHz, Acetone) ppm \uf020\uf064: = 8.11\u20137.98 (m, 2H, H-1, 8), 7.56-7.40 (m, 2H, H-4, \n5), 7.33 (dd, 1H, H-3), 7.12 (dd, 1H, H-7), 4.33 (t, 2H, 3J = 7.2 Hz, H-18), 3.99 (d, 1H, \n3J = 7.0 Hz, H-14), 3.14 (s, 3H, H-17), 1.46 (d, 3H, ,3J = 7.0 Hz, H-15), 1.88-1.66 (m, 3H, \nH-19), 1.35-1.02 (m, 10H, CH 2), 0.83-0.65 (m, 3H, H-25). \n13C NMR  (125 MHz, Acetone) ppm \uf020\uf064: =  171.8 (C-16), 140.3 (C-10), 138.3 (C-13), 125.2 \n(C-1), 123.8 (C-11), 122.4 (C -12), 121.0 (C-6), 120.8 (C-8),  119.2 (C-3), 117.4 (C-2), 108.9 \n(C-4), 106.9 (C-5), 47.3 (C -17), 46.4 (C-14), 42.3 (C -18), 30.7 (C-15), 28.3, 28.1, 27.9), \n26.3, 21.6, 17.3 (CH 2), 13.1 (C-25).  \nMS (m/z, 70 eV, EI) = 462 [M+].  \nIR (KBr, cm-1): \uf06e\uf020 = 3460 (NH), 1687 (C=O), 1468 (S=O). \n  \n 153NClOO\noctylNCl\noctylNaSMe, DMSO\nMW, 170\u00b0C\nBSc3018 BSc4053  \nScheme SI8: Detailed synthesis of BSc4053. \n \n6-Chloro-2-ethyl-9-octyl-9 H-carbazole  (BSc4053) \n9 123 4\n5\n6\n7\n8101112\n131415\n16\n17\n18\n19\n20\n21N\n22\n23Cl\n \nTo a solution of  BSc3018 (0.005 mg, 0.01 mmol) in DM SO (0.200 mL) was added MeSNa \n(0.001 g, 0.02 mmol) and the mixture was heated at 170\u00b0C for 60 min under microwave irradiation. The reaction mixture was quenched with H\n2O (5 mL), extracted with CH 2Cl2 (3x \n5 mL). The combined organic layers we re washed with brine, dried over MgSO 4, concentrated \nin vacuo  and purified by silica gel ch romatography (gradient cyclohexane to CH 2Cl2) to give \n0.003 g (89%) of BSc4053  as a colourless solid. \nHPLC: 11.3 min (99%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.92-7.86 (m, 2H, H-1/8), 7.30-7.00 (m, 4H, \nH-3/4/5/7), 4.16 (t, 2H, H-16) , 2.77 (q, 2H, H-14), 1.77-1.74 (m, 2H, H-17), 1.55-1.53 (m, \n3H, H-15), 1.29-1.17 (m, 10H, H-18/19/20/21/22), 0.80 (t, 3H, H-23).  \n13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: =  124.0 (C-7), 119.3 (C-8), 118.7 (C-3), 118.6 (C-1), \n108.4 (C-4), 106.8 (C-5), 42.1 (C -16), 30.8 (C-14), 28.7 (C-15), 28.3 (C-17), 28.1 (C-18), \n27.9 (C-19), 26.3 (C-20), 21.6 (C- 21), 15.2 (C-22), 13.0 (C-23).  \nMS (m/z, 70 eV, EI) = 341 [M]+.  \nIR (cm-1): \uf06e\uf020 = 1464 (C=O). \n \n \n \n    \n 154  \n 1553.5 Untersuchungen zur Identifizierung d er Bindungsstelle von NSAID-abgeleiteten \n\uf067-Sekretase Modulatoren \n \nDer Inhalt dieses Kapitels wu rde zur Ver\u00f6ffentlichung eingereicht:  \nNicole H\u00f6ttecke, Matthias Gralle, Maria An gela C. Dani, Karlheinz Baumann, Fred \nWouters, Christian Czech, Boris Schmidt Nature Chem. Biol. , eingereicht. \u201cThe Modulation \nof A\uf062 production involves di merization of APP.\u201d \n \nWeitere Untersuchungen bez\u00fcglich der Bindungsstelle unserer \uf067-Sekretase Modulatoren \nwurden vorgenommen. Hierbei  wurde BSc3040, unser potentester \uf067-Sekretase Modulator , \nverwendet (IC 50(A\uf06242) = 3.0 \u00b5M. Die beschriebene drei stufige Synthese (Route 1) konnte \ndurch eine Einstufige (Route 2) ersetzt werden. Hierf\u00fcr wu rde das Carprofen mit einem \n\u00dcberschuss der Base NaH in ein Dianio n \u00fcberf\u00fchrt. Die h\u00f6here Nukleophilie des \nStickstoff-Anions im Vergleich zu dem Saue rstoff-Anion erlaubt es  selektiv nur den \nStickstoff zu substituieren. Diese Synthese  konnte mit 80%iger Ausbeute und >99%iger \nReinheit durchgef\u00fchrt werden, weitere Au freinigungsschritte waren nicht n\u00f6tig. \n \nN\nHO\nOH\nCl\nNO\nOH\nCl\nnonyl4 \u00c4q. NaH\nNonylbromid\nK2CO3\nBnBr\nN\nHO\nOBn\nClNaH\nNonylbromid\nNO\nOBn\nCl\nnonylPd/C\nH280%\n97%\n60%90%Route 2\nRoute 1  \nAbb. 23:  Entwicklung einer Eintopf Synthese f\u00fcr BSc3040. \n \nDa APPwt kein stabiles Dimer bildet, das sich \u00fcber Western Blot-Analyse nachweisen l\u00e4sst, \nwurde eine K624C-APP Mutante von unseren Kooperationspartnern bei Hoffmann-LaRoche \ngeneriert. Diese Mutante kann \u00fcber das eingef \u00fchrte Cystein eine kovalente Disulfidbr\u00fccke \nausbilden und dadurch quantitativ dimerisieren  und durch Western Blot  detektiert werden. \nUm sicher zu stellen, dass die Dimerisierung \u00fcber  die Disulfidbr\u00fccke stattfindet, wurde als \nKontrolle reduktives DTT (Dithiothreitol) zuge ben, welches die entsta ndene Disulfidbr\u00fccke \nwieder zu den zwei Thiolen des Cysteins reduzierte. Durch Zugabe von BSc3040 oder einem \n\uf067-Sekretase-Modulator von Merck (GSM-1 ) konnte jedoch keine Reduktion des  \n 156 Dimerisierungsgrades der K624C-Mutante fe stgestellt werden. Weitere Untersuchungen \nwurden in Kooperation mit der Gruppe von Fred  Wouters in G\u00f6ttingen durchgef\u00fchrt. In dem \netablierten Dimerisationsassay wurde der Dime risierungsgrad des APP- Dimers untersucht. \nEs konnte nach Zugabe von 10 \u00b5M BSc3040 (der 3-fachen IC 50-Konzentration f\u00fcr A \uf06242) \neine Verringerung des APPwt Dimerisierungsgrades  um 40% detektiert werden. Bei der \nK624C-Mutante wurde keine Verringerung des Dimerisierungsgrades festgestellt. Dieses \nResultat stimmt auch mit der zuvor durc hgef\u00fchrten Western Blot-Analyse \u00fcberein . Wir \nspekulieren, dass die kovalente Disulfidbr\u00fccke zu stark ist,  als dass BSc3040 diese brechen \nk\u00f6nnte. BSc3040 scheint als ein Dimerisier ungsinhibitor durch Interaktion mit dem \nMonomer zu agieren, wobei der lipophile A nker und die Carbons\u00e4urefunktion notwendig f\u00fcr \ndie modulatorische Aktivit\u00e4t sind.     \n 157The Modulation of A \uf062 production involves \ndimerization of APP \nNicole H\u00f6tteckea, Matthias Gralleb, Maria Angela C. Danic, Karlheinz Baumannd, Fred \nWoutersc, Christian, Czechd, Boris Schmidt.a* \n \naClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry, Technische Universit\u00e4t \nDarmstadt, Petersenstr. 22, D-64287 Darmstadt, Germany.  \nbDept. Evolutionary Genetics, Max Planck Institute for Evolutionary Anthropology, \nDeutscher Platz 6, D-04103 Leipzig, Germany.  \ncLaboratory for Molecular and Ce llular Systems, Dept. of Ne uro- and Sensory Physiology \nCentre II, Physiology and Pathophysiology, Un iversity of G\u00f6ttingen, Humboldtallee 23, \nD-37073 G\u00f6ttingen, Germany. \n \ndF. Hoffmann-La Roche Ltd., Pharmaceuticals Di vision, Preclinical Research CNS, Bldg. \n70/345, CH-4070 Basel, Switzerland.         \n \n[*] Prof. Dr. Boris Schmidt, Clemens Sch\u00f6pf-Institute of Chemistry and Biochemistry, Technische Universit\u00e4t Darmstadt, Petersenstr. 22, D-64287 Darmstadt, Germany. Tel: (+49) 6151-163075 Fax: (+49) 6151-163278 E-mail: schmidt_boris@t-online.de\n   \n 158 Introduction: \n\uf067-Secretase is a promising target for the treatm ent of Alzheimer\u2019s disease (AD) because this \nintramembrane aspartylprotease catalyzes th e crucial step in the generation of \namyloid-\uf062-peptide (A \uf062) of various lengths (38,  40 or 42 amino acids). A \uf062 aggregates, so \ncalled plaques, are one of the pathological char acteristics of AD. These extracellular plaques \ncontain A \uf06240 and A\uf06242, which are the most pathogenic A \uf062\uf020agents due to their aggregation \nproperties. The shorter A \uf062\uf033\uf038 species is not associated with AD pathology. Several \uf067-secretase \ninhibitors (GSI) were reported, but the majority of them inhibits the cleavage of other \n\uf067-secretase substrates like Notc h, which is crucial for cellula r differentiation. A subset of \nNSAIDs (non-steroidal anti-in flammatory drugs) was repor ted to alter the cleavage \npreferences of the \uf067-secretase to favour the non-toxic species A \uf06238 and reduce A \uf06242 levels.1 \nCompounds with such pr operties are called \uf067-secretase modulators (GSM) and are subjects \nof clinical investigation. Narlawar et al.  reported the potent \uf067-secretase modulator BSc3040, \na derivative of the NSAID Carprofen, which decreases A \uf06242 with an IC 50 = 3.0 \u00b5M in \nH4-cells while increasing A \uf06238 and leaving A \uf06240 levels unchanged, without significant \neffects on cyclooxygenase-1 and -2.2 (Figure 1) \n \nNO\nOH\nN\nHO\nOH\nCarprofennonyl\nBSc3040Cl Cla) b)\n-7 -6 -5 -40100200300400500600\nconc. / log MA\uf062 / %\nNO\nOH\nN\nHO\nOH\nCarprofennonyl\nBSc3040Cl Cla) b)\n-7 -6 -5 -40100200300400500600\nconc. / log MA\uf062 / %\n \nFigure 1:  a) potent GSM based on the NSAID Ca rprofen, b) dose-response-curve of \nBSc3040 in APP overexpressing H4-cells.  \nRecent investigations by Kukar et al on the binding site of NS AID-derived GSMs utilized a \nreconstituted \uf067-secretase assay.\n3 A crosslink experiment with  biotinylated photoprobes of \nR-flurbiprofen labelled amyloid precursor pr otein (APP), APP-C-terminal fragment and A \uf062 \nat the A\uf062 region 29-36 (= 625-632 APP695) indicati ng a binding site on APP. This region \ncontains a GxxxG motif and was identified  as a hinge region responsible for APP \ndimerization, which may influence the orientation of APP and ultimately the A \uf062 secretion.4-5 \nThis GxxxG motif is locate d within the membrane at the amino acids 625-629. Lysine624 is \nlocated directly next to this motif and may be targeted by GSMs equipped with a carboxylic  \n 159acid. This carboxylic acid may interact with the lysine624 by a either hydrogen bond or salt \nformation. The equally essent ial lipophilic chain of BSc3040 is supposed to act as a \nmembrane anchor, which may be necessary to increase the effective concentration of the \ninhibitor at the membrane and thus reduce the fraction of the dimerized form of APP.2,6 \n(Figure 2) \n \n\uf061-secretase\n-----------------------------------------------------\n-----------------------------------------------------R\nD\nGE HQ\nFV\nAK\nEFH\nS\nY VH\nF\nEDVGSN\nAGIIGK\nV\nVTVL\nIVM\nI\nKLMITLV\nKKAPP-NTF\nAPP-CTFCytosolLumen\nDAM\nLK\nG\nV\uf062-secretase\n\uf067-secretaseAN\nOHOCl\uf061-secretase\n-----------------------------------------------------\n-----------------------------------------------------R\nD\nGE HQ\nFV\nAK\nEFH\nS\nY VH\nF\nEDVGSN\nAGIIGK\nV\nVTVL\nIVM\nI\nKLMITLV\nKKAPP-NTF\nAPP-CTFCytosolLumen\nDAM\nLK\nG\nV\uf062-secretase\n\uf067-secretaseA\uf061-secretase\n-----------------------------------------------------\n-----------------------------------------------------R\nD\nGE HQ\nFV\nAK\nEFH\nS\nY VH\nF\nEDVGSN\nAGIIGK\nV\nVTVL\nIVM\nI\nKLMITLV\nKKAPP-NTF\nAPP-CTFCytosolLumen\nDAM\nLK\nG\nV\uf062-secretase\n\uf067-secretaseAN\nOHOCl\n \nFigure 2: schematic: suggested mode of action of  BSc3040. The carboxylic acid interacts \nwith lysine624 while the lipophilic anchor localizes th e inhibitor at the correct position to \ninhibit APP dimerization within the lipid bilayer. \n \nThe precise mechanism of subs trate recognition and cleavage by \uf067-secretase is still subject to \ndebate, the 1:1:1:1 stoichiometry of the active \uf067-secretase complex was recently established \nand there are several lines of evidence for a dimeric APP as one substrate among others.7 \nMunter et al.  reported that the \uf067-secretase cleavage of APP is  intimately linked to the \ndimerization strength of the transmembrane substrate.4 \nHowever, this APP dimer hypothesis stands in  contrast to the ot her substrates of \uf067-secretase, \nwhich are cleaved as monomers and thus  stipulate high flexibility in this \nrecognition/cleavage process. This issue is co mplicated further by the identification of \ndifferent \uf067-secretase complexes varying in their subcomponent assembly.8 The structural \norganisation of this complex responds to GSM treatment, wh ich can take place through \nallosteric binding to \uf067-secretase or binding to the substrate/ \uf067-secretase complex. Berezoska et \nal. used GFP/RFP labelled PS1 mutants to monitor this GSM induced structural \nreorganisation of the \uf067-secretase complex. The analyzes of fluorescence lifetime imaging \n(FLIM) and fluorescence resonance energy tr ansfer (FRET) studies support a two state \nmodel of \uf067-secretase involving an open and a closed state of PS1.9 \n  \n 160 Results: \nInvestigation of APP dimerizati on by Western blot analysis \nDimerization of wild-type APP is very difficult to detect by SDS-PAGE and \nWestern-blotting. In order to stabilize the APP dimers and to detect them by SDS-PAGE, we \ngenerated a mutated APP, replacing lysine at position 624 by cysteine. This APP K624C \nmutant forms stable dimers which can be  detected by SDS-PAGE and subsequent \nWestern-blotting. APP dimers appear as an additional band running at approximately double \nsize of the APP monomer in the lysate of transfected cells. (Fig 3)  To confirm the formation \nof the K624C-dimer, the mutant was treated with the reductive agent DTT, reducing the disulfide bridge formed by the two cysteines.\n10 This dimer formation does not seem to be cell \ntype specific. It can be detected readily in the lysate of cells of neur onal origin (SY5Y, N2a) \nor HEK293 cells (Figure 3). Inte restingly, the anal ysis of APP proces sing shows that the \nextracellular portion of both wild-type and K624C mutant APP is secreted into the \nconditioned medium (Figure 3c), while A \uf062 secretion is strongly reduced in the mutant \n(Figure 3d). This reduction of A \uf062 was confirmed using ELISA measurements of the \ntransfected cells (data not shown). \npcDAPP\nKCAPP\nwt\n pcDAPP\nKCAPP\nwtpcDAPP\nKCAPP\nwtN2a SY5Y HEK\nAPPAPP dimer\nAPP\nAPPa)\nb)\nc)\nd)pcDAPP\nKCAPP\nwt pcDAPP\nKCAPP\nwt\n pcDAPP\nKCAPP\nwt pcDAPP\nKCAPP\nwtpcDAPP\nKCAPP\nwt pcDAPP\nKCAPP\nwtN2a SY5Y HEK\nAPPAPP dimer\nAPP\nAPPa)\nb)\nc)\nd) \nFigure 3: Western Blot analysis of the dimeriza tion for APP-K624C mutant and APPwt:  \na) cell lysate  b) cell lysate with DDT  c) conditioned medium with DDT  d) A\uf062 secretion. \nAPP-KC-mutant forms a stable dimer based on th e disulfide bridges in N2a, SY5Y and HEK \ncells. A\uf062 secretion was strongly reduced. \n \nAPP dimerization state measurem ents by GFP-labelled APP \nFurther investigations were required to confir m the direct effect of the inhibitor on the \nsubstrate APP, preferentially a cellular a ssay. Therefore BSc3040 was tested in the \ndimerization assay established by Gralle et al.  based on a GFP-labelled APP construct.11   \n 161We investigated the oligomerization state of  APP in living B103 neuroblastoma cells by \nmeasuring F\u00f6rster resonance energy transf er using fluorescence lifetime imaging \nmicroscopy.11 The association of a donor fluorophor e in APP-mGFP with an acceptor \nfluorophore in APP-mCherry is refl ected in the characteristic re duction in the excited state \nlifetime of mGFP. In the presence of BSc 3040, we observed that energy transfer from \nAPP-mGFP to APP-mCherry was significantly re duced by 40% (Figure 4). These data show \nthat a compound with clear \uf067-secretase modulatory activity in fluences APP dimerization at \nthe concentrations required for all GSM like activity. \n \n012345678\nwild type APP K624C APPFRET efficiancy [%]** ***\n012345678\nwild type APP K624C APPFRET efficiancy [%]** ***\n \nFigure 4:  Action of BSc3040 APP dimers. 10 \u00b5M BSc3040 for 1h at 37\u00b0C decreases FRET \nefficiency in APPwt dimers by 40%. BSc3040 has no effect on FRET efficiency in covalently linked dimers of K624C mutant  APP. (black contro l; grey: BSc3040) **: \np < 0.01, ***: p < 0.001. n=14-25 cells per conditi on, 4 wells in transfections done on two \ndifferent days.  \nDiscussion: \nA 40% reduction of cellular APPwt dimerization was observed for BSc3040 at a \nconcentration of 10 \u00b5M, the 3-fold IC\n50 for A\uf06242 secretion. This reduction indicates either the \ncomplete dissociation of a subpopulation of APP dimers, or a conformational change \nincreasing the distance between the C-termini of the APP molecules within the dimer. The \nspecificity of this effect was tested using th e K624C mutant of APP,  which has been shown \nto form disulfide-bridged dimers  and to dimerize quantitatively.10-11 Under the same \nconditions as for wild-type APP, BSc3040 ha d no effect on the energy transfer within \nK624C-APP dimers. This finding strongly suggest s a disruption of non-covalent APP dimers \nby BSc3040. A potential binding site for NSAID derived \uf067-secretase modulators was \nidentified by Kukar et al. in the transmem brane domains of the APP monomer involving a  \n 162 GxxxG sequence.3 The K624C mutant seems not to be a suitable dimerization model, as it \ndoes not lead to a measurable secretion of A \uf062, however contradictor y observations were \ndescribed recently.5,10 The inactivity of BSc3040 on this  mutant can be explained by two \nnon-exclusive hypotheses: either the covalent cystin e bridge in the mutant is so strong that it \ncannot be disrupted by BSc3040, or the modulator re quires a salt bridge like interaction with \nlysine624 and therefore cannot bind to cy steine nor cystine. In eith er case, the clear difference \nin the effects of BSc3040 on wild-type and K6 24C mutant APP supports  the interaction of \nthe modulator with the substrate, which stan ds in line with the observations by Munter, \nKukar and Eggert et al.3-4,12 The cystine-linked dimer of the K624C mutant is suspected to \ninterfere with APP metabolism independent of APP dimerizati on, this impairs the control \nvalue of this mutant. However, a regulatable dimerization of APP was established by Eggert \net al. utilizing APP fused to a FKBP domain.12 The dimerization of this chimera was induced \nby a FKBP binding membrane permeating drug. The controlled dimerization reduced A \uf062 \nsecretion in N2a cells. In accordance with our findings, the induced dimers resist modulation \nof \uf067-secretase activity and some APP cleavage oc curs independent of APP dimerization.  \nThus the observed \uf067-secretase modulatory effects of BSc3040 may be explained by the \ninhibition of cellular APP dimerization in cells.  \n  \n 163Supporting information:  \nMethods:  \nA\uf062 liquid phase electrochem iluminescence (LPECL) assay \nWe used the LPECL assay to measure A \uf062 isoforms to evaluate the compounds for their \npotency in modulating \uf067-secretase activity. APP-overexpressi ng cell lines were generated by \nstably transfecting human neuroglioma H4 -cells obtained from ATCC (accession no. \nCRL-1573 or HTB-148) with human APP695 in vector pcDNA3.1.2 \n \nTransfection of cells  \nCells were plated in 3x6 well  plates and transfected with  SatisFection according to \nmanufacturer\u2019s instructions. After 48h, conditioned medium was collected and cells were \nlysed for 20 min at 0\u00b0C in lysis buffer of eukaryotic cells (10 mM Tris, pH 7.5, 1 mM \nEDTA, 20 mM glycerolphosphate, 50 mM NaF, 1 mM Na 3VO 4, 1 \u00b5M ocadaic acid, 0.5% \nNP-40, 0.5% TritonX-100) and supplemented with  protease inhibitor.  After centrifugation \nfor 10min at 13000rpm, supernatants were coll ected and divided in reduced (DTT added) \nand not reduced samples. \n \nSDS electrophoresis and immunoblotting  \nEqual protein quantities (15 \u00b5g) were separa ted on a 4-12% Criteriom XT Bis Tris Gel \n\u201cBioRad no: 345-0125\u201d for each samples reduced and not reduced and then transferred to a \nHybond-C Extra nitrocellulose membrane. To detect APP and A \uf062\uf02c membranes were \nincubated with the anti A \uf062 monoclonal antibody WO-2, (T he Genetic Company, Z\u00fcrich, \nSwitzerland) at 4\u00b0C over night. Binding of  the primary antibody was detected using \nsubsequent incubation with anti mouse IgG, Horseradish peroxidase  and ECL detection \nsystem (Amersham) and exposure on film for 5 min.  \nDimerization assay \nB103 neuroblastoma cells (a kind gift from Da vid Schubert, Salk Institute, La Jolla, CA) \nwere plated at 10\n5 cells/well in DMEM+10% fetal calf serum on poly-L-ornithine-coated \nglass coverslips in 24-well plates (Corning Life  Sciences, Lowell, MA) and were transfected \nwith 0.3 \uf06dg wtAPP-mGFP and 0.3 \uf06dg wtAPP-mCherry or with 0.3 \uf06dg K624C-mGFP and \n0.3 \uf06dg K624C-APP-mCherry and 0.6 \uf06dl magnetic nanoparticle MaTra beads per well on a \n24-magnet plate (beads and magnet fr om IBA GmbH, G\u00f6ttingen, Germany).11 The medium \nwas changed 1 h after transfection, and expr ession was allowed to proceed for a further  \n 164 18-24 h. 1 h before measurements, 10 \uf06dM of BSc3040 was added to the medium. Coverslips \nwere washed by a short immersion in PBS and mounted on a drop of imaging buffer \n(135 mM NaCl, 10 mM KCl, 0.4 mM MgCl 2, 2 mM CaCl 2, 10 mM HEPES, 0.1 % BSA) \nusing a homemade silicone rubber gasket on a glass slide. Fluoresce nce lifetime imaging \nmeasurements were performed on a frequency domain setup using an Ar laser (Innova 304C, \nCoherent, Dieburg, Germany) at 488 nm.13 The presence of APP-mCherry was confirmed \nusing HBO lamp excitation. The filter cube  from AHF (T\u00fcbingen, Ge rmany) contained a \ndichroic LP495 and emission filter BP 515/30. Th e optimal threshold was set automatically \n(opthr module for MatLab by F. T. Mar ti, www.oersted.dtu.dk/per sonal/jw/jwpublic-\n/matlab/contrib/opthr.m). All further opera tions were performed with custom-written \nroutines (Alessandro Esposito and Matthias Gr alle) in MatLab (MathWorks, Natick, MT). \nThe lifetime and total intensity values of each pixel in the threshold mask were stored, and \nthe lifetimes for all pixels in the appropria te masks of all cells were joined for each \nexperimental condition and imported into Igor Pro (WaveMetrics, Lake Oswego, Oregon) for \ndisplay.  \nExperimental data:  \nGeneral remarks Thin-layer chromatography (TLC) was carried out using aluminium sheets precoated with \nsilica gel 60 F254 (0.2 mm; E. Merck). Chro matographic spots were visualized by UV \nand/or spraying with a methanolic solution of vanillin/H\n2SO 4 or aq. KMnO 4 solution \nfollowed by heating. Flash column chromatogr aphy was carried out using Merck silica gel \n60 (0.063-0.2 mm). Melting Points were determined on a Mettler FP 51 melting point apparatus and are uncorrected. The \n1H and 13C spectra were recorded on a Bruker AC 300 \n(300 MHz) and AC 500 spectrometer (500 MHz). Ch emical shifts are re ported as % values \n(ppm) and adjusted at the central line of the deuterated solvent (MeOD, CDCl 3). Mass \nspectrometry was performed on a Bruker-Franzen  Esquire LC mass spectrometer (ESI) and a \ndouble focused MAT 95 (EI).  IR-spectroscopy was detected by an FT-IR spectrometer (Perkin Elmer Paragon 1000 PC) \nusing KBr carrier material. Elementary analys is was determined using a Perkin Elmer CHN \n240B. HPLC analysis was carried out using: an Agilent 1100 w ith a reversed phase column \n(Zorbax Eclipse XDB-C8; 4.6*150 mm) and a 254 nm detector. The eluent is composed of \nH\n2O (1% TFA) (A) and acetonitrile (B) with a gradient: 30 to 90% B within 12 min. All \nreagents and solvents (THF, DMF, CH 2Cl2, ethyl acetate, MeOH) we re purchased at ABCR,  \n 165Acros and Alfa Aesar, TCI, Sigma Aldrich a nd VWR. Methanol abs. was additionally dried \nover magnesium. \nExperimental data 2-(6-chloro-9-nonyl-9 H-carbazol-2-yl)propanoic acid (BSc3040) \nCarprofen was isolated from Pfizer\u2019s Rimadyl\n\u00ae (100 mg per tablet). 15 tablets were \npowdered and suspended with 2N HCl (75 mL),  extracted three times with ethyl acetate \n(50 mL). The combined organic layers were dried over MgSO 4 and concentrated in vacuo  to \ngive 1.43 g (95%) of Carprofen as a white solid. To a suspension of NaH (0.37 g, 9.13 mmol) in  THF (15 mL) was added Carprofen (0.50 g, \n1.83 mmol) at a temperature of 0\u00b0C. After 30 min stirring nonylbromide (1.89 g, 9.13 mmol) was added. The reaction mixture was allowed to warm up to rt. After 12h the reaction \nmixture was quenched drop wise with H\n2O until gas formation stops  and was extracted once \nwith CH 2Cl2. The precipitate was filtered of, dissolve d in water and acidified to pH 5 with \n2M HCl. The aqueous solution was extracted twice with CH 2Cl2, dried over MgSO 4 and \nconcentrated in vacuo  to give 0.58 g (80%) of BSc3040  as a colourless solid. Mp: 103.4\u00b0C \nHPLC: 9.977 min (98%) \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.99 (d, 4J = 2.1, Hz, 1H, H-1), 7.96 (d, 3J = 8.1, Hz, \n1H, H-5), 7.38 (dd, 3J = 8.6 Hz, 4J = 2.1 Hz, 1H, H-7), 7.32 (d, 4J = 2.1 Hz, 1H, H-8), 7.27 \n(d, 3J = 8.6 Hz, 1H, H-4), 7.19 (dd, 3J = 8.1 Hz, 4J = 1.3 Hz, 1H, H-7), 4.22 (t, 3J = 7.3, Hz, \n2H, H-17), 3.93 (q, 3J = 7.1 Hz, 1H, H-2), 1.82 (quin., 3J = 7.3 Hz, 2H, H-18), 1.63 (d, \n3J = 7.2 Hz, 3H, H-16), 1.38-1.19 (m, 12H, H-19/20/21/22/ 23/24), 0.87 (t, 3J = 7.1 Hz, \n3H;H-25). 13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 180.4 (C-15), 141.0 (C-13), 139.0 (C-12), \n138.1 (C-2), 125.5 (C-7), 124.2 (C-6 ), 123.6 (C-10), 121.2 (C-11), 120.6 (C-5), 119.9 (C-4), \n118.7 (C-3), 109.5 (C-8), 107.8 (C-1), 45.8 (C -14), 43.1 (C-17), 31.7 (C-18), 29.3, 29.1, \n29.1, 28.8, 27.1, 22.5 (CH 2), 18.5 (C-16), 14.0 (C-25). MS (m/z, 70 eV, EI) = 399 (M+), 401, \n286, 388, 400, 287. IR (KBr, cm-1): ~\uf06e = 1699.85 (COOH). EA: calculated for C 24H30ClNO 2 \n(399.95): C: 72.07, N: 3.50, H: 7.56, found: C: 72.13, N: 3.39, H: 7.69. \n  \n 166 References: \n1 Weggen, S.  et al.  A subset of NSAIDs lower amyloidogenic A \uf06242 independently of \ncyclooxygenase activity. Nature  414, 212-216 (2001). \n2 Narlawar, R.  et al.  Scaffold of the cyclooxygenase-2  (COX-2) inhibitor carprofen \nprovides Alzheimer \uf067-secretase modulators. J. Med. Chem.  49, 7588-7591 (2006). \n3 Kukar, T. L.  et al.  Substrate-targeting \uf067-secretase modulators. Nature  453, 925-929 \n(2008). \n4 Munter, L. M.  et al.  GxxxG motifs within the amyloid precursor protein \ntransmembrane sequence are critical for the etiology of A \uf06242. Embo J.  26, 1702-1712 \n(2007). \n5 Kienlen-Campard, P.  et al.  Amyloidogenic processing but not amyloid precursor \nprotein (APP) intracellular C-terminal domain production requires a precisely \noriented APP dimer assembled by transmembrane GXXXG motifs. J. Biol. Chem.  \n283, 7733-7744 (2008). \n6 Narlawar, R.  et al.  N-Substituted carbazolyloxyaceti c acids modulate Alzheimer \nassociated \uf067\uf02dsecretase. Bioorg. Med. Chem. Lett.  17, 176-182 (2007). \n7 Sato, T.  et al.  Active \uf067-secretase complexes contain only one of each component. J. \nBiol. Chem.  282, 33985-33993 (2007). \n8 Serneels, L.  et al.  \uf067-Secretase heterogeneity in the Aph1 subunit: relevance for \nAlzheimer's disease. Science (New York, N.Y.)  324, 639-642 (2009). \n9 Uemura, K.  et al.  Allosteric modulation of PS1/ \uf067-secretase conformation correlates \nwith Amyloid \uf062(42/40) ratio. PLoS One  4, e7893, doi:10.1371/journal.pone.0007893 \n(2009). \n10 Scheuermann, S.  et al.  Homodimerization of amyloi d precursor protein and its \nimplication in the amyloidogenic pathway of Alzheimer's disease. J. Biol. Chem.  276, \n33923-33929 (2001). \n11 Gralle, M., Botelho, M. G. & Wouters, F. S. Neuroprotective secreted amyloid \nprecursor protein acts by disruptin g amyloid precursor protein dimers. J. Biol. Chem.  \n284, 15016-15025 (2009). \n12 Eggert, S., Midthune, B., Cottrell, B. & Koo, E. H. Induced dimerization of the \namyloid precursor protein (APP)  leads to decreased amyloid- \uf062 protein (A \uf062) \nproduction. J. Biol. Chem.  284, 28943-28952 (2009). \n13 Esposito, A., Gerritsen, H. C. & Wouters,  F. S. Fluorescence lifetime heterogeneity \nresolution in the frequency domai n by lifetime moments analysis. Biophys. J.  89, \n4286-4299 (2005). \n    \n 1673.6 Untersuchungen zum Einfluss d er Casein Kinase 1 auf die \uf067-Sekretase  \n \nDer Inhalt dieses Kapitels wu rde zur Ver\u00f6ffentlichung eingereicht:  \nNicole H\u00f6ttecke, Miriam Liebeck, Karlhein z Baumann, Robert Schubenel, Edith Winkler, \nHarald Steiner, Boris Schmidt ChemMedChem , eingereicht: 02.12.09. \u201cInhibition of \n\uf067-secretase by the CK1 inhibito r IC261 does not depend on CK1.\u201d \n \nDer selektive Casein Kinase 1 I nhibitor IC261 reduziert auch die A \uf062-Sekretion, weshalb ein \nEinfluss von CK1 auf die \uf067-Sekretase vermutet wird. Im Rahmen einer \nStruktur-Aktivit\u00e4ts-Analys e wurden 15 Derivate von  IC261 synthetisiert um den Einfluss der \nCasein Kinase 1 auf die \uf067-Sekretase zu untersuchen.  \nN\nHCl\nO\nN\nHCl\nONHCl\nO++O\nRR\nR\nPiperidin, MeOH\nMW, 180\u00b0C, 30 min\n \nAbb. 24:  Synthese der IC261 Derivate.   \n \nDie Wasserstoffbr\u00fccken-Akzeptoren (Methoxy)  des Aryl-Substituenten von IC261 wurden \ndurch alternative Wasserstoffbr\u00fccken-Akzeptore n, wie Fluor oder Sulfons\u00e4ure ausgetauscht. \nHierbei erwiesen sich die Methoxy-Substituenten al s essentiell, da alle alternativ getesteten \nWasserstoffbr\u00fccken-Akzeptoren keine inhibitorische Aktivit\u00e4t auf die \uf067-Sekretase zeigten. \nDie Positionen der Methoxy-Gruppen wurden systematisch variiert, wobei alle Derivate die \n\uf067-Sekretase inhibierten. Ausschlie\u00dflich IC261 ze igte inhibitorische Aktivit\u00e4t auf die CK1 \uf064. \nDurch Methylierung des Indolidon-Stickstoffes in  IC261 wurde eine Abnahme der Potenz im \nVergleich zu IC261 erwartet, da die Ausbildung von zwei Wasserstoffbr\u00fccken-Bindungen verhindert wird. Im Gegensatz dazu wurde aber eine h\u00f6here i nhibitorische Aktivit\u00e4t auf die \n\uf067-Sekretase ermittelt. Dieses Ergebnis schlie\u00dft einen direkten Einfluss der CK1 auf die \n\uf067-Sekretase aus. Auch eine di rekte Inhibition von IC261 auf die \uf067-Sekretase konnte durch \nden Kooperationspartner an der LMU M\u00fcnchen in einem aufgereinigten \uf067-Sekretase Assay \nausgeschlossen werden. Es bleibt unklar durch welchen Mechanismus die \uf067-Sekretase durch \nIC261 und deren Derivate inhibiert wird. Wi r vermuten, dass Abbauprodukte von IC261 eine \ninhibitorische Aktivit\u00e4t aus\u00fcben k\u00f6nnen, aber  auch der Einfluss einer noch nicht \nidentifizierten Kinase ist vereinbar mit den experimentellen Ergebnissen.  \n 168 Alle Verbindungen wurden von Nicole H\u00f6ttecke von 2006-2009 synthetisiert au\u00dfer dem \nkommerziell erh\u00e4ltlichen Sunitinib.  \n 169FULL PAPERS \nDOI: 10.1002/cmdc.200((will be filled in by the editorial staff))\nInhibition of \uf067-secretase by the CK1 \ninhibitor IC261 does not depend on CK1 \nNicole H\u00f6tteckea, Miriam Liebecka, Karlheinz Baumannb, Robert Schubenelb, \nEdith Winklerc, Harald Steinerc, Boris Schmidt.a* \n \naClemens Sch\u00f6pf-Institute of Chemis try and Biochemistry, Technische \nUniversit\u00e4t Darmstadt, Petersenstr . 22, D-64287 Darmstadt, Germany. \nbF. Hoffmann-La Roche Ltd., Pharmaceutic als Division, Preclinical Research \nCNS, Bldg. 70/345, CH-4070 Basel, Switzerland. \ncGerman Center for Neurodegenerative Dis eases (DZNE) and Adolf-Butenandt-\nInstitute, Biochemistry, Ludwig-Maximili ans-University, Schillerstr. 44, 80336 \nMunich, Germany \n \n[*] Prof. Dr. Boris Schmidt, \nClemens Sch\u00f6pf-Institute of Chemistry and Biochemistry, \nTechnische Universit\u00e4t Darmstadt, Petersenstr. 22, D-64287 Darmstadt, Germany. \nTel: (+49) 6151-163075 \nFax: (+49) 6151-163278 E-mail: schmidt_boris@t-online.de\n  \n \nAbstract: CK1 and \uf067-secretase are interesting targets \nfor therapeutic intervention in the treatment of cancer \nand Alzheimer\u2019s disease. The CK1 inhibitor IC261 was \nreported to inhibit \uf067-secretase activity . The question is: \nDoes CK1 inhibition directly influence \uf067-secretase \nactivity? Therefore we analyzed the SAR of 15 \nanalogues and their impact on \uf067-secretase activity. The most active compounds were investigated on CK1 \uf064 \nactivity\uf02e\uf020 These findings exclude a direct influence of \nCK1 on \uf067-secretase, because any change in the \nsubstitution pattern of IC261 diminished CK1 inhibition, \nwhereas \uf067-secretase inhibition is still exerted by several \nanalogues. \n  \n 170Introduction \nAlzheimer\u2019s disease is a devastating illness, which \nrobs patients off the ability to manage their lives on \ntheir own. This illness is accompanied by protein aggregates in the brain composed of the \namyloid- \uf062-peptide (A \uf062), which are called amyloid \nplaques.\n[1] The amyloid- \uf062-peptide is generated by \nthe subsequent degradation of the amyloid \nprecursor protein (APP), a type I transmembrane \nprotein, by two aspartyl proteases, the \uf062-secretase \nand the \uf067-secretase. The \uf067-secretase is a promising \ntarget for therapeutic intervention as it liberates \nvarious A \uf062-peptides with a length of 38, 40, or 42 \namino acids.[2] The toxicity depends on the length: \nA\uf06242 is the most toxic species while A \uf06238 is regarded \nto be non-toxic as increased production of A \uf06238 \ndoes not diminish cellular viability. Several \n\uf067-secretase inhibitors (GSI), which decrease total \nA\uf062\uf020 levels, and several \uf067-secretase modulators \n(GSM), which shift the cleavage-site to the non toxic \nA\uf06238, have been identified so far.[3-5]  \nFlajolet  et al .[6] reported IC261 ( 1) (scheme 1), \na presumably selective casein kinase 1 \uf064 (CK1\uf064) \ninhibitor (IC 50 = 2.57 \u00b5M in cells), to exert potent \nGSI like activity.[6-9] IC261  causes a significant \nreduction of A \uf06240 (68%) and A \uf06242 (61%) levels in \nN2a cells within 5-50 \u00b5M concentration at 3h after \nincubation. A toxic effect was excluded, as toxicity \nwas observed at a concentration of 50 \u00b5M only and \n24h incubation time.  The potential influence of CK1 \uf064 \non \uf067-secretase activity and the similarity of IC261 \nwith known, potent GSMs (Sulindac-S ( 2), Sulindac \n(3) and Sulindac-sulfon ( 4)) stimulated us to \ninvestigate the oxoindole- backbone of IC261, which \nis a common scaffold to kinase inhibition (scheme \n1). \nResults and Discussion \nSynthesis of SAR: \nA dual structure-activity-relationship analysis (SAR) \ntowards \uf067-secretase and CK1 activity was carried \nout by systematical variation of the oxoindole \nsubstitution utilizing the CK1/IC261 co-crystallized \nstructure (PDB: 1EH4). (Table 1) This structure guided the variation of the compounds aiming either at enhanced interaction with CK1 or to exclude \ninteraction with CK1 (R\n3 = Me, 15). All compounds \nwere tested in the cellular A \uf062 generation assay.[10] \nThe four most potent GSIs were subsequently \ninvestigated on their CK1 \uf064 activity to confirm the \nreported influence of CK1 \uf064 on the \uf067-secretase.[6] A \nfurther aim of this investi gation was the identification \nof selective GSIs or even GSMs, void off \ncross-activity on CK1 \uf064 or related kinases.  \nThe Knoevenagel condensation of these \nIC261-derivatives utilizes an oxoindole-derivative, a \nrespective aldehyde and piperidine as a base. The \nreaction is carried out under microwave irradiation \nat 100\u00b0C for 30 min to provide the products in \nmoderate to good yields.[11] The Z-isomer was \nenriched in the subsequent re-crystallisation. The \nproportion of the  E/Z isomers was analyzed by \nHPLC-MS signal integrat ion and the HPLC signals \nwere definitely assigned to the molecular mass. \n(Scheme 2) The assignment of the two isomers to \nthe two HPLC signals was established by \n1H NMR-spectroscopy.  \nThe isomerization of the pure Z-isomer to the \nequilibrium of E- and Z-isomers was monitored by \nHPLC-MS for 9 (Scheme 2)  and \n1H NMR-spectroscopy for 14[12] (Scheme 3) to be \ncomplete within 2 days in methanol solution, which compares to the assay conditions: buffered H\n2O, 24 \nh. Thus the cellular data are obtained for E/Z \nmixtures regardless of the pur ity of the initial isomer. \nA\uf062 determination: H4-cells \nIC261  (1) is a competitive ATP-binding-site inhibitor. \nThe interaction with this binding-site was reported \nby Mashhoon et al.  based on the co-crystallisation \n(PDB: 1EH4) of CK1 with IC261.[13] \n1 features both a hydrogen-bond-donor in \nform of the indole-amin and three methoxy-substituents as hydrogen-bond-acceptors, \nwhich can be divided in two o- and one \np-substitution. The structure analysis suggests two \nhydrogen-bonds of the indole-amine with Asp\n86 and \nLeu88.[13] Notable interactions were assigned to the \no-methoxy-group and Lys41 and an intermolecular \ninteraction with a benzene hydrogen and \ninteractions of the p-methoxy-group with Ser22 and \nAsp154. (Figure 1)  \nThe symmetric substitution pattern with two \no-methoxy-groups enables interactions of both  \n 171rotamers. Both the E-isomer purity and the \natrop-isomerism found in the co-crystal were \ncaptured from the equilibrium conformations in \nsolution. The influence of the o-substitution was \ndetermined by a derivative bearing just one o-\nmethoxy-group ( 5) and several derivatives where \nthe methoxy-groups were replaced by fluorine ( 6), \nnitro ( 7) or sulfonic acid ( 8). \nJust one out of these derivatives ( 5 \nA\uf06238 = 62%, A \uf06240 = 76%, A \uf06242 = 65%) displayed a \nsignificant decrease in A \uf062-levels comparable to the \nactivity of IC261 (A \uf06238 = 55%, A \uf06240 = 77%, \nA\uf06242 = 77%). The single o-substituent and the \nabsence of a p-substituent may cause these minor \nchanges in potency of 5. A complete loss of activity \nwas observed for those derivatives which lacked o-methoxy-groups. This observation demonstrates \nthe essential role of the o-methoxy-group which fits \nexactly into the ATP-binding-site. This assumption \nwas confirmed by introduction of an \nbenzo[\uf064][1,3]dioxole ( 9) which did not display any \nsignificant activity on A \uf062-levels. This group bears \noxygen in the m-position, but has an additional \nmethylene bridge to another oxygen in the p-position. The activity loss can be explained by \nsterical hindrance of the dioxole group, which may \ndisplace Asp\n154 thus disrupting essential \nhydrogen-bonds. Secondary, m-substitution is \ndetrimental to activity, this was additionally tested \nby two fluorines ( 10) in the m-positions, which \ndisplayed surprisingly increased A \uf06242 generation of \nup to 112% at a concentration of 5 \u00b5M. This may be \ndue to inverse modulation; such a switch from \nstraight to inverse \uf067-secretase modulation on a \ncommon scaffold was observed previously.[6, 14]  \nTwo additional hydrogen-bonds are formed by \nthe p-substituted methoxy-group with Ser22 and \nAsp154. Ser22 exerts the role of a gate keeper in \nCK1: Entry of the ATP in the binding site causes a \nconformational change into the closed form by \nSer22, which locks the binding site and prevents \nATP-diffusion out of the binding site. This in turn \nstabilizes CK1 in the active  conformation. The ability \nof 1 to form a hydrogen-bond with Ser22 locks the \nATP-binding-site permanently. The position of Ser22 \nis fixed in the closed form of the pocket and thereby prevents the replacement of IC261 by ATP. \nThe interaction of a p-substituent with Ser\n22 \nwas investigated by the introduction of both sterically demanding and functional groups ( 11, 12 ). \nThese groups should prevent the conformational change into the closed form of the ATP-binding-site. \nThe FDA-approved kinase inhibitor Sunitinib ( 16) \nwas included into the investigation for the same \nrational. 11 did not show any effect on A \uf062 levels, but \nan unexpected inverse modulation of the \n\uf067-secretase was observed for 12, which decreased \nthe A\uf062\n38 levels and increased A \uf06242 levels. (Figure 2) \nThe inverse modulation by 12 as well as 10 \nindicates the mechanism to be different from total \ninhibition of A \uf062 generation. The moderate inhibition \nof A\uf062 secretion (A \uf06238 = 26%, A \uf06240 = 53%, \nA\uf06242 = 26%) by 16 was not observed in the \nreconstituted assay. This indicates an indirect, \npotentially upstream  mode of action. \nAs the IC261 substitution pattern \n(2,4,6-trimethoxybenzene) was found to be important for the activity , it was systematically \nvaried into 2,3,4- and 3,4,5-trimethoxybenzene ( 13, \n14). These two derivatives also exert a significant \nreduction in total A \uf062\uf02e\uf020Although the o-positions of 14 \n(A\uf062\n38 = 54%, A \uf06240 = 72%, A \uf06242 = 65%) are \nsubstituted with hydrogens, it is equipotent to 1 \n(A\uf06238 = 55%, A \uf06240 = 77%, A \uf06242 = 77%). A distinct \nrise in activity was observed for 13 (A\uf06238 = 27%, \nA\uf06240 = 66%, A \uf06242 = 47%) with a methoxy-group in o-\n, m- and p-position.  \nThe most important interaction was \nanticipated to be the indole-nitrogen forming two hydrogen-bonds with Asp\n86 and Leu88.[13] This \ncrucial interaction was challenged by a \nmethyl-substitution of the nitrogen, expecting a 90% loss of activity. Surprisingly, a rise in activity of 15 \ncompared to IC261 was observed. The three \nA\uf062-species were significantly decreased to 35% for \nA\uf062\n38 and to 65% for A \uf06240 and A\uf06242 each. Particularly \nthis observation was the first major evidence \nagainst the involvement of CK1 in our biological \nassay.  \nActivity determination on kinases \nIC261 and the three most potent derivatives 13, 15 \nand 12 were tested for inhibitory activity on CK1 \uf064 \nand 42 other kinases to evaluate the influence of \nCK1 on \uf067-secretase (Figure 3). Surprisingly only \nIC261 shows a significant inhibition of CK1 \uf064\uf020 (81% \ninhibitory activity, Table 1,  Figure 3). As soon as the  \n 172substitution pattern differs from \n2,4,6-trimethoxybenzene, no significant CK1 \ninhibition (> 80%) was observed. This is shown e.g. \nin the case of 13, which bears a methoxy-group in \nthe m- instead of the o-position. It exerts an \ninhibition of a mere 1% under the same conditions \n(Figure 3). In addition, no significant inhibitory \nactivity on CK1 \uf064 was found for 15 and 12.  \n12 and 13 are inactive on CK1 \uf064 yet display \nsignificant inhibition (98%  and 89%) of the tyrosine \nkinase Flt3, which plays an important role in \nleukemia. However, Flt3 is not known to exert effects on APP metabolism. \nOnly the N-methylated indolinone 15 lacked \nsignificant inhibition (inhibitory activity < 20%) for all \nkinases tested, which confirms the relevance of \nN-methylation of indolinones in kinase inhibition. \nThis N-H bond is essential for the inhibition of most kinases by indolinones. \nA\uf062 determination: purified \uf067-secretase \nThese data agree with three possible explanations: \n1) IC261 does not directly affect \uf067-secretase activity \nbut a degradation product is responsible for \n\uf067\uf02dsecretase inhibition, 2) IC261 is coincidently a \nweak \uf067-secretase inhibitor, which independently \ntargets CK1 activity. 3) Another, yet unidentified \nkinase is responsible for the cellular activity. To \ninvestigate a direct effect on \uf067-secretase activity, \nIC261 was tested in a cell-free assay using lipid-\nreconstituted purified \uf067-secretase and purified APP \nC100-His\n6 as substrate for A \uf062 generation,[15] i.e. \nunder conditions, where no additional metabolism is \npresent (Figure 4). No effect on the A \uf062 production \nby \uf067-secretase was observed at 50 \u00b5M, the highest \neffective concentration used in cultured cells by the \nstudy of Flajolet et al.[6] IC261 did also not exert a \nmodulatory effect on the production of A \uf06238, A\uf06240 \nand A\uf06242 species in the cell-free assay at this \nconcentration. \uf067-Secretase activity was also not \naffected at 150 \u00b5M IC261, however, \uf067-secretase \ninhibition was observed at a five-fold higher dose.  \nThis may be due to the resemblance of IC261 to \nknown \uf067-secretase inhibitors derived from NSAIDs, \nwhich are characterized by IC 50ies around \n100-300 \u00b5M e.g. 2.[16-18] Consistent with previous \nresults,[15, 19] presence of the highly potent GSI L-685,458 [20] at 0.5 \u00b5M completely blocked \n\uf067-secretase activity in this assay.  \n \nScheme 1.  Structural similarity of IC261 and the GSM of the \nSulindac-series ( 2-4). \n \nScheme 2. E/Z isomerization of 9 analyzed by HPLC-MS. \n \n \n  \n \n \nScheme3. E/Z isomerization of 14 analyzed by \n1H-NMR-\nspectroscopy. \n \n  \n \nFigure 1. ATP-binding site interaction of 1 according to \nMashhoon et al. (PDB: 1EH4).\n[13]  \nNO OOO\nN\nLeu88Asp86OSer22\nNAsp154\nOO Tyr59 OGlu55\nOOGlu43\nOO\nN Lys41\nOH\nHNPhe23\nNHOCl\nNHOClsoln.OO O\nO\nO\nO\nEE E Z\nZZZ Z b)a)\nE \nE\na)\nbN\nHCl\nOO\nN\nHCl\nOpiperidine\nMeOH\nN\nHCl\nO++OO\nOO\nOO\n9 : 1 \n 173 \n \n \n \n \nFigure 2. Modelled ATP-binding site interaction of 12 (based on \nPDB: 1EH4) and its dose-response curve \n \n \n  \nFigure 3. Kinase screening of 43 kinases from compounds 1 \n(BSc3930), 12 (BSc3944), 13 (BSc3890), 15 (BSc3927). Kinase inhibition is indicated by positive values. Negative values indicate kinase activation. \n \nFigure 4: Cell-free \uf067-secretase assay in the presence of IC261, \nSunitinib, or L-685,458[20] GSI as control.  \n \n            \n \n \nTable 1.  Activity of A \uf062 generation of oxindoles at a concentration of 10 \u00b5M in H4-cells. \n[%] \nCpd Code  R1 R2 R3 CK1\uf064b \n[%] A\u03b238 A\u03b240 A\u03b242\n1 BSc3930 \nIC261 2,4,6-trimethoxy-benzene H H 81 55 77 77 \n5 BSc3926 2-methoxybenzene Cl H n.t.c 62 76 65 \n6 BSc3921 2-fluorobenzene Cl H n.t.c 87 88 91 \n7 BSc3923 2-nitrobenzene Cl H n.t.c 94 88 83 \n8 BSc3922 2-benzene sulfonic acid Cl H n.t.c 101 96 88 \n9 BSc3928 benzo[\uf064][1,3]dioxole Cl H n.t.c 86 93 90 \n10 BSc3914 3,5-difluorobenzene Cl H n.t.c 81a 106a 112a \n11 BSc3929 4-benzeneacetamide Cl H n.t.c 99 97 97 \n12 BSc3944 4-chloropropoxy-benzene Cl H 9 66 93 123 \n13 BSc3890 2,3,4-trimethoxy-benzene Cl H 1 27 46 47 \n14 BSc3925 3,4,5-trimethoxy-benzene Cl H n.t.c 54 72 65 \n15 BSc3927 2,4,6-trimethoxy-benzene H Me 13 35 65 65 \n16 Sunitinib N-(2-(diethylamino)-ethyl)-\n2,4-dimethyl-1 H-pyrrole-3-\ncarboxamide F H n.t.c 26 53 26 \n[a] Activity at a concentration of 5 \u00b5M \n[b] Inhibitory activity at 10 \u00b5M  \n[c] n.t. = not tested \nConclusion \nThe cellular activity of IC261 and its activity in \ncell-free assays is inconsistent with an exclusively \nCK1\uf064 mediated effect on A \uf062\uf020secretion via \n\uf067-secretase inhibition. As the cell-free assay is not \nsubject to CK1 \uf064 dependent regulation, a pleiotropic \neffect is suggested for the interference of \nA\uf062\uf020secretion by IC261: a.) cellular \uf067-secretase \ninhibition may occur at high concentration of IC261 \nor through a metabolic activa tion of IC261.  It is not \nclear, however, whether the interference of IC261 \nwith \uf067-secretase activity at high concentration (in the \ncell-free assay at 250 \u00b5M, i.e. five times above the \nconcentration used by Flajolet et al.[6] in the cellular \nassay) does reflect enzyme inhibition. The observed \nreduction in \uf067-secretase activity could also be due to \nInhibitor y \nActivity  \n[%] \nKinases IC50 (A\uf06238) = 12.5 \n\u00b5M  \nIC50 (A\uf06240) = > 40 \n \n 174a damage of the lipid environment by this particular \ncompound in the in vitro assays; b.) upstream \nmodulation of A \uf062\uf020metabolism by an unidentified \nmode of action, which does not necessarily involve \nCK1\uf064\uf020at low concentrations. Sunitinib, a \npromiscuous kinase inhibitor, was selected for \nstructural similarity to IC261 and submitted to the \nassay panel. It reduces A \uf062\uf020secretion in the cellular \nassay. However, Sunitinib did not display an effect \non A\uf062 generation in the cell-free assay suggesting \nthat an unidentified kinase may be involved in \nA\uf062\uf020secretion in the cellular assay.  \nEven a subtle variation of the IC261 substitution \npattern resulted in complete loss of CK1 inhibition \nbut still exerts A \uf062\uf020 lowering capability (e.g. 13). \nIn conclusion, our IC261 SAR data are \ninconsistent with CK1-dependent inhibition of \n\uf067-secretase. The most potent compounds are not \nsuitable as lead structure for \uf067-secretase modulation \nin vivo, as long as they display significant inhibition \nof Flt3. Such off-target activity will impair further development.  \nExperimental Section \nAssays:  \nA\uf062 liquid phase electrochemiluminescence \n(LPECL) assay: \nWe used the LPECL assay to measure A \uf062 isoforms to \nevaluate the compounds for their potency in modulating \n\uf067-secretase activity as  previously described.[10] \n \nCell-free \uf067-secretase assay: \n\uf067-Secretase activity was assessed in vitro  using \npurified components as described previously using the \nfinal Q-Sepharose eluate fraction of \uf067-secretase as \nenzyme source.[15] For these assays, IC261 obtained \nfrom Sigma and Sunitinib fr om LC Laboratories, were \nused.  \n ProfilerPro Kinase Selectivity Assay System:\n[22] \nProfilerPro Kits 1 and 2 were used to investigate kinase activity. Each of these ki ts contains all necessary \nreagents to carry out in-house compound profiling against a panel of 48 kinases  for twelve compounds \nand were utilized as described.\n[21] The ProfilerPro \nplates were read using of Caliper off-chip mobility shift assay technology. Results are displayed as % inhibition value.  General remarks:\n \nThin-layer chromatography (TLC) was carried out using aluminium sheets precoated with silica gel 60 F254 (0.2 mm; E. Merck). Chromatographic spots were visualized by UV and/or spraying with a methanolic solution of vanillin/H\n2SO 4 or aq. KMNO 4 solution \nfollowed by heating. Flash column chromatography was carried out using Merck silica gel 60 (0.063-0.2 mm). Melting Points were determined on a Mettler FP 51 melting point apparatus and are uncorrected. The \n1H NMR and 13C NMR spectra were recorded on a \nBruker AC 300 (300 MHz) and AC 500 spectrometer (500 MHz). Chemical shifts are reported as % values \n(ppm) and adjusted at the central line of the deuterated solvent (MeOD, CDCl\n3). Mass spectrometry was \nperformed on a Bruker-Franzen Esquire LC mass spectrometer (ESI) and a double focused MAT 95 (EI). The reaction was performed using a microwave from Biotage (Initiator 300 W). HPLC analysis was carried out using an Agilent 1100 with a reversed phase column (Zorbax Eclipse XDB-C8; 4.6*150 mm) and a 254 nM detector. The eluent is composed of H\n2O (1% \nTFA) (A) and acetonitrile (B) with a gradient: 30 to 90% B within 12 min. All reagents and solvents (THF, DMF, CH\n2Cl2, ethyl acetate, MeOH) were purchased at \nABCR, Acros and Alfa Aesar, TCI, Sigma Aldrich and \nVWR. Methanol abs. was additionally dried over magnesium.  Experimental data:\n \n3-(2,4,6-Trimethoxybenzylidene)indolin-2-one (1) [BSc3930] A mixture of 39 mg oxoindole (0.3 mmol), 58 mg 2,4,6-trimethoxybenzaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 80 mg (77%) as a yellow solid, mp 188\u00b0C. \n1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf064: = 9.96 (s, 1H, NH), \n7.50 (s, 1H, H-10), 7.03 (t, 3J = 7.6 Hz, 1H H-4), \n6.83-6.70 (m, 3H, H-5/6/7), 6.15 (s, 2H, H-14/16), 3.82 (s, 3H, CH\n3-16), 3.70 (s, 6H, CH 3-15), MS (m/z, \n70 eV) = 311 (M+), 280, 265, 158. \n5-Chloro-3-(2-methoxybenzylidene)indolin-2-one (5) [BSc3926] A mixture of 50 mg chlorooxoindole (0.3 mmol), 41 mg o-anisaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL \nmethanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 21 mg (25%) as a yellow solid, mp 241\u00b0C.  \n 1751H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.50 (s, 1H, \nNH), 7.71 (s, 1H, CH-10), 7.76 (dd, 4J = 1.3 Hz, \n3J = 7.6 Hz, 1H, H-7), 7.43 (t, 3J = 7.2 Hz, 1H, H-15), \n7.30 (d, 4J = 1.3 Hz, 1H, H-4), 7.13-7.00 (m, 3H, \nH-13/14/16), 6.79 (d, 3J = 8.1 Hz, 1H, H-6),  MS (m/z, \n70 eV, EI) = 285 (M+), 287, 254, 256. \n5-Chloro-3-(2-fluorobenzylidene)indolin-2-one (6) [BSc3921] A mixture of 50 mg chlorooxoindole (0.3 mmol), 37 mg 2-fluorobenzaldehyde, 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 30 mg (37%) as a yellow solid, mp 279\u00b0C. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.80 (s, 1H, NH), \n7.75 (t, 3J = 8.2 Hz, 1H, H-15), 7.62 (d, 4J = 2.1 Hz, 1H, \nCH-10),  7.58 (t, 3J = 8.2 Hz, 1H, H-14), 7.43 (d, \n3J = 8.2 Hz, 1H, H-16), 7.37 (d, 3J = 8.2 Hz, 1H, H-13), \n7.30 (dd, 4J = 2.1 Hz,  3J = 8.3 Hz, 1H, H-6), 6.89 (d, \n3J = 8.3 Hz, 1H, H-7),  MS (m/z, 70 eV) = 273 (M+), 275, \n254, 245, 178. 5-Chloro-3-(2-nitrobenzylidene)indolin-2-one (7) [BSc3923] A mixture of 50 mg chlorooxoindole (0.3 mmol), 45 mg o-nitrobenzaldehyde (0.3 mmol), 30 \u00b5L piperidine in \n1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 52 mg (58%) as a yellow solid, mp 221\u00b0C. \n1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf020\uf064: = 10.16 (s, 1H, NH), \n8.23 (d, 3J = 7.7 Hz, 1H, H-6), 7.91 (s, 1H, CH-10), \n7.72-7.62 (m, 3H, H-14/15/16), 7.05 (d, 3J = 7.7 Hz, 1H, \nH-7), 6.75 (s, 1H, H-4), 6.70 (d,  3J = 9.5 Hz, 1H, H-13), \nMS (m/z, 70 eV) = 300 (M+), 270, 254, 256, 219, 190. \n2-((5-Chloro-2-oxoindolin-3-ylidene)methyl)benzoic acid (8) [BSc3922] A mixture of 50 mg chlorooxoindole (0.3 mmol), 62 mg 2-formylbenzenesulfonic acid (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 42 mg (43%) as a yellow solid, mp >245\u00b0C. \n1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf020\uf064: = 10.16 (s, 1 H, NH), \n8.39 (s, 1 H, CH-10), 8.06 (d, 3J = 9.1 Hz, 1H, H-7), \n7.40 (d, 3J = 5.1 Hz, 1H, H-13), 7.38-7.20 (m, 2H, \nH-14/15), 7.05 (d, 4J = 2.1 Hz, 1H, H-4), 6.98 (dd, \n3J = 9.1 Hz, 4J = 2.1, 1H, H-6), 6.70 (d,  3J = 9.3 Hz, 1H, \nH-13), MS (m/z, 70 eV) = 335 (M+), 255, 253, 190, 167. \n3-(Benzo[1,3]dioxol-5-ylmethylene)-5-chloroindolin-2-one (9) [BSc3928] A mixture of 50 mg chlorooxoindole (0.3 mmol), 45 mg benz[1,3]dioxole-5-carbaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C \nunder microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 35 mg (40%) as a yellow solid, mp 229\u00b0C. \n1H NMR  (500 MHz, Acetone) ppm \uf020\uf020\uf064: = 8.63 (s, 1H, \nNH), 7.74 (s, 1H, CH-10), 7.66 (s, 1H, H-15), 7.64 (d, \n4J = 2.4 Hz, 1H, H-4), 7.28 (dd, 4J = 1.7 Hz, 3J = 8.0, \n1H, H-12), 7.22 (dd, 4J = 1.7 Hz, 3J = 8.0 Hz, 1H, H-13) \n7.01 (d, 3J = 8.0 Hz, 1H, H-7), 6.92 (dd, 3J = 8.0 Hz, \n4J = 2.4 Hz, 1H, H-6), 6.09 (s, 2H, CH 2-14), MS (m/z, \n70 eV, ESI) = 300 (M+H+). \n3-(3,5-Difluorobenzylidene)indolin-2-one (10) [BSc3914] A mixture of 30 mg chlorooxoindole (0.18 mmol), 45 mg 3,5-difluorobenzaldehyde (0.18 mmol), 18 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 12 mg (23%) as a yellow solid. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.86 (br.s, 1H, \nNH), 8.17-8.12 (m, 1H, H-12 Z), 7.93 (s, 1H, H-10 Z), \n7.82 (d, 4J = 2.0 Hz, 1H, H-4 Z), 7.64 (s, 1H, H-10 E), \n7.45 (d, 3J = 6.6 Hz, 1H, H-12 E), 7.43-7.36 (m, 1H, \nH-6 E/Z), 7.35-7.26 (m, 2H, H-4 E/H-7 E/Z), 6.90 (d, \n3J = 8.3 Hz, 1H, H-14 E), 6.85 (d, 3J = 8.3 Hz, 1H, \nH-14 Z), MS (m/z, 70 eV) = 291 (M+), 263, 178. \n2-(4-Formylphenoxy)acetamide 85 mg 4-hydroxybenzaldehyde (0.7 mmol) and 130 mg 4-chloroacetamide were added to a suspension of 20 mL acetone, 290 mg potassium carbonate and \ncatalytic amounts of potassium iodide. The mixture was \nrefluxed for 48h, the precipitate was filtrated afterwards and the solvent was removed in vacuo  to give 143 mg \n(99%) as a light yellow solid.  2-(4-((5-Chloro-2-oxoindolin-3-ylidene)methyl)phenoxy)acet-amide (11) [BSc3929] A mixture of 50 mg chlorooxoindole (0.3 mmol), 53 mg 2-(4-formyl-phenoxy)acetamide (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 42 mg (43%) as a yellow solid, mp 132\u00b0C. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.53 (s, 1H, NH), \n8.40 (d, 3J = 8.9 Hz, 1H, H-7), 8.11 (s, 1H, CH-10), \n7.71 (s, 1H, H-4), 7.50-7.32 (m, 2H, NH 2), 7.14-7.04 \n(m, 2H H-12), 6.96 (dd, 3J = 8.9 Hz, 1H, H-6), 6.73 (d, \n3J = 8.2 Hz, 2H, H-13), 4.46 (s, 2H, CH 2-15), MS (m/z, \n70 eV) = 328 (M+), 271, 243, 178. \n4-(3-Chloropropoxy)benzaldehyde A mixture of 616 mg 4-hydroxybenzaldehyde (5.0 mmol), 1 mL 1-bromo-2-chloropropane (10.0 mmol), 2000 mg potassium carbonate in 14 mL  \n 176acetone were refluxed for 48h, the precipitate was \nfiltered off. The filtrate was concentrated in vacuo to \ngive 980 mg (99%) as a brown solid.[22-24]  \n5-Chloro-3-(4-(3-chloropropoxy)benzylidene)indolin-2-one (12) [BSc3944] A mixture of 50 mg chlorooxoindole (0.3 mmol), 59 mg 4-(3-chloropropoxy)benzaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 25 mg (25%) as a yellow solid, mp 124\u00b0C. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.03 (s, 1H, NH), \n8.32 (d, 3J = 8.9 Hz, 2H, H-12 E), 7.65 (s, 1H, CH-10 Z), \n7.58 (d, 4J = 2.0 Hz, 1H, H-4 Z), 7.55 (d, 3J = 8.9  Hz, 2H, \nH-12 Z), 7.40 (s, 1H, CH-10 E), 7.40 (d, 4J = 2.0 Hz, 1H, \nH-4 E), 7.07 (dd, 4J = 2.0 Hz, 3J = 8.5 Hz, 1H, H-6 Z), \n7.06 (dd, 4J = 2.0 Hz,  3J = 8.5 Hz, 1H, H-6 E), 6.96 (d, \n3J = 8.9 Hz, 2H, H-13 Z), 6.89 (d, 3J = 8.9 Hz, 2H, \nH-13 E), 6.76 (d, 3J = 8.5 Hz, 1H, H-7 Z), 6.75 (d, \n3J = 8.5 Hz, 1H, H-7 E). 4.15 (t, 3J = 5.9 Hz, 2H, H-15 Z), \n4.14 (t, 3J = 5.9 Hz, 2H, H-15 E), 3.72 (t, 3J = 6.3 Hz, 2H, \nH-17 Z), 3.69 (t, 3J = 6.3 Hz, 2H, H-17 E), 2.25-2.18 (m, \n2H, H-16 E/Z), MS (m/z, 70 eV) = 347 (M+), 350, 271, \n243, 178. 5-Chloro-3-(2,3,4-trimethoxybenzylidene)indolin-2-one (13) [BSc3890] A mixture of 50 mg chlorooxoindole (0.3 mmol), 59 mg \n2,3,4-trimethoxybenzaldehyde (0.3 mmol), 30 \u00b5L \npiperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 62 mg (60%) as a yellow solid, mp 198\u00b0C. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.72 (br.s, 1H, \nNH), 8.61 (d, 3J = 9.0 Hz, 1H, H-12 E), 7.88 (s, 1H, \nH-10 E), 7.73 (d, 4J = 2.1 Hz, 1H, H-4 E), 7.65 (s, 1H, \nH-10 Z ), 7.44 (d, 3J = 9.4 Hz, 1H, H-12 Z), 7.46 (s, 1H, \nH-4 Z), 7.26 (dd, 3J = 8.3 Hz, 4J = 2.1 Hz, 1H, H-6 Z), \n7.21 (dd, 3J = 8.3 Hz, 4J = 2.1 Hz, 1H, H-6 E), 7.00 (d, \n3J = 8.8 Hz, 1H, H-13 Z), 6.90 (d, 3J = 9.1 Hz, 1H, H-13 E) \n6.88 (dd, 3J = 8.3 Hz, 1H, H-7 Z), 6.81 (d, 3J = 8.3 Hz, \n1H, H-7 E), 3.91 (s, 3H, H-15 E), 3.90 (s, 3H, H-15 Z), 3.88 \n(s, 3H, H-16 E), 3.83 (s, 3H, H-16 Z), 3.81 (s, 3H, H-17 Z), \n3.78 (s, 3H, H-17 E), MS (m/z, 70 eV) = 345 (M+), 314, \n299, 217. 5-Chloro-3-(3,4,5-trimethoxybenzyliden)indolin-2-one (14) [BSc3925] A mixture of 50 mg chlorooxoindole (0.3 mmol), 58 mg 3,4,5-trimethoxybenzaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 35 mg (34%) \nas a yellow solid, mp 228\u00b0C. \n1H NMR  (300 MHz, DMSO) ppm \uf020\uf020\uf064: = 10.70 (s, 1H, NH), \n8.04 (s, 2H, H-12), 7.89 (s, 1H, CH-10), 7.80 (d, \n3J = 2.1 Hz, 1H, H-4), 7.20 (dd, 3J = 8.3 Hz, 4J = 2.1 Hz,  \n1H, H-6), 6.63 (d, 3J= 8.3 Hz, 1H, H-7), 3.84 (s, 6H, \nH-16), 3.75 (s, 3H, H-17), MS (m/z, 70 eV) = 368 \n(M+Na). 1-Methyl-3-(2,4,6-trimethoxybenzyliden)indolin-2-one (15) [BSc3927] A mixture of 44 mg N-methyloxoindole (0.3 mmol), \n58 mg 2,4,6-trimethoxybenzaldehyde (0.3 mmol), 30 \u00b5L piperidine in 1 mL methanol was heated at 100\u00b0C under microwave irradiation for 30 min. The precipitate was re-crystallized from methanol to give 82 mg (84%) as a yellow solid, mp 206\u00b0C. \n1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf064: = 7.69 (s, 1H, \nCH-10 Z), 7.18 (s, 1H, CH-10 E), 7.14-7.08 (m, 1H, H-6), \n6.91-6.88 (m, 1H, H-4), 6.81-6.76 (m, 1H, H-5), 6.71-6.68 (m, 1H, H-7), 6.11 (s, 2H, H-13), 3.81 (s, 3H, CH\n3-16), 3.68 (s, 6H, CH 3-15), 3.19 (s, 3H, N-CH 3), MS \n(m/z, 70 eV) = 325 (M+), 194, 279, 172. \nAcknowledgements \nFunding: This work was supported by the \nCompetence Network for Neurodegenerative \nDiseases (KNDD) \u201cDegenerative Dementias: Target \nidentification, Validation and Translation into \nTreatment Strategies\u201d of the Bundesministerium f\u00fcr \nBildung und Forschung (BMBF) (H.S., N.H.). \nKeywords:  ((IC261 \u00b7 CK1 \u00b7 \uf067-secretase inhibition \n\u00b7 cancer \u00b7 Alzheimer\u2019s disease)) \n \n \nReferences \n [1] R. Jakob-Roet ne, H. Jacobsen, Angew. Chem. Int. \nEd. 2009 , 48, 3030-3059. \n[2] D. Beher, J. D. Wrigle y, A. P. Owens, M. S. \nShearman, J. Neurochem. 2002 , 82, 563-575. \n[3] S. Weggen, J. L. Eriksen, P. Das, S. A. Sagi, R. \nWang, C. U. Pietrzik, K. A. Findlay, T. E. Smith, M. P. Murphy, T. Bulter, D. E. Kang, N. Marquez-Sterling, T. E. Golde, E. H. Koo, Nature 2001 , 414, \n212-216.  \n 177[4] L. Gasparini, E. Ongini, G. Wenk, J. Neurochem. \n2004 , 91, 521-536. \n[5] S. Weggen, J. L. Eriksen, S. A. Sagi, C. U. Pietrzik, \nV. Ozols, A. Fauq, T. E. Golde, E. H. Koo, J. Biol. \nChem. 2003 , 278, 31831-31837. \n[6] M. Flajolet, G. He, M. Heiman, A. Lin, A. C. Nairn, \nP. Greengard, Proc. Natl. Acad. Sci. U S A 2007 , \n104, 4159-4164. \n[7] G. Cozza, A. Gianoncelli, M. Montopoli, L. \nCaparrotta, A. Venerando, F. Meggio, L. A. Pinna, \nG. Zagotto, S. Moro, Bioorg. Med. Chem. Lett. \n2008 , 18, 5672-5675. \n[8] R. Narlawar, B. I. Perez Revuelta, K. Baumann, R. \nSchubenel, C. Haass, H. Steiner, B. Schmidt, \nBioorg. Med. Chem. Lett. 2007 , 17, 176-182. \n[9] S. Baumann, N. Hoe ttecke, R. Schubenel, K. \nBaumann, B. Schmidt, Bioorg. Med. Chem. Lett. \n2009 , 19, 6986-6990. \n[10] R. Narlawar, B. I. Perez Revuelta, C. Haass, H. \nSteiner, B. Schmidt, K. Baumann, J. Med. Chem. \n2006 , 49, 7588-7591. \n[11] W. Zhang, M. L. Go, Bioorg. Med. Chem. 2009 , 17, \n2077-2090. \n[12] R. Cincinelli, G. Cassi nelli, S. Dallavalle, C. Lanzi, \nL. Merlini, M. Botta, T. Tuccinardi, A. Martinelli, S. Penco, F. Zunino, J. Med. Chem. 2008 , 51, 7777-\n7787. \n[13] N. Mashhoon, A.  J. DeMaggio, V. Tereshko, S. C. \nBergmeier, M. Egli, M. F. Hoekstra, J. Kuret, J. Biol. \nChem. 2000 , 275, 20052-20060. \n[14] R. Narlawar, M. Pickh ardt, S. Leuchtenberger, K. \nBaumann, S. Krause, T. Dyrks, S. Weggen, E. Mandelkow, B. Schmidt, ChemMedChem 2008 , 3, \n165-172. \n[15] E. Winkler, S. Hobson, A. Fukumori, B. Dumpelfeld, \nT. Luebbers, K. Baumann, C.  Haass, C. Hopf, H. \nSteiner, Biochemistry 2009 , 48, 1183-1197. \n[16] D. Beher, E. E. Clarke, J.  D. J. Wrigley, A. C. L. \nMartin, A. Nadin, I. Chur cher, M. S. Shearman, J. \nBiol. Chem. 2004 , 279, 43419-43426. [17] Y. Takahashi, I. Hayashi,  Y. Tominari, K. Rikimaru, \nY. Morohashi, T. Kan, H.  Natsugari, T. Fukuyama, \nT. Tomita, T. Iwatsubo, J. Biol. Chem. 2003 , 278, \n18664-18670. \n[18] P. C. Fraering, W. Ye, J. -M. Strub, G. Dolios, M. J. \nLaVoie, B. L. Ostaszewski , A. van Dorsselaer, R. \nWang, D. J. Selkoe,  M. S. Wolfe, Biochemistry \n2004 , 43, 9774-9789. \n[19] Y. M. Li, M. T. Lai, M. Xu, Q. Huang, J. DiMuzio-\nMower, M. K. Sardana, X. P.  Shi, K. C. Yin, J. A. \nShafer, S. J. Gardell, PNAS 2000 , 97, 6138-6143. \n[20] M. S. Shearman, D. B eher, E. E. Clarke, H. D. \nLewis, T. Harrison, P. Hunt, A. Nadin, A. L. Smith, \nG. Stevenson, J. L. Castro, Biochemistry 2000 , 39, \n8698-8704. \n[21] G. Manning,  D. B. Whyte, R. Ma rtinez, T. Hunter, S. \nSudarsanam, Science 2002 , 298, 1912-1934. \n[22] R. Apodaca, C. A. Dvorak , W. Xiao, A. J. Barbier, J. \nD. Boggs, S. J. Wilson, T. W. Lovenberg, N. I. Carruthers, J. Med. Chem. 2003 , 46, 3938-3944. \n[23] C. Ekambome Bassene, F. Suzenet, N. Hennuyer, \nB. Staels, D.-H. Caignard,  C. Dacquet, P. Renard, \nG. Guillaumet, Bioorg. Med. Chem. Lett. 2006 , 16, \n4528-4532. \n[24] N. Mahindroo, C.-C. Wang, C.-C. Liao, C.-F. \nHuang, I. L. Lu, T.-W. Lien, Y.-H. Peng, W.-J. Huang, Y.-T. Lin, M.-C. Hsu,  C.-H. Lin, C.-H. Tsai, \nJ. T. A. Hsu, X. Chen, P. -C. Lyu, Y.-S. Chao, S.-Y. \nWu, H.-P. Hsieh, J. Med. Chem. 2006 , 49, 1212-\n1216. \n \nReceived: ((will be filled in by the editorial staff)) \nPublished online: ((will be filled in by the editorial staff)) \n \n  \n 178 \n 1793.7 Synthese des selektiven ADAM10 Inhi bitors GI254023X f\u00fcr Untersuchungen von \nEntz\u00fcndungsprozessen \n \nDer Inhalt dieses Kapitels wurde zu r Ver\u00f6ffentlichung bereits ver\u00f6ffentlicht:  \nNicole H\u00f6ttecke, Andreas Ludwig, Sabine Foro, Boris Schmidt Neurodegener. Dis. , Zur \nPublikation angenommen: 09.1209. \u201cImproved synthesis of the ADAM10 inhibitor \nGI254023X.\u201d \nJessica Pruessmeyer, Christian Martin, Franz M. Hess, Nicole Schwarz, Sven Schmidt, Tanja \nKogel, Nicole Hoettecke, Boris Schmidt, Antonio Sechi, Stefan Uhlig, Andreas Ludwig J. \nBiol. Chem.  Zur Publikation angenommen: doi: 10.1074/jbc.M109.059394. \u201cThe disintegrin \nand metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 \nand -4 by lung epithelial cells.\u201d \n \nUm ADAM10 mediierte Entz\u00fcndungsprozesse unt ersuchen zu k\u00f6nnen wurde (angelehnt an \ndie Synthese von GlaxoSmith&Kline) de r Inhibitor GI254023X synthetisiert.  \n \nOOH O\nOOH O\nOHOH O\nN\nHOH O\nO\nN\nO OOH\nN OH\nO\nOH\nNHN\nOO\nN\nHONH\nN\nOO\nN\nHO\nHONH\nN\nOO\nN\nHO\nGI254023X, 90%OOH O\n93% 98% 91%\n75% 92% 91%\n79% 86%Cinnamylbromid \nLDA, THF,\n -78\u00b0C, 30min, 0\u00b0C, 12hPd/C, H 2, \nMeOH\nrt, 16h2M NaOH/THF/MeOH\n 23\u00b0C, 18hBnO-NH 2,*HCl ,\nEDC, CH2Cl2 \n23\u00b0C, 16h\n1) MsCl, Pyridin, CH 2Cl2, \n     0\u00b0C-23\u00b0C, 12h\n2) K2CO3, Aceton, \n    rf, 18h1M NaOH, \nDioxan \n25\u00b0C, 8h\nN-Formylbenzotriazol, \nTHF\n 3d, rtL-tert.-Leucinmethylamid,\n EDC, HOBt, DMAP, DMF \nrt, 12h\nPd/C, H 2, \nMeOH\nrt, 6h\n \nAbb. 25:  Verbesserte Synthese des ADAM10 Inhibitors GI254023X. Die Synthese erfolgte durch Nicole \nH\u00f6ttecke von 2008-2009. \n \nEs konnte eine Verbesserung der Synthe se bez\u00fcglich Detektionsm\u00f6glichkeit und \nS\u00e4urestabilit\u00e4t der Intermediate erzielt werden. Dieses gelang durch den Austausch  \n 180Tetrahydropyranyl-Schutzgruppe, welche  bei 220 nM absorbiert, durch eine \nBenzyl-Schutzgruppe, was eine De tektion bei 254 nM erlaubt. Eb enso verhindert der Wechsel \nder Schutzgruppe das Auftreten von diastereomer en Intermediaten w\u00e4hrende der Synthese. \nEin weiterer Vorteil der Benzyl -Schutzgruppe ist di e kommerzielle Verf\u00fcgbarkeit, welche die \nSynthesekosten drastisch reduzierte.  Durch die Kombination von den Peptidkupplung sreagenzien EDC, HOBt und DMAP konnte \ndas Einf\u00fchren des L-tert.-Leucinmethylamides von der in der Literatur beschriebenen \nAusbeute von 33% auf 79% erh\u00f6ht  werden. Mit diesem verbesse rten Syntheseschritt erh\u00f6hte \nsich die Gesamtausbeute meiner Synthese auf 38% im Vergleich zu den 22% der beschriebenen GSK Syntheseroute.   \n 181Improved synthesis of the ADAM10 inhibitor \nGI254023X \n \nNicole Hoetteckea, Andreas Ludwigb, Sabine, Foroa, Boris Schmidt.a* \n \n \naClemens Sch\u00f6pf-Institute of Chemistry and Bioche mistry, Technische Universit\u00e4t Darmstadt, \nPetersenstr. 22, D-64287 Darmstadt, Germany. \nbInstitute of Pharmacology and Toxicology, RWTH Aachen University, Pauwelsstr. 30, \nD-52074 Aachen.   Running head:  Improved GI254023X synthesis. \n Keywords:  Metalloproteinase, ADAM10/17, neurodege nerative disease, inflammation, \ncancer         [*] Prof. Dr. Boris Schmidt, Clemens Sch\u00f6pf-Institute of Chemistry and Biochemistry, Technische Universit\u00e4t Darmstadt, Petersenstr. 22, D-64287 Darmstadt, Germany. Tel: (+49) 6151-163075 Fax: (+49) 6151-163278 E-mail: schmidt_boris@t-online.de\n  \n  \n 182Abstract:   \nThe metalloproteinase ADAM10 and ADAM 17 are involved in various diseases: \nneurodegeneration, cancer and inflammation. Inhi bition of these proteases is a promising \ntarget in the treatment of inflammation and ca ncer. Herein we present an improved synthesis \nof the ADAM10 reference inhibitor GI254023X in higher overall yield, enhanced detection \nability and increased acid stability, providing easie r handling. This upscaled synthesis, free of \ndiastereomeric intermediates ensures single batc h identity, thus warranting reproducibility in \nfurther biological  investigation. \n \nIntroduction: \nThe disintegrin and metall oproteinase proteases ADAM10  and ADAM17 are involved in \nneurodegenerative diseases, cancer and inflammation.[1] The surface expressed proteases \nADAM10 and ADAM17 cleave the amyloid precursor  peptide APP and thereby prevent the \ngeneration of the A \uf062 fragment which is implicated in the generation of amyloid plaques and \nthe development of Alzheimer\u2019s disease. ADA M10 and ADAM17 also shed several members \nof the EGF-receptor ligand family leading to th e generation of functiona lly active ligands that \nsignal cell proliferation in vari ous types of cancer and hyperpro liferative diseases. Finally, \nboth proteases shed inflammatory medi ators including IL-6 receptor, TNF \uf061, TNF\uf061-receptors, \ntransmembrane chemokines, L-selectin and endothelial adhesion molecules (VCAM-1, \nJAM-A, VE-cadherin) and th ereby affect activation and recruitment of leukocytes. \nThe inhibition of shedding by ADAM10 and ADAM17 is considered a promising strategy to \ntarget cell proliferation and migration in ca ncer and inflammation. Se veral inhibitors for \nADAM10 and ADAM17 have been described, many of these belong to the peptidomimetic hydroxamic acid inhibitors for metalloproteinase such as batimastat ( 1) and marimastat \n(2).\n[2-4] These inhibitors affect numerous metalloprot einases, this lack of selectivity may have \ncontributed to their failure in clinical trials. Rece nt research has demonstrated that ADAM10 \nand ADAM17 differentially mediate various shedding events depend ing on the substrate, cell \ntype and stimulatory conditions. Th erefore, it is advantageous to increase the specificity of the \ninhibitors for selected ADAMs. We have r ecently characterized the reference inhibitor \nGI254023X ( 3) for ADAM10 (IC 50 = 5.3 \u00b5M) with only minimal effect on ADAM17 \n(IC 50 = 541 \u00b5M), while no additional ADAM is affected (Scheme 1).[5, 6] Inhibition of the \nmetalloproteinases 9 and 13 were observed at lo w micromolar level, bu t they do not interfere \nwith the investigated shedding events,[6] however, a sAPP \uf061 reduction to 30% were detected in \nneuroblastoma cells at a concentration of 10 \u00b5M.[7] This inhibitor served in a number of  \n 183collaborative studies as an important tool to study cell proliferation an d migration in models \nof cancer and inflammation.[1] Unfortunately, this reference i nhibitor is no longer available by \ncommercial suppliers. Glaxo Smith&Kline disclosed a synthesis of GI254023X ( 3) in a patent application.\n[8] \n(Scheme 2). The original synthesis started with LiNEt 2 mediated alkylation of the \nenantiomerically pure ( R)-(-)-hyxdroxybutyrate ( 4) with cinnamylbromide followed by a \nsubsequent hydrogenation over pa lladium on carbon to obtain ( R)-methyl-2-(( R)-1-\nhydroxyethyl)-5-phenylpentanoate  (6). The following saponification to 7 was performed with \n1M NaOH in a mixture of THF/MeOH. The hydroxylamine moiety was introduced using \n2-tetrahydropyranyl-oxy amine in combination with EDC. Activation of the hydroxyl group \nwith methanesulfonyl chloride and s ubsequent cyclization resulted in the \uf062-lactam ring ( 9). \nBasic cleavage of the \uf062-lactam ring and formylation of the amine with a mixed anhydride \nprovided the key building block of GI254023X in 81% yield. Introduction of \nL-tert.-leucinemethylamide ( 21), which was prepared in two steps from Boc- L-tert.-leucine \nwith BOP reagent, HOBt and nMM, led to 12 in a moderate yield of 36%. The final \ndeprotection of 12 with acetic acid in water provided GI254023X in an overall yield of \n20%.[8] \nAn upscaled synthesis of 3 in an overall yield of a mere  20% yield implies high costs for \nreagents and starting materials. Furthermore, the THP protected intermediates ( 8-12) do not \nabsorb at 254 nM wavelengths, which impair s their handling by stan dard TLC and HPLC \nequipment. The undefined stereogenic centre  of the tetrahydropyrane (THP) results in \ndiastereomeric intermediates, complicating analysis and purification even further. An upscalable synthesis is thus required for this reference inhibitor, as single batch identity is essential for reproducibility and comparability of animal trials. Therefore our aim was to \nimprove the synthesis of 1 with respect to costs, yields and detectability.  \n \nMaterial and Methods \nSynthesis: The first three steps of the improved synthesis follow the Glaxo synthesis.\n[8] However, the \nTHP-hydroxylamine was replaced by benzyl-hydroxylamine, which was introduced using EDC in a DMF/water mixture in good yield (75%) (Scheme 4).\n[9] This exchange provides \nseveral advantages in respect of costs and substance handli ng. The latter is due to the \ndetection at 254 nM compared to 215 nM of the THP-protected analogue. Additionally, the intermediates 13-17  are less acid labile and diastereomers were avoided at all reaction steps.  \n 184The alcohol 13 was activated with methanesulfonyl  chloride and cyclized to the \uf062-lactam \nintermediate 14 in very good yield (92%).[8] Single crystal X-ray diffraction analysis of 14 \nconfirmed the relative configuration, (Figure1) of the intermediate lactam. \nThe high yielding (91%) \uf062-lactam-cleavage is followed by the amide generation with \nL-tert.-leucinemethylamide ( 21). This sterically hindered amid e formation typically proceeds \nin yields around 35%. Careful optimisatio n delivered EDC hydrochloride, HOBt and \nadditional activation with DMAP, as superior  reagents. This allowed the isolation of 16 in \ngood yield (76%).  We replaced Glaxo\u2019s L-tert.-leucinemethylamide ( 21) synthesis starting with \nBoc- L-tert.- leucine by Malons\u00b4 et al.  method (Scheme 4).\n[10, 11] This method requires a 2 step \nprotocol from commercial buildin g blocks replacing the previous  formal 3 step synthesis. \nHowever L-tert.-leucine ( 18) is far more suitable for upsca led synthesis due to the ease of \nhandling and atom economy. Preparation of the formamide 17 was carried out in two variants: 1) by usage of the reported \nmixed anhydride (64%),  or 2) by usage of N-formylbenzotriazole as formylation reagent \n(83%).\n[14, 15] The decision to introduce the formamide at the end of this route is reasoned by \nthe ability of formamides to form E/Z isomers, which complicate spectroscopic analysis.[16, 17] \nHydrogenation of 17 delivered GI254023X in very good yield (90%).[9] Noteworthy, 3 is not \ndetectable at 254 nM, but rather  at a range from 210-220 nM a nd is thus the single compound \nin this synthesis requiring more than standard detec tion equipment. (Figure 2) \nCellular CX3CL1-cleavage assay: \nCX3CL1-expressing ECV304 cells were grow n on 6-well plates in DMEM medium \ncontaining 10%FCS. Confluent ce ll layers were washed and incubated in DMEM medium \ncontaining the indicated concen trations of metalloproteinase  inhibitor GI254023X (n=3 for \neach concentration) for 16 h. Subsequently, supe rnatants were harvested, cleared by 10 min \ncentrifugation at 10000g and anal yzed for the presence of soluble and transmembrane \nCX3CL1, respectively. Quantific ation was carried out by us e of a specific ELISA for \nCX3CL1 as described previously.[5] Means were calculated from  triplicate determinations, \nresults were plotted as dose-response curve and EC 50 values were determined using \nGraphPadPrism 5.01 software (San Diego, CA).  \n \n \n   \n 185Results: \nIn conclusion we have developed an improved synthesis for GI254023X ( 3) with respect to \ncosts, yields and detectability. This allowe d us to produce multigram quantities for ongoing \nbiological studies. The batch obtained by the new route displays si gnificantly enhanced \nbiological activity in comparison to an origin al batch obtained from Glaxo Smith&Kline in \n2007. We credit this activity difference to a de composition of the reference sample over the \nstorage period of two years at 4\u00b0C. This decomposition was re vealed by HPLC analysis in \ncomparison to a fresh batch of BSc4075. (Figure 2) Thus we recommend storage at -20\u00b0C for \nprolonged periods.   \nDiscussion:  \nThe exchange of the THP pr otective group by the inexpensiv e benzyl group results in \nimproved detectability with standard laborator y equipment at 254 nM. Additional advantages \nare: improved stabil ity of the less acid labile  benzyl group and the a voidance of formation of \ndiastereomeric intermediates w ith the undefined stereogenic centre as an accompaniment of \nthe usage of the THP protective group.  L-tert.-leucinemethylamide ( 21) was generated in a \ntwo step synthesis starting with L-tert.-leucine ( 18) to replace Boc- L-tert.-leucine ( 19) from \nthe Glaxo synthesis. Furthermore, the am ide formation of the two building blocks 15 and 21 \nwas improved from 36% to 79%, which improved overall yield of the divergent synthesis to \n38% from the reported 20%.   \n 186References:  \n[1] Pruessmeyer J, Ludwig A: The good, th e bad and the ugly substrates for ADAM10 \nand ADAM17 in brain pathol ogy, inflammation and cancer . Semin. Cell Dev. Biol. \n2009;20:164-74. \n[2] Marimastat: BB 2516, TA 2516. Drugs R. D, 2003;4:198-203. \n[3] Groves MD, Puduvalli VK, Conrad CA, G ilbert MR, Yung WK, Jaeckle K, Liu V, \nHess KR, Aldape KD, Levin VA: Phase II trial of temozolomide plus marimastat for \nrecurrent anaplastic gliomas: a relati onship among efficacy, joint toxicity and \nanticonvulsant status. J.  Neurooncol. 2006;80:83-90. \n[4] Parsons SL, Watson SA, Steele RJ: Phase I/II trial of batimastat, a matrix \nmetalloproteinase inhibitor, in patients with  malignant ascites. Eur. J. Surg. Oncol. \n1997;23:526-31. \n[5] Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann \nD, Fahrenholz F, Postina R, Matthews V, Kallen K-J, Rose-John S, Ludwig A: The disintegrin-like metalloprot einase ADAM10 is involved in  constitutive cleavage of \nCX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood \n2003;102:1186-95. \n[6] Ludwig A, Hundhausen C, Lambert MH , Broadway N, Andrews RC, Bickett DM, \nLeesnitzer MA, Becherer JD : Metalloproteinase inhibitors for the disintegrin-like \nmetalloproteinases ADAM10 and ADAM17 that differentially block constitutive and \nphorbol ester-inducible shedding of cell surface molecules. Comb. Chem. High \nThroughput Screen 2005;8:161-71. \n[7] Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F.: Shedding of the amyloid \nprecursor protein-like protein APLP2 by disintegrin-metalloproteinases. \nFebs J. 2005; \n272:5808-20. \n[8] Andrews RC, Andersen MW, Cowan DJ, Deaton DN, Dickerson SH, Drewry DH, \nGaul MD, Luzzio MJ, Marron BE, Rabino witz MH. Preparation of peptidyl \nformamide compounds as therapeutic agen ts. (Glaxo Group Limited, UK; et al.). \n2000. 127 pp. \n[9] Walz AJ, Miller MJ: Synt hesis and biological  activity of hydroxa mic acid-derived \nvasopeptidase inhibitor anal ogues. Org. Lett. 2002;4:2047-50. \n[10] Malon P, Pancoska P, Budesinsky M, Hl avacek J, Pospisek J, Blaha K: Amino acids \nand peptides. CLXXXII. Chiroptical  properties and conformation of N-acetyl-L-amino  \n 187acids N'-methylamides with aliphatic side  chains. Collect. Czech. Chem. Commun. \n1983;48:2844-61. \n[11] Randolph JT, Chen H-J, Degoey DA, Fl entge CA, Flosi WJ, Grampovnik DJ, Huang \nPP, Hutchinson DK, Kempf DJ, Klein LL, Yeung MC. Preparation of amino acid hydrazide derivatives as HIV protease i nhibitors. (Abbott Labor atories, USA). 2005. \n281 pp. \n[12] Thorstensson F, Wangsell F, Kvarnstr oem I, Vrang L, Hamelink E, Jansson K, \nHallberg A, Rosenquist A, Samuelsson B: S ynthesis of novel potent hepatitis C virus \nNS3 protease inhibitors: Discovery of  4-hydroxy-cyclopent-2-ene-1,2-dicarboxylic \nacid as a N-acyl- L-hydroxyproline bioisostere. Bioorg. Med. Chem. 2007;15:827-38. \n[13] Rosenquist A, Thorstensson F, Johansson P-O, Kvarnstroem I, Ayesa S, Classon B, \nRakos L, Samuelsson B. Preparation of  peptidomimetic compounds as HCV NS3 \nserine protease inhibitors. (Medivir AB, Swed.). 2005. 179 pp. \n[14] Ten Haken P, Naisby TW, Gary ACG. Fungicides of certain N-acyl amino acid \nderivatives and their use. (S hell Internationale Research  Maatschappij B. V., Neth.). \n1982. pp. 29 pp. \n[15] Katritzky AR, Chang HX, Yang B: N-Formylbenzotriazole: a stable and convenient \nN- and O-formylating agent. Synthesis 1995:503-5. \n[16] Liu M-H, Chen C, Liu C-W: Theo retical Study of Formamide Tautomers-A \nDiscussion of Enol-Keto Isomerizations and Their Corresponding Energies. Struct. \nChem. 2004;15:309-16. \n[17] Siddall TH, III: Di rect measurement of th e rate of internal rotation in a formamide. \nInorg. Nucl. Chem. Lett. 1965;1:155-9. \n \nAcknowledgements:  \nWe would like to thank Prof. Harald Kolm ar and his group (Technische Universit\u00e4t \nDarmstadt, Clemens Sch\u00f6pf-Institute of Chemis try and Biochemistry, Petersenstrasse 22, \nD-64287 Darmstadt) for the use of their HPLC. We also thank Prof. Dr. Hartmut Fuess, \nTechnische Universit\u00e4t Darmstadt, FG  Strukturforschung, FB Material- und \nGeowissenschaften, Petersenst rasse 23, D-64287 Darmstadt, for diffractometer time. This \nwork was supported in part by the SFB 542; proj ect A12 of the German Research Foundation.  \n    \n 188Figures: \n3 GI254023X 1 Batimastat 2 MarimastatHOH\nN\nN\nHOSS\nO\nHNOHOH\nN\nNH\nOOH O\nHNO\nHONH\nN\nOO\nN\nHO\n \nScheme 1: ADAM10 inhibitors.  \n \nOOH O\nOOH O\nOHOH O\nN\nHOH O\nO\nN\nO OOH\nN OH\nO\nON\nOONH\nN\nOO\nN\nHO\nHONH\nN\nOO\nN\nHO\n3 GI254023XOOH O a) b) c) d)\ne) f) g)\nh) i)485% 100% 83% 100%\n75% 99% 81%\n36% 93%O\nOH567\n89 1 0\n11 12O\nOO\nO O\n \nScheme 2: Reagents and conditions:  a) Cinnamylbromide, LDA, THF, -78\u00b0C, 30min, 0\u00b0C, 16h; b) Pd/C, H 2, \nMeOH, rt, 16h; c) 2M NaOH/THF/MeOH = 1/3/1, 23\u00b0C, 20h; d) 2-tetrahydropyranyl-oxyamine, EDC, CH 2Cl2, \n23\u00b0C, rt, 16h; e) 1) MsCl, pyridine, CH 2Cl2, 0\u00b0C-23\u00b0C, 14h; 2) K2CO 3, acetone, rf, 28h; f) 1M NaOH, dioxane, \n23\u00b0C, 23h; g) pyridine, formic acetic anhydride 0\u00b0C \uf0e025\u00b0C; h) L-tert.-leucinemethylamide, BOP reagent, \nHOBt, nMM, DMF, 25\u00b0C, 20h; i) acetic acid/water, 4/1, 50\u00b0C, 16h. Overall yield of the divergent synthesis \nstrategy: 20%. \n  \n 189OOH O\nOOH O\nOHOH O\nN\nHOH O\nO\nN\nO OOH\nN OH\nO\nOH\nNHN\nOO\nNH ONH\nN\nOO\nNHO\nHONH\nN\nOO\nN\nHO567\n13 14 15\n16 17 3 BSc4075OOH O a) b) c) d)\ne) f) g)\nh) i)49 3 %9 8 % 9 1 %7 5 %\n92% 91% 79%\n86% 90%\n \nScheme 3:  Reagents and conditions:  a) Cinnamylbromide, LDA, THF, -78\u00b0C, 30min, 0\u00b0C, 12h; b) Pd/C, H 2, \nMeOH, rt, 18h; c) 2M NaOH/THF/MeOH = 1/3/1, rt, 18h; d) O-benzylhydroxylamine*HCl, EDC*HCl, \nDMF/H 2O = 1/6, pH 4.5, rt, 8h; e) 1) MsCl, pyridine, CH 2Cl2, 0\u00b0C-rt, 12h; 2) K 2CO 3, acetone, rf, 18h; f) 1M \nNaOH, dioxane, 8h, 25\u00b0C; g) L-tert.-leucinemethylamide, EDC, HOBt, DMAP, DMF, rt, 12h; h) \nN-formylbenzotriazole, THF, 3d, rt; i) Pd/C, H 2, MeOH, rt, 6h. Overall yield of the divergent synthesis strategy: \n38% \n \n \nFigure 1:  X-Ray analysis of 14. \n  \n 190H2NOHOd)\n99%H\nNOHO\nO\nOe)\n75%H2NN\nHOHN\nOHO\nO\nOButb)\n100%H\nNNHO\nO\nOButc)\n79%H2NN\nHO1)\n2)19 20 21\n18 22 21H2NOHO\n78-99%\n18a)\n \nScheme 4:  Reagents and conditions:  1) patent synthesis: a) Boc 2O, triethylamine, dioxane[9, 10] b) CDI, methyl-\namine*HCl, triethylamine, CH 2Cl2, 25\u00b0C, 19h; c) TFA, CH 2Cl2, 0\u00b0C\uf0e025\u00b0C, 18h. 2) Alternative route: d) ethyl \nchloroformate, 2M NaOH, 60\u00b0C, 12h; e) acetyl chloride, rf, 6h, methylamine (etheral solution), 0\u00b0C, 12h. \n \n \n \n \nFigure 2: a)  GI254023X and BSc4075 were assayed for inhibition of ADAM10-mediated cleavage of the \ntransmembrane chemokine CX3CL1 expr essed on ECV304 cells. Soluble CX3C L1 released by the cells in the \npresence of increasing concentrations of the inhibitors over a time period of 16h was determined by ELISA . b) \nHPLC analysis of GI254023X at 220 nM, b) HPLC analysis of BSc4075 at 220 nM.  \n \n  \n 191Supporting information:  \nGeneral remarks: \nThin-layer chromatography (TLC) was carried out using aluminium sh eets precoated with \nsilica gel 60 F254 (0.2 mm; E. Merck). Chromat ographic spots were visualized by UV and/or \nspraying with a methanolic solution of vanillin/H 2SO 4 or aq. KMNO 4 solution followed by \nheating. Flash column chromatography was carried out using Merck silica gel 60 \n(0.063-0.2 mm). Melting Points were determined on a Mettler FP 51 melting point apparatus \nand are uncorrected. The 1H and 13C spectra were recorded on a Bruker AC 300 (300 MHz) \nand AC 500 spectrometer (500 MHz). Chemical sh ifts are reported as % values (ppm) and \nadjusted at the central line of the deuterated solvent (MeOD, CDCl 3). Mass spectrometry was \nperformed on a Bruker-Franzen Esquire LC ma ss spectrometer (ESI) and a double focused \nMAT 95 (EI).  HPLC analysis was carried out using: 1) an Agilent 1100 w ith a reversed phase column \n(Zorbax Eclipse XDB-C8; 4.6*150 mm) and a 254 nM detector. The eluent is composed of \nH\n2O (1% TFA) (A) and acetonitrile (B) with a gradient: 30 to 90% B within 12 min. 2) a \nvarian prepstar with a re versed phase column (phenom enex synergi hydro RP 80A; \n4.6*250 mm) and a variable detector (Varian pr o star) using wavelengths of 220 nM and \n280 nM. The eluent is composed of H 2O (0.1% TFA) (A) and acetonitr ile (B) with a gradient: \n10 to 60% B (30 min rather 3) 40 min) and 5 min 90 acetonitrile for re-equilibration. All \nreagents and solvents (THF, DMF, CH 2Cl2, ethyl acetate, MeOH) we re purchased at ABCR, \nAcros and Alfa Aesar, TCI, Sigma Aldrich and VWR. Methanol abs. was additionally dried over magnesium. X-Ray analysis was carried out with CAD-4/PC Software (Nonius, 1996); \ncell refinement: CAD-4/PC Software; data re duction: REDU4 (Stoe & Cie, 1987); program(s) \nused to solve structure: SHELX S97 (Sheldrick, 1997); program(s) used to refine structure: \nSHELXL97 (Sheldrick, 1997); molecular graphics : PLATON (Spek, 2003); software used to \nprepare material for publication: SHELXL97.   \n 192Experimental data: \n(R,E)-Methyl 2-(( R)-1-hydroxyethyl)-5-phenylpent-4-enoate (5) \nTo a solution of diisopropylamine (18.85 g, 186.23 mmol) in THF (200 mL) was added \nn-BuLi (2.5 M, 74.49 mL, 186.23 mmol) at a temperature of -78\u00b0C. After 30 min stirring 4 \n(10.00 g, 84.65 mmol) was added slowly within 20 min. After additional 30 min stirring \ncinnamylbromide (18.35 g, 93.12 mmol) and DMPU (32 mL, 10%v/v) were added. The \nreaction mixture was allowed to warm up to 0-1\u00b0C (fridge). After 16h the reaction mixture \nwas quenched with saturated NH 4Cl (30 mL), poured into 1M HCl (200 mL) and was \nextracted three times with ethyl  acetate (200 mL) The combined  organic layers were dried \nover MgSO 4, filtered and concentrated in vacuo  and purified by silica gel chromatography \n(with a gradient from cyclohexane to 3:1 cycl ohexane : ethyl acetate) to give 16.15 g (81%) of \n5 as a yellow solid. 1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.29 (m, 5H, H-10/H-11/H-12), \n6.46 (m, 1H, H-7), 6.22-6.06 (m, 1H, H-8), 4.00 (b r.s, 1H, H-4), 3.71 (s , 3H, H-1), 2.70 (m, \n1H, H-3), 2.61-2.55 (m, 2H, H-6), 1.31-1.22 (d, 3J = 6.4 Hz, 3H, H-5). HPLC: 5.758 min \n(method: 1).   \n(R)-Methyl-2-(( R)-1-hydroxyethyl)-5-phenyl-pentanoate (6) \nTo a solution of 5 (16.15 g, 68.93 mmol) in MeOH (150 mL) was added 10% Pd on activated \ncarbon (0.162 g, 10 w/w). The resulting suspension was flushed over a period of 5 min with \nhydrogen and then stirred for 1h at rt and no rmal pressure. The catalyst was removed by \nfiltration through Celite and th e filtrate was concentrated in vacuo  to give 16.00 g (98%) of 6 \nas a yellow solid. \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.22-7.17(m, 2H, H-11), 7.14-7.04 \n(m, 3H, H-10/12), 3.89-3.75 (m, 1H, H-4), 3.62 (s, 3H, H-1), 2.62-2.48 (q, 3J = 6.3 Hz, 2H, \nH-8), 2.43-2.26 (m, 1H, H-3), 1. 17-1.07 (m, 4H, H-6/7), 1.58 (d, 3J = 6.4 Hz, 3H, H-5). \nHPLC: 5.758 min (method: 1). \n \n(R)-2-(( R)-1-Hydroxyethyl)-5-phenylpentanoic acid (7) \nTo a solution of 6 (16.00 g, 67.71 mmol) in MeOH (50 mL) and THF (150 mL) was added \n2M NaOH (50 mL). The reaction mixture wa s stirred at rt for 24h, concentrated in vacuo  and \nextracted once with cyclohexane (100 mL). The aqueous layer was acidified to pH=2 with aq. \nH2SO 4 and extracted three times w ith ethyl acetate (100 mL). Th e combined organic layers \ncombined ethyl acetate layers were dried over MgSO 4, filtered and concentrated in vacuo  to \ngive 13.68 g (91%) of 7 as a yellow solid. 1H NMR  (300 MHz, CDCl 3) ppm\uf020\uf064: = 7.35-7.25 \n(m, 2H, H-10), 7.20 (m, 3H, H-10/H- 11), 6.93 (br.s, 2H, OH), 3.96 (q, 3J = 6.4 Hz, 1H, H-3),  \n 1932.75-2.57 (m, 2H, H-7), 2.47-2.41 (m, 1H, H-2) , 1.80-1.60 (m, 4H, H-5/H-6), 1.28-1.23 (m, \n3H, H-4). HPLC: 4.417 min (method: 1). \n \n(R)-N-(Benzyloxy)-2-(( R)-1-hydroxyethyl)-5-phenylpentanamide (13) \nTo a solution of 7 (0.20 g, 0.90 mmol) in H 2O (6 mL) and DMF (6 mL) was added \nO-benzyl-hydroxylamine-hydrochloride (0.22 g, 1.35 mm ol) at rt and the pH was adjusted to \n4.5 with aq. NaHCO 3. To the reaction mixture was added EDC (0.17 g, 0.9 mmol) and the pH \nof the solution was kept at pH=4 with 1M HCl. After stirring at  rt for 1h the reaction mixture \nwas extracted twice with ethyl acetate (30 mL).  The combined organic layers were washed \nsequentially with 1M citric acid (100 mL), NaHCO 3 aq. (100 mL) and brine (100 mL). The \norganic layer was dried over MgSO 4, filtered and concentrated in vacuo  to give 0.22 g (75%) \nof 13 as a colourless solid. 1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.37-7.08 (m, 10H, \nH-9-11/H-14-16), 4.83 (s, 2H, H- 12), 3.93-3.73 (m, 1H, H-2), 2.55 (t, 3J = 7.3 Hz, 2H, H-8), \n1.87 (d, 3J = 3.4 Hz, 1H, H-3), 1.76-1.35 (m, 4H, H-5/H-6), 1.24-1.01 (m, 3H, H-1). HPLC: \n6.019 min (method: 1).  \n(3R,4S)-1-(Benzyloxy)-4-methyl-3-(3-phenylpropyl)azetidin-2-one (14) \nTo a solution of 13 (1.27 g, 3.89 mmol) in CH\n2Cl2 (10 mL) was added pyridine (1.66 g, \n20.93 mmol) and mesyl chloride (0.54 g, 4.67 mm ol) at 0\u00b0C. The reaction mixture was \nallowed to warm to rt and stirred for 16h. Th e reaction was quenched with 2M HCl (10 mL) \nand extracted three times with CH 2Cl2 (20 mL). The combined organic layers were washed \nwith brine (50 mL), dried over MgSO 4 and concentrated in vacuo , to give 1.51 g (96%) of the \nintermediate as a yellow solid. A suspensi on of the intermediate (1.513 g, 3.73 mmol) and \nK2CO 3 (1.548 g, 11.20 mmol) in acetone (10 mL) was heated under reflux for 24h. The \nsuspension was filtered, the filtrate concentrated in vacuo  and purified by silica gel \nchromatography (with a gradient cyclohexane to CH 2Cl2) to give 1.11 g (96%) of 14 as an oil. \n1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.42-7.34 (m, 5H, H-9/H-15/H-16), 7.30-7.25 (m, 2H, \nH-14), 7.20-7.15 (m, 3H, H-8/H-10), 4.96 (d, 2J = 11.3 Hz, 1H, H-12), 4.91 (d, 2J = 11.3 Hz, \n1H, H-12), 7.35 (dt, 3J = 5.5 Hz, 3J = 6.3 Hz, 1H, H-3), 2.82 (dt, 3J = 7.5 Hz, 3J = 7.6 Hz, 1H, \nH-2), 2.71-2.55 (m, 2H, H-6), 1.88- 1.40 (m, 4H, H-4/H-5), 1.01 (d, 3J = 6.4 Hz, 3H, H-10). \nMS (m/z, 70 eV, EI) = 310 (M+), 194, 277, 250, 236. HPLC: 8.382 min (method: 1). \n \n \n  \n 194(R)-2-(( S)-1-(Benzyloxyamino)ethyl)-5- phenylpentanoic acid (15) \nTo a solution of 14 (0.47 g, 1.51 mmol) in dioxane ( 4.9 mL, 3.250 mL/mmol) was added 1M \nNaOH (2.27 mL, 1.5 mL/mmol) and the reaction mixture was stirred at 25\u00b0C for 6h. The \nreaction mixture was extracted with cyclohexane and the aqueous layer was acidified to pH=3 \nwith 1M HCl and extracted three times with ethyl acetate (20 mL). The combined ethyl \nacetate layers were washed with brine (50 mL), dried over MgSO 4, filtered and concentrated \nin vacuo  to give 0.45 g (91%) of 15 as a colourless solid. 1H NMR  (300 MHz, CDCl 3) \nppm\uf020\uf064: = 7.44-7.31 (m, 5H, H-7/H-8, H-14), 7.32-7.24 (m, 2H, H-6), 7.23-7.14 (m, 3H, \nH-13/H-15), 4.79 (q, 3J = 11.6, Hz, 2H, H-4), 3.31 (dq, 3J = 6.8 Hz, 4J = 4.2 Hz, 1H, H-3), \n2.84-2.76 (m, 1H, H-2), 2.71-2.58 (m, 2H, H-12) , 1.97-1.57 (m, 3H, H-11/12), 1.47-1.32 (m, \n1H, H-11/12), 1.06 (d, 3J = 6.8 Hz, 3H, H-9). \uf061-D (DCM. 2 mg/2 mL): + 9.0 HPLC: \n6.410 min (method: 1). \n \n(R)-2-(( S)-1-(Benzyloxyamino)ethyl)- N-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-\n2-yl)-5-phenylpentanamide (16) \nTo a solution of 15 (0.30 g, 0.92 mmol) in DMF abs. (6 mL) under argon atmosphere was \nadded EDC (0.21 g, 1.10 mmol) and HOBt (0.12 g, 0.87 mmol). After stirring at rt for 15 min \nDMAP (0.11 g, 0.87 mmol) and 20 (0.16 g, 1.10 mmol) were added. The reaction mixture \nwas quenched after 12h with 1M citric acid (2 0 mL) and extracted twice with ethyl acetate \n(30 mL). The combined organic layers we re washed sequentially with aq. NaHCO 3 and brine, \ndried over Na 2SO 4, filtered and concentrated in vacuo  to give 0.33 g (79%) of 16 as a \ncolourless solid. 1H NMR  (500 MHz, CDCl 3) ppm\uf020\uf064: = 7.29-7.21 (m, 5H, H-10/H-11/H-18), \n7.18-7.14 (m, 2H, H-9), 7.08 (dd, 3J = 7.5 Hz, 3J = 7.5 Hz, 2H, H-17/H- 19), 6.61 (br.s, 1H, \nNH), 4.75 (d, 2J = 11.5 Hz, 1H, H-7), 4.71 (d, 2J = 11.5 Hz, 1H, H-7), 4.28 (d, 3J = 9.3 Hz, \n1H, H-4), 3.17-3.15 (m, 1H, H-1), 2.62 (t, 3J = 8.1 Hz, 3H, H-6), 2.56-2.46 (m, 3H, H-2/H-\n15), 1.71-1.64 (m, 1H, H-15), 1.56-1.46 (m, 2H , H-13/H-15), 1.40-1.31 (m, 1H, H-13), 0.99 \n(d, 3J = 6.5 Hz, 3H, H-12), 0.91 (s, 9H, H-21). 13C NMR  (125 MHz, CDCl 3) ppm\uf020\uf064: = 173.2 \n(C-3), 171.2 (C-5), 142.0 (C-16), 128.5, 128.4, 128.3, 128.2, 128.1 (CH), 125.7 (C-19), 76.5 \n(C-7), 60.5 (C-4), 57.6 (C-1), 47.7 (C-2), 35.8 (C-15), 34.4 (C-20), 29.4 (C-14), 28.3 (C-13), \n26.8 (C-21), 25.9 (C-6), 14.2 (C-12). MS (m/z, 70 eV, EI) = 455 (M+), 394, 304, 273, 91, 86. \nHPLC: 6.444 min (method: 1). \n \n \n  \n 195(R)-2-(( S)-1-(N-(Benzyloxy)formamido)ethyl)- N-((S)-3,3-dimethyl-1-(methylamino)-1-\noxobutan-2-yl)-5-phenylpentanamide (17) \nTo a solution of 16 (1.14 g, 2.51 mmol), in THF (22 mL) under argon atmosphere was added \nN-formylbenzotriazole (0.66 g, 4.46 mmol). The reac tion mixture was stirred at rt for 3d and \nthen concentrated in vacuo . The residue was dissolved in et hyl acetate (20 mL) and extracted \nthree times with 1M NaOH (20 mL). The organic layer was dried over Na 2SO 4, filtered and \nconcentrated in vacuo . The compound was purified by si lica gel chromatography (50:1, \nCH 2Cl2 : MeOH) to give 1.04 g (86%) of 17 as a colourless solid. Mp: 137\u00b0C. 1H NMR  (500 \nMHz, D6-DMSO) ppm \uf020\uf064: = 8.45-8.34 (br.s, 1H, H-7), 8.17-8.08 (br.s, 1H, H-7), 8.02 (d, \n3J = 9.5 Hz, 1H, NH), 7.81 (d, 3J = 4.5 Hz, 1H, NH), 7.48 (d, 3J = 6.7 Hz, 2H, H-11), \n7.43-7.37 (m, 3H, H-10/H-12), 7.22-7.19 (m, 3H, H-18), 7.13-7.10 (m, 3H, H-17/H-19), \n5.56-5.47 (d, 3J = 7.8 Hz, 1H, NH\u00b4), 5.08-4.83 (m, 2H, H-8), 4.32 (br.s, 1H, H-6\u00b4), 4.28-4.26 \n(m, 1H, H-3), 3.87 (br.s, 1H, H-6) 2.96 (br. s, 1H, H-5), 2.59-2.55 (m, 1H, H-15), 2.53 (d, \n3J = 4.2 Hz, 3H, H-1), 2.46-2.38 (m, 3H, H-15), 1.77-1.69 (m, 1H, H-15\u00b4), 1.67-1.57 (m, 1H, \nH-14), 1.53-1.49 (m, 1H, H-14\u00b4) 1.46-1.35 (m, 2H , H-13), 1.30-1.25 (m, 1H, H-14) 1.25 (s, \n3H, H-22\u00b4), 1.24-1.20 (d, 3J = 6.6 Hz,, 3H, H-22), 1.18-1.13 (m, 1H, H-14\u00b4), 1.07-1.05 (m, \n1H, H-15\u00b4) 0.94 (s, 9H, H-21), 0.90 (s, 3H, H-21\u00b4). 13C NMR  (125 MHz, D6-DMSO) \nppm\uf020\uf064: = 173.0 (C-4), 170.9 (C-2), 142.5 (C-16), 129.6, 129.4, 128.7, 128.5, 128.4, 125.8 \n(CH), 60.3 (C-3), 48.7 (C-5), 47.9 (C-5\u00b4), 35.3 (CH 2), 34.3 (C-10), 33.7,30.0, 28.5 (CH 2), \n27.2 (C-21), 25.7 (CH 2), 25.5 (CH 3), 25.3 (CH 3), 24.8 (CH 2). MS (m/z, 70 eV, ESI) = 504 \n(M+Na). HPLC: 7.173 min (method: 1) . \n \n(R)-N-((S)-3,3-Dimethyl-1-(methylamino)-1-oxobutan-2-yl)-2-(( S)-1-(N-hydroxyform-\namido)ethyl)-5-phenylpentanamide (3) \nTo a solution of 17 (3.03 g, 6.29 mmol) in MeOH (236 mL) was added 10% Pd on activated \ncarbon (0.300 g, 10% w/w). The resulting suspensi on was flushed over a period of 5 min with \nhydrogen and then stirred at rt and normal pre ssure for 6h. The cata lyst was removed by \nfiltration through a 0.30 \u00b5m filter,  the filtrate was concentrated in vacuo  and recrystallized \nfrom CH 2Cl2 with Et 2O to give 2.22 g (90%) of 3 as a colourless solid. 1H NMR  (500 MHz, \nD4-MeOH) ppm \uf020\uf064: = 8.29 (s, 1H, H-7\u00b4), 8.00 (s, 1H, H-7), 7.21 (t, 3J = 7.6 Hz, 2H, H-14), \n7.16-7.07 (m, 3H, H-13/H-15), 4.55-4.48 (m, 1H, H- 6\u00b4), 4.27 (s, 1H, H-3), 3.87-3.81 (m, 1H, \nH-6), 2.89-2.85 (m, 1H, H-5), 2.81-2.77 (m, 1H , H-5\u00b4), 2.63 (s, 3H, H-1), 2.61-2.56 (m, 1H, \nH-11), 2.52-2.46 (m, 1H, H-11), 1.89-1.81 (m, 2H, H-11\u00b4), 1.75-1.66 (m, 2H, H-10\u00b4), \n1.57-1.42 (m, 4H, H-9/H-10), 1.28 (d, 3J =6.5 Hz, 3H, H-8), 1.19 (d, 3J = 6.7 Hz, 3H, H-8\u00b4),  \n 1961.00 (s, 9H, H-17). 13C NMR  (125 MHz, D4-MeOH) ppm \uf020\uf064: = 175.9 (C-4), 173.1 (C-2), \n164.1 (C-7), 159.6 (C-7), 143.7 (C-12), 129.4, 126.7 (C-13/C-14/C-15), 62.2 (C-3), 58.7 \n(C-6), 53.7 (C-5\u00b4), 50.2 (C-5), 36.8 (C-12), 35.2 (C-16), 34.8 (C-12\u00b4), 31.3 (C-11), 31.2 \n(C-10\u00b4), 30.0 (C-11\u00b4), 27.2 (C-17), 26.1 (C-10), 17.6 (C-8), 16.5 (C-8\u00b4), HPLC: 18.37 min \n(method: 2).  \n(S)-2-(Ethoxycarbonylamino)-3,3-d imethylbutanoic acid (22) \nTo a suspension of L-tert.-leucine (18) (1.50 g, 11.43 mmol) in dioxane (7.5 mL) was added \n2M NaOH (18 mL) and ethyl chloroformate (2.36 g, 21.73 mmol). After stirring at 60\u00b0C for \n12h the reaction mixture was allowed to cool to rt and extracted with CH\n2Cl2 (40 mL). The \naqueous layer was acidified to pH=3 with 1M HCl and extracted three times with ethyl acetate (40 mL). The combined organic layers  were washed with brine, dried over Na\n2SO 4, \nfiltered and concentrated in vacuo  to give 2.29 g (99%) of 22 as a colourless rubber. 1H NMR  \n(300 MHz, D4-MeOH) ppm \uf020\uf064: = 4.10 (tt, 3J = 5.3 Hz, 3J = 4.6 Hz, 2H, H-4), 4.00 (s, 1H, \nH-2), 1.31-1.19 (m, 3H, H-5), 1.01 (s, 9H, H-9). 13C NMR  (75 MHz, D4-MeOH) \nppm\uf020\uf064: = 174.7 (C-1), 158.9 (C-3),  63.9 (C-2), 62.1 (C-4), 34.9 (C -6), 27.1 (C-7), 14.5 (C-5). \n \nL-tert.-Leucinemethylamide (21) \nAcetyl chloride (1.77 g, 22.56 mmol ) was added to a solution of 22 (2.29 g, 11.29 mmol) in \ntoluene (20 mL). After stirring at 110\u00b0C for 6h th e reaction mixture was allowed to cool to rt \nand concentrated in vacuo . The residue was solved in an etheral methylamide (1.00 mmol \nmethylamide hydrochloride, 1.00 mmol KOH, in 1.3 mL Et 2O) solution (80 mL) and kept at \n1\u00b0C for 12h. The reaction mixture was fi ltrated, the residue dissolved in Et 2O and precipitated \nwith petroleum ether to give 1.22 g (75%) of  21 as a colourless solid. 1H NMR  (300 MHz, \nD4-MeOH \uf029\uf020\uf070\uf070\uf06d\uf020\uf064 : = 6.77 (br.s, 1H, NH), 3.07 (s, 1H, H-3), 2.81-2.69 (m, 1H, H-1), \n1.98-1.86 (m, 2H, NH 2), 0.93 (s, 9H, H-5). \n \n \n      \n 197\n \n 198\n \n 199\n \n 200\n \n 201\n \n 202\n \n 203\n \n 204\n \n 205\n \n 206\n \n 207\n \n 208\n \n 209\n \n 210\n \n 211\n \n 212\n \n 213\n \n 214\n \n 215\n  \n 216 \n 2174 Zusammenfassung \n \nIn dieser Arbeit wurden die zwei notwendige n funktionellen Gruppen f\u00fcr die Aktivit\u00e4t von \n\uf067-Sekretase Modulatoren mit einem Carbazol- Grundger\u00fcst untersucht: der lipophile Rest, am \nCarbazol-Stickstoff und die Carbons\u00e4urefunkti on der Seitenkette. Es wurde ein Modell \nentwickelt, welches die modulatorischen Ei genschaften der auf NSAID-basierenen GSMs \nerkl\u00e4rt: Die Carbons\u00e4urefunktion interagier t mit einer Aminos\u00e4ure (vermutlich Lysin624) auf \ndem Substrat C99. Dieses Lysin liegt direkt am Membrandurchtritt vor einem GxxxG-Motiv, \n\u00fcber welches ein C99-Dimer bilden kann. Der lipophile Rest scheint als Membrananker zu \nagieren, welcher die Orientierung des GSM sich erstellt und die Bil dung des C99-Dimers \u00fcber \ndas GxxxG-Motiv in der Membran verhindert. Es wird vermutet, dass die Ausbildung dieses \nDimers mit der Erh\u00f6hung der A \uf06242-Sekretion assoziiert ist. \nDurch die Variation des lipophilen Restes  wurde die Vermutung, dass dieser als \nMembrananker fungiert, gefes tigt. Durch Einf\u00fchrung von rigide n linearen lipophilen Resten \nwurde die modulatorische Aktivit\u00e4t gesteigert, da  die Einlagerung in di e Membran erleichtert \nwird. Weitere Untersuchungen der Seitenkette zeigten die Notwendigkeit eines aziden H-\nAtoms, das anscheinend in einem pKa-Bereich zwischen 7-15 liegen muss um noch modulatorische Eigenschaften zu  besitzen. Dieses azide H-At om muss au\u00dferdem \u00fcber einen \nLinker von 2-3 Atomen mit dem Carbazol-Grundge r\u00fcst verbunden sein. Zus\u00e4tzlich konnte ein \nm\u00f6gliches Prodrug-System \u00fcber Esterfunktionen identifiziert werden, welches noch weiter \nuntersucht werden muss. Bez\u00fcglich der Bindun gsstelle unserer GSMs wurde die Vermutung \ngefestigt, dass die Carbons\u00e4ure fuktion mit der basischen Ami nos\u00e4ure Lysin an der Position \n624 des Substrates C99 wechselwirkt. Durch diese Wechselwirkung wird die Dimerisierung \ndes Substrates verhindert, welche vermutlich mit der Erh\u00f6hung der A \uf062\n42-Sekretion assoziiert \nist. \nFerner konnte durch eine Struktur-Aktivit\u00e4ts-An alyse ein direkter Einfluss der Casein Kinase \n1 auf die \uf067-Sekretase ausgeschlossen werden. \nAbschlie\u00dfend gelang eine Optimierung der Synthese des ADAM10 Inhibitors GI254023X, in \nverbesserter Gesamtausbeute zusammen mit ei nfacheren Detektion bei 254 nm statt 220 nm.   \n 218 \n 2195 Ausblick \nEine Substitution des Carbazol-Grundger\u00fcstes an  dem unsubstituierten Phenylring stellt eine \ngute M\u00f6glichkeit dar, die Gr\u00f6\u00dfe der Bindungstasc he zu bestimmen. Ziel dieser Untersuchung \nist es ein Derivat zu identifizieren, welc hes optimal in die Bindungstasche passt und \nInteraktionen mit dieser zur Folge hat, wie z.B. Wasserstoffbr\u00fccken-Bindungen. Eine \nverbesserte Interaktion mit der Bindungstasche sollte eine St eigerung der modulatorischen \nAktivit\u00e4t der GSMs zur Folge haben, vielleicht  sogar bis in den nanomolaren Bereich.  \nEin Austausch des planaren Carbazol-Grundger\u00fcstes ( 42), welches eine \nRinggr\u00f6\u00dfenkombination von 6-5-6 au fweist, hin zu einer 6-6-6 oder 6-7-6 Kombination wie \nim 9,10-Dihydroakridin ( 43) oder Iminodibenzyl ( 45) sowie der Einbau von weiteren \nHeteroatomen ( 44) lie\u00dfe einen R\u00fcckschluss auf die ge ometrische Anordnung der essentiellen \nSubstituenten, der Carbons\u00e4ure und des lipophilen Restes, zueinander zu (Abb.26)  \n \nNO\nOHO\nR2R1\nN\nHX\n43 X = CH 2: 9,10-Dihydro-\n    akridin\n44 X = S: PhenothiazianN\nHXX\n45 X = CH 2: Iminodibenzyl 42\n \nAbb.  26 \u00dcbersicht der weiterer Derivatisierungen f\u00fcr GSMs.  \n \nNach der Lipinsky-Regel, der Rule of Five , sind die in dieser Arbe it synthetisierten GSMs als \nnicht drug-like  einzuordnen. Durch den langen lipophile n Rest sind diese Verbindungen zu \nunpolar (clogP > 5), um bioverf \u00fcgbar zu sein. Die Carbons\u00e4ure  verleiht diesen GSMs einen \namphiphilen Charakter was zu einer Micellenbildung f\u00fchren k\u00f6nnt e. Da diese Carbons\u00e4ure \ntragenden GSMs trotzdem die Blut-Hirn-Schr anke \u00fcberwinden k\u00f6nnen, scheint dies durch \neinen spezifischen Transporter zu erfolge n. Diesen zu identifizieren w\u00e4re eine gute \nM\u00f6glichkeit den Transportmechanismus \u00fcber die Blut-Hirn-Schran ke aufzukl\u00e4ren. Ein \nKandidat ist der MCT1-Transporte r, der auf den Transport von ansonsten nicht hirng\u00e4ngigen \nCarbons\u00e4ure-tragenden Substanzen \u00fcber die Blut-H irn-Schranke spezialisiert ist. Auch die \nIdentifizierung der Bindung sstelle erfordert noch weiterer Untersuchungen. C ross-linking  \nExperimente mit einem geringeren Abstand zwis chen der vermeintlichen Interaktionsstelle, \nder Carbons\u00e4ure und der photoreaktiven Gruppe von <10 \u01fa k\u00f6nnten unser postuliertes \nModulationsmodell best\u00e4tigen.  \nEs wurde in dieser Arbeit ein Einfluss der Casein Kinase 1 auf die \uf067-Sekretase Aktivit\u00e4t \nausgeschlossen; ebenso eine direkte Inhibtion der \uf067-Sekretase durch IC261. Durch  \n 220Identifizierung des I nhibitions-Mechanismus k\u00f6nnten eventuell weitere \n\uf067-Sekretase-regulierende Stoffwechselwege identi fiziert werden, welche  in der AD-Forschung \nAnwendung finden k\u00f6nnten. \nDie verbesserte Synthese des ADAM10 Inhib itors GI254023X gelang in dieser Arbeit \nausgehend von chiralen Ausga ngsverbindungen. Eine Ver\u00e4nder ung der Syntheseschritte bis \nzum ersten Building Block  (50) durch den Einsatz von achiral en Ausgangsprodukten, wie in \nAbb. 27 vorgeschlagen, w\u00fcrde den Zugang zu  diesem Inhibitor vereinfachen und die \nSyntheseroute von 9 auf vier  Schritte verk\u00fcrzen.  \nOO OOO O\nON OO\nOH\nN O\nOOH\nN OH\nOK2CO3, Br(CH 2)3Ph\nAceton, 27h, rfNH2OBn*HCl, NaOAc\nMeOH, H 2O, 24h, rt\n1M NaOH/Dioxan\n8h, 25\u00b0C46 47 48\n49 50distereo- und \nenantioselektive \nReduktion?\n \nAbb. 27  Synthese des ersten Building Blocks  (50) in der Synthese des ADAM10 Inhibitors aus achiralen \nAusgangsprodukten. \n \nZiel dieser Route ist es das Benzyl-gesch\u00fctze Oxim 48 zu generieren, welches in einer \ndiastereo- und enantioselekti ven Reduktion das gew\u00fcnschte1 S-2R-konfigurierte Produkt 49 \nliefert. Die Herausforderung hierbei ist die Id entifizierung eines chiralen Liganden oder \nReagenzes, so dass 49 diastereoselektiv mit sehr gutem  Enantiomeren\u00fcberschuss generiert \nwird und ohne Aufreinig ungsschritte weiter zu 50 umgesetzt werden kann.   \n 2216 Literaturverzeichnis  \n[1] S. Baumann, N. Hoettecke, R. Narlawar, B. Schmidt, Med. Chem. Alzheimer's Dis. \n2008 , 193-224. \n[2] N. Hoettecke, S. Baumann, Bioforum 2008 , 31, 32-34. \n[3] N. H\u00f6ttecke, S. Baumann, A. Ta ghavi, H. A. Braun, B. Schmidt, Frontiers in \nMedicinal Chemistry 2009 , 4, 730-766. \n[4] B. Schmidt, H. A. Braun, R. Narlawar, Curr. Med. Chem. 2005 , 12, 1677-1695. \n[5] S. Parvathy, E. H. Karran, A. J. Turner, N. M. Hooper, FEBS Lett. 1998 , 431, 63-65. \n[6] D. Beher, J. D. Wrigley, A. P. Owens, M. S. Shearman, J. Neurochem. 2002 , 82, \n563-575. \n[7] W. T. Kimberly, M. J. LaVoie, B. L. Osta szewski, W. Ye, M. S. Wolfe, D. J. Selkoe, \nPNAS 2003 , 100, 6382-6387. \n[8] M. S. Wolfe, Biochemistry 2006 , 45, 7931-7939. \n[9] B. De Strooper, Neuron 2003 , 38, 9-12. \n[10] A. L. Brunkan, A. M. Goate, J. Neurochem. 2005 , 93, 769-792. \n[11] G. Yu, F. Chen, M. Nishimura, H. Stei ner, A. Tandon, T. Kawarai, S. Arawaka, A. \nSupala, Y. Q. Song, E. Rogaeva, E. Holmes, D. M. Zhang, P. Milman, P. Fraser, C. Haass, P. St George-Hyslop, Acta Neurol. Scand. Suppl. 2000 , 176, 6-11. \n[12] W. T. Kimberly, W. Xia, T. Rahmati, M. S. Wolfe, D. J. Selkoe, J. Biol. Chem. 2000 , \n275, 3173-3178. \n[13] W. G. Annaert, L. Levesque, K. Craessa erts, I. Dierinck, G. Snellings, D. Westaway, \nP. S. George-Hyslop, B. Cordell, P. Fraser, B. De Strooper, J. Cell Biol. 1999 , 147, \n277-294. \n[14] G. Thinakaran, D. R. Borchelt, M. K. Lee, H. H. Slunt, L. Spitzer, G. Kim, T. \nRatovitsky, F. Davenport, C. Nordstedt, M.  Seeger, J. Hardy, A. I. Levey, S. E. \nGandy, N. A. Jenkins, N. G. Copeland, D. L. Pri ce, S. S. Sisodia, Neuron 1996 , 17, \n181-190. \n[15] D. Selkoe, R. Kopan, Annu. Rev. Neurosci. 2003\n, 26, 565-597. \n[16] T. Sato, T. S. Diehl, S. Narayanan, S. F unamoto, Y. Ihara, B. De Strooper, H. Steiner, \nC. Haass, M. S. Wolfe, J. Biol. Chem. 2007 , 282, 33985-33993. \n[17] G. Yu, M. Nishimura, S. Arawaka, D.  Levitan, L. Zhang, A. Tandon, Y. Q. Song, E. \nRogaeva, F. Chen, T. Kawarai, A. Supa la, L. Levesque, H. Yu, D. S. Yang, E. \nHolmes, P. Milman, Y. Liang, D. M. Zhang, D. H. Xu, C. Sato, E. Rogaev, M. Smith, \nC. Janus, Y. Zhang, R. Aebersold, L. S. Farre r, S. Sorbi, A. Bruni, P. Fraser, P. St \nGeorge-Hyslop, Nature 2000 , 407, 48-54. \n[18] W. P. Esler, C. Das, W. A. Campbell, W.  T. Kimberly, A. Y. Kornilova, T. S. Diehl, \nW. Ye, B. L. Ostaszewski, W. Xi a, D. J. Selkoe, M. S. Wolfe, Nat. Cell Biol. 2002 , 4, \nE110-111; author reply E111-112. \n[19] S. Zhou, H. Zhou, P. J. Walian, B. K. Jap, Biochemistry 2007 , 46, 2553-2563. \n[20] W. P. Esler, W. T. Kimberly, B. L. Ostaszewski, T. S. Diehl, C. L. Moore, J. Y. Tsai, \nT. Rahmati, W. Xia, D. J. Selkoe, M. S. Wolfe, Nat. Cell Biol. 2000 , 2, 428-434. \n[21] C. Goutte, M. Tsunozaki, V. A. Hale, J. R. Priess, PNAS 2002 , 99, 775-779. \n[22] H. Steiner, E. Winkler, D. Edbauer, S.  Prokop, G. Basset, A. Yamasaki, M. Kostka, C. \nHaass, J. Biol. Chem. 2002 , 277, 39062-39065. \n[23] R. Francis, G. McGrath, J. Zhang, D. A. Ruddy, M. Sym, J. Apfeld, M. Nicoll, M. \nMaxwell, B. Hai, M. C. Ellis, A. L. Parks, W.  Xu, J. Li, M. Gurney, R. L. Myers, C. S. \nHimes, R. Hiebsch, C. Ruble, J. S. Nye, D. Curtis, Dev. Cell 2002 , 3, 85-97. \n[24] W. J. Luo, H. Wang, H. Li , B. S. Kim, S. Shah, H. J. L ee, G. Thinakaran, T. W. Kim, \nG. Yu, H. Xu, J Biol Chem 2003 , 278, 7850-7854. \n[25] J. Eder, U. Ho mmel, F. Cumin, B. Ma rtoglio, B. Gerhartz, Curr. Pharm. Des. 2007 , \n13, 271-285.  \n 222[26] V. K. Lazarov, P. C. Fraering, W. Ye , M. S. Wolfe, D. J. Selkoe, H. Li, PNAS 2006 , \n103, 6889-6894. \n[27] M. S. Brown, J. Ye, R. B. Rawson, J. L. Goldstein, Cell 2000 , 100, 391-398. \n[28] T. Ogura, K. Mio, I. Hayashi, H. Mi yashita, R. Fukuda, R. Kopan, T. Kodama, T. \nHamakubo, T. Iwatsubo, T. Tomita, C. Sato, Biochem. Biophys. Res. Commun. 2006 , \n343, 525-534. \n[29] S. Zhou, H. Zhou, P. J. Walian, B. K. Jap, PNAS 2005 , 102, 7499-7504. \n[30] S. F. Lichtenthaler, R. Wang, H. Grimm, S. N. Uljon, C. L. Masters, K. Beyreuther, \nPNAS 1999 , 96, 3053-3058. \n[31] C. Esh, L. Patton, W. Kalback, T. A. K okjohn, J. Lopez, D. Brune, A. J. Newell, T. \nBeach, D. Schenk, D. Games, S. Paul, K. Ba les, B. Ghetti, E. M. Castano, A. E. \nRoher, Biochemistry 2005 , 44, 13807-13819. \n[32] L. M. Munter, P. Voigt, A. Harmeier , D. Kaden, K. E. Gottschalk, C. Weise, R. \nPipkorn, M. Schaefer, D. Langosch, G. Multhaup, Embo J. 2007 , 26, 1702-1712. \n[33] P. Kienlen-Campard, B. Tasiaux, J. Van Hees , M. Li, S. Huysseune, T. Sato, J. Z. Fei, \nS. Aimoto, P. J. Courtoy, S. O. Smith, S. N. Constantinescu, J. N. Octave, J. Biol. \nChem. 2008 , 283, 7733-7744. \n[34] M. Vooijs, E. H. Schroeter,  Y. Pan, M. Blandford, R. Kopan, J. Biol. Chem. 2004 , \n279, 50864-50873. \n[35] R. Kopan, M. X. Ilagan, Nat. Rev. Mol. Cell Biol. 2004 , 5, 499-504. \n[36] D. M. Barten, V. L. Guss, J. A. Corsa, A. Loo, S. B. Hansel, M. Zheng, B. Munoz, K. \nSrinivasan, B. Wang, B. J. Robertson, C. T.  Polson, J. Wang, S. B. Roberts, J. P. \nHendrick, J. J. Anderson, J. K. Loy, R. De nton, T. A. Verdoorn, D.  W. Smith, K. M. \nFelsenstein, J. Pharmacol. Exp. Ther. 2005 , 312, 635-643. \n[37] H.-K. Wong, T. Sakurai, F. Oyama, K. Kaneko, K. Wada , H. Miyazaki, M. Kurosawa, \nB. De Strooper, P. Saftig, N. Nukina, J. Biol. Chem. 2005 , 280, 23009-23017. \n[38] T. A. Comery, R. L. Ma rtone, S. Aschmies, K. P. Atch ison, G. Diamantidis, X. Gong, \nH. Zhou, A. F. Kreft, M. N.  Pangalos, J. Sonnenberg-Reine s, J. S. Jacobsen, K. L. \nMarquis, J. Neurosci. 2005 , 25, 8898-8902. \n[39] A. F. Kreft, R. Martone, A. Porte, J. Med. Chem. 2009 , 52, 6169-6188. \n[40] H. Li, M. S. Wolfe, D. J. Selkoe, Structure 2009 , 17, 326-334. \n[41] P. Osenkowski, H. Li, W. Ye, D. Li, L. Aeschbach, P. C. Fraering, M. S. Wolfe, D. J. \nSelkoe, J. Mol. Biol. 2009 , 385, 642-652. \n[42] D. Pissarnitski, Curr. Opin. Drug Discov. Devel. 2007 , 10, 392-402. \n[43] B. Schmidt, S. Baumann, H. A. Braun, G. Larbig, Curr.Top. Med. Chem. 2006 , 6, \n377-392. \n[44] P. C. Fraering, M. J. LaVoie, W. Ye, B. L.  Ostaszewski, W. T. Kimberly, D. J. Selkoe, \nM. S. Wolfe, Biochemistry 2004 , 43, 323-333. \n[45] A. Y. Kornilova, C. Das, M. S. Wolfe, J. Biol. Chem. 2003 , 278, 16470-16473. \n[46] B. Zhao, M. Yu, M. Neitzel, J. Marugg, J.  Jagodzinski, M. Lee, K. Hu, D. Schenk, T. \nYednock, G. Basi, J. Biol. Chem. 2008 , 283, 2927-2938. \n[47] A. Weihofen, M. K. Lemberg, E. Friedm ann, H. Rueeger, A. Schm itz, P. Paganetti, G. \nRovelli, B. Martoglio, J. Biol. Chem. 2003 , 278, 16528-16533. \n[48] M. S. Shearman, D. Beher, E. E. Clarke, H. D. Lewis, T. Harrison, P. Hunt, A. Nadin, \nA. L. Smith, G. Stevenson, J. L. Castro, Biochemistry 2000 , 39, 8698-8704. \n[49] J. L. Castro Pineiro, A. L. Smith, G. I. Stevenson, (Merck Sharp + Dohme Limited, \nUK). WO20010166564, 2001 . \n[50] J. E. Audia, T. E. Mabry, J. S. Nissen, S. L. McDaniel, in PCT Int. Appl. , (Elan \nPharmaceuticals, Inc., USA; E li Lilly and Company). WO9932453, 1999 . \n[51] H. F. Dovey, V. John, J. P. Anderson, L. Z. Chen, P. de Saint A ndrieu, L. Y. Fang, S. \nB. Freedman, B. Folmer, E. Goldbach, E.  J. Holsztynska, K. L. Hu, K. L.  \n 223Johnson-Wood, S. L. Kennedy, D. Kholodenko, J. E. Knops, L. H. Latimer, M. Lee, \nZ. Liao, I. M. Lieberburg, R. N. Motter, L.  C. Mutter, J. Nietz, K. P. Quinn, K. L. \nSacchi, P. A. Seubert, G. M. Shopp, E. D. Thorsett, J. S. Tung, J. Wu, S. Yang, C. T. Yin, D. B. Schenk, P. C. May, L. D. Altsti el, M. H. Bender, L. N. Boggs, T. C. \nBritton, J. C. Clemens, D. L. Czilli, D. K. Dieckman-McGinty, J. J. Droste, K. S. \nFuson, B. D. Gitter, P. A. Hyslop, E. M. J ohnstone, W. Y. Li, S. P. Little, T. E. \nMabry, F. D. Miller, J. E. Audia, J. Neurochem. 2001 , 76, 173-181. \n[52] T. A. Lanz, C. S. Himes, G. Pallante , L. Adams, S. Yamazaki, B. Amore, K. M. \nMerchant, J. Pharmacol. Exp. Ther. 2003 , 305, 864-871. \n[53] A. Capell, H. Steiner, M. Willem, H. Kaiser, C. Meyer, J. Walter, S. Lammich, G. \nMulthaup, C. Haass, J. Biol. Chem. 2000 , 275, 30849-30854. \n[54] B. K. Hadland, N. R. Manley, D.-M. Su, G.  D. Longmore, C. L. Moore, M. S. Wolfe, \nE. H. Schroeter, R. Kopan, PNAS 2001 , 98, 7487-7491. \n[55] A. Geling, H. Steiner, M. W illem, L. Bally-Cuif, C. Haass, EMBO Rep. 2002 , 3, \n688-694. \n[56] T. A. Lanz, J. D. Hosley, W. J. Adams, K. M. Merchant, J. Pharmacol. Exp. Ther. \n2004 , 309, 49-55. \n[57] G. T. Wong, D. Manfra, F. M. Poulet, Q.  Zhang, H. Josien, T. Bara, L. Engstrom, M. \nPinzon-Ortiz, J. S. Fine, H. J. Lee, L.  Zhang, G. A. Higgins, E. M. Parker, J. Biol. \nChem. 2004 , 279, 12876-12882. \n[58] F. Panza, V. Solfrizzi, V. Frisardi, C. Capurso, A. D'Introno, A. M. Colacicco, G. \nVendemiale, A. Capurso, B. P. Imbimbo, Drugs Aging 2009 , 26, 537-555. \n[59] H. Fuwa, Y. Takahashi, Y. Konno, N. Watanabe, H. Miyashita, M. Sasaki, H. \nNatsugari, T. Kan, T. Fukuyama , T. Tomita, T. Iwatsubo, ACS Chemical Biology \n2007 , 2, 408-418. \n[60] G. M. Rishton, D. M. Retz, P. A. Tempes t, J. Novotny, S. Kahn, J. J. S. Treanor, J. D. \nLile, M. Citron, J. Med. Chem. 2000 , 43, 2297-2299. \n[61] A. F. Kreft, D. C. Cole, K. R. Woller, J. R. Stock, G. Diamanitis, D. M. Kurbrak, K. \nM. Kutterer, W. J. Moore, D. S. Case bier, (Wyeth, John, and Brother Ltd., USA; \nArqule, Inc.). WO2002057252, 2002 , p. 133 pp. \n[62] A. W. Konradi, M. N. Mattson, C. M. Semko, X. M. Ye, (Elan Pharmaceuticals, Inc., \nUSA). WO2007024651, \n2007 , p. 102 pp. \n[63] S. Bowers, A. W. Garofalo, R. K. Hom, A. W. Konradi, M. N. Mattson, M. L. Neitzel, \nC. M. Semko, A. P. Truong, J. Wu, Y.-Z. Xu, (Elan Pharmaceuticals, Inc., USA). WO2007022502, 2007 , p. 141 pp. \n[64] M. Neitzel, (Elan Pharm aceuticals, Inc., USA). WO2006078753, 2006 , p. 111 pp. \n[65] J. Netzer William, F. Dou, D. Cai, D. Veach, S. Jean, Y. Li, G. Bornmann William, B. \nClarkson, H. Xu, P. Greengard, PNAS 2003 , 100, 12444-12449. \n[66] P. C. Fraering, W. Ye, M. J. LaVoie, B. L. Ostaszewski, D. J. Selkoe, M. S. Wolfe, J. \nBiol. Chem. 2005 , 280, 41987-41996. \n[67] S. Cheng, D. D. Comer, L. Mao, G. P. Ba low, D. Pleynet, (Neurogenetics, Inc., USA). \nWO 2004110350, 2004 , p. 178 pp. \n[68] A. Fisher, N. Bar-Ner, Y. Karton, (Israel  Institute for Biological Research, Israel). \nWO2003092580, 2003 , p. 102 pp. \n[69] A. Caccamo, S. Oddo, L. M. Billings, K. N. Green, H. Martinez-Coria, A. Fisher, F. \nM. LaFerla, Neuron 2006 , 49, 671-682. \n[70] www.torreypinestherapeutics.com. [71] N. Shimomura, S. Yoshikawa, Y. Hisa take, A. Imai, (Eisai R & D Management Co., \nLtd., Japan). WO2008140111, 2008 , p. 29pp.  \n 224[72] D. Beher, M. Bettati, G. D. Checksfield, I. Churcher, V. A. Doughty, P. J. Oakley, A. \nQuddus, M. R. Teall, J. D. Wrigley, (Merck Sharp & Dohme Limited, UK). WO 2005013985, 2005 , p. 74 pp. \n[73] P. Blurton, F. Burkamp,  I. Churcher, T. Harrison, J.  Neduvelil, (Merck Sharp & \nDohme Limited, UK). WO2006008558, 2006 , p. 58 pp. \n[74] F. Wilson, A. Reid, V. Reader, R. J. Ha rrison, M. Sunose, R. Hernandez-Perni, J. \nMajor, C. Boussard, K. Smelt, J. Taylor, A. Leformal, A. Cansfield, S. Burckhardt, \n(Cellzome A.-G., Germany). WO2006045554, 2006 , p. 57 pp. \n[75] N. Ramsden, F. Wilson, (Cellzome A.-G., Germany). WO2006048219, 2006 , p. 35 \npp. \n[76] D. Pratico, J. Q. Trojanowski, Neurobiol. Aging 2000 , 21, 441-445. \n[77] P. L. McGeer, E. G. McGeer, Arch. Neurol. 2001 , 58, 1790-1792. \n[78] S. Weggen, J. L. Eriksen, P. Das, S. A. Sagi, R. Wang, C. U. Pi etrzik, K. A. Findlay, \nT. E. Smith, M. P. Murphy, T. Bulter, D. E.  Kang, N. Marquez-Sterling, T. E. Golde, \nE. H. Koo, Nature 2001 , 414, 212-216. \n[79] J. L. Eriksen, S. A. Sagi, T. E. Sm ith, S. Weggen, P. Das, D. C. McLendon, V. V. \nOzols, K. W. Jessing, K. H. Zav itz, E. H. Koo, T. E. Golde, J. Clin. Invest. 2003 , 112, \n440-449. \n[80] L. Gasparini, L. Rusconi, H.  Xu, P. del Soldato, E. Ongini, J. Neurochem. 2004 , 88, \n337-348. \n[81] Y. Takahashi, I. Hayashi, Y. Tominari , K. Rikimaru, Y. Morohashi, T. Kan, H. \nNatsugari, T. Fukuyama, T. Tomita, T. Iwatsubo, J. Biol. Chem. 2003 , 278, 18664-\n18670. \n[82] D. Beher, E. E. Clarke, J. D. J. Wrigley, A. C. L. Martin, A. Nadin, I. Churcher, M. S. \nShearman, J. Biol. Chem. 2004 , 279, 43419-43426. \n[83] T. Morihara, T. Chu, O. Ubeda, W. Beech, G. M. Cole, J. Neurochem. 2002 , 83, \n1009-1012. \n[84] S. Weggen, J. L. Eriksen, S. A. Sagi, C. U. Pietrzik, T. E. Golde, E. H. Koo, J. Biol. \nChem. 2003 , 278, 30748-30754. \n[85] G. P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K. H. \nAshe, S. A. Frautschy, G. M. Cole, J. Neurosci. 2000 , 20, 5709-5714. \n[86] B. P. Imbimbo, J. Alzheimer's Dis. 2009 , 17, 757-760. \n[87] T. L. Kukar, T. B. Ladd, M. A. Bann, P.  C. Fraering, R. Narlawar, G. M. Maharvi, B. \nHealy, R. Chapman, A. T. Welzel, R. W. Pri ce, B. Moore, V. Rangachari, B. Cusack, \nJ. Eriksen, K. Jansen-West, C. Verbeeck, D. Yager, C. Eckman, W. Ye, S. Sagi, B. A. \nCottrell, J. Torpey, T. L. Ro senberry, A. Fauq, M. S. Wolfe, B. Schmidt, D. M. Walsh, \nE. H. Koo, T. E. Golde, Nature 2008 , 453, 925-929. \n[88] R. Narlawar, B. I. Perez Revuelta, C. Haass, H. Steiner, B. Schmidt, K. Baumann, J. \nMed. Chem. 2006 , 49, 7588-7591. \n[89] R. Narlawar, B. I. Perez Revuelta, K. Ba umann, R. Schubenel, C. Haass, H. Steiner, \nB. Schmidt, Bioorg. Med. Chem. Lett. 2007 , 17, 176-182. \n[90] S. Mochizuki, Y. Okada, Cancer Sci. 2007 , 98, 621-628. \n[91] T. G. Wolfsberg, P. Primakof f, D. G. Myles, J. M. White, J. Cell Biol. 1995 , 131, \n275-278. \n[92] J. W. Fox, J. B. Bjarnason, Methods Enzymol. 1995 , 248, 368-387. \n[93] M. S. Rosendahl, S. C. Ko, D. L. Long, M. T. Brewer, B. Rose nzweig, E. Hedl, L. \nAnderson, S. M. Pyle, J. Moreland, M. A. Meyers, T. Kohno, D. Lyons, H. S. Lichenstein, J. Biol. Chem. 1997 , 272, 24588-24593. \n[94] F. X. Gomis-Ruth, L. F. Kress, W. Bode, Embo J. 1993 , 12, 4151-4157. \n[95] E. Lolis, G. A. Petsko, Annu. Rev. Biochem. 1990 , 59, 597-630.  \n 225[96] R. A. Black, C. T. Rauch, C. J. Kozlosky, J. J. Peschon, J. L. Slack, M. F. Wolfson, B. \nJ. Castner, K. L. Stocking, P. Reddy, S. Srinivasan, N. Nelson, N. Boiani, K. A. \nSchooley, M. Gerhart, R. Davi s, J. N. Fitzner, R. S. Johnson, R. J. Paxton, C. J. \nMarch, D. P. Cerretti, Nature 1997 , 385, 729-733. \n[97] E. A. Clark, J. S. Brugge, Science 1995 , 268, 233-239. \n[98] R. O. Hynes, Cell 1992 , 69, 11-25. \n[99] J. Pruessmeyer, A. Ludwig, Semin. Cell Dev. Biol. 2009 , 20, 164-174. \n[100] J. Walter, C. Kaether,  H. Steiner, C. Haass, Curr. Opin. Neurobiol. 2001 , 11, 585-590. \n[101] M. Sastre, J. Walter, S. M. Gentleman, J. Neuroinflammation 2008 , 5, 25. \n[102] F. Fahrenholz, S. Gilbert, E. Kojro, S. Lammich, R. Postina, Ann. N.Y. Acad. Sci. \n2000 , 920, 215-222. \n[103] Y. Avramovich, T. Amit, M. B. Youdim, J. Biol. Chem. 2002 , 277, 31466-31473. \n[104] C. B. Xue, X. He, R. L. Corbett, J. Roderick, Z. R. Wasser man, R. Q. Liu, B. D. \nJaffee, M. B. Covington, M. Qian, J. M. Trzaskos, R. C. Newton, R. L. Magolda, R. \nR. Wexler, C. P. Decicco, J. Med. Chem. 2001 , 44, 3351-3354. \n[105] S. L. Parsons, S. A. Watson, R. J. Steele, Eur. J. Surg. Oncol. 1997 , 23, 526-531. \n[106] A. Ludwig, C. Hundhausen, M. H. Lamber t, N. Broadway, R. C. Andrews, D. M. \nBickett, M. A. Leesnitzer, J. D. Becherer, Comb. Chem. High Throughput Screen \n2005 , 8, 161-171. \n[107] J. S. Fridman, E. Caulder, M. Hans bury, X. Liu, G. Yang, Q. Wang, Y. Lo, B. B. \nZhou, M. Pan, S. M. Thomas, J. R. Grandi s, J. Zhuo, W. Yao, R. C. Newton, S. M. \nFriedman, P. A. Scherle, K. Vaddi, Clin. Cancer Res. 2007 , 13, 1892-1902. \n  \n  \n Lebenslauf: \nPers\u00f6nliches \nName  Nicole H\u00f6ttecke  \nAdresse Pankratiusstrasse 65 \n64289 Darmstadt \nTelefon  0049/61511544467 Mobil 0049/17620329457 E-Mail nicole@hoettecke.net\n \nNationalit\u00e4t Deutsch \nGeburtstag 30.04.1982 in Lippstadt \nSprachen Deutsch (Muttersprache), Englisch (sehr gut) \nPromotion \n10.2006-12.2009 Beginn der Promotion bei Prof. Dr . Schmidt, Technische Universit\u00e4t Darmstadt \nmit dem Thema \u201eEntwicklung und Synthese von \u03b3-Sekretase-Modulatoren zur \nBehandlung von Morbus Alzheimer\u201c \n04.2008 - 09.2008 Kooperation mit der RWTH Aachen bei PD Dr . Andreas Ludwig im Rahmen des \nDFG-Projektes LU869/4-1 \u201e Shedding  proinflammatorischer Mediatoren durch die \nMetalloproteinasen ADAM10 und ADAM 17 bei der entz\u00fcndlichen Leuko-\nzytenrekrutierung\u201c \n04.2008 Praktikum bei der Firma Hoffmann-LaRo che in Basel (Schweiz) im Rahmen einer \nKooperation auf dem Gebiet der Alzhei mer-Forschung (Pharma Research Basel \nDiscovery- Neuroscience) \nStudium \n10.2001 Beginn des Studiums der Biochemie an der Ernst-Moritz -Arndt-Universit\u00e4t \nGreifswald \n09.2004 Vordiplom: \u201eGut\u201c (1.9), organische Chemie: \u201eSehr gut\u201c (1.0), andere \u201eGut\u201c 02.2005 \u2013 03.2005 Betriebsprakti kum in der Abteilung \u201eThrombose & Angiogenese\u201c der Firma \nSanofi-Aventis in Frankfurt am Main \n09.2005  Diplompr\u00fcfungen: Organische Chemie: \u201eSehr gut\u201c (1.3),  \n                               Pharmazeutische Biologie: \u201eGut\u201c (2.3),  \n                               Biochemie: \u201eGut\u201c (2.3) \n10.2005 Diplomarbeit im Fac hbereich Organische Chemie im Arbeitskreis von Prof. \nLanger an der Universit\u00e4t Rostock mit de m Thema: \u201eSynthese antibiotisch aktiver \n2-Vinyl-chroman-4-one\u201c, Note:1.0 \n09.2006 Abschluss des Studiums der Diplom-Bioch emie zum Ende des 10. Fachsemesters, \nNote: \u201eSehr Gut\u201c (1.5)\n  \n Schulbildung  \n1988 Einschulung in der Paul-Gerhard-Schule R\u00fcthen \n1989 \u2013 1992 Nikolaus Grundschule R\u00fcthen 1992 \u2013 2001 Friedrich-Spee-Gymnasium R\u00fcthen 1996 Teilnahme an einem Englandaustausch nach Dereham \n1999 \u2013 2001 Aktive Teilnahme in einer Theatergr uppe des Gymnasiums, sowohl auf der B\u00fchne \nals auch in der Organisation \n06.2001 Erhalt der allgemeinen Ho chschulreife (Abitur) Note: 2.5 \nKenntnisse / F\u00e4higkeiten \n Grundlagen der medizinalchemischen Fo rschung: Optimierung einer Leitstruktur, \nAuswertung von Struktur-Aktivit\u00e4ts -Untersuchungen, biochemische \nUntersuchungsmethoden (Western Blot, ELISA) \n Sehr gute theoretische und praktische Kenntnisse der organischen Synthesechemie \n(insbesondere Heterocyclenchemie, asymmetrische Synthese und Medizinalchemie) und g\u00e4ngiger analyti scher Methoden (NMR, IR, MS, HPLC, \nLC, LCMS, DC). \n Erfahrungen in der Handhabung von Schl enck-Techniken und metallorganischer \nVerbindungen. \n F\u00fchrungserfahrung durch Betreuung von Pr aktikanten sowie Bachelor-, Diplom- \nund Examensarbeiten. \n Sehr gute Kenntnisse von MS/Mac-Office-Anwendungen (Word, Excel, \nPowerPoint), chemischen Datenbanken (SciFinder, Beilstein Online) sowie \nChemDraw und IsisDraw. \nReferenzen  \nPromotion Prof. Boris Schmidt, TU Darmstadt, Petersenstr. 22, 64287 Darmstadt \nTel: 06151-163075 \nDiplom Prof. Peter Langer, Universit\u00e4t Rostock,  Albert-Einstein-Str. 3a, 18059 Rostock \nTel: 0381-4986410 \n \n  \n Publikationsliste:  \n \nNicole Hoettecke, Sven Rotzoll, Uwe Albrecht,  Michael Lalk, Christine Fischer, Peter Langer \nBioorganic & Medicinal Chemistry  2008 , 16, 10319\u201310325. \n\u201cSynthesis and antimicrobial activity of 2- alkenylchroman-4-ones, 2-alkenylthiochroman-\n4-ones and 2-alkenylquinol-4-ones.\u201d  Nicole H\u00f6ttecke, Christine Fische r, Helmut Reinke, Peter Langer, Zeitschrift f\u00fcr \nNaturforschung B , 2009 , 64b, 699-706. \n\u201eSynthesis of Bicyclic Salicylat es by [3+3] cyclization of 1,3- Bis(Silyl Enol Ethers) with \nCyclic 3-(Silyloxy)alk-2-en-1-ones.\u201c  Stefanie Baumann, Nicole H\u00f6ttecke, Robert Schubenel, Karlheinz Baumann, Boris Schmidt  \nBioorg. Med. Chem. Lett.  2009 , 19, 6986-6990. \n\u201cNSAID-derived \uf067-secretase modulators. Part III: Membrane anchoring.\u201d \n \nJessica Pruessmeyer, Christian Martin, Franz M. Hess, Nicole Schwarz, Sven Schmidt, Tanja \nKogel, Nicole Hoettecke, Boris Schmidt, Antonio Sechi, Stefan Uhlig, Andreas Ludwig J. \nBiol. Chem.  accepted 29.10.2009. (http://www.jbc.org/cgi/doi/10.1074/jbc.M109.059394) \n\u201cThe disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced \nshedding of syndecan-1 and -4 by lung epithelial cells.\u201d  Nicole H\u00f6ttecke, Andreas Ludwig, Sabine Foro, Boris Schmidt Neurodegener. Dis. , Zur \nPublikation angenommen: 09.12.09. \u201cImprove d synthesis of the ADAM10 inhibitor \nGI254023X.\u201d \n \nNicole H\u00f6ttecke, Miriam Liebeck, Karlheinz Baumann, Robert Schubenel, Edith Winkler, \nHarald Steiner, Boris Schmidt ChemMedChem , eingereicht: 02.12.09. \u201cInhibition of \n\uf067-secretase by the CK1 inhibito r IC261 does not depend on CK1.\u201d \n \nNicole H\u00f6ttecke, Matthias Gralle, Maria Angela  C. Dani, Karlheinz Ba umann, Fred Wouters, \nChristian Czech, Boris Schmidt Nature Chem. Biol. , eingereicht. \u201cThe Modulation of A \uf062 \nproduction involves dimerization of APP.\u201d \n  \nBuchkapitel: \n \nStefanie Baumann, Nicole H\u00f6 ttecke, Boris Schmidt, \u201c \uf067-Secretase as a target for AD\u201c, in \nMedicinal Chemistry of Alzheimer Diseas e, ed. A. Martinez, Research Signpost, 2008 . \n Nicole H\u00f6ttecke, Stefanie Baumann, Ali Tagh avi, Hannes A. Braun and Boris Schmidt, \n\u201cDrug Development and Diagnostics for Alzheimer's Disease Up to 2008\u201c, in Frontiers in \nMedicinal Chemistry Vol. 4, Ed.:  Atta-ur-Rahman, A.B. Reitz, pp. 730-766, Bentham Books \n2009 . \n  \n\u00dcbersichtsartikel: \n \nNicole H\u00f6ttecke, Stefanie Baumann Bioforum  2008 , \n6, 32-34. \n\u201cAlzheimer-Demenz: Ein Pla(qu) e mit Hoffnung auf Besserung?\u201c \n  \n Poster: \n \nStefanie Baumann, Nicole H\u00f6ttecke, Daniel Kieser, Boris Schmidt, \u201cTIC Ta \uf062 Tau \u2013\nAsystematic approach to protein a ggregation with small molecules.\u201d \nGesellschaft Deutscher Chemiker Wissenschaftsforum , 16.-19. September 2007, Ulm.  \n Stefanie Baumann, Nicole Hoettecke, Rajeshwa r Narlawar, Thomas Kukar, Todd E. Golde, \nKarlheinz Baumann, \u201cMapping the binding site of \uf067-secretase modulators by small (and not so \nsmall) organic molecules\u201d \nAlzheimer\u00b4s Association , 26.-31. Juli 2008, Chicago, USA. \n Boris Schmidt, Andrea Zall, Daniel Kieser , Nicole Hoettecke, Karlheinz Baumann, \n\u201eReplacement of a carboxylic acid by isosteres on a carbazolic scaffold provides \u03b3-secretase \nmodulators\u201d  \nGesellschaft Deutscher Chemiker Wissenschaftsforum , 31. August-02. September 2009, \nFrankfurt am Main.  Boris Schmidt, Andrea Zall, Daniel Kieser , Nicole Hoettecke, Karlheinz Baumann, \n\u201eCarboxylic acid isosteres linked on a carbazolic scaffold as \uf067-secretase modulators\u201d  \nChemBioNet , 30. Novermber-01. Dezember 2009, Frankfurt am Main.  \n Nicole H\u00f6ttecke                 16.12.2009 \nPankratiusstr. 65 64289 Darmstadt\n \n \n  \n \n   \nEidesstattliche Erkl\u00e4rung \nIch erkl\u00e4re hiermit an Eides Statt, dass ich meine Dissertation selbst\u00e4ndig und nur mit den \nangegebenen Hilfsmitteln angefertigt habe.  \n \n          Nicole H\u00f6ttecke               \n  \n Nicole H\u00f6ttecke                 16.12.2009 \nPankratiusstr. 65 64289 Darmstadt\n \n \n \n \n  \nErkl\u00e4rung \nIch erkl\u00e4re hiermit, noch keinen Pr omotionsversuch unternommen zu haben.  \n \n       \nNicole H\u00f6ttecke  \n \n  ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}